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The present book, Antioxidants in Health and Disease, explores the effects of dietary 
antioxidants and/or antioxidant supplementation on various stages of the human life 
cycle, as well as on disease states, in a very balanced way.
Since the development of the “antioxidant hypothesis,” which is based on the 
assumption that oxidation in the body has deleterious effects on health, and thus 
subsequent antioxidant intake may prove beneficial, numerous studies have been car-
ried out to test this hypothesis. After decades of scientific output, this area remains 
controversial. This book systematically explores these controversies and provides 
answers to key questions.
The book aims to critically review and synthesize the latest evidence-based find-
ings in this area, and subsequently inform health professionals, such as physicians, 
dietitians, nutritionists, and nurses, and additionally biochemists, policy makers, and 
the general audience about the true role of antioxidants in health and disease. It 
disentangles myths from facts associated with antioxidant intake and further pro-
vides practical advice about recommended intakes whether from diet, supplements, 
or both.
The book is divided into three major sections. In Section I, mechanisms of action 
and major food sources are given. In Section II, the role of antioxidants in different 
stages of the life cycle is explored. Finally, in Section III, the effect of dietary anti-
oxidants and/or antioxidant supplementation on the prevention and the treatment of 
various diseases are investigated.
In Chapter 1, the way by which reactive oxygen species are formed and regulated 
is presented. As stated, free radicals are not always harmful, and mechanisms to 
maintain a balance between essential functions and potential pathologies are out-
lined in this chapter.
In Chapter 2, the major natural antioxidants are classified and their distribution 
in food sources is presented. The major antioxidants presented include phenols and 
polyphenols, carotenoids, and essential oils, while major food sources are fruits, 
grapes and wine, vegetables, herbs, olive, and olive oil.
In Chapter 3, the implications of oxidative stress in pregnancy are explored. This 
chapter also reviews the most recent evidence available regarding the clinical poten-
tial of antioxidants in preventing some common and serious conditions in pregnancy.
Chapter 4 initially explores the effects of oxidative stress on children’s health. 
Then, a very balanced overview of the effects of antioxidants on various conditions 
during childhood is given, such as their effects on growth, physical and cognitive 
performance, treatment of deficiencies, and asthma and allergies.
Chapter 5 explores the needs of adults and the elderly in antioxidants. Owing to 
population aging, especially in westernized societies, and more people reaching the 
ages of 70, 80, or even 90 years, the possible effects of antioxidants on diseases such 
as cataract and Alzheimer’s are of great interest.
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Chapter 6 explores the mechanisms involved in the increased oxidative stress 
in people who smoke. It also gives an overview on the prevention and treatment 
of diseases caused by smoking, relying on a combined application of antioxidants, 
substitution of important factors for human oxidant defense, and metal-detoxifying 
agents.
Chapter 7 discusses the role of endogenous and exogenous antioxidants on physi-
cal exercise and human performance. More specifically, it focuses on the need for, as 
well as the advantages and disadvantages of, antioxidant supplements for the physi-
cally active population and gives a special emphasis on thiol antioxidants, which 
play a key role in cellular redox regulation.
Chapter 8 initially gives a brief overview of the potential relationship between 
oxidation and the development of cardiovascular diseases, namely coronary heart 
disease and stroke. Then, data on the effects of antioxidants on risk factors and on 
end points of the diseases are presented.
Diabetes is a disease where increased oxidative stress is present. Chapter 9 explores 
mechanisms that contribute to increased oxidative stress in diabetic patients, and it 
also gives an overview of the antioxidant effects on the disease and the controversies 
related to antioxidant supplements.
Chapter 10 initially gives an overview of the effects of free radicals on cancer 
development. Then it gives, in extensive detail, the impact and the controversies of 
antioxidant intake through dietary sources or supplementation on cancer prevention 
and on the treatment of some types of cancer.
Chapter 11 explores the influence of antioxidants on neurodegenerative diseases. 
It explores mechanisms and gives data from interventions with more specific focus 
on the thioredoxin protein family (Trxs).
Chapter 12 provides an overview on the role of oxidative stress in the pathogen-
esis of inflammation-based gastrointestinal tract diseases, namely celiac disease and 
inflammatory bowel diseases, as well as the potential role of antioxidants in their 
prevention and treatment.
Oxidative stress is one of the unifying mechanisms underlying the development 
of obesity-related comorbidities, mainly type 2 diabetes and cardiovascular diseases. 
Chapter 13 explores the multiple contributing factors that may promote increased 
oxidative stress in obesity, including hyperglycemia, hyperleptinemia, increased 
tissue lipid availability that leads to lipotoxicity, inadequate antioxidant capacity, 
and chronic subclinical inflammation. It also gives a very balanced overview of the 
effects of antioxidants on oxidative stress in obese patients.
During immune response, activated immunocompetent cells produce large 
amounts of reactive oxygen species and reactive nitrogen species as a defense strat-
egy. Chapter 14 focuses on the interference of antioxidants with the immune re sponse, 
and discusses the possible consequences of unconsidered high-dose  anti oxidant 
supplementation.
Chapter 15 discusses controversies regarding antioxidant supplementation on 
HIV/AIDS patients.
Finally, Chapter 16 explores the role of herbs. The chapter argues that although 
spices are typically consumed at relatively low levels, some data indicate that spices 
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are in fact a very concentrated source of antioxidants and may provide a meaningful 
level of antioxidant activity if consumed at higher levels.
We hope that this book will provide all the valuable information to unravel cur-
rent myths and straighten out facts associated with antioxidant intake, and that any 






It was some years ago when Ira Wolinsky approached me and enquired whether I 
would be interested in editing a book on antioxidants. It is obvious that this field 
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This chapter provides basic information and background to set the stage for the sub-
sequent chapters that address health or disease conditions in which reactive oxygen 
species (ROS) and oxidant stress play important roles. The major forms of ROS are 
described along with mechanisms that account for their production. Strictly defined, 
ROS include chemically reactive oxygen ions and peroxides. Abnormally high levels 
of ROS initiate reactions that structurally alter important molecules, such as DNA, 
RNA, proteins, and lipids, particularly lipids comprising cellular membranes [1,2]. 
Such events contribute to a number of pathological conditions. Ischemic muscle 
damage, desynchronies in growth due to excessive apoptosis, necrosis, inflamma-
tion, and insulin resistance are examples.
Despite their destructive potential, however, ROS also play essential roles in cell 
turnover and replacement (e.g., apoptosis or programmed cell death), as second-
ary messengers in a variety of cellular processes and as catalyst in the modulation 
of protein structure, host defense mechanisms, wound repair, chemotaxis, and the 
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mobilization of cellular transport systems [2,3]. Whether ROS serve as healthful 
biological agents or initiate oxidative damage depends on the delicate equilibrium 
between ROS production and their scavenging.
A free radical is an atom or molecule that contains unpaired electrons and main-
tains an independent existence. Free radicals can have positive, negative, or neutral 
charges. In most instances, free radicals initiate a change in other atoms or molecules 
by abstracting a hydrogen atom from C–H, N–H, or O–H bonds within biomol-
ecules or an electron from a metal or metal complex capable of catalyzing oxidation/
reduction (redox) reactions [2]. In simple reactions, there may be only a change in 
a given redox state of the targeted molecule. However, if the free radical does not 
reattach to the redox molecule or another molecule that can act as a free radical 
acceptor (e.g., an antioxidant), such reactions can become potentially harmful. The 
descriptions that follow outline the mechanisms important to maintaining the bal-
ance between essential functions and potential pathologies.
some oxygen chemIstry BasIcs
Oxygen is the third most abundant element in the universe and constitutes 20.8% of 
the volume of air [4,5]. In most compounds containing oxygen, the oxidation state of 
oxygen is −2. An oxidation state of −1 is found in peroxides. From an evolutionary 
perspective, the dominant forms of early life on Earth were anaerobic organisms 
until oxygen began to accumulate in the atmosphere. The accumulation of atmo-
spheric oxygen started about 2.5 billion years ago, and the first aerobic organisms 
followed about a billion years later [5].
Oxygen is an unusual element in several ways. For example, at temperatures com-
patible with life, molecular oxygen exists in a triplet state, whereas almost all mole-
cules encountered in daily life exist in a singlet state. Triplet oxygen (not to be confused 
with the oxygen allotrope ozone, O3) is the ground state for dioxygen, O2. Oxygen in 
the triplet state needs to transition into a singlet state before chemical reactions can 
more easily occur (Figure 1.1). The need for such transitions makes the vast bulk of 
atmospheric oxygen kinetically nonreactive on a relative scale despite being a strong 
oxidant from a thermodynamic perspective. For example, although dioxygen is not a 
highly reactive molecule, its two unpaired electrons give it free radical character. There 
are also other allotropic states of oxygen ranging from molecular oxygen (O2), the most 
familiar form, to highly reactive ozone (O3) and oxygen in several solid states [1–5].
The electron configuration of ground-state oxygen has two unpaired electrons 
occupying two degenerate molecular orbitals, i.e., orbitals that have different quan-
tum states but the same energy level [2,4]. Degenerate orbitals are antibonding, which 
prevents molecular oxygen from reacting directly or readily with other molecules.
Ground-state oxygen (O2): common representations of electron distributions
 σ1s│σ°1s│σ2s│σ°2s│σ2p│π2p│π°2p 
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To iterate, O2 in its ground state can absorb energy and be transformed into the 
more reactive singlet oxygen (Figure 1.1). This achieves the goal of producing a 
molecule in which there is the same number of electrons but with a pair of outer elec-
trons that have antiparallel spin. When this occurs, one of the electrons can poten-
tially jump to an empty orbital, creating an unpaired electron. Singlet oxygen is not 
a radical, but is more reactive than dioxygen, because it can react with atoms with 
outer shell electrons in either spin direction. In this regard, singlet oxygen violates 
Hund’s rule, which states that every orbital in an atom’s subshell is singly occupied 
with one electron before any one orbital is doubly occupied, and all electrons in 
singly occupied orbitals have the same spin. Singlet oxygen has eight outer electrons 
existing in pairs, leaving one orbital of the same energy level empty [2,5].
In nature, singlet oxygen is formed from water during photosynthesis, using the 
energy of sunlight [5,6]. It can also be produced in the troposphere by the photolysis 
of ozone O ultraviolet light O O3 2+ → +( ) , and in mammalian systems by reactions 
that occur in cells of the immune system (also cf. comments related to HOCl in 
“Types of O2-Derived ROS”).

















































FIgure 1.1 ROS are generated as by-products and intermediates from many types of oxi-
dation reactions. Some relationships between oxygen in the triplet state and major forms of 
ROS are given. Triplet oxygen (3O2) has two unpaired electrons occupying two degenerate 
molecular orbitals, which are antibonding. However, triplet oxygen can be transformed into 
several forms of singlet oxygen, which contains paired electrons, and with the addition of an 
electron, the superoxide anion radical. Singlet oxygen is more reactive than triplet oxygen. 
Various ROS may then be formed from singlet oxygen and superoxide in steps involving one 
electron and/or one or two H+ transfers. In the Lewis structures corresponding to a given form 
of oxygen, the electrons that have “free radical” potential are designated with small open 
circles (◦) and arrows represent potential spin states.
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Another oxygen species that can be formed from ground-state oxygen is superox-
ide anion [1,2,4,7]. Superoxide anion is formed from the one-electron reduction of 
dioxygen and exists as a negatively charged free radical of oxygen. The systematic 
name of the anion is dioxide−1. One electron reduction of the ground-state molecular 
oxygen gives rise to superoxide anion radical O2
−( ) .
Superoxide anion radicals undergo another one-electron reduction to yield hydro-
gen peroxide (H2O2, cf. “Types of O2-Derived ROS”; Figure 1.1). In spite of its des-
ignation as a superoxide, superoxide anion has a relatively low reduction potential 
(Table 1.1), and as a consequence is not a strong oxidizing agent. Nevertheless, 
taBLe 1.1
standard reduction Potentials for ros redox couples and relative rate 
constants for selected ros







H2O2, H+/H2O, OH• +320
Ascorbate−•, H+/ascorbate +282
CoQH•, H+/CoQH2 (ubiquinol) +200
Cu2+/Cu1+ +150
Fe3+/Fe2+ (aqueous) +110
CoQ (ubiquinone), H+/CoQH• −40
Dehydroascorbate/dehydroascorbate−• −170







relative half-Lives of reactive oxygen species
Hydroxyl radical 10−9 seconds (s)
Alkoxyl radical 10−6 s
Singlet oxygen 10−5 s
Peroxyl radical 1–10 s
Nitric oxide radical 1–10 s
Semiquinones Days
Hydrogen peroxide (aqueous solutions, pH ~7) Minutes to days
Superoxide anion radical Seconds to minutes
Source: Sies, H., Eur. J. Biochem., 215, 213, 1993.
Note: The half-lives of ROS markedly differ, which underscores the need for different types of defense 
mechanisms.
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because of its ability to reduce transition metals capable of reduction, such as iron 
and copper, and act as a precursor to compounds, such as H2O2, it is clearly a major 
facilitator of free radical reactions (cf. “Production and Types of O2-Derived ROS”).
Superoxide anion radical: common representations of electron distributions 
representations
 σ1s│σ°1s│σ2s│σ°2s│σ2p│π2p│π°2p 
ProductIon and tyPes oF o2-derIVed ros
ROS PROductiOn
ROS are not an entity, but a group of compounds, each with distinct features. 
Accordingly, ROS can be produced by multiple chemical, physical, and biological 
mechanisms. Numerous examples are developed in subsequent chapters that range 
from pollutants, tobacco smoke, excessive drug or xenobiotic exposure, to radiation 
exposure. With respect to cellular metabolism, from 2% to 4% of the total oxygen 
during both rest and exercise can be potentially converted to some type of ROS 
(Refs. [1–4]; also cf. Chapters 4, 5, and 7). This amounts to ~0.44–0.9 mol of ROS 
equivalents generated per day for a person weighing ~70 kg and consuming 500 liters 
of O2, i.e., equivalent to an energy expenditure of ~2500 kcal  or  ~10.5  MJ/day 
[8]. ROS production is particularly associated with metabolic processes that take 
place within  mitochondria, peroxisomes, and the endoplasmic reticulum (ER) 
(Figure 1.2):
•	 In mitochondria, high rates of ATP production are often associated with 
increased levels of ROS as a result of the superoxide radical generation 
associated with the increase in oxygen flux through the mitochondrial 
respiratory complex [9,10]—an increase that can be dissipated in part by 
uncoupling electron transport from ATP synthesis. Uncoupling proteins 
(UCPs), located in the mitochondrial inner membrane, dissipate mitochon-
drial proton gradients before they can be used to provide the energy for 
oxidative phosphorylation leading to ATP generation [10]. Although the 
major function of UCPs is heat regulation, UCPs also help modulate mito-
chondrial ROS levels (Figure 1.3).
•	 In peroxisomes, an organelle designed for branched and long-chain fatty 
acid and d-amino acid oxidations, ROS are produced predominantly by the 
actions of various oxidases. As an example, the first step in the oxidation of 
fatty acids is catalyzed by the enzyme acyl-CoA oxidase, which results in 
H2O2 and a dehydroacyl moiety:
 Acyl-CoA + O2 → trans-2,3-dehydroacyl-CoA + H2O2
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•	 In the ER, particularly the smooth ER, numerous reactions occur that in -
volve oxidases and oxygenases. The smooth ER is important to the synthesis, 
catabolism, or modification of complex lipids, phospholipids, and steroids 
not metabolized directly by peroxisomes or mitochondria. The smooth ER 
is also essential for detoxification and the modification of xenobiotics (for-
eign chemical substances found within an organism that are not normally 
produced by the organism, e.g., drugs and food-derived pigments). Families 































































FIgure 1.2 ROS generation and regulation. Oxidative stress is the balance between events 
that are important to the control of ROS synthesis versus catabolism. Cellular regulation of 
ROS is organized at several levels and involves expression of enzymes and proteins involved 
in both ROS generation and catabolism. The reactions occur predominantly in the ER, mito-
chondria, and peroxisomes. Many small molecules are also involved in acting as antioxidants 
and reductants (e.g., ascorbic acid, reduced glutathione, NADPH, thioredoxins, vitamin E, 
and carotenoids). Apolar antioxidants, such as vitamin E or carotenoids, are localized in cel-
lular and organelle membranes. External factors, such as chemical and ultraviolet radiation, 
can also be important to ROS generation. Not shown is the contribution of dietary antioxi-
dants, which can serve as an important defense to excessive generation of ROS. The need 
for a balance relates in large degree to the important roles ROS play in cellular signaling 
and defenses that require strong oxidants (e.g., inflammation caused by foreign substances). 
Cellular signaling involves recognition by receptors that are linked to pathways important 
to generating protein kinase cascades or expression of transcription factors that control the 
enzymes involved in ROS production (synthesis/catabolism).
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[D]ioxygenases, Cyt P450) modify toxins and useful secondary metabolites 
to facilitate their partitioning into pathways for further transport or eventual 
elimination [11]. Oxygen is a co-substrate for many of the reactions carried 
out by such enzymes. Superoxide radicals are produced when the flow of 
electrons from the respective substrates for a given Cyt P450 to the reac-
tion intermediates to the final products is compromised. Moreover, reduced 
glutathione (GSH) is used as a co-substrate for some of the modifications in 
the smooth ER. In situations where glutathione is used faster than it can be 
resynthesized, one result is reduced levels of GSH for antioxidant enzymes, 
such as glutathione peroxidase that use GSH as a reductant [12].
As an additional point, regardless of the process involved, changes in pH, tem-
perature, the presence of sequestrants or inhibitors, and the polarity of the environ-
ment are noteworthy as factors important to free radical formation and stability. For 
example, the dielectric constant of the cellular environment can have a significant 
influence on the rates of free radical reactions [12]. The dielectric constant is a mea-
sure of solvent polarity and its ability to reduce the field strength of an electric field 
surrounding a charged particle. Solvents most often encountered in biology have 
dielectric constants >15; at <15, a solvent is usually defined as nonpolar. For perspec-
tive, superoxide radical generated from redox cycling systems (e.g., the repetitive 
coupling of a given reduction and subsequent oxidation reactions) can vary several 
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FIgure 1.3 Relationships between H+ flux, ATP synthase, and uncoupling protein com-
plexes in mitochondria. In mitochondria, there is balance between the respiratory system, 
ATP synthase (for work-related functions), and the UCP complexes (for control of heat regula-
tion). In part, this is achieved by regulating the H+ concentrations in the compartments defined 
by the outer and inner mitochondrial membranes. The presence of protons in the intermem-
brane space together with the difference in membrane potential between this space and the 
mitochondrial matrix is a driving force for the conversion of ADP to ATP. Furthermore, an 
increase in ATP levels can slow mitochondrial respiration, owing to the ability of ATP to 
regulate the phosphorylation of ADP by ATP synthase. In this regard, uncoupling the proton 
flux is an adaptive way to avoid excessive inhibition of mitochondrial respiration. Uncoupling 
the proton flux from ATP synthase also helps buffer ROS production by controlling the rate 
of respiration. As an additional control, when the rates of respiration and substrate oxidation 
are high, O2
− production increases. The increase in O2
− levels activates UCPs. This is another 
important control in that it occurs when the dismutation of O2
− is insufficient to avoid ROS-
related damage to mitochondria. (From Ricquier, D, Proc. Nutr. Soc., 64, 47, 2005.)
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orders of magnitude when the reaction is examined in water (dielectric constant, ~70) 
versus in alcohol (dielectric constant, ~25) or in lipid micelles.
Such medium effects, however, are never simple. This is particularly true when 
addressing questions related to free radical centers located in biological macromol-
ecules such as DNA, a lipid membrane, or a given protein. The hydration sheath 
asso ciated with such complex molecules can have dielectric properties that are 
quite different from bulk water or a mixture of protonic versus aprotonic solvents. 
Accordingly, as a general admonition, predictions of biological responses related to 
free radical– mediated phenomena derived from simple systems, although helpful for 
hypothesis generation, may not be universal or straightforward.
tyPeS Of O2-deRived ROS
hydrogen Peroxide
H2O2 is not a free radical and is freely permeable across cell membranes. Analogous 
to its precursor, superoxide anion radical, in its radical form, it is also less reactive 
than other ROS and compounds capable of oxidation or initiation of free radical 
cascades (Table 1.1, Ref. [13]):
 O e H H O HOO H2 2 22
− + ++ + → → +   
From a chemical and biological perspective, this has some advantages. It is well 
appreciated that within cellular membranes, carbon chains associated with membrane 
lipids are major sites of oxidative damage. In lipids containing unsaturated, nonconju-
gated carbon chains, the hydrogen associated with the carbon not involved in π-bonding 
(–CH=CH–C[H2]–CH=CH–) is more easily abstracted than hydrogens associated with 
π-bonded carbons in conjugated carbon chains or completely saturated carbon chains. 
The resulting radical (–CH=CH–CH•–CH=CH–) is highly reactive and can lead to the 
formation of other radicals or cause isomerization and polymerization. In the presence 
of O2, a likely free radical product of a nonconjugated lipid is lipid peroxide:
 –CH=CH–CH•–CH=CH– + O2 → –CH=CH–CHOO•–CH=CH–
Reactions initiated by ROS that result in free radicals as products are called chain 
reactions because the product may also serve as reactant, thereby creating a chain of 
events that only stops when the reagents are used up or blocked by antioxidants. In 
this regard, as a consequence of being a slower-reacting free radical, lipid peroxides 
are more easily controlled and quenched in the presence of antioxidants. O2 may 
even be viewed as an important free radical modulator in this context.
Whether H2O2 is going to act as a potentially useful versus destructive chemical 
often depends on its concentration in a given tissue. All aerobic organisms studied 
to date from prokaryotes to humans appear to tightly regulate their intracellular 
H2O2 concentrations at relatively similar levels. H2O2 concentrations range from 
~0.001 μM to as high as ~0.1 μM during peak periods of H2O2 generation. In mito-
chondria, it is estimated that the steady-state level of H2O2 is ~0.04 μM [14,15].
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At controlled and low concentrations, H2O2 is involved in oxidative reactions 
important to (i) the regulation of protein function by altering structure via the modi-
fication of critical amino acid residues, (ii) cell signaling, (iii) thyroxin production, 
and a number of cellular and organismal defense systems [14,15]. Examples related 
to important protein modifications include the oxidation of cysteinyl residues to form 
sulfenic (–SOH), sulfinic (–SO2H), sulfonic (–SO3H), or S-glutathionylated (–SSG) 
derivatives. Such reactions can result in protein dimerization or modification of Fe–S 
moieties or other metal complexes at the active sites of certain enzymes [16,17]. As 
noted, thyroxin formation (particularly iodination of tyrosyl residues in thyroglobu-
lin) also requires H2O2 generation. Moreover, H2O2 is required for the oxidation of 
tyrosine residues, and, in some proteins, is essential for their cross-linking to form 
active dimers, oligomers, and even polymers.
Hydrogen peroxide is also important to cell signaling. A number of kinase-driven 
pathways important to cell proliferation, migration, survival, and autophagy depend 
on H2O2, which aids in catalyzing changes in the redox state of given kinases [13–15]. 
H2O2 is also essential in phagocytic processes by cells such as neutrophils, monocytes, 
macrophages, dendritic cells, and mast cells, i.e., cells that are critical in fighting 
infections, as well as removing dead and dying cells that have reached the end of their 
lifespan [13–15]. Compounds with well-defined roles are usually highly regulated 
either through control of synthesis and catabolism (Figure 1.2); H2O2 is no exception.
With regard to synthesis, H2O2 is generated from the spontaneous or enzyme-
catalyzed dismutation (simultaneous oxidation and reduction) of superoxide anion or 
enzymes that catalyze the electron reduction of molecular oxygen (e.g., xanthine oxi-
dase; Refs. [1–4]). Furthermore, as noted previously, inefficient metabolism by cyto-
chrome P450 enzymes in the smooth ER or oxidases associated with peroxisomes is 
often associated with the production of superoxide radical or excessive amounts of 
hydrogen peroxide [1–4]. Other cellular sources of hydrogen peroxide are NADPH 
oxidase [1–4,18], which is found in all major classes of phagocytic cells. A general 
scheme for the NADPH oxidase reaction is
 NADPH O NADP O H+ ↔ + ++ − +2 22 2

 
The production of superoxide anion by NADPH (nicotinamide adenine dinucleo-
tide phosphate) oxidase and the eventual production of hydrogen peroxide by super-
oxide dismutase (SOD) serve as good examples of the complexity of H2O2 regulation 
[18]. NADPH oxidase is a membrane-bound enzyme complex found in the cellular 
plasma membrane as well as in the membranes of phagosomes used by neutrophils. 
The production of superoxide anion by NADPH oxidase is commonly referred to as 
the oxidative or respiratory burst reaction. There is first rapid generation of superox-
ide anion. Next, in the presence of the enzyme SOD, which is found in high concen-
trations in both the cytosol and mitochondria of cells, superoxide anion is converted 
to hydrogen peroxide [1–4]:





where M = Cu (n = 1), Mn (n = 2), Fe (n = 2), and Ni (n = 2).
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Owing to the need for a high level of control, both the activities of SOD and 
NADPH oxidase are controlled by a number of regulatory strategies at the cellular 
and organismal levels. As examples, NADPH oxidase activity is controlled both by 
the transcriptional regulation of NADPH oxidase complex components as well as 
factors that control their rates of assembly [18]. Moreover, depending on the meta-
bolic need or function, the number of agents may stimulate assembly or act as acti-
vators, such as growth factors and cytokines (platelet-activating factor, interleukin 
[IL]-8), various physical stimuli, ATP, and N-formylated peptides. This suggests that 
H2O2 production is linked to processes that use a number of differing cellular sig-
nals depending on the metabolic function that is needed. There are also a number of 
well-controlled events that extend from the activation of the NADPH oxidase com-
plex at the cell surface. For example, NADPH oxidase activation is followed by the 
hydrolysis of membrane-associated phosphatidylinositol bisphosphate, which results 
in an increase in the levels of inositol trisphosphate (inositol 1,4,5-trisphosphate) 
and diacylglycerol [18]. These molecules, in turn, promote the opening of calcium 
channels, and the combination of diacylglycerol and calcium causes the activation 
of protein kinase C. Many other cell signaling factors are also involved, such as 
Rac, a transcription factor associated with the Rho family of “G-protein” GTPases. 
G proteins act as molecular switches and play roles in cellular events ranging from 
organelle development, cytoskeletal dynamics, and cell movement.
Regarding SOD, there are three major families of SOD, each requiring specific 
metal cofactors: (i) Cu/Zn (the cytosolic form); (ii) Fe and Mn types (the mito-
chondrial form); and (iii) the Ni type, which is found mostly in prokaryotes [19]. 
SOD overcomes the potentially damaging reactions of superoxide by catalyzing its 
dismutation. Dietary deficiencies of dietary copper and manganese can influence 
SOD activity [19]. SOD activity is lower and superoxide anion concentrations are 
higher in Cu-deficient animal models, which can be accompanied by malformations 
and ROS-related developmental defects. In mitochondria, SOD upregulation has 
been associated with the extension of lifespan, using invertebrates and arthropods 
as experimental models [19]. In this regard, whenever there is complex cellular 
regulation of molecules, the reasons often center on maintaining plasticity. Owing 
to the both healthful and potentially deleterious effects of oxidants, regulation must 
have features that address both specificity and safety, particularly when there are 
opportunities for nonspecific or deleterious modifications to normal cell signaling 
function.
hydroxyl radicals
Hydroxyl radicals are produced from the decomposition of hydrogen peroxides 
(often as the result of Fenton-type reactions or photolysis) or water (as a result of 
radiolysis). In the Fenton reaction, transition elements are usually used as catalysts 
[1–4,20] if they are capable of engaging in redox cycling reactions. For example, the 
addition of metals such as iron and copper (most often encountered in biology) to 
a solution containing hydrogen peroxide can result in the following reactions with 
hydroxyl radical and peroxyl radical as products:
 Mn + H2O2 → Mn+1 + HO• + OH−
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 Mn+1 + H2O2 → Mn + HOO• + H+
In cells, these reactions are modulated by the presence of proteins such as ferritin 
(binds iron) and metallothionein (binds Cu, Zn, and Cd). An important observation is 
that metal-binding proteins keep the concentrations of many redox transition metals 
(e.g., Cu or Fe) at extremely low levels. For example, it has been calculated that the 
concentration of free copper in cells is maintained at less than one atom per cell [21], 
thereby assuring that the probability of nonspecific interactions with OH• remains low.
Exposure of H2O2 to ultraviolet light can also cause the homolytic cleavage of 
hydrogen peroxide to yield hydroxyl radicals; in particular, ultraviolet light as a form 
of electromagnetic radiation (i.e., between 400 and 10 nm, corresponding to photon 
energies from 3 to 124 eV). In a homolytic cleavage of a chemical bond, each frag-
ment retains one of the original electrons involved in bonding; that is, the exposed 
electrons are distributed equally within the two resulting fragments [1–4,20]:
 H2O2 → HO• + HO•
Water, in the presence of alpha radiation, dissociates into hydrogen and hydroxyl 
radicals:
 H2O → H• + HO•
Regardless of the process, the hydroxyl radicals that are produced have high 
reduction potentials and rapid rates of reaction (Table 1.1). In this regard, the rates 
of reactions are very near the diffusion limit; that is, the reactions take place at sites 
where hydroxyl radicals are generated. Hydroxyl radicals also react nonselectively 
and are probably the most responsible for the injury induced by ionizing radiation 
or when tissues are exposed to excessive levels of H2O2. Furthermore, unlike super-
oxide, which can be detoxified by SOD, the hydroxyl radical cannot be eliminated 
by an enzymatic reaction [20]. Accordingly, hydroxyl radicals are the most reactive 
of the known ROS.
Peroxynitrite
The free radical nitric oxide (NO) is an essential endothelial-derived relaxing factor 
and powerful vasodilator [22]. Low nanomolar concentrations of NO activate gua-
nylyl cyclase to produce cGMP. The production of NO is derived from arginine by a 
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There are several forms of NOS. The endothelial isoform (eNOS) is the primary 
signal generator of NO in the control of vascular tone. It is also involved in the regu-
lation of insulin secretion, cardiac function, and angiogenesis. The neuronal isoform 
(nNOS) is involved in the regulation and development of the nervous system. There 
is also an inducible isoform (iNOS) that is capable of producing large amounts of 
NO. NO is synthesized in response to inflammatory cytokines in phagocytic cells 
(monocytes, macrophages, and neutrophils) and is important to defense against para-
sites, infections, and even tumor growth. At high levels of NO (usually the result of 
iNOS activation), there is reduced mitochondrial activity [22]. As a consequence, 
there can be an increase in tissue oxygen saturation, followed by increases in super-
oxide anion radical, hydrogen peroxide, and NO levels [22].
Such conditions can lead to the formation of peroxynitrite via a reaction in which 
superoxide reacts rapidly with NO to form peroxynitrite anion (ONOO−):
 i i ∼NO O ONOO rate constant+ →− −2
1010( , )k  
Peroxynitrite is a very strong oxidizing and nitrating agent. Although not a 
free radical, peroxynitrite is much more reactive than superoxide and NO; accord-
ingly, peroxynitrite can damage a wide array of molecules in cells. Peroxynitrite 
can react with CO2 to form nitrosoperoxycarbonate ONOOCO2
−( ). Potentially 
 damaging effects  in  cells may result from the decomposition to ONOOCO2
−, 
which yields carbonate CO3
( ) and nitrogen dioxide radicals N O+ −( )2 . Such radi-
cals can react with tyro sine to form phenoxy radical intermediates that can initiate 
free radical chain reactions.
hypochlorous acid (hocl) and myeloperoxidase
HOCl is synthesized largely by the action of myeloperoxidase in phagocytic cells (e.g., 
mostly neutrophils) using H2O2 and chloride anion as substrates [23]. Myeloperoxidase 
is expressed as a part of the respiratory burst reaction. Myeloperoxidase can also oxi-
dize tyrosine to tyrosyl radical using hydrogen peroxide as an oxidizing agent:
 H2O2 + Cl− → HOCl + OH−
The reaction of HOCl with superoxide radical produces hydroxyl radical (A) and 
with H2O2 produces singlet oxygen (B):
 ( )A HOCl O O Cl HO+ → + +− −2 2
 
 
 ( )B HOCl H O O H O HCl+ → + +2 2 2
1
2  
In addition, hypochlorous acid can be the precursor of potent oxidizing species 
that react with proteins, lipids, nucleic acids, and carbohydrates and even foreign 
substances (e.g., inhaled particles, molds, and dust). In this regard, HOCl plays an 
integral part in the innate or nonspecific immune defense system designed to kill 
15Reactive Oxygen Species
microorganisms or destroy substances that may lead to more serious cell and tissue 
injury [23]. However, as with other oxidants, when in excess, HOCl can be toxic. 
Moreover, the amount of HOCl required for toxicity is markedly lower than the 
concentrations of H2O2 needed to destroy otherwise healthy cells. HOCl can cause 
an irreversible loss of intracellular GSH, an essential reductant in cells, and is more 
likely to oxidize thiol groups in proteins than H2O2 [24]. Glutathione is only replaced 
by resynthesis.
singlet oxygen and ozone
The reaction of ozone with a number of biological molecules produces singlet oxy-
gen in high yield. In turn, singlet oxygen is an important intermediate in the bio-
chemical damage attributed to ozone exposure. Both can be produced in vivo by 
reactions and processes associated with inflammation and, analogous to the other 
ROS, play both healthful and potentially damaging effects in biological systems. 
A number of consequences of the interactions between ROS and inflammation are 
described in the chapters focusing on gastrointestinal disorders (cf. Chapters 12 
through 15).
Singlet Oxygen
In plants, singlet oxygen is produced during the process of photosynthesis [6]. In 
animals, singlet oxygen is often associated with lipoprotein oxidation and skin pho-
tosensitivity. Singlet oxygen reacts with many kinds of biological molecules, par-
ticularly reactions that often involve carbon–carbon double bonds. Singlet oxygen 
is a powerful electrophile. Schenck-ene reactions and Diels–Alder reactions are 
examples [25]. The addition of singlet oxygen to an ene-containing molecule, such 
as a polyunsaturated fatty acid, often results in a peroxide adduct, which can result in 






In nature, atmospheric ozone is formed from dioxygen by the action of ultraviolet 
light and electrical discharges. Typical ozone concentrations found in the natural 
atmosphere range from 0.001 to 0.125 ppm. The levels of concentration vary with 
altitude, atmospheric conditions, and locale [1–4,26].
In animals, compounds with the chemical signatures of ozone are produced as a 
product of innate immune reactions; more specifically, the intrinsic ability of anti-
bodies to generate hydrogen peroxide from singlet oxygen via the so-called antibody-
catalyzed water oxidation pathway [27,28]. The process is independent of antigenic 
specificity and is triggered upon binding of 1O2 to conserved (specific) binding sites 
within the antibody’s structure:
 x xO H O H O O2
1
2 2 2 21 3+ → + −( )  
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Like other ROS, ozone also can play a role in combating foreign substances and 
bacteria [27,28]. For example, exposure to ozone triggers responses, such as secre-
tion of various cytokines, tumor necrosis factor, and γ-interferon. Given that ozone 
is highly reactive, it would be expected that at higher than normal levels, ozone’s 
interaction with biologically important molecules may lead to premature cell death 
and inflammation.
Epithelial cells lining the respiratory tract are the main target of ozone and its 
products. Moreover, epithelial cells in response to ozone exposure release a number 
of inflammatory mediators that may initiate events leading to pathologies related 
to small airway obstruction and decreased integrity of the airway epithelium (e.g., 
prostaglandin E2, IL-6 and IL-8, granulocyte-macrophage colony-stimulating fac-
tor, monocyte chemotactic protein-1, chemokine [ligand 5], which is also known as 
RANTES or “regulated on activation, normal T-cell expressed and secreted” protein 
[27,28]).
Regarding levels of ozone that are considered a hazard, the allowable limit in 
many countries (United States, United Kingdom, Japan, France, Netherlands, and 
Germany) is 0.1 ppm or less. In many industrial cities, levels of 0.15–0.51 ppm are 
often observed. High ozone levels usually occur in summer months and reach their 
peak in mid to late afternoon because of an increase in exhaust fumes from morn-
ing traffic and industrial activities. Exposures of 0.4-ppm ozone are often used in 
experimental animal studies to induce lung pathology. A 3-h exposure at 12 ppm is 
usually lethal for guinea pigs. Those exposed to 5–9 ppm ozone concentrations plus 
other air pollutants may be subject to major lung damage [26].
oxidative stress
The term “oxidative stress” is used to characterize an imbalance between the ROS 
concentration and the ability to detoxify excesses of ROS (production via synthesis 
and/or catabolic processes) and their reactive intermediates, or to facilitate the repair 
of ROS-mediated damage (Figure 1.2). Accordingly, cellular protection against the 
deleterious effects of ROS is organized at several levels (prevention, interception, 
and repair) [29–31]. Regulation involves both small molecules that act as antioxi-
dants and enzymatic strategies to control either the rate of synthesis or catabolism of 
potential oxidants or oxygen utilization.
As examples, H2O2 is catabolized by catalase (2H2O2 → 2H2O + O2) and various 
hydrogen peroxidases [32]. Catalase is found in most organisms exposed to oxygen. 
In particular, catalase has high catalytic capacity or turnover number, the maximum 
number of molecules of substrate that an enzyme can convert to product per catalytic 
site per unit of time. The value for catalase is 40 million s–1. However, the biological 
significance of catalase is not straightforward. For example, mice genetically engi-
neered without catalase remain phenotypically normal. In addition to catalase, thiol 
and selenol peroxidases are also important to H2O2 regulation. There are two main 
subfamilies: peroxiredoxins (Prx) and glutathione peroxidases.
The Prx are antioxidant enzymes that have thiol groups at their active centers and 
control peroxide levels that are mediated mostly by changes in cytokine levels [33]. 
Prx are regenerated by thioredoxins (Trx), small molecular weight redox proteins 
known to be present in all organisms [34]:
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 Prx(reduced) + H2O2 → Prx(oxidized) + 2H2O
 Prx(oxidized) + Trx(reduced) → Prx(reduced) + Trx(oxidized)
As a consequence, Prx are often important to cell signaling involving oxidant-
related processes and are relatively abundant in cells in which oxygen tension is 
high. Mammalian cells express six known Prx isoforms. The oxidized active-site 
cysteine in Prx can be reduced by cellular thiols, such as one of the Trx. Regulation 
of Prx can also occur through phosphorylation by kinases that respond to extracel-
lular cytokines and related cellular signals. Of additional importance, the oxidation 
state of the active-site cysteine of Prx can be transferred to other proteins that cannot 
effectively sense changes in peroxide concentrations.
Glutathione peroxidase is a selenium-containing enzyme [35]. Glutathione 
peroxidases are novel because instead of sulfhydryl moieties, they employ seleno 
moieties  at their active centers (R–SeH [red] or R–Se–Se–R [ox]). Glutathione 
peroxidase also catalyze both H2O2 and lipid peroxides to water or lipid alcohols, 
respectively:
 2GSH + H2O2 → GS–SG + 2H2O
where GSH represents reduced glutathione as substrate and G–S–S–G oxidized glu-
tathione as product. With regard to importance, similar to catalase knockout mice, 
mice genetically engineered to lack various isoforms of glutathione peroxidase or 
Prx only demonstrate modest phenotypic changes; however, they are more sensitive 
to certain exogenous sources of oxidative stress, such as hyperoxia.
Table 1.2 includes other proteins, enzymes, and examples of other molecules 
found in tissues that are involved in the control of ROS levels and related metabo-
lites. Although a discussion of each of the molecules that act as reductants or antioxi-
dants is beyond the scope of this chapter, it is important to appreciate that many of 
the enzymes involved in ROS regulation utilize these molecules as reductants [1–4]. 
As examples:
 1. Ascorbic acid is important in maintaining iron and copper in reduced states 
at the active sites of many oxidases and peroxidases [36].
 2. GSH, a tripeptide containing cysteine, is the principal reductant for gluta-
thione peroxidase [35].
 3. NADPH is essential as a cofactor for GSH regeneration from oxidized glu-
tathione (2GSH ←→ GS–SG) via glutathione reductase, and for oxygen-
ases and oxidases associated with the ER [35].
 4. Vitamin E and carotenoids are often referred to as the first lines of defense 
in cellular membranes and act to sequester HOO• radicals and retard reac-
tions involving singlet oxygen [37].
Also listed in Table 1.2 are a number of dietary antioxidants that putatively 
counter ROS damage by scavenging free radicals (Refs. [4,29–31,38–40]; also cf. 
Chapter 2).
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taBLe 1.2
substances and compounds with antioxidant activity
substance or compound ros target or Function
essential compounds (Vitamins) and related derivatives
Α-, β-, γ-, and δ-Tocopherols Lipid peroxide–initiated chain reaction breakers
β-Carotenes Singlet oxygen quencher
Lycopene Singlet oxygen quencher





Proteins and enzymes (Primary)
Superoxide dismutase Dismutation of superoxide anions
GSH peroxidases Reduce lipid hydroperoxides to their 
corresponding alcohols and reduce free hydrogen 
peroxide to water
Myeloperoxidase Controls hypochlorous acid production from 
hydrogen peroxide and chloride anion
Hydrogen peroxidases Converts hydrogen peroxide to water
Catalase Catalyzes the decomposition of hydrogen 
peroxide to water and oxygen 
Alpha-1-microglobulin Degrades heme and is a radical scavenger as well 
as a reductase
Proteins and enzymes (secondary)
Metal-binding proteins (e.g., metallothionein, 
chaperones, ceruloplasmin)
Sequestration, transport, and regulation of 
transition metals capable of redox
Cytochrome P450s Catalyzes phase 1 metabolism, most often 
characterized by the addition of –OH groups to 
nonpolar and/or aromatic compounds to facilitate 
transport or elimination
Conjugation enzymes (e.g., glutathione-S- and 
UDP-glucuronosyl-transferases)
Conjugate phase 1 Cyt P450 products to more 
polar compounds (phase II reactions) to facilitate 
transport, delivery, or elimination
NADPH quinone oxidoreductases Two electron reductions
GSSG reductase GSH regeneration
NADPH-generating enzymes NADPH production
DNA repair enzymes DNA repair




cOmmOn taRgetS Of the damaging effectS Of ROS
Carbohydrates, lipids, proteins, and nucleic acids (RNA and DNA) are all targets 
of ROS and their derived products [4]. Carbohydrates and lipids can be oxidized 
to carbonyl compounds. Such oxidation reactions can lead to the formation of the 
advanced glycation or lipoxidation end products (often abbreviated as AGEs/ALEs), 
rearrangement of double bonds, changes in conformation, and carbon chain cleavage 
leading to end products such as malondialdehyde [41]. When glucose is involved, 
the initial products are Schiff base products followed by Amadori rearrangements. 
A good example of an AGE is glycated hemoglobin (hemoglobin A1c), which cor-
relates with blood glucose levels [41].
Hours
Schiff baseGlucose + NH2-R





When proteins interact with ROS, additional responses may include (i) oxidative 
attack of the polypeptide backbone; (ii) peptide cleavage due to ROS attack of glutamyl, 
aspartyl, and prolyl side chains; (iii) oxidation of amino acid side chains; or (iv) cross-
linking or N-terminal modifications due to reactions with carbohydrate or lipid-derived 
carbonyls such as malondialdehyde. In this setting, the accumulation of damaged protein 
is dependent on the balance between prooxidant, antioxidant, and associated proteolytic 
taBLe 1.2 (contInued)
substances and compounds with antioxidant activity
substance or compound ros target or Function
diet-derived antioxidants/nutraceuticals
Polyphenol antioxidants (e.g., flavonoids, various 
flavones, flavanols such as catechins or 
epicatechins, flavanones, flavanols, isoflavone 
phytoestrogens such as daidzein and genistein, 
quercetin, rutin, resveratrol, pyrroloquinoline 
quinone, and hydroxytyrosol)
More than 4000 distinct species: many have 
antioxidant activity; others affect cell-to-cell 
signaling, receptor sensitivity, inflammatory 
enzyme activity, or gene regulation
Phenolic acids (e.g., cinnamic acid, caffeic acid, 
salicylic acid, and vanillin)
Redox cycling, general antioxidant activity
Carotenoid (e.g., lutein, zeaxanthin, carotenes) More than 600 known carotenoids in two classes: 
xanthophylls (which contain oxygen) and 
carotenes (which are hydrocarbons, and contain 
no oxygen); quench singlet oxygen
Lipoic acid Reducing agent, free radical scavenger
Selenium Co-factor for glutathione peroxidase
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activities [1–4,16,17,20,41]. When ROS interact with DNA, oxidation usually occurs at 
guanine residues due to the high oxidation potential of this base relative to cytosine, 
thymine, and adenine. DNA stand breaks occur with 8-oxoguanine (8-hydroxyguanine) 
as a measurable product in blood and urine [20]. Moreover, ROS can also randomly 
damage RNAs. Oxidation of mRNAs in vitro and in vivo can result in lower rates of 
mRNA translation efficiency and aberrant protein products [20].
FInaL PersPectIVes
Many compounds have gained acceptance as antioxidant supplements independent 
of their original dietary source (i.e., as nutraceuticals). Indeed, currently, one of the 
most active areas of nutrition-related research focuses on foods or food-derived com-
pounds with putative antioxidant potential (Refs. [38–43], cf. Table 1.2). Moreover, 
an additional dimension includes the products derived from such compounds and 
their potential interactions with the intestinal microbiota [44].
Although under most conditions, combinations of conventional nutrients with anti-
oxidant or reducing potential in addition to endogenous enzymes and their corre-
sponding co-factors appear sufficient to regulate of ROS levels, additional secondary 
metabolites and compounds, particularly those found in fruits and vegetables, are 
now viewed by many as not only having complimentary but also potentially indepen-
dent roles in oxidant defense [42]. Nevertheless, important caveats are in order when 
making claims about dietary antioxidants [43–47]. As examples, some claims are 
based on assays in vitro that measure antioxidant chemical potential and may have 
little relevance in vivo [47]. Furthermore, experimental studies using more diverse sets 
of experimental end points, rather than single end points, and clinical studies using 
larger pools of subjects, tend to demonstrate less benefit related to supplements than 
that proposed in many of the earlier preliminary studies (cf., Refs. [45,46]). It is also 
becoming increasingly apparent that ingestion of a complex food may set into motion 
dozens of cell signaling strategies and feedback loops that are likely not to occur with 
a single dietary supplement [38,39]. Moreover, many compounds (particularly poly-
phenols) with antioxidant potential at low concentrations can catalyze redox cycling 
and may cause free radical generation at higher concentrations [47,48]. With that said, 
however, the antioxidant potential of a number of natural compounds in foods remains 
to be a major factor in the correlation between ingestion of fruit- and vegetable-rich 
diets and the a reduction in pathological events that are influenced by free radicals.
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2 Major Dietary 
Antioxidants and 
Their Food Sources
Moschos Polissiou and Dimitra Daferera
IntroductIon
The plant kingdom boasts of a great number of species consumed by humans in 
various ways: fresh, dry, cooked, processed, or as decoctions. These are fruits, 
vegetables, herbs and spices, olive and olive oil, grapes and wines, and juices and 
beverages, which contain in their chemical composition more or less antioxidant 
compounds classified to structurally different categories. The quality and quantity 
of these naturally occurring compounds depend on a number of parameters, such as 
the plant material, plant part, development stage, seasonal variation, environmental 
conditions, geographic origin, genetic factors and evolution, dehydration procedure, 
storage conditions, cooking method, isolation techniques, and analytical methods 
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An antioxidant has been defined as “any substance that, when present at low con-
centrations compared to those of an oxidizable substrate, significantly delays or pre-
vents oxidation of that substrate” (Halliwell and Gutteridge 1995). Plant secondary 
metabolites have been the subject of research for many decades in order for their 
chemical structure to be characterized and their possible antioxidant effect to be 
attributed to this structure. In this chapter, the classification of these phytochemicals 
and their distribution in food sources is presented.
classIfIcatIon of natural antIoxIdants
Phenols and PolyPhenols
Phenols and polyphenols constitute one of the most numerous and widely distributed 
group of secondary metabolites in the plant kingdom. This group of compounds is 
characterized by the presence of at least one phenolic ring to their chemical struc-
ture, and is divided into subgroups that may differ significantly in stability, bioavail-
ability, and physiological functions in relation to human health (Tsao 2010). More 
than 8000 phenolic structures have been identified from various sources; among 
them, fruits, grains, vegetables, spices, herbs, wine, and decoctions are important 
(Boskou 2006, Tsao 2010).
simple Phenols
The most common simple phenols are thymol, carvacrol, and eugenol. The first two 
compounds are found in high amounts in the essential oils of many Lamiaceae spe-
cies belonging to the genus Origanum, Thymus, and Satureja, which display various 
biological activities. Tyrosol, hydroxytyrosol, and oleuropein are natural phenolics 
occurring in olive and olive oil. Along with tocopherols, other natural antioxidants 
contribute to the high nutritional value of olive oil. Tocopherols consist of a chroman 
ring and a long, saturated phytyl chain, and are found in nature in four homologs, 
namely α-, β-, γ-, and δ-tocopherol (Figure 2.2). They are lipophilic compounds and 
are present in all oilseeds.
Phenolic acids
Phenolic acids are usually found in plant tissues in the form of ester, salt, or gly-
cosides, constituting the aglycone part of the compound. The aglycone part can be 
liberated by acid or alkaline hydrolysis, or by enzymes. Free phenolic acids can be 
found in fruits and vegetables; however, in other plant tissues such as grains, seeds, 
and in herbs, they are usually present in bound form (Tsao 2010, Hossain et al. 
2010). Phenolic acids can be divided into two main categories, namely benzoic and 
cinnamic acid derivatives (Figure 2.1). The known representatives of benzoic acid 
derivatives in plants are p-hydroxybenzoic, vanillic, syringic, protocatechic, gallic, 
and salicylic acids. Among the cinnamic acid derivatives, also known as phenyl-
propanoids, ferulic, caffeic, p-coumaric, chlorogenic, and sinapic acids have been 
reported. Rosmarinic acid, an ester of caffeic acid and 3,4-dihydroxyphenylacetic 
acid, is an important naturally occurring phenolic bioactive compound found in 
important quantities in plants of the Lamiaceae family (Saltas et al. 2013).
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fIGure 2.1 Molecular structures of characteristic phenols and polyphenols found in natu-
ral sources.
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flavonoids
Flavonoids are the most abundant group of natural phenolic compounds for which 
>4000 molecules have been identified (Tsao 2010). According to their chemical 
structure, flavonoids can be distinguished into two main categories: the flavone 
derivatives and the anthocyanins. The most popular flavone derivatives are flavones, 
flavonoles, flavanones, flavanonols, isoflavones, chalcones, and flavanols (Figure 
2.1). They are usually found in food sources in the form of glycosides. The basic 
flavone structure is presented in Figure 2.1.
Flavones are considered to be the hydroxylated derivatives of this basic structure at 
positions 5 and 7, and one, two or three hydroxyls can be found at positions 3′, 4′, and 5′. A 
characteristic flavone compound is luteolin, including its glycosides, which are widely 
distributed in many plant families. Dietary sources of luteolin include herbs and spices 
such as oregano, rosemary, thyme, and pepper; vegetables such as carrots, celery, spin-
ach, lettuce, and parsley; and olive oil (Justesen 2000, Boskou 2006, Lopez-Lazaro 
2009, Cecchi et al. 2013). Luteolin 7-O-glycosides are the most frequently occurring; 
for example, cynaroside or luteolin 7-O-glucoside is found in artichoke (Lattanzio et 
al. 2009) and in aqueous infusion of dried sage leaves (Zimmermann et al. 2011).
Flavonols are the 3-hydroxy derivatives of flavones (Figure 2.1). Quercetin and 
kaempferol hold prominent positions among the studied flavonols, followed by 
myricetin. The literature has presented at least 279 and 348 different glycosidic 
combinations of quercetin and kaempferol, respectively (Tsao 2010). They are found 
in fruits as 3-O-glycosides mainly, and more rarely as 7-O-glycosides (Belitz et al. 
2009). Quercetin-3-O-glucoside is found in significant amounts in the berry skin of 
grapes and in the wine made from them, constituting 42.6% and 39.4% of the total 
flavonol content, respectively (Nisco et al. 2013). Quercetin and its glycosides have 
also been found in dill, cress, tarragon, and in several Lamiaceae plants such as 
rosemary, oregano, sage, basil, and thyme (Hossain et al. 2010, Miron et al. 2011).
Flavanones contain in their molecule the basic flavone structure with the lack of 
double bond at C3 (Figure 2.1). This subgroup of flavonoids is mainly presented in 
citrus species (Ghafar et al. 2010). Hesperetin and its glycoside hesperidin (hesp-7-
O-rutinoside) have been considered as the characteristic compounds of orange fruits. 
Naringenin and its glycosidic form, naringin, are found in the bark of grapefruit. 
Eriodictyol-7-O-rutinoside is one of the detected flavanones in lemon bark (Belitz et 
al. 2009). However, in fewer cases, the above-mentioned aglycones, alone or in com-
bination with the same or different sugar moieties, contribute to the phenolic content 
of lemon balm (Melissa officinalis), wild thyme (Thymus serpyllum), and oregano 
(Origanum vulgare) extracts (Dastmalchi et al. 2008, Miron et al. 2011). Flavanonols 
or dihydroflavonols are the 3-hydroxy derivatives of flavanones. Taxifolin is a famous 
flavanonol found in citrus fruits and fruits of Rosa canina and R. micrantha (Tsao 
2010, Guimarães et al. 2013).
Two other subgroups of flavonoids, closely related to the flavone structure, are 
isoflavones and chalcones (Figure 2.1). Isoflavones have the B ring attached to the 
C3 position of the C ring, and they are found in natural sources either in free or gly-
cosidic form. The food sources of isoflavones are mainly plants of the Leguminosae 
family, such as beans and soya (Tsao 2010). Studies presented daidzein, genistein, 
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and their β-glucosides conjugates as being >80% of the total determined isoflavones 
in soya milk (Toro-Funes et al. 2014). In chalcones, rings A and B are joined together 
by an unsaturated carbonyl system. They play an important role in the biosynthesis 
of flavonoids, as chalcone is enzymatically isomerized to a flavanone intermediate 
where all classes of flavonoids branch out (Tsao 2010). They have an intense yellow 
color and are mainly present in fruits. Phloretin is a characteristic dihydrochalcone 
found in the free form, and in varying glycosidic structures in apples, apple pomaces, 
and juices (Ramirez-Ambrosi et al. 2013).
Flavanols or flavan-3-ols are noncolor flavonoids widely distributed in all common 
fruits, while among herbs, black and green tea are rich sources. Flavan-3-ols are also 
known as catechins, and they exhibit a strong antioxidant activity. Tea polyphenols 
are already used in the food industry as natural antioxidants (He et al. 2009). They 
are structurally differentiated from the other flavonoids because they do not contain 
carbonyl at C4, or the double bond between C2 and C3 of the C ring (Figure 2.1). The 
well-known flavan-3-ols are catechin, catechin gallate, gallocatechin, gallocatechin 
gallate, and their corresponding isomers, namely epicatechin, epicatechin gallate, 
epigallocatechin, and epigallocatechin gallate. In the biosynthesis of flavonoids, it is 
possible to form dimeric or oligomeric compounds of flavan-3-ols, which are called 
proanthocyanidins or condensed tannins. Proanthocyanidins are the noncolor pre-
cursors of anthocyanins, and they usually coexist with flavanols in plant tissues.
Four catechins and six catechin gallates have been identified in the fresh young 
shoots of tea (Camellia sinensis) grown in Australia, with epigallocatechin gallate 
constituting up to 116 mg/g on a dry basis (Yao et al. 2004). In aqueous extracts of 
Chinese green tea, the total catechin content was determined to be 93.6% (w/w) of 
infusions, with the catechin gallates accounting for >82% (w/w) of the tea extract 
(He et al. 2009). Other good sources of flavanols and proanthocyanidins are plants 
of the genus Cistus (Danne et al. 1993, Barrajón-Catalan et al. 2011), which nowa-
days are a part of several natural mixtures used as decoctions. Other food sources of 
flavanols are the fruits of plants from the Ericaceae and Rosaceae families, orange 
juice, chocolate, red wine, and beans (Boskou 2006, Guimarães et al. 2013).
The anthocyanins are a famous flavonoid group that causes the red to violet and 
blue color of flowers and fruits. They exist in plants as glycosides, mainly at the 
C3 position, and their aglycone parts, known as anthocyanidins, are produced by 
acid hydrolysis. The most important anthocyanidins are pelargonidin, cyanidin, and 
delphinidin. Especially the last two, together with their ether derivatives, peonidin, 
petunidin, and malvidin, are responsible for the color of grapes, red currants, morel-
los, cherries, and various berries such as blackberry, blueberry, and raspberry, mak-
ing them a valuable source of anthocyanins (Pantelidis et al. 2007, Nisco et al. 2013, 
Carrieri et al. 2013). The anthocyanin contents in black and red grapes are estimated 
at 70% and 23% of their total phenols, respectively (Carrieri et al. 2013). Vegetables 
are another food source of anthocyanins. A delphinidin glycoside was found in egg-
plant, two pelargonidin derivatives in radish, a cyanidin derivative in red cabbage, 
and a cyanidin glycoside with peonidin-3-arabinoside in red onion peel (Belitz et al. 
2009). Artichoke heads were found to contain several cyanidin glycosides mainly, but 
two peonidin and one delphinidin derivatives are also referred (Lattanzio et al. 2009).
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other Polyphenols
In food, there are also other polyphenols, besides the simple phenols, phenolic acids, 
and flavonoids, that are of great biological interest.
Resveratrol (trans-3,4′,5-trihydroxystilbene) belongs to the stilbenes, and is a nat-
ural antioxidant mainly found in berries, leaves, and canes of grapes, as well as in red 
wine and lesser in white wines. Hydrolyzable tannins are another group of polyphe-
nols found mainly in the wood and bark of oak and chestnut tree. They are divided 
into simple hydrolyzable tannins, which are esters of gallic acid or its glycosides or 
its esters with glucose, and ellagitannins, which contain in their structure a glyco-
side of glucose and ellagic acid (a gallic acid dimer) (Figure 2.1). Ellagitannins have 
been found in aqueous extracts of many Cistus species of the subgenus Leucocistus 
and Halimioides in quantities ranging from 0.63 to 15.79 mg/mL; however, they are 
mostly absent from plants of the subgenus Cistus (Barrajón-Catalan et al. 2011). 
Punicalin, punicalagin, and punicalagin gallate are common ellagitannins found in 
Cistus salvifolius, C. ladanifer, and C. monspeliensis. It is believed that they con-
tribute substantially to the antioxidant properties of the crude aqueous leaf extracts 
of Cistus spp. (Saracini et al. 2005, Barrajón-Catalan et al. 2011).
Lignans are phytoestrogens present in seeds, cereals, legumes, fruits, and veg-
etables. Their consumption is believed to have positive effects on human health 
(Gerstenmeyer et al. 2013). Sesame and flax seeds are good sources of lignans, which 
are also found in rye grains and rye products in lesser amounts. Secoisolariciresinol 
and its diglycoside isolariciresinol; lariciresinol and its monoglycoside 7-hydroxyma-
tairesinol; syringaresinol; pinoresinol with mono-, di-, and triglycosides; sesaminol 
with di- and triglucosides; and sesamolinol and its diglucoside have been detected 
in the extracts of the above-mentioned sources (Gerstenmeyer et al. 2013). Sesame 
seeds and oil also contain sesamin and sesamolin, which are considered antioxidant 
compounds (Rangkadilok et al. 2010). The sesamin and sesamolin contents in sesame 
range between 0 and 7.23 mg/g seed and between 0 and 2.25 mg/g seed, respectively, 
strongly depending on of the sesame type and origin (Rangkadilok et al. 2010).
Carotenoids
Carotenoids are a group of tetraterpenes widely distributed in nature, giving fruits 
and vegetables from a light yellow to a dark red color. They are divided into caro-
tenes, which are unsaturated hydrocarbons, and to xanthophylls, which are their oxy-
genated derivatives. Typical representatives of this group are β-carotene, α-carotene, 
lycopene, zeaxanthin, and lutein (Figure 2.2). Carotenoids are the precursors of vita-
min A. Food sources of carotenoids are fruits like citrus, peaches, apricots, water-
melon, and melon, and vegetables including all yellow ones, corn, carrots, tomatoes, 
red pepper, etc. Carotenoids constitute the major pigment in carrots. Apocarotenoids 
are natural polyenes with a shortened carbon skeleton structurally related to carot-
enoids. Such apocarotenoids are present in the red dark stigmas of Crocus sativus 
flowers, whose dried form is the famous and expensive spice saffron, and are known 
as crocins. Crocins are very water-soluble colorings, mainly found as all-trans- and 
13-cis-glycosyl esters of crocetin (Tarantilis et al. 1995). Crocins are mainly com-
posed of digentiobiosyl crocetin (Figure 2.2). Saffron, especially in powder form, is 
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often confused and adulterated with curcumin, which is a diphenylheptanoid com-
pound extracted from turmeric rhizome and used in the food industry as a coloring 
with strong antioxidant properties (Figure 2.1). The antioxidant potential of carot-
enoids has been reported in the literature and may play an important role in human 
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fIGure 2.2 Molecular structures of characteristic essential oil compounds, carotenoids, 
and α-tocopherol found in natural food sources.
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singlet oxygen. β-Carotene can act as an antioxidant or as prooxidant, depending on 
both its concentration and the low or high concentration of oxygen (Lee et al. 2004). 
By studying the in vitro antioxidant activity of crocins with the 2,2-diphenyl-1-pic-
rylhydrazyl (DPPH) test, a correlation with the crocin concentration was observed—
crocins showed an IC50 value of 44 ± 1 μg/mL; at a concentration of >50 μg/mL, the 
antioxidant activity started to decrease (Kanakis et al. 2009).
essential oils
Essential oils (EO) are natural mixtures of volatile compounds that belong principally 
to the terpenes group and found in a special category of plants called aromatic plants. 
A great variability of monoterpenes and sesquiterpenes constitute the EO composition 
of plants of different families, such as Lamiaceae, Asteraceae, Apiaceae, Verbenaceae, 
and Cistaceae, whose aerial parts are used as herbs and spices, or consumed in their 
fresh form as vegetables (Daferera et al. 2002, Candan et al. 2003, Güllüce et al. 2003, 
Petropoulos et al. 2004). Thymol and carvacrol, primarily, γ-terpinene and p-cymene 
secondarily, are basic EO compounds in oregano, thyme, marjoram, dittany, and 
savory. Limonene is a common monoterpene predominantly found in the peel of citrus 
fruits, and also present in lemongrass EO. α-Pinene is one of the main components in 
the EO of rosemary, mountain tea, and sage (Aligiannis et al. 2001). β-Phellandrene 
is a basic compound in the EO of parsley and dill leaves. Eucalyptol and camphor are 
characteristic compounds in sage, rosemary, and Achillea. Pulegone predominates in 
the EO composition of pennyroyal. Monoterpene alcohols such as α-terpineol, ter-
pinen-4-ol, and borneol are found in Achillea, marjoram, and rosemary. Neral and 
geranial are the principal components of lemongrass EO. Farnesene and chamazulene 
are parts of the EO composition of chamomile.
Phenylpropanoid derivatives, such as cinnamaldehyde, eugenol, and myristicin, 
frequently constitute the EO composition. Cinnamaldehyde is the predominant cin-
namon EO compound; eugenol is found in clove and basil oil; and myristicin is a 
characteristic compound in parsley EO (Petropoulos et al. 2004). In some cases, 
the volatile compounds are the thermal degradation products of carotenoids. For 
example, safranal and isophorone are considered such compounds, and are the prin-
cipal EO compounds in saffron spice (Tarantilis and Polissiou 1997). Organosulfur 
compounds are common among the Allium species. Garlic oil consists of diallyl 
sulfides, methyl allyl sulfides, and vinyl dithiins, in quantities that vary according to 
the extraction technique, extraction temperature, and the solvent used for their isola-
tion (Kimbaris et al. 2006). The bioactive properties of garlic oil are attributed to its 
acyclic sulfur compounds (Figure 2.2).
dIstrIbutIon of natural antIoxIdants 
In selected food sources
Fruits
Fruits are very good sources of various phenolic compounds and carotenoids (Belitz 
et al. 2009). The content of carotenoids among different fruits varies widely, from 
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0.3 mg/kg of fresh weight (fw) in pears to 27 mg/kg (fw) in peaches (Belitz et al. 
2009). Oranges, pears, peaches, and sweet melons contain relatively high amounts of 
β-carotene, cryptoxanthin, and zeaxanthin. Peaches are also rich in lycopene, phytoene, 
phytofluene, and ζ-carotene. Moreover, in the carotenoid composition of oranges, the 
epoxy carotenoids are found in significant amounts. Fruits like pineapples, bananas, 
figs, and grapes are poor in β-carotene, lutein, and neoxanthine (Belitz et al. 2009).
The total phenol content in fruits shows fluctuations. Apples and grapes contain 
0.1–1.0 g/100 g (fw), plums contain 0.2–1.4 g/100 g (fw), whereas peaches contain 
0.03–0.14 g/100 g (fw). Cinnamic acid derivatives are the most popular phenolic 
compounds in fruits, mainly found as esters of p-coumaric, ferulic, and caffeic acids 
with quinic acid and often with d-glucose. Chlorogenic acid (syn. 5-caffeoylquinic 
acid) is the predominant compound in apples and pears. The major cinnamic acid 
derivatives found in cherries, morellos, plums, peaches, and apricots are neochlo-
rogenic (syn. 3-caffeoylquinic) and chlorogenic acids. Cherries and morellos also 
contain 3-p-coumaroylquinic acid in significant amounts. In the case of strawber-
ries and various types of berries such as blackberries, a diversity of cinnamic acid 
derivatives exist. Chlorogenic acid is the major one in blackberries, while the most 
commonly occurring, regardless of its quantity, is p-coumaroylglucose. Benzoic acid 
derivatives are found in strawberries, grapes, and citrus fruits. Salicylic acid is the 
most widespread, followed by gentisic acid. In strawberries, p-hydroxybenzoic, gal-
lic, ellagic, protocatechic, and vanillic acids are also found. The content of phenolic 
acids in fruits depends of the fruit variety, degree of maturation, and storage period.
l-Ascorbic acid (a form of vitamin C) also exists in fruits, influencing their total 
antioxidant capacity. Small fruits of various blackberries, raspberries, gooseberries, 
red currants, and cherries contain variable amounts of phenols, among them antho-
cyanins. The anthocyanin content ranged from 1.3 to 223.0 mg cyanidin-3-glucoside 
equivalents per 100 g (fw), and the total phenol content from 657 to 2611 mg gal-
lic acid equivalents per 100 g dry weight (dw) (Pantelidis et al. 2007). The largest 
amount of anthocyanins was found in a native Cornelian cherry population with red 
color, while the highest total phenol content was found in a raspberry × blackberry 
cultivar (sunberry). The anthocyanin content in three sweet cherry varieties was esti-
mated to be between 2 and 24 mg cyanidin 3-O-rutinoside equivalent/100 g (Pappas 
et al. 2011). The ascorbic acid content in such fruits ranged from 14 to 103 mg/100 g 
(fw); however, it was negatively correlated with ferric reducing antioxidant power 
(FRAP) values, leading the authors to hypothesize that no direct correlation can be 
established between ascorbic acid content and total antioxidant capacity (Pantelidis 
et al. 2007). Literature reports show that ascorbic acid can act as an antioxidant or 
prooxidant depending on certain conditions (Lee et al. 2004). The major anthocya-
nins found in common fruits such as apples, pears, peaches, plums, figs, oranges, 
morellos, cherries, and blackberries are glycosides of cyanidin; those in strawber-
ries are glycosides of pelargonin; and those in bananas are glycosides of petunidin 
(Belitz et al. 2009). Cyanidin 3-O-glucoside and cyanidin 3-O-rutinoside are pre-
dominant compounds in plums, sweet cherries (Prunus avium L.), and blackberries, 
although variations among different varieties were observed. The above-mentioned 
common fruits also contain flavonols and flavan-3-ols, with major representatives 
being quercetin 3-O-glucoside and epicatechin, respectively.
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table 2.1
distribution of natural antioxidants in selected food sources
food source natural antioxidant Group references
fruits and fruit Products
Pears, peaches Carotenoids, phenolic acids, 
flavonols, flavanols
Belitz et al. 2009
Apricots Phenolic acids, flavonols, flavanols Belitz et al. 2009
Cherries Anthocyanins, flavanols, phenolic 
acids, flavonols




Anthocyanins, phenols Pantelidis et al. 2007
Strawberry tree Anthocyanins, flavanols, flavonols, 
galloyl derivatives, 
proanthocyanidins
Guimarães et al. 2013
Blackthorn Phenolic acids, flavones, flavonols, 
anthocyanins
Guimarães et al. 2013
Wild roses, dog roses Flavononols, flavanones, 
anthocyanins, flavanols, flavonols, 
proanthocyanidins
Guimarães et al. 2013
Apples, cider apples, 
pomace, juice
Anthocyanins, proanthocyanidins, 
phenolic acids, dihydrochalkones, 
flavonols, flavanols
Ramirez-Ambrosi et al. 2013, 
Belitz et al. 2009
Citrus, citrus juice Flavanones, carotenoids Ghafar et al. 2009
Mandarin peel Polymethoxylated flavones, 
flavanones, chalcones
Zhang et al. 2012
Grapes Anthocyanins, phenolic acids, 
stilbenes, flavonols, flavanols, 
proanthocyanidin
Teixeira et al. 2013, Nisco et al. 
2013, Carrieri et al. 2013, 
Cantos et al. 2002
Olive oil Phenolic alcohols, phenolic acids, 
secoiridoids, lignans, flavones, 
flavonols, anthocyanins, 
carotenoids, tocopherols
Tripoli et al. 2005, Boskou 2006, 
Christophoridou and Dais 2009
seeds
Sesame, flax, rye grains Lignans Gerstenmeyer et al. 2013
Vegetables
Artichoke Cinnamic acid derivatives, flavones, 
flavanones, flavonols, anthocyanins
Lattanzio et al. 2009, Palermo et 
al. 2013
Eggplant, red cabbage, 
radish, red onion
Anthocyanins Belitz et al. 2009
Spinach Flavonoids, p-coumaric acid Boskou 2006
Garlic/onion Volatile sulfur compounds Kimbaris 2006, Belitz et al. 2009
Dill Essential oil, flavonols Justesen 2000
Parsley Essential oil, flavones Petropoulos et al. 2004, Justesen 
2000
(Continued)
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Strawberry tree (Arbutus unedo), blackthorn (Prunus spinosa), dog rose (Rosa 
canina), and wild rose (Rosa micrantha) fruits, consumed fresh or as jams, liqueurs, 
or decoctions, are good sources of phenolic acids and flavonoids (Guimarães et al. 
2013) (Table 2.1). Blackthorn fruits presented the highest amounts of anthocyanins 
(100.40 mg/100 g), flavones/flavonols (57.48 mg/100 g), and phenolic acids (29.78 
mg/100 g) compared with strawberry tree and wild roses. Strawberry tree contained 
the largest quantity of flavan-3-ol (36.30 mg/100 g), followed by wild rose (32.62 
mg/100 g) and dog rose (19.90 mg/100 g), while it was not detected in blackthorn. 
Among the identified phenolic acids, 3-O-caffeoylquinic acid was the most abun-
dant, quercetin 3-O-rutinoside was the most detected flavonol, and (+)-catechin was 
the predominant flavan-3-ol. Cyanidin 3-O-glucoside was detected in all samples 
to be the major anthocyanin, with the exception of blackthorn where cyanidin 
3-O-rutinoside and peonidin 3-O-rutinoside predominated.
Nowadays, modern analytical techniques are applied in food analysis, which 
allows the identification of more compounds not previously reported. Nineteen new 
compounds were characterized in the case of cider apples (two flavanols, four dihy-
drochalcones, nine hydroxycinnamic acids, and four flavonols), while in apple pom-
ace and juice, five new compounds were identified (two dihydrochalcones and three 
flavonols) (Ramirez-Ambrosi et al. 2013).
The flavonoid composition of citrus fruits is characterized by the presence of fla-
vanones, which naturally occur in glycosidic form and are responsible for the bitter 
table 2.1 (contInued)
distribution of natural antioxidants in selected food sources
food source natural antioxidant Group references
Herbs
Oregano, sage, rosemary Essential oils, phenolic acids, 
flavones, flavonols, phenolic 
triterpenes
Miron et al. 2011, Zimmermann 
et al. 2011, Hossain et al. 2010
Thyme, basil Essential oils, phenolic acids, 
flavones, flavonols
Hossain et al. 2010
Lemon balm Essential oil, phenolic acids, 
flavones, flavanones
Dastmalchi et al. 2008
Tarragon Phenolic acids, caftaric acid, 
flavonols
Miron et al. 2011
Herbal Infusions
Oregano, pennyroyal Flavanols, essential oil compounds, 
phenolic acids, triterpenic acids
Kogiannou et al. 2013
Marjoram, savory, 
mountain tea, chamomile
Flavanols, essential oil compounds, 
phenolic acids
Kogiannou et al. 2013
Tea Flavanols Yao et al. 2004, He et al. 2009
Cistus Flavanols, proanthocyanidins, 
ellagitannins
Barrajón-Catalan et al. 2011, 
Danne et al. 1993, Saracini et al. 
2005
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taste in those fruits. The intensity of the bitterness depends on the type of substitu-
ents in the basic aglycone part of the glycosides. Hesperidin is the characteristic 
flavanone of sweet oranges, also found in lemon peel, which has a neutral taste. The 
bitter taste of some orange cultivars is attributed to the compound neohesperidin. 
Naringin is the bitter compound of grapefruits (Belitz et al. 2009). Mandarin peel 
was found to contain polymethoxylated flavones, flavanones, and chalcones. It was 
mentioned that polymethoxylated flavonoids have high oral bioavailability, show-
ing, among others, antioxidant activity (Zhang et al. 2012). Citrus juices are a good 
source of phenolic compounds whose quantity range between 105 and 490 mg of 
gallic acid equivalent/100 mL juice, depending on the citrus species. Their flavonoid 
content in different lime species and in oranges was determined to be from 2.99 to 
22.25 mg of hesperidin equivalent/100 mL juice (Ghafar et al. 2010).
GraPes and Wine
Table and wine grapes are a special category of fruits constituting a major source 
of phenolic compounds. Phenolics in grapes are responsible for the color, flavor, 
and stringency of wine, contributing to its antioxidant properties. Phenolics in table 
and wine grape cultivars present qualitative similarities; however, quantitative dif-
ferences were observed. The anthocyanin content in grapes fluctuates depending on 
the cultivar. In four red table cultivars, it was estimated to be from 69 to 151 mg/kg 
(fw) (Cantos et al. 2002). The berry skin and wine of the grape cultivar Vitis vinifera 
L. (cv. Aglianico), grown in southern Italy, was characterized to be a valuable source 
of anthocyanins, with an amount of 9996.1 mg/kg (fw) and 716.3 mg/L, respectively 
(Nisco et al. 2013). Malvidin and petunidin glycosides constitute the majority of the 
anthocyanin composition, with malvidin-3-glucoside being the predominant com-
pound (Nisco et al. 2013). In three black table grapes, malvidin was found to be the 
predominant anthocyanin, while in four red ones petunidin was distinguished to 
be predominant (Carrieri et al. 2013). The major anthocyanin in red table grapes is 
peonidin-3-glucoside, while in wine grapes it was reported to be malvidin-3-gluco-
side (Cantos et al. 2002, Nisco et al. 2013).
Red grape cultivars contain higher amounts of phenolic compounds relative to 
white grapes, owing to the presence of anthocyanins in their composition (Cantos et 
al. 2002). However, the average total phenolic content in black, red, and white table 
grapes was determined to be 297 ± 70, 138 ± 15, and 196 ± 103 mg/kg (fw), respec-
tively, indicating that, in the some white cultivars, exceptions exist (Carrieri et al. 
2013). The relatively high amount of total phenolics in some white grape cultivars was 
attributed to the presence of flavonols and flavan-3-ols, occurring in higher quanti-
ties and contributing to the higher percentages to the total phenolic content (Cantos 
et al. 2002, Carrieri et al. 2013). Quercetin 3-glucuronide, quercetin 3-glucoside, and 
quercetin 3-rutinoside have been determined as the main flavonols in all table grapes 
(Cantos et al. 2002). Studies on the relation between antithrombotic activity and the 
polyphenolic profile of 12 table grapes showed that quercetin and cyanidin displayed 
a positive correlation, suggesting that the greater their concentration, the stronger 
the inhibition of tissue factor synthesis (Carrieri et al. 2013). Cinnamic acid deriva-
tives were also found in grapes, constituting about 4–13% of the total phenol content. 
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Caffeoyltartaric acid and p-coumaroyltartaric acid are the most common (Cantos et al. 
2002). The trans- and cis-isomers of resveratrol are both present in grapes, although 
the trans-isomers exist in larger quantities. In berry skin and wine from the Aglianico 
cultivar, trans-resveratrol was determined at 444.41 mg/kg (fw) and 3.79 mg/L respec-
tively, while the corresponding detected levels for the cis-isomer was 2.7% and 1.8% 
lower (Nisco et al. 2013). Resveratrol is present in the skin and seeds of berry grapes 
but not in the flesh (Teixeira et al. 2013). The groups of phenolic compounds and their 
distribution in tissues of mature grape berry are presented in Table 2.1.
VeGetables
Vegetables are consumed by humans daily as fresh, cooked, or processed (e.g., canned). 
As with other food sources, their contents of natural, possible antioxidant compounds 
vary both qualitatively and quantitatively. Besides fruits, vegetables are also rich 
sources of phenolic compounds, mainly benzoic and cinnamic acid derivatives, fla-
vones, and flavanols. Vegetables with red, violet, and blue color also contain anthocya-
nins. Eggplant has a delphinidin glycoside; radish contains two pelargonidin glycosides; 
red cabbage has a cyanidin derivative; and onions with red peel contain cyanidin and a 
peonidin glycoside in its anthocyanin composition (Belitz et al. 2009). Some plant spe-
cies are considered vegetables, despite their content of EO or other volatile compounds, 
such as parsley, dill, onion, and garlic. α-Phellandrene is the main component of dill 
leaves EO. In aqueous methanol extract of dill, the flavonols isorhamnetin, kaempferol, 
and quercetin were detected as glucuronyl conjugates. Quercetin–rhamnoglucoside was 
also detected as a minor component of dill (Justesen 2000). β-Phellandrene was deter-
mined as the predominant compound in the EO composition of three types of parsley, 
namely plain, curly, and turnip-rooted. Fluctuations were observed in the relative per-
centages of their EO compounds, strongly depending on the sowing date, growth stage, 
and plant part (Petropoulos et al. 2004). Myristicin was present in notable percentages 
in all types of parsley; however, the highest values were observed in curly parsley. The 
aqueous methanol extract of parsley was found to contain a flavone fraction, consist-
ing of apigenin-7-apiosylglucoside (apiin), apigenin-acetyl-apiosylglucoside, diosmetin-
apiosylglucoside, and diosmetin-acetyl-apioglucoside (Justesen 2000).
Alliin (S-allyl-l-cysteine sulfoxide) is considered the precursor of the aromatic 
compounds of onion and garlic, and is present in fresh tissues. When garlic is chopped 
or crushed, the enzyme allinase is activated and acts on alliin, producing allicin (dial-
lyl thiosulfinate). Under certain conditions, allicin is converted directly to acyclic 
sulfur compounds or, via thioacrolein, produces vinyl dithiins isomers, which can fur-
ther decompose to acyclic sulfides with heating. Garlic EO consists mainly of acyclic 
polysulfides and vinyl dithiin isomers (Figure 2.2). These two groups have different 
properties, and their content in garlic EO is related to the applied temperature dur-
ing the isolation process, as well as the time that affects the heating. Thus, the rela-
tive percentage of polysulfides decreased from 77.4% to 8.7%, whereas that of vinyl 
dithiin isomers increased from 4.7% to 70.8%, when the isolation techniques changed 
from harsh thermal (simultaneous distillation extraction, 2 h) to short time thermal 
(microwave-assisted hydrodistillation extraction, 30 min) and room temperature isola-
tion (ultrasound-assisted extraction) (Kimbaris et al. 2006).
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Among other vegetables, reference will be made to artichoke (Cynara cardun-
culus subsp. solymus), a native plant in Mediterranean countries that contains large 
amounts of polyphenols with high antioxidant activity and display high bioavailabil-
ity (Lattanzio et al. 2009). The edible part of artichoke is the immature inflorescence, 
called head; however, its by-products, leaves, external bracts, and stems, also contain 
bioactive polyphenols and could be used as an antioxidant source. The total phenol 
content in artichoke heads, external bracts, and leaves was determined to be 2.32, 
1.67, and 1.01 g gallic acid equivalent per 100 g of dry weight, respectively (Palermo 
et al. 2013). The principal phenolic group found in artichoke heads and leaves are 
the phenolic acids. There is a wide range of caffeoylquinic derivatives, with chloro-
genic acid (5-O-caffeoylquinic acid) being the most abundant. In artichoke extracts, 
cryptochlorogenic (4-O-caffeoylquinic acid), neochlorogenic (3-O-caffeoylquinic 
acid), 1-O-caffeoylquinic, 1,3-O-dicaffeoylquinic (cynarin), 3,4-O-dicaffeoylquinic, 
1,5-O-dicaffeoylquinic, and many other dicaffeoylquinin acids are also found. Their 
content in artichoke tissues is related to the physiological stage of the tissue, rang-
ing from 8% (dw) in young to 1% (dw) in senescent tissues (Lattanzio et al. 2009). 
Flavonoids represent <10% of the total phenol content in artichoke. Luteolin and 
apigenin are the major flavones, found both as 7-O-glucoside and 7-O-rutinoside. 
Luteolin-7-O-glucoside is also known as cynaroside. Recent studies also report 
the presence of flavanones, mainly found as naringenin and eriodictyol glycosides, 
and flavonols that are represented by many quercetin and two myricetin glycosides 
(Palermo et al. 2013). Anthocyanins are present only in artichoke heads and con-
sist of cyanidin, peonidin, and delphinidin glycosides. The most abundant are the 
cyanidin glycosides with the cyanidin 3,5-diglucoside and cyanidin 3-O-β-glucoside 
being among the principal ones (Lattanzio et al. 2009). The cooking method is one 
factor that affects the total phenol content and the percentage composition of the var-
ious phenolic compounds. Compared with the raw material, cooked artichoke con-
tained reduced relative percentages of chlorogenic acid but increased percentages of 
cryptochloregenic acid and 4,5-O-dicaffeoylquinic acid, while steamed artichoke 
showed a higher phenolic content than the microwaved ones (Palermo et al. 2013). 
The antioxidant activity of artichoke extracts is related to its total phenol content, 
and probably to cynarin and caffeic acid, as they both present antioxidative proper-
ties. These compounds coexist in artichoke extracts with other bioactive compounds 
such as luteolin and cynaroside, indicating a possible additive or synergistic effect 
(Lattanzio et al. 2009).
herbs
Herbs are used in food as flavorings and spices, but also for making various decoc-
tions such as sage, chamomile, mountain tea, black and green tea, etc. The flora 
of the Mediterranean region includes many aromatic taxa, most of them endemic. 
Traditionally, people living in this region have introduced these herbs into their daily 
diet.
Herbs contain a variable amount of EO, which is constituted by numerous com-
pounds in different qualitative and quantitative combinations (Aligiannis et al. 2001, 
Daferera et al. 2002, Güllüce et al. 2003, Candan et al. 2003, Petropoulos et al. 2004, 
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Tepe et al. 2004). Eucalyptol, camphor, and α-terpineol are the major components 
in Achillea millefolium EO (oil yield 0.6% v/w), as well as in many other Achillea 
species (Candan et al. 2003). Bisabolol oxides are also found in considerable percent-
ages (total 7.1%) in Achillea EO. The EO of A. millefolium displayed a strong antioxi-
dant effect on the in vitro free radical (IC50 = 1.56 μg/mL in DPPH, IC50 = 2.70 μg/
mL in hydroxyl), and lipid peroxidation generation (IC50 = 13.50 μg/mL), compared 
with the corresponding values of ascorbic acid, curcumin, and butylated hydroxy 
toluene (BHT) (Candan et al. 2003). α-Pinene, eucalyptol, camphor, camphene, and 
borneol are found as basic compounds in Salvia cryptantha and S. multicaulis plants 
(oil yield 0.37–0.42% v/w). The EO of both Salvia species had greater antioxidant 
activity relative to the controls in DPPH and hydroxyl radicals, while their methano-
lic extracts were efficient only in the DPPH test (Tepe et al. 2004).
Carvacrol, thymol, γ-terpinene, and p-cymene are characteristic compounds of 
many Origanum, Thymus, and Satureja species (Daferera et al. 2002, Güllüce et 
al. 2003). Satureja hortensis (savory) EO displayed a lesser ability to act as a donor 
for hydrogen atom or electron (IC50 = 350 μg/mL) compared with the water sub-
fraction of the methanol extract (IC50 = 30.89 μg/mL) in the DPPH test, although 
it inhibited 95% of the linoleic acid oxidation. The methanol extract of S. hortensis 
callus culture also showed a strong effect in the DPPH test (IC50 = 23.76 μg/mL) 
and it was comparable to the BHT effect (IC50 = 19.8 μg/mL) (Güllüce et al. 2003). 
The strong antioxidant capacity of the water/methanol extracts of S. hortensis can 
be attributed to the presence of phenolic acids, mainly rosmarinic acid, which are 
widespread in plants of the Lamiaceae family. Moreover, the rosmarinic acid content 
of 11 Lamiaceae samples of lemon balm (M. officinalis), sage (Salvia officinalis), 
oregano (O. vulgare ssp. hirtum), rosemary (Rosemary officinalis), basil (Ocimum 
basilicum), thyme (Thymys vulgaris), hyssop (Hyssopus officinalis), and savory, was 
determined. The rosmarinic acid content fluctuated from 81 ± 4 mg/g (in lemon 
balm) to 12 ± 3 mg/g (in hyssop) of dried plant material, while its quantity in savory 
was estimated at 56 ± 6 mg/g (dw) (Saltas et al. 2013).
Aqueous methanol extracts of rosemary, sage, oregano, basil, and thyme included 
various phenolic compounds belonging to the phenolic acids, flavones, phenolic ter-
penes, and flavonols (Hossain et al. 2010). A variety of phenolic acids was observed 
in all samples, among them gallic, caffeic, syringic, vanillic, protocatechuic, chlo-
rogenic, p-coumaric, and rosmarinic acids. Luteolin and apigenin (in free or glyco-
sidic form), quercetin, and quercetin-3-O-hexoside were also present. Carnosol and 
carnosic acid were present in oregano, rosemary, and sage extracts. Similar quali-
tative results have been observed in the aqueous and aqueous/ethanol extracts of 
Romanian oregano and wild thyme (T. serpyllum), apart from the phenolic triter-
penes (Miron et al. 2011). Oregano water extract presented high content of total phe-
nols (184.9 mg gallic acid eq./g, dw) showing important antioxidant activity (EC50 = 
6.98 μg/mL) (Miron et al. 2011). The corresponding extracts of tarragon (Artemisia 
dracunculus) was found to contain 3-O-caffeoylquinic acid (neochloregenic), 
4-O-caffeoylquinic acid (cryptochlorogenic), caftaric acid, various dicaffeoylquinic 
acid isomers,  isorhamnetin, and quercetin (Miron et al. 2011). The aqueous ethanol 
extract of lemon balm leaves (M. officinalis) contain a phenolic fraction estimated 
at 268.9 ± 21.3 mg gallic acid eq./g (dw), which contained rosmarinic acid, caffeic 
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acid, m-coumaric acid, eriodictyol-7-O-glucoside, naringin, naringenin, hespiridin, 
and hesperetin (Dastmalchi et al. 2008). Rosmarinic acid was the major constituent 
and was quantified at 96.45 ± 0.13 mg/g (dw). Lemon balm extracts possess strong 
antioxidant activity that can be explained by its phenolic composition (Dastmalchi et 
al. 2008). In the literature, qualitative and quantitative differences may be observed 
in the phenolic profile of the same herbs owing to the differences in plant origin, 
isolation method, extracting solvent system, and analytical technique (Kivilompolo 
et al. 2007, Dastmalchi et al. 2008, Miron et al. 2011).
The antioxidant properties, by the oxidation of trans-2-hexenal into the corre-
sponding carboxylic acid, of 14 individual EOs from black and white pepper (Piper 
nigrum L.), cardamom (Elettaria cardamomum L.), nutmeg (Myristica fragrans 
Houtt.), mace (Myristica fragrans Houtt), juniper berry (Juniperus communis L.), 
fennel seed (Foeniculum vulgare Mill., var. dulce Thelling), caraway (Carvum carvi 
L.), dry cinnamon leaves (Cinnamomum zeylanicum Bl.), marjoram (Origanum 
majorana L.), laurel (Laurus nobilis L.), ginger (Zingiber officinalis L.), garlic 
(Allium sativum L.), and clove bud (Caryophyllus aromaticus L.) have been exam-
ined (Misharina et al. 2009). The EOs of garlic, clove bud, ginger, and leaves of cin-
namon showed maximal efficiency, inhibiting hexenal oxidation at 80–93%, while 
black pepper oil showed minimal efficiency (49%). Garlic oil was the most effective. 
The antioxidant activity of an EO is attributed mainly to its major components; how-
ever, the synergistic or antagonistic effect of one compound present in the mixture in 
a minor percentage is also considered (Misharina et al. 2009, Amorati et al. 2013).
The total phenol contents in infusions of some Greek herbs, namely oregano (O. vul-
gare), Cretan marjoram (O. microphyllum), pink savory (Satureja thymbra), mountain 
tea (Sideritis syriaca), pennyroyal (Mentha pulegium), and chamomile (Matricaria 
chamomilla), have been determined (Kogiannou et al. 2013). The concentration of the 
total phenols in the herbal infusions was determined at high levels, ranging from 30.9 
to 109.1 mg gallic acid equivalent per cup (200 mL). The flavanol content, also mea-
sured in these infusions, ranged between 8.3 and 40.0 mg rutin per cup. Oregano infu-
sion was the most abundant both in total phenol and flavanol content, followed by pink 
savory. Pennyroyal infusion contains a high amount of phenols (82.9 mg gallic acid 
equivalent per cup); however, its flavanol content was estimated at only 13.2 mg/cup. 
On the contrary, the flavanol content in chamomile infusion (25.2 mg/cup) was high, 
>50% of the total phenol content (46.4 mg gallic acid equivalent per cup). The anti-
oxidant capacity of the herbal infusion measured by the DPPH and FRAP methods 
showed the following sequence: oregano > pennyroyal > pink savory > chamomile > 
mountain tea and Cretan marjoram. The highest antioxidant activity of oregano infu-
sion is attributed to its carvacrol, thymol, and caffeic acid contents. Carvacrol was 
detected in all herbal infusions, although higher amounts were measured in oregano. 
The herbal infusions were also rich in phenolic acids displaying a varied qualitative 
profile (Kogiannou et al. 2013). Protocatechic acid was the major one in oregano, 
mountain tea, and chamomile infusions. Syringic acid was primarily found in pink 
savory and Cretan marjoram infusions, while vanillic acid was the basic content in 
pennyroyal infusion. Among the detected cinnamic acid derivatives, caffeic acid was 
predominant in all cases, ranging from 73.57 μg/cup in mountain tea to 895.19 μg/cup 
in oregano infusion. Catechin and epicatechin were found in all herbal infusions, while 
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kaempferol, quercetin, genistein, and naringenin were detected in specified plant cases 
(Kogiannou et al. 2013). Ursolic acid, a triterpenic acid, was quantified in the oregano 
and pennyroyal infusions, and it positively correlated with antiradical activity and 
FRAP, indicating that the antioxidant activity of herbal infusions can also be attributed 
to the presence of nonphenolic compounds (Kogiannou et al. 2013).
Another study on herbal infusions used 70 commercial medicinal plants from a 
local market, and their total phenol content correlated with the antioxidant capac-
ity of the infusions (Katalinic et al. 2006). The total phenol concentration in all 
plant infusions varied between 9.0 and 2218.0 mg catechin equivalents (CE) per 
liter of infusion. The total phenol content for Thymi herba, Serpylli herba, Mentha 
piperita folium, S. officinalis folium, Basilici herba, Hyperici herba, Majoranae 
folium, Tiliae officinalis flos, Satureja herba, Chamomillae flos, Lauri folium, and 
Rormarini folium, was estimated to be between 136 and 876 mg CE/L infusion. 
The highest value was determined in Melissa folium infusion (2218.0 mg CE/L), 
which showed the strongest antioxidant property. In the DPPH test, M. folium infu-
sion showed a similar behavior to catechin, but not as good as quercetin; however, it 
was more efficient as a free ABTS radical scavenger, compared with trolox and vita-
min C (Katalinic et al. 2006). In infusions of different samples of dried sage leaves, 
rosmarinic acid and luteolin-7-O-glucoside were the predominant compounds with 
values ranging between 12.2 and 296 mg/L and between 37.9 and 166 mg/L, respec-
tively. The phenolic triterpene carnosic acid was another compound found in signifi-
cant amounts (9.1–32.9 mg/L). Moreover, the phenolic composition of sage infusion 
include caffeic acid, chlorogenic acid, salvianolic acid I and isomers, carnosol, ros-
manol, apigenin glycosides, and other luteolin glycosides (Zimmermann et al. 2011).
oliVe and oliVe oil
Table olives and virgin olive oil are valuable food for people of all countries around 
the Mediterranean basin. Greece, Turkey, Spain, and Italy are the most important 
producer countries. Phenolics are responsible for the stability of olive against oxida-
tion and contribute to its nutritional properties, including its antioxidant effect. The 
polyphenol content differ among the produced olive oils, depending on the olive 
cultivar, geographical origin, ripening degree, extraction procedure, and storage 
(Tripoli et al. 2005, Cecchi et al. 2013). The major phenols found in virgin olive 
oil are hydroxytyrosol and oleuropein, which are responsible for its bitter and pun-
gent taste (Tripoli et al. 2005). Other phenolics that can be found in olive oil are 
caffeic acid, p-coumaric acid, p-hydroxybenzoic acid, ferulic acid, cinnamic acid, 
2,3-dihydroxybenzoic acid, homovanillic acid, vanillic acid, vanillin, syringic 
acid, apigenin, luteolin, quercetin, 1-acetoxy-pinoresinol, pinoresinol, oleuropein, 
ligstroside, sinapic acid, and tyrosol derivatives (Tripoli et al. 2005, Boskou 2006, 
Christophoridou and Dais 2009). The lignans 1-acetoxy-pinoresinol and pinoresinol 
are present in extra virgin olive oil (Christophoridou and Dais 2009). Tocopherols 
are included in the lipophilic phenolic fraction of olive oil.
Oleuropein is found in significant amounts in olive fruit and becomes reduced 
with the maturation of the fruit. The oleuropein content is higher in the first stages 
of fruit maturation, and in green cultivars compared with black ones, while the 
40 Antioxidants in Health and Disease
amounts of hydroxytyrosol and tyrosol increase as the fruits ripen (Tripoli et al. 
2005). Olive ripening is a crucial factor affecting the quality of the produced oil 
and its total phenolic content (Cecchi et al. 2013). The basic phenolic fraction in 
the ethanolic extracts (80%, v/v) of olive pastes of different cultivars and harvesting 
times was oleuropein (mean value, 139.6 ± 12.0 mg/kg on dry material [dm]) and 
isomers of oleuropein aglycone (sum of mean values, 667.4 mg/kg, dm), followed by 
verbascoside (mean value, 241.9 ± 8.9 mg/kg, dm). The hydroxytyrosol content was 
estimated at 35.7 ± 8.5 mg/kg, dm (Cecchi et al. 2013).
Nuclear magnetic resonance analysis of the phenolic extracts received from extra 
virgin olive oils using a mixture of ethanol–water (80:20, v/v) led to the qualifica-
tion and quantification of hydroxytyrosol (34.03–64.37 μmol/100 g of oil), tyrosol 
(25.06–61.26 μmol/100 g), oleuropein, ligstroside and their aglycones (sum 22.62–
61.74 μmol/100 g), pinoresinol (1.25–1.61 μmol/100 g), 1-acetoxy-pinoresinol (2.01–
2.87 μmol/100 g), p-coumaric acid, vanillin, vanillic acid, homovanillyl alcohol, 
luteolin, apigenin, and syringaresinol (Christophoridou and Dais 2009). Although 
all examined samples showed the same qualitative pattern, quantitative differences 
among the individual components were observed, because of the different cultivars 
and locations. The largest quantitative differences were observed between olive oils 
of the same cultivar from the same prefecture but different locations (Christophoridou 
and Dais 2009).
In this chapter, the components of natural sources used in human nutrition were 
described. The literature reports several in vitro or in vivo biological activities, includ-
ing antioxidant activity, for these compounds. The evaluation of such activities is not 
easy, as various components exist simultaneously and can act synergistically or antag-
onistically (Amorati et al. 2013). In addition, it is not necessary for a natural antioxi-
dant to exist in high concentration in the food source to present a positive result, as 
each compound displays different bioavailabilities in humans (Pantelidis 2007).
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3 Oxidative Stress 
in Pregnancy
Ung Lim Teo and Andrew Shennan
IntroductIon
The role of antioxidants in pregnancy is promising as we move toward disease pre-
vention rather than cure, and recent findings that oxidative stress may be linked to 
some maternal–fetal conditions in pregnancy has been encouraging. Studies have 
been carried out to investigate interventions in the pre- and periconceptual periods, 
as well as in the antenatal period, to prevent adverse pregnancy disorders related to 
oxidative stress, particularly preeclampsia because of its impact on both morbidity 
and mortality in both mother and fetus. Oxidative stress has also been implicated in 
fertility and miscarriage. This chapter reviews the most recent evidence available 
about the clinical potential of antioxidants in the prevention of some common and 
serious conditions in pregnancy.
FertIlIty
Human sperm is vulnerable to oxidative stress because of its high contents of polyun-
saturated fatty acids, which leads to the destruction of its DNA strands [1]. Defective 
DNA strands in sperm can cause impaired fertility, abnormal embryonic development, 
high rates of miscarriage, and an increased risk of defects in offspring. Antioxidants 
have been found in the epididymis (extracellular superoxide dismutase, selenocys-
teine-independent glutathione peroxidase, GPx5), seminal fluid (vitamin C, uric 
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reverse the effects of oxidative stress [2]. Smoking, alcohol intake, and obesity can 
all increase oxidative stress and therefore deplete the antioxidant stores, causing male 
subfertility. A recent Cochrane review of 34 randomized controlled trials, but only 
involving 2876 couples, suggests that antioxidant supplements such as vitamin C and 
E can increase live births in male factor subfertility [3]. A large, well-designed, robust 
placebo-controlled clinical trial needs to be carried out to confirm these findings.
The oocyte is also prone to oxidative stress induced by reactive oxygen species 
(ROS), and high levels in smokers and women with increased alcohol consumption have 
been reported. Low levels of ROS are necessary for the induction of oocytes (meiosis I), 
and high levels of ROS impair oocyte maturation, ovulation, and fertilization [1].
A study has shown that older women (aged 39–45 years) have increased ROS 
and reduced antioxidants compared with younger women (aged 27–32 years), and 
therefore reduced antioxidant capacity to neutralize the amount of ROS in the fol-
licular fluid of ovarian follicles. This could cause mitochondrial DNA changes and 
chromosomal aneuploidy, possibly leading to a higher risk of miscarriage and fetal 
anomaly, explaining this age-related morbidity [4].
Although male subfertility has been found to improve with antioxidant supple-
ments, less robust clinical evidence is available to recommend antioxidant supple-
ments to treat female subfertility. Antioxidant supplementation, in certain cases, can 
cause adverse effects in women, but usually only in very high doses [5].
MIscarrIage
Studies have shown an increase in placental oxygenation from 8 to 12 weeks’ ges-
tation corresponding to placental perfusion before early miscarriage. It was also 
shown that markers of oxidative stress were increased in the placenta of women 
with early miscarriage compared with controls. Therefore, it has been hypothesized 
that they resulted from premature placental perfusion. Another study demonstrated 
an increased amount of ROS and reduced antioxidants in the peritoneal cavity of 
women with miscarriages. Sperm DNA damage could cause miscarriage [6]; how-
ever, studies showing potential treatment with antioxidants are very limited.
Increased natural killer cells are found in the endometrium of women with 
recurrent miscarriage. Natural killer cells release angiogenic factors in the endo-
metrium, causing increased preimplantation angiogenesis. This causes abnormal 
placentation, early intraplacental maternal circulation, and increased oxidative 
stress possibly leading to miscarriages [7]. ROS (plasma lipid peroxidase, reduced 
glutathione [GSH], malondialdehyde [MDA]) have been found elevated while anti-
oxidant enzymes (GPx, superoxide dismutase and catalase, vitamin E, β-carotene) 
are decreased in women with recurrent miscarriages [4]. However, meta-analyses of 
studies to date with periconceptual and early pregnancy supplementation of vitamins 
or antioxidants have shown no benefit in the prevention of early miscarriage [1,8].
PreeclaMPsIa
Preeclampsia is a syndrome that can occur after 20 weeks’ gestation, with multi-
organ involvement characterized by new onset of hypertension (≥140/90 mm Hg), 
49Oxidative Stress in Pregnancy
proteinuria (≥300 mg/24 h), and symptoms such as visual disturbances, epigastric 
pain, or headache. The incidence of preeclampsia is around 2–7% of all pregnan-
cies [1]. The spectrum of preeclampsia includes HELLP syndrome and eclampsia. 
HELLP is manifested as a deranged liver function test, breakdown of hemoglobin 
(hemolysis), and low platelet count. Eclampsia is described as seizure activity with 
hypertension that can be life-threatening to both mother and fetus. Other compli-
cations of preeclampsia include pulmonary edema, liver and renal failure, stroke, 
and thromboembolism. Moreover, of the women who die, many will not have a 
seizure; that is, eclampsia is not the inevitable endpoint of the untreated disease. 
Preeclampsia can also affect fetal growth in utero, causing growth restriction, low 
birth weight fetus, and often the need for premature birth and sometimes stillbirth. 
Preeclampsia, therefore, can have a devastating effect in terms of morbidity and 
mortality in both mother and fetus.
The mechanism of preeclampsia is unknown but is thought to occur because of 
defective placental implantation. After fertilization, trophoblast forms two layers 
called cytotrophoblast and syncytiotrophoblast. The cytotrophoblast invades the 
decidua and remodels the spiral arteries by breaking down the smooth muscle layer 
to enable low resistance blood flow to the placental bed. In preeclampsia, the spiral 
arteries do not break down completely, causing persistent high resistance blood flow. 
This causes reduced perfusion leading to hypoxia. Intermittent reperfusion of the pla-
centa is thought to cause the release of ROS, which have been found in elevated levels 
in the placentas of women with preeclampsia [1]. Placental villi are also found to be 
less well developed in preeclamptic placenta, with fewer branches and less complex 
vascular loops, compared with a placenta with a normal pregnancy outcome [9].
Antioxidant supplementation during pregnancy, therefore, would theoretically 
be able to reduce oxidative stress in the placenta and may be able to prevent pre-
eclampsia. Meta-analyses of 10 trials involving 6533 women found no reduction in 
preeclampsia, high blood pressure, or preterm birth with antioxidant supplementa-
tion [10]. Antioxidant supplementation has been reported to cause a small increase 
in the risk of low birth weight [1]. Therefore, routine antioxidant supplementation in 
pregnancy is not recommended.
IntrauterIne growth restrIctIon
As described in the pathogenesis of preeclampsia, abnormal placentation due to oxi-
dative stress is thought to be the cause of intrauterine growth restriction (IUGR). 
Owing to reduced perfusion from defective spiral arteries, there is utero–placental 
insufficiency leading to restricted growth of the fetus. Raised ROS like lipid perox-
ides [11], MDA, and xanthine oxidase [12] with low antioxidants have been found in 
plasma, placenta, and umbilical cord of women with IUGR. There is little evidence 
that supplementation aids this process, but little research has been done.
PreterM labor
Preterm labor is defined as cervical change with strong, regular uterine contrac-
tions leading to delivery before 37 weeks’ gestation. Worldwide, the rate of preterm 
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birth ranges between 5% and 18% of babies, but is increasing [13]. Preterm delivery, 
which causes significant mortality and morbidity in newborns, can be categorized 
into spontaneous or indicated [4]. Causes of spontaneous preterm labor include uter-
ine overdistension, infection, cervical disease, and endocrine disorders. However, 
the exact mechanism and pathway leading to preterm labor is not clear. Various 
studies have been and still are being done to find answers, with the hope of finding 
treatment or prevention.
Raised oxidative stress markers like MDA and 8-hydroxydeoxyguanosine with 
lower antioxidant levels such as GPx, GSH, and selenium [14] are found in women 
with preterm labor. Activities of FKBP12 rapamycin-associated protein and gluta-
thione S-transferase (providing defense against oxidative stress) are also reduced 
in women with preterm labor. Other study findings also indicate inflammation 
and oxidative stress with lower antioxidant levels, demonstrating a reduced capacity 
to counter oxidative stress as a cause of preterm labor [4]. However, a recent random-
ized controlled trial using vitamin C and E supplementation in low-risk pregnant 
women showed no significant difference in the incidence of preterm labor [11,15]. 
Vitamin C supplementation in pregnancy may even increase the risk of preterm 
labor [16].
PreterM PreMature ruPture oF MeMbrane
There are postulations that preterm premature rupture of membrane (PPROM) stems 
from ROS and pro-inflammatory cytokines that cause collagen remodeling [17] and 
the activation of collagenolytic enzymes [18,19], leading to reduced strength and 
integrity of the fetal membrane. In vivo and in vitro studies of vitamin C and E in 
the strengthening of fetal membrane showed that a combination of vitamin C and E 
did not prevent the weakening of the fetal membrane and, unexpectedly, vitamin C 
supplementation alone can cause weakening of the fetal membrane in vitro [17]. 
A controlled double-blind trial of 109 patients found that daily supplementation of 
100 mg vitamin C reduced the incidence of premature rupture of membrane [20]. A 
larger placebo-controlled double-blinded randomized controlled trial of 697 women 
at risk of preeclampsia reported that supplementation of vitamin C and E at doses of 
1000 mg and 400 IU, respectively, was associated with increased risk of both prema-
ture rupture of membrane (i.e., occurring at term) and PPROM [21].
A recent prospective randomized controlled study, looking at prolonging the 
latency period after PPROM with vitamin C and E supplementation and maternal 
and neonatal outcome, demonstrated that supplementation does prolong the latency 
period after PPROM with no significant difference in adverse maternal and neo-
natal outcome [22,23]. These studies are still preliminary, and routine vitamin C 
and E supplementation after PPROM in the general population is not currently 
recommended.
gestatIonal dIabetes MellItus
Elevated levels of ROS and low antioxidant levels are found in women with gesta-
tional diabetes mellitus, which could be related to the pathogenesis or complication 
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of hyperglycemia [24–27]. The placenta of women with gestational diabetes mel-
litus are found to have increased antioxidant gene expression but is less responsive 
to exogenous oxidative stress compared with tissues of normal pregnant women, 
possibly owing to the protective or adaptive mechanism in response to the increased 
oxidative stress [28].
conclusIon
Oxidative stress has been implicated in many important disorders in pregnancy; how-
ever, studies to date have failed to show significant benefit in antioxidant supplemen-
tation in pregnancy. Antioxidant supplementation is, therefore, not recommended 
for the prevention or treatment of disorders in pregnancy currently. However, there 
is little doubt that oxidative stress is implicated in the pathophysiology of certain 
disorders in pregnancy. Vitamin C and E have been most commonly used as anti-
oxidant supplements in trials to date. Further trials should look into different doses, 
regimens, and other types of antioxidant supplements. More research and robust 
large placebo-controlled clinical trials are needed to investigate the role of oxidative 
stress in pregnancy disorders, and the safety and benefit of antioxidant supplementa-
tion in pregnancy.
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IntroductIon
Micronutrients and early developMent
The first years of life are crucial for the adequate physical, cognitive, and emotional 
development of children and future adults. Childhood is the life period with the 
highest developmental rate, and a continuous, adequate, and balanced provision of 
nutrients is essential to ensure optimal development and health. However, the pres-
ence of undernourishment during childhood is still a matter of great concern world-
wide. Data from the United Nations Children’s Fund (UNICEF, 2006) show that one 
in four children are underweight and at increased risk for disease and mortality. This 
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is a major problem in developing countries, where access to food is limited and child 
malnutrition has been traditionally caused by energy and/or macronutrient (mainly 
protein) deficiency, leading to impaired growth and development (Figure 4.1). In 
recent years, however, the concern for underweight has been paralleled by another, 
not less important, issue: the steep rise in pediatric overweight and obesity in both 
industrialized and developing countries. The increase in overweight children should 
not mask another form of malnutrition—that which comes from an inadequate sup-
ply of nutrients in the diet. This fact can be the result of limited access to food, but 
also of the poorer nutritional values of current diets worldwide, promoted by the 
switch in dietary habits toward consumption of highly refined foods to the detriment 
of fresh products, the lower nutrient content of fresh foods due to modern growth and 
husbandry practices and long-distance transport, or the reluctance of children to eat 
certain foods such as fruits and vegetables (Maggini et al., 2010; Singh, 2004). The 
combined contributions of these factors may lead to suboptimal, if not overtly insuf-
ficient, provision of nutrients that are essential for maximum growth and develop-
ment during childhood, such as vitamins and minerals. This, in turn, leads to clinical 
or subclinical deficiencies of not just isolated nutrients but rather a group of them 
(Thurlow et al., 2006), and that can be observed in children from developing coun-
tries as well as from the most industrialized ones (Maggini et al., 2010; Singh, 2004).
oxidative stress and children’s health
Oxidative stress results from an imbalance between the body’s production of reac-
tive oxygen species (ROS) and the antioxidant mechanisms in place. Generation of 
ROS can be the result of environmental injury (toxic chemicals, air pollutants, etc.); 
however, it is also a normal physiological process that can be part of the defense 
response against pathogens and abnormal cells, or a by-product of metabolism and 
respiration. However, when exceeding certain levels, ROS can oxidize cellular com-
ponents, mainly membrane fatty acids, genetic material, and proteins, leading to 
(even irreversible) cell damage and loss of function. To keep ROS levels within a 
healthy physiological range, the organism depends on a series of enzymes, such as 
glutathione peroxidase (GSH-Px), with the capacity to protect the cell from oxida-
tive damage (Granot and Kohen, 2004). Research conducted in the last decades sug-
gests a role for oxidative stress in growth and development disturbances in children. 
For example, broncho-pulmonary diseases, enterocolitis, perinatal brain damage, 
and neonatal hemochromatosis in newborns, or asthma, cystic fibrosis, diarrhea, and 
kwashiorkor in older children, have all been associated with oxidative stress (revised 
by Granot and Kohen, 2004).
Vitamins such as A, E, or C; minerals like zinc or selenium; and certain phy-
tochemical compounds such as polyphenols are known to be natural antioxidants, 
and as such they have been suggested to have a protective effect against some of 
the above-mentioned diseases. In fact, it has been reported that deficiencies in anti-
oxidant vitamins and minerals during childhood may contribute to alterations in 
growth and physical and mental development, as we will discuss below. In addition, 
recent evidence suggests that other food components with antioxidant properties 







































































































































































































































56 Antioxidants in Health and Disease
(i.e., polyphenols), for which deficiencies have not been described (and are therefore 
not named nutrients), may contribute to optimal health in this period of life.
This chapter aims to provide an overview of the current knowledge on the role 
of antioxidants in physical and cognitive development during childhood and ado-
lescence, looking at both classic antioxidants (vitamins, minerals) and the emerg-
ing ones (polyphenols). We will discuss their implication in development-associated 
pathologies, and the effectiveness of supplements based on evidence from interven-
tion studies and trials.
AntIoxIdAnts, Growth, And PhysIcAl develoPment
antioxidants and Growth
The recommended daily intakes for antioxidant micronutrients for children and ado-
lescents are shown in Table 4.1. Intakes below the recommendations are relatively 
common for some of them.
Micronutrient deficiency can impair growth and development in children. In 
pediatric populations at risk of or experiencing malnutrition, supplementation with 
micronutrients, not only energy and macronutrients, can improve growth outcomes 
(Branca and Ferrari, 2002; Goyle, 2012). For example, vitamin A deficiency has 
been shown to contribute to stunting (impaired growth leading to short stature) in 
children (Beaton et al., 1993; Kirkwood et al., 1996; Underwood, 1994). Vitamin A 
deficiency is one of the most frequent micronutrient deficiencies. According to data 
tABle 4.1













0–6 months 375 25 2.7 1.1–6.6 6
7–12 months 400 30 2.7 0.8–8.3 10
1–3 years 400 30 5.0 2.4–8.4 17
4–5 years 450 30 5.0 3.1–10.3 21
6–9 years 450–500 30–35 5.0–7.0 3.1–11.3 21
10–13 years 600 40 7.5 (G), 10 (B) 4.6–15.5 (G), 
5.7–19.2 (B)
26 (G), 34 (B)
14–19 years 500–600 (G),
600 (B)
40–45 7.5 (G), 10 (B) 3.0–15.5 (G), 
4.2–19.2 (B)
26 (G), 34 (B)
Source: FAO/WHO. Requirements of vitamin A, iron, folate and vitamin B12, Report of a joint FAO/
WHO Expert Consultation. In Food and Nutrition Series No. 23 (ed.), Rome, 1988. FAO/WHO. 
Human Vitamin and Mineral Requirements. Report of a joint FAO/WHO expert consultation. In 
Bangkok, Thailand (published in Rome), 2002.
Note: B, boys; G, girls.
a Zinc recommendations depend on bioavailability.
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from the World Health Organization (WHO) in 2005, its prevalence in regions at risk 
of hipovitaminosis A was estimated in 33.3% of preschool children, which translates 
to 190 million children worldwide (WHO, 2009). A prospective study on stunted 
Sudanese infants and children (6 months to 6 years of age) showed that the intake of 
vitamin A and carotenoids was associated with the extent of growth recovery with 
time, especially in the youngest children (Sedgh et al., 2000). Therefore, ensuring 
adequate levels of vitamin A in children is a goal to achieve.
Studies on vitamin A supplementation, however, suggest that this measure may 
be useful for stimulating growth only in those children with impaired growth at 
baseline or experiencing the specific deficiency. A study conducted in Indonesian 
preschool children showed that vitamin A supplementation (103,000 IU for children 
<2 years of age and 206,000 IU for older children, once every 4 months) could 
improve height and weight gain under certain conditions. For example, the effective-
ness of the supplementation was influenced by age (more effective in older children) 
and breast-feeding (before 2 years of age, growth improvement was only observed in 
non-breast-fed children), but especially by nutritional status, as those children with 
serum retinol levels >0.35 μmol/l showed no significant height or weight gain (Hadi 
et al., 2000). Another study in older (4–14 years) Brazilian children, on the contrary, 
found no significant effect of a similar single dose of vitamin A (200,000 IU) in 
growth during the 6 months after the intervention (Saccardo Sarni et al., 2003). The 
authors assessed the dietary intake of the participants and found that a consider-
able percentage of them (>60%) had intakes of retinol and carotenoids far below 
the recommendations; as they associated this low intake with an overall insufficient 
consumption of fruit and vegetables, they understandably concluded that such an 
unbalanced diet would result in multiple micronutrient deficiencies, making a single-
nutrient supplement useless (Saccardo Sarni et al., 2003).
Another antioxidant deficiency that has been related to impaired growth is that of 
zinc, first described in the 1960s (Prasad et al., 1963). In addition, zinc deficiency is 
associated with delayed puberty, skin conditions, impaired wound healing, altered 
immune function, and increased susceptibility to infections (Maggini et al., 2010). 
Interestingly, the availability of zinc in human milk is higher than in cow’s milk or 
infant formulae (Sandström et al., 1983), which indicates another way in which breast-
feeding contributes to optimal growth in newborns during the first months of life.
Several studies have shown a benefit for zinc supplementation in improving 
children’s weight and height (Brown et al., 2002; Lind et al., 2004; Umeta et al., 
2000), with effects being more significant in those children who were underweight 
or stunted (Brown et al., 2002; Perrone et al., 1999; Sayeg et al., 2000; Umeta et 
al., 2000). Interestingly, the work by Lind and colleagues (2004) showed that while 
supplementation with zinc (10 mg/day) improved growth, and supplementation with 
iron (10 mg/day) improved cognitive development, the combination of both miner-
als did not have a significant effect on either outcome compared with placebo (Lind 
et al., 2004), due perhaps to the interactions between the minerals at the absorptive 
level (Sandström, 2001). However, in the study by Perrone and colleagues (1999), 
the combination of zinc and iron (12.5 mg/day + 12 mg/day, respectively) was more 
effective for improving growth than zinc alone; even more, zinc alone was effec-
tive only in those children with higher ferritin levels (i.e., better iron status). The 
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different conclusions arising from Lind’s and Perrone’s studies might be perhaps 
explained by two important methodological differences: first, zinc and iron supple-
ments in Perrone’s study were provided 12 h apart, which could prevent interac-
tions at the absorptive level, while in Lind’s intervention both minerals were given 
together. Second, Perrone’s study specified that all children were stunted, while this 
characteristic was not specifically stated in Lind’s work (Lind et al., 2004; Perrone 
et al., 1999).
Recently, a new level has been revealed in the relationship between physical devel-
opment and antioxidant levels according to the HELENA study results, where a sig-
nificant association between vitamin status and cardiorespiratory and muscular fitness 
has been shown (Gracia-Marco et al., 2012). According to this study, after controlling 
for potential confounders, cardiorespiratory fitness in boys was positively associated 
with retinol and vitamin C serum concentrations, while muscular strength was associ-
ated with levels of retinol, carotenoids, and vitamin E. In girls, cardio respiratory and 
muscular fitness were both positively correlated with carotenoid levels.
antioxidants in the treatMent of deficiency diseases
Kwashiorkor, a typical protein-malnutrition disease, has been associated with low lev-
els of antioxidant vitamins C, A, and E, and lower levels of GSH-Px and its cofactor 
selenium (Ashour et al., 1999; Fechner et al., 2001). However, despite the consistent 
findings linking kwashiorkor, oxidative stress, and low antioxidant (both endogenous 
and dietary) levels, intervention studies have not provided support for antioxidant 
supplementation in the treatment of the disease. Early work with vitamin E supple-
mentation (10 mg/day) did not find any significant improvement in growth in children 
with kwashiorkor (Beau and Sy, 1996); later, another trial using multisupplementation 
(1.8/day mg riboflavin, 23 mg/day vitamin E, 55 μg/day selenium, and 300 mg/day 
N-acetylcysteine for 20 weeks) again found no significant increases in weight gain or 
height, or amelioration of disease-related symptoms (edema, diarrhea, or fever) when 
compared with placebo (Ciliberto et al., 2005). More recently, a systematic review of 
trials involving supplementation with riboflavin, vitamin E, selenium, and cysteine 
isolated or in combination demonstrated the lack of a significant difference in the 
prevalence of kwashiorkor or its associated mortality (Odigwe et al., 2010).
Anemia is another of the most common nutrition-related diseases in children, 
with prevalence ranging between 20% and 31% in school-aged children and between 
46% and 49% in preschool children (WHO 2008, data from 2005). Although the 
main nutritional deficiency leading to anemia is that of iron, other micronutrients, 
and antioxidants in particular, like vitamins A, C, and zinc, have been associated 
with increased risk of anemia (Konomi and Yokoi, 2005 and Sommer et al., 2002 
as cited in Chen et al., 2012; Maggini et al., 2010). Vitamin C, for example, contrib-
utes to optimal growth by reduction of non-heme iron from ferric to ferrous form, 
increasing its absorption by the intestinal epithelium (Sandström, 2001; Siegenberg 
et al., 1991). On the contrary, zinc and some polyphenols may sequester iron and 
reduce its bioavailability (Sandström, 2001; Siegenberg et al., 1991).
Supplementation with vitamin A has been found to improve markers of iron 
status and anemia. In China, preschool children (up to 6 years of age) were given 
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supplements of vitamin A alone, vitamin A plus zinc, or vitamin A plus multivi-
tamin/mineral cocktail, which included calcium, vitamin C, and B vitamins, for 6 
months (Chen et al., 2012). The multinutrient supplementation proved to be the most 
effective for improving anemia, whereas the combination of vitamin A and zinc 
provided the best results in terms of stimulating growth (increased height). Similar 
results were obtained with another intervention with a multimicronutrient supplement 
including vitamin A, vitamin B-12, iron, and zinc, conducted in older children (6–11 
years) in Haiti (Ianotti et al., 2014). Vitamin A alone can as well improve hemoglobin 
status; Mwanri and colleagues (2000), working with Tanzanite children, found that 
vitamin A (5000 IU, 3 days/week for 3 months) increased the beneficial effect of 
iron supplementation (200 mg ferrous sulfate) when given together. Similarly, both 
micronutrients alone improved height and weight gain when compared with placebo; 
however, the combination provided the best results (Mwanri et al., 2000).
antioxidants, asthMa, and allerGies
Particularly interesting is the role that antioxidants can play in the development and/
or treatment of asthma and allergies, two of the most prevalent diseases in childhood, 
with figures on the rise (Asher et al., 2006; Williams et al., 2008). Vitamins C and 
E, through their antioxidant and immunomodulatory actions, have been shown to 
improve lung function and hyperreactivity (Romieu and Trenga, 2001; Rubin et al., 
2004). There is even evidence for a relationship between maternal antioxidant intake 
(vitamin E in particular) during pregnancy and the development of asthma later in 
childhood (Devereux et al., 2006). A study in Iraqi children showed reduced serum 
levels of vitamin C and E in those with asthma, when compared with healthy chil-
dren, and also a negative association between serum antioxidants and the severity 
of asthma symptoms (Al-Abdulla et al., 2010). However, little information is avail-
able, to our knowledge, regarding the effectiveness of the use of dietary antioxidant 
supplements in the treatment of asthma and allergies in children.
Similarly, studies in the last two decades suggest beneficial actions of polyphenols 
(especially quercetin and catechins) in alleviating the symptoms of allergic diseases 
and immune hypersensitivity (revised by Singh et al., 2011). A role for polyphenols in 
reducing food allergies in children and associated asthma and rhinitis has been pro-
posed; however, most data come from in vitro or animal studies, or from interven-
tions in adults, and little is known about the potential or safety of these compounds 
in children.
antioxidants and obesity
When considering the relationship between antioxidants and growth, the most imme-
diate association arising is that between antioxidant deficits and impaired growth. 
However, antioxidants can contribute to the healthy growth of children by helping 
prevent overweight and obesity; in other words, deficiencies in antioxidant micronu-
trients have been linked to a higher risk of obesity in early ages.
Oxidative stress has been found to play a relevant role in the etiopathogenesis of 
obesity, which could be mediated by food intake (revised in Puchau et al., 2010). 
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Some authors have found overweight and obese children and adolescents to present 
lower serum levels of antioxidant vitamins and minerals, like zinc, selenium (Azab 
et al., 2014), vitamins C and E (García et al., 2013), carotenoids, and α-tocopherol 
(Gunanti et al., 2014). Interestingly, higher concentrations of vitamin A (García et al., 
2013) and retinol (Gunanti et al., 2014) have been associated with higher adiposity.
Information from intervention studies in relation to the effect of supplementa-
tion on obesity in children is still scarce. Some trials that combined dietary treat-
ments for obesity with antioxidant supplementation have reported improvements 
in markers of oxidative stress (Codoñer-Franch et al., 2010; D’Adamo et al., 2013; 
Murer et  al., 2014) and obesity-related alterations, such as cardiometabolic risk 
parameters (D’Adamo et al., 2013; Hashemipour et al., 2009) or impaired liver 
function (Murer et al., 2014). However, none of these studies has reported a sig-
nificant effect of supplementation on body weight or indices of adiposity, or else 
some have reported no significant effect on these measurements (Hashemipour 
et al., 2009). In fact, it is interesting to mention that voices have risen to warn 
about the potential detrimental effects of excessive or unnecessary vitamin supple-
mentation on the risk of developing obesity in children (Zhou and Zhou, 2014). 
Some evidence suggest a relationship between vitamin intake (mainly B vitamins) 
and weight gain, and although this relationship has not been directly established 
with antioxidant vitamins, and it could well not be the case for them, it should be 
remembered that the most usual method of micronutrient supplementation is the 
administration of multivitamin–multimineral complexes. Therefore, further evi-
dence is needed before a clear relationship between antioxidant status and pediat-
ric obesity can be established, and especially before antioxidant supplementation 
can be considered as a therapeutic tool.
AntIoxIdAnts, coGnItIve FunctIon, 
BehAvIor, And mentAl develoPment
antioxidants and brain developMent
The high metabolic activity and demand for nutrients of the brain, combined with the 
lack of storage structures within it, make this organ highly dependent on dietary pro-
vision of energy and essential nutrients for its correct functioning. The first years of 
life are crucial with regard to brain plasticity and development; in consequence, diet 
plays a key role in cognitive development, behavior, and mental health in children 
and adolescents. In fact, quite often the nutritional deficiencies that impair physical 
growth are also associated with impaired cognitive function (it is the case, e.g., with 
iron-deficiency anemia; Falkingham et al., 2010).
Antioxidant micronutrients have multiple functions, and can act as coenzymes or 
prostatic parts of enzymes essential to brain growth and development (Benton, 2001). 
Zinc, for instance, is important for neurodevelopment, and research has shown that 
early (pre- or perinatal) deficiency may have permanent adverse effects on cogni-
tive development (Benton, 2010). In addition, low zinc intakes have been associated 
with behavioral problems in children, such as attention-deficit hyperactivity disorder 
(ADHD) (DiGirolamo et al., 2010). However, results from intervention studies have 
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not provided sound evidence in favor of zinc supplementation for improving cogni-
tive abilities and/or mental health.
There have been attempts at using antioxidant supplements to improve cognitive 
and academic performance in children, but with uneven results (reviewed in Benton, 
2001), and suggesting a significant effect mainly (or only) on those children who 
had learning difficulties or were malnourished. For example, in a study where chil-
dren (9–14 years old) were given orange juice daily for 6 months, IQ was increased 
only in those with poor initial vitamin C status (Kubula and Katz, 1960, as cited 
in Benton, 2001). Interventions with multivitamin–multimineral supplements have 
provided positive results with regard to behavior and intellectual capacities (Benton, 
2001, 2010); however, it is difficult to discern to which extent these benefits could be 
attributed to the antioxidants present in the supplements.
A special role can be attributed to vitamin E, not so much as a therapeutic agent 
in itself but as adjuvant of fatty acid supplementation for children with neurodevelop-
mental impairment. A growing body of evidence supports the use of polyunsaturated 
fatty acids (PUFA) of the ω-3 family in the treatment of disorders with either an 
inflammatory or a neurological component. Owing to their characteristic chemical 
structure, these fatty acids are essential for cell membrane formation, especially in the 
nervous and immune systems; in addition, they are precursors of anti-inflammatory 
eicosanoids. These properties make ω-3 PUFA important candidates for the treatment 
of neurodevelopmental disorders (Grassmann et al., 2013; Sinn, 2008). However, that 
same chemical nature makes them highly susceptible to lipid peroxidation, and that is 
where vitamin E exerts its protective action, preserving the integrity of the fatty acids. 
For that reason, combined supplementations of ω-3 PUFA and vitamin E have been 
proposed to treat neuronal alterations in children (Gumpricht and Rockway, 2013).
antioxidants and behavioral/coGnitive alterations: adhd
ADHD is characterized by impulsivity, excess of activity, and limited capacity to 
keep attention (American Psychiatric Association [APA], 1994). Its prevalence is 
estimated to be between 2% and 18% of children (Rowland et al., 2002), although 
these figures may rise with the new diagnostic criteria proposed by the APA in the 
DSM-V (Ghanizadeh, 2013). Both genetic and nongenetic factors are involved in the 
pathogenesis of ADHD. Among them, oxidative stress appears again as an important 
agent (Ross et al., 2003). Therefore, antioxidants are receiving growing interest for 
their potential to reduce oxidative stress in the brain, which may help in the treat-
ment of ADHD and other neurodevelopmental disorders (Gumpricht and Rockway, 
2013; Ng et al., 2008).
Observational studies have found an inverse relationship between zinc status in 
children and attention, including ADHD (Benton, 2010). Intervention studies also 
suggest a therapeutic potential for zinc supplementation. For example, 55 mg/day 
zinc sulfate in combination with the standard drug treatment with methylphenidate 
for 6 weeks seemed to improve parent- and teacher-reported behavior in children 
aged 5–11 years (Akhondzadeh et al., 2004), although these authors remained cau-
tious about the need to replicate the study with different zinc doses. In the same year, 
a large controlled clinical trial was published showing how zinc supplementation 
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(150 mg/day zinc sulfate during 12 weeks) improved hyperactivity, impulsivity, and 
socialization, but not lack of attention (Bilici et al., 2004). On the contrary, although 
a significant negative association has been found between serum zinc levels and 
symptoms of depression or anxiety, no differences have been observed in those 
parameters between children receiving the supplement (10 mg ZnO/day for 5 days/week 
during 6 months) and their controls (DiGirolamo et al., 2010). Ghanizadeh and Berk 
(2013), in their systematic review of clinical trials, concluded that there is still not 
enough sound evidence of zinc supplements being useful for ameliorating ADHD in 
children and adolescents (Ghanizadeh and Berk, 2013).
Research with polyphenol supplements is still in a preliminary stage; however, 
the maritime pine bark extract known commercially as Pycnogenol®, rich in phe-
nolic acids, catechin, taxifolin, and procyanidins, could be useful for treating the 
symptoms of ADHD. An intervention with this extract (1 mg/kg body weight/day 
for 4 weeks) caused a significant reduction of hyperactivity and improved attention, 
concentration, and visual–motor coordination in children with ADHD (Trebatická et 
al., 2006); however, further research is clearly needed.
antioxidants in autisM spectruM disorders
Oxidative stress has been proposed to be also involved in the etiopathology of dis-
orders of the autism spectrum, and, consequently, it could be a therapeutic target 
(Deth and Muratone, 2010; Ghanizadeh et al., 2012). There is evidence of lower 
levels of glutathione in children with these conditions, when compared with healthy 
ones (Geier et al., 2009). The antioxidant action of glutathione is important for pro-
tecting the brain tissue from oxidative stress and associated neuroinflammation in 
autism. Supplementation with glutathione in children with autism spectrum disor-
ders has been shown to improve the levels of some of the transsulfuration metabo-
lites (Kern et al., 2011); however, the effects on clinical symptoms still deserve 
further exploration.
The oxidative stress hypothesis has led to test the efficacy of dietary antioxi-
dants, like zinc, to treat these disorders and/or their symptoms. In this line, recent 
studies have demonstrated that serum zinc concentrations are reduced in children 
with autism spectrum disorders (Faber et al., 2009; Yasuda et al., 2011), while other 
studies do not support such findings (Adams et al., 2011). We still lack results from 
clinical trials with zinc supplementation in children with autism spectrum disorders.
Similarly, supplementation with polyphenols can represent an option worth ex -
ploring in the future. Recently, results have been published from two interventions in 
which combinations of luteolin, quercetin, and rutin were given to children (ranging 
from 4 to 14 years) for at least 4 months (Theoharides et al., 2012) or for 6 months 
(Taliou et al., 2013). After the treatments, significant improvements were reported in 
communication skills, social interaction, and overall behavior in both studies (Taliou 
et al., 2013; Theoharides et al., 2012).
Also worth mentioning is the study by Gvozdjáková and co-workers (2014), in 
which children with autism were treated with the nondietary antioxidant ubiquinol 
(a reduced form of coenzyme Q10). Twenty-four children, aged 3–6 years, received 
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100 mg/day ubiquinol for 3 months; after that period, both coenzyme Q10 levels and 
various symptoms of autism were reported to be improved.
antioxidants in down syndroMe
Down syndrome is one of the most frequent congenital conditions, with a preva-
lence of 1–2 in 1000 births (Weijerman and de Winter, 2010), and associated with 
learning disabilities and a higher risk of cognitive deterioration and of developing 
dementia at an earlier age (Thiel and Fowkes, 2005). As with the other diseases here 
mentioned, comorbidities of Down syndrome, especially cognitive impairment, have 
been proposed to be caused by oxidative stress. The gene that codifies one of the 
most relevant enzymes in ROS production, superoxide dismutase (SOD), is located 
in chromosome 21; because of the extra copy of this chromosome present in indi-
viduals with Down syndrome, this gene is overexpressed by up to 50%, and in con-
sequence generation of ROS is increased in affected individuals. In addition, IQ has 
been positively associated with GSH-Px activity in individuals with Down syndrome 
(reviewed in Ani et al., 2000). This has led to the suggestion that nutritional supple-
mentation could ameliorate oxidative stress in individuals with Down syndrome and 
improve some of the comorbidities of their condition, although evidence available 
provides inconclusive results. For example, serum zinc levels have been reported 
to be lower in Down syndrome, suggesting that supplementation with this mineral 
could be beneficial; however, clinical trials proving the efficacy of such supplements 
are lacking (Ani et al., 2000).
As a natural component of GSH-Px, selenium is one of the antioxidant micro-
nutrients proposed for the treatment of Down syndrome. Back in 1990, Antila and 
co-workers gave selenium supplements (15–25 μg of selenium/kg/day) to individuals 
with Down syndrome and reported a 25% increase in the activity of GSH-Px and 
a 24% reduction in the SOD/GSH-Px ratio compared with corresponding controls 
(Antila et al., 1990). This intervention, however, was conducted on a very small sam-
ple (only seven subjects), varying greatly in age (1–54 years) and length of treatment 
(4–18 months); also, it did not report any measurements of cognitive function, mak-
ing it difficult to draw conclusions regarding the effectiveness of selenium adminis-
tration for treating the cognitive comorbidities of Down syndrome.
Almost two decades later, Ellis and coworkers (2008) provided an antioxidant 
cocktail (10 μg selenium + 5 mg zinc + 0.9 mg vitamin A + 100 mg vitamin E + 
50 mg vitamin C daily) to 156 infants (up to 7 months of age) with Down syndrome. 
At 18 months follow-up, the authors failed to observe any significant effect on SOD 
activity or any of the cognitive outcomes measured, like locomotor activity or hear-
ing and language development, when compared with placebo. Later on, Lott and col-
leagues (2011) conducted a similar intervention with adults (aged 40 years or older; 
900 IU α-tocopherol, 200 mg ascorbic acid, and 600 mg α-lipoic acid per day), and 
again observed neither improvement in cognitive function nor a stabilization of cog-
nitive decline compared with the controls (Lott et al., 2011).
Finally, as a summary, Figure 4.2 shows the potential effects of oxidative stress 
and antioxidants in child growth and development.
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conclusIons
With the experimental evidence available thus far, there seems to be little doubt 
regarding the involvement of antioxidants, including dietary, in the physical and 
mental development of children, and of the role of antioxidant deficiencies in growth 
impairment and the occurrence of diseases that hinder children’s physical and cogni-
tive performance.
Less clear is the efficacy of antioxidant supplements for increasing growth and 
cognitive function in the early years of life, or for treating disease, except in those 
cases where specific nutritional deficiencies exist and must therefore be corrected.
It is also important to remark that vitamins, minerals, and polyphenols have pleio-
tropic roles in the body—in other words, one single compound will exert a wide 
range of functions other than sequestering ROS; for example, polyphenols have anti-
inflammatory properties, and zinc is a cofactor for enzymes involved in gene tran-
scription. It is therefore difficult to discern whether the effects of the antioxidants 
discussed in this chapter are due to their capacity to protect cells and molecules from 
oxidation, or to their other functions.
However, some areas of research, like those related to neurodevelopmental dis-
orders in children, are still young but pointing at potentially interesting pathways 
to follow, like the use of zinc and polyphenol supplements, regardless of the actual 




























FIGure 4.2 Potential impact of oxidative stress and antioxidants in child growth and 
development.
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Antonios E. Koutelidakis and Maria Kapsokefalou
Dietary antioxiDants in aDulthooD
Adult Needs ANd ImportANce of dIetAry ANtIoxIdANts
Adulthood is the longest period of human life. Scientific evidence supports that diet 
in this life period is correlated with possible progression of degenerative diseases in 
older age (Zampelas, 2003). Higher intake of antioxidant-rich foods is clearly associ-
ated with health improvement and longevity in adulthood. The specific mechanisms 
are under investigation; however, several studies have shown that a diet rich in plant-
based, antioxidant-rich foods, herbs, and beverages may promote health and could 
decrease the risk of various age-related diseases (Benzie & Choi, 2014). Nevertheless, 
a major parameter that determines the final effect of natural antioxidants on the human 
body is their bioavailability. Antioxidant bioavailability, and consequently their bio-
activity, is affected by multiple interactions in the lumen during digestion and may 
release a variety of metabolites with different pharmacokinetic actions (Kapsokefalou 
et al., 2006; Karabela et al., 2011; Koutelidakis et al., 2013).
Antioxidants are molecules that can interact with free radicals and terminate the 
chain reaction procedure before it destroys the vital molecules (Jacob, 1995). 
The ability of antioxidants to eliminate free radicals from the body and thus reduce 
the destruction of cellular organelles, such as lipids and DNA, may be the most 
important protective mechanism that prevents the pathophysiological processes of 
several diseases (Osawa et al., 1999; Saffari & Sadrzadeh, 2004; Sies et al., 2005). 
Although the human body has an enzymatic system (superoxide dismutase, catalase, 
glutathione peroxidase, etc.) with antioxidant scavenging/defense properties, the 
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primary antioxidant defense of the body is dependent on dietary micronutrients such 
as vitamin E, vitamin C, β-carotene, and lycopene (Wootton-Beard & Ryan, 2011). 
In recent years, several studies have demonstrated the important role of the antioxi-
dant selenium and the role of various phytochemicals such as polyphenols, and spe-
cifically flavonoids (Morton et al., 2000; Cabrera et al., 2006; Benfeito et al., 2013).
Ascorbic acid is a major plasma antioxidant factor that is needed for collagen syn-
thesis. Humans must obtain an adequate intake of vitamin C to maintain its plasma 
and tissue levels. Current dietary recommendations suggest an ascorbic acid intake 
of at least 70 mg/day for women and 100 mg/day for men, with higher levels advised 
in pregnant women and in smokers, because of increased oxidative stress (Yoshihara 
et al., 2010; Doll & Ricou, 2013; Benzie & Choi, 2014). The typical concentration 
of ascorbic acid in fasting plasma is 10–60 μM, and its best food sources are fruits, 
particularly citrus, kiwi fruit, and strawberries (Benzie & Choi, 2014). The National 
Health and Nutrition Examination Surveys (NHANES) have shown that low serum 
levels of vitamin C is associated with an increased risk for all-cause mortality (Simon 
& Hudes, 1999). In contrast, the Nurses’ Health Study did not find evidence for a 
protective effect of vitamin C against cardiovascular disease (Osganian et al., 2003).
Vitamin E is a fat-soluble antioxidant and has been proposed as the most impor-
tant inhibitor of lipid peroxidation. Vitamin E prevents platelet activation and 
adhesion, and is the basic antioxidant factor of low-density lipoprotein (LDL). 
The recommended daily allowance (RDA) for men and for women is 15 mg/day 
α-tocopherol (Masella et al., 2004; Yoshihara et al., 2010). The typical concentration 
of α-tocopherol in fasting plasma is 16–40 μM (Benzie & Choi, 2014). Vitamin E 
consumption is difficult to assess as it depends on the processing and storage meth-
ods; however, the best food sources of tocopherols are plant oils, wheat germ, sun-
flower seeds, and nuts (Benfeito et al., 2012; Benzie & Choi, 2014). The Nurses’ 
Health Study showed that supplemental vitamin E use for >2 years resulted in lower 
predicted cardiovascular disease risk; however, this beneficial effect was lost at lower 
doses and for shorter periods of use (Stampfer et al., 1993).
Carotenoids, such as lutein, zeaxanthin, and β-carotene, are lipophilic antioxidant 
compounds that are present in various plant and animal food sources. Their typical 
concentration in plasma ranges from 0.160 to 0.354 μΜ (Benzie & Choi, 2014), and 
they are linked to known mechanisms of action, such as protection from lipid peroxi-
dation, immune function, DNA damage protection, and gene regulation. The recom-
mended daily intakes for vitamin A are 900 μg retinoic acid (RA) and 700 μg retinol 
activity equivalents (RAE) for adult men and women, respectively (Pokorny et al., 
2001). Another important dietary antioxidant is selenium, a nutrient associated with 
protein foods. The role of selenium is the defense against oxidation procedure and 
the regulation of thyroid hormone. The recommendation (RDA) for adults is 55 μg 
selenium per day, and the best food sources include seafood, meat, whole grains, and 
vegetables (depending on soil content) (Pokorny et al., 2001).
Recently, experimental data suggest the important role of polyphenols and espe-
cially of flavonoids on cell protection against oxidative stress (Benfeito et al., 2012). 
They can prevent or minimize oxidative damage processes by scavenging free radical 
species and enhancing the endogenous antioxidant system by stimulating the synthe-
sis of endogenous antioxidants (Pokorny et al., 2001; Yoshihara et al., 2010; Benfeito 
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et al., 2013). The typical concentration of anthocyanins in fasting plasma is 0.046 μM 
and that of quercetin is 0.001 μM (Benzie & Choi, 2014). It is also considered to 
confer further protective function owing to the synergistic action of different antioxi-
dant components, such as flavonoids, into the food matrix (Koutelidakis et al., 2013). 
Nevertheless, there are no recommendations for daily flavonoid consumption because 
of the complex and multifactorial process of its absorption and because its metabolism 
differs among individuals. Furthermore, the European Food Safety Authority (EFSA) 
does not yet verify the nutritional or health claims for flavonoids and foods rich in 
antioxidants, such as herbal infusions (EFSA Panel on Dietetic Products, 2011).
BIoAvAIlABIlIty of NAturAl ANtIoxIdANts ANd Its 
effect oN ANtIoxIdANt BIomArkers IN Adults
The antioxidant effect of several foods or beverages has been linked to the absorp-
tion and metabolism of its bioactive constituents; that is, a prerequisite for bioactiv-
ity is bioaccessibility and bioavailability. This means that food components must 
be absorbed into the enterocyte, and moved and distributed to the organ tissues. 
Absorption, metabolism, pharmacokinetics, tissue distribution, and rate of excretion 
in urine or feces reflect the bioavailability of the components and thus the biological 
role of food into the organism (Duthie et al., 2000; Scalbert et al., 2002; Manach et 
al., 2005; Koutelidakis & Kapsokefalou, 2012).
The holistic range of the possible health benefits of antioxidant-rich diets sug-
gests their effect on various biomarkers in the human body (Koutelidakis et al., 2009; 
Koutelidakis & Kapsokefalou, 2012). The total antioxidant capacity of plasma, oxidized 
LDL, malondialdehyde, and oxidized DNA are some examples of biomarkers that indi-
rectly indicate the synergistic effect of the antioxidant compounds on humans. Table 
5.1 presents the effect of the consumption of several beverages, such as tea, cacao, or 
wine, on specific antioxidant biomarkers (Duffy et al., 2001; Erba et al., 2005; Hodgson 
et al., 2005; Widlansky et al., 2005).
Although many studies had indicated an increase of total antioxidant capacity or 
decrease of oxidized products after consumption of foods rich in antioxidants (Duffy 
et al., 2001; Erba et al., 2005), other studies suggest that natural antioxidants such as 
flavonoids are purely absorbed and have an extended metabolism in the body; thus, 
their contribution to serum total antioxidant activity and their final effect on organ 
tissues are controversial (Lotito & Frei, 2006). For example, the plasma concentra-
tion of all polyphenols, including catechins, quercetin, and anthocyanins, is only 
1 mM, even with a diet that provides up to 1 g/day of polyphenols from fruits and 
vegetables (Manach et al., 2005). The plasma concentrations of ascorbic acid and 
α-tocopherol are 80 and 40 mM, respectively, while their daily consumption are 200 
and 10 mg in healthy adults, respectively (Benzie & Choi, 2014).
According to the “EFSA Panel on Dietetic Products, Nutrition, and Allergies,” 
it is not established that changes in the overall antioxidant capacity of plasma exert 
a beneficial physiological effect on humans, as required by Regulation (EC) No. 
1924/2006. Furthermore, the induction of antioxidant enzymes, such as catalase or 
hyperoxide dismutase, cannot be used alone as evidence for claims related to the 
“antioxidant defense system” for nonessential food constituents. The EFSA panel 
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concludes that “for biomarkers relative to antioxidant capacity, changes in anti-
oxidant status, oxidative damage to proteins, lipids and DNA, nonoxidative DNA 
damage and neoplastic degeneration of cells no definition has been provided of ‘pre-
mature aging’ or of ‘healthy aging’ in relation to the antioxidant properties of foods, 
and therefore the claimed effect is considered to be general and nonspecific, and 
thus does not comply with the criteria laid down in Regulation (EC) No. 1924/2006” 
(EFSA Panel on Dietetic Products, 2011).
dIetAry ANtIoxIdANts ANd dIseAse preveNtIoN IN Adulthood
Recent research data suggest that the beneficial biological role of natural antioxi-
dants is focused not only on their antioxidant scavenging activity but also on their 
involvement in multiple metabolic signaling pathways at the cellular level. For exam-
ple, flavonoids may influence the expression of genes encoding the overproduction 
or underproduction of substances associated with the pathophysiology of cancer and 
cardiovascular diseases. For example, tea catechins are possibly involved in the tran-
scription of regulatory factors that determine the form of protein synthesized in cells 
of various tissues (Morton et al., 2000; Bauer et al., 2004; Ho et al., 2009).
Regarding atherosclerosis pathophysiology, several antioxidants have been shown 
to possibly alter metabolic pathways associated with endothelial function, inflam-
matory process, platelet aggregation, and hemostasis (Hodgson et al., 2005; Kaliora 
et al., 2005). In some cases, antioxidants such as catechins modify the expression 
of cyclooxygenase through suppressing factor AP-1; increasing the expression of 
an endogenous antioxidant of LDL, paraoxonase 1 (PON-1); deregulating the gene 
expression of inflammatory factors such as vascular endothelial growth factor, 
interferon-γ, and interleukin (IL)-4; and modulating the transcription factor nuclear 
factor (NF)-κB in endothelial cells and macrophages (Jochman et al., 2008).
Regarding cancer, antioxidants may affect genes associated with tumorigenesis. 
They may affect the cell cycle and act on the process of apoptosis. For example, 
flavonoids have been found to promote apoptosis in cancer cells via deregulation of 
the gene p53, which regulates the cell cycle phases. Flavonoids seem to inhibit the 
transcription of AP-1, preventing the transformation of DNA and affecting c-jun 
and c-foc expression. Thus, by promoting the expression of proteins associated with 
the c-jun-form heterodimers, they may decrease the activation of genes that cause 
cancer. Although for cardiovascular disease, research data show a direct effect of 
antioxidants and particular flavonoids in the pathophysiology of the disease, the data 
for the effect on cancer prevention are controversial, and further research is needed 
(Ahmad & Mukhtar, 1999).
ANtIoxIdANt supplemeNts ANd Adult heAlth
Although the consumption of a diet rich in antioxidants is correlated with specific health 
benefits, there is no clear evidence supporting the claim that the intake of supplementary 
individual antioxidants exerts significant bioactivity (Benzie & Choi, 2014). This may 
be explained by the holistic antioxidant effect of a whole food or diet, which is the result 
of the synergistic action of specific antioxidants (Koutelidakis & Kapsokefalou, 2012).
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In a meta-analysis of the effect of antioxidant supplements for the prevention of 
mortality in healthy participants and patients with various diseases, Bjelakovic and 
coworkers showed that antioxidant supplements had no significant effect on mortality 
in a random-effects meta-analysis (RR, 1.02; 95% CI, 0.99–1.06), but significantly 
increased mortality in a fixed-effect model (RR, 1.04; 95% CI, 1.02–1.06). In trials 
with a low risk of bias, the antioxidant supplements significantly increased mortal-
ity (RR, 1.05; 95% CI, 1.02–1.08). When the different antioxidants were assessed 
separately, analyses found increased mortality with vitamin A, β-carotene, and vita-
min E, but no significant detrimental effect of vitamin C (Bjelakovic et al., 2008). 
In another study, Kris-Etherton and coworkers (2004) suggested that the existing 
scientific databases do not justify the routine use of antioxidant supplements for the 
prevention and treatment of cardiovascular disease. Furthermore, in vivo studies 
have shown that the administration of vitamin E raised the plasma lipid peroxidation 
product levels in smokers on a high-fat diet and increased the fat content of livers in 
rats fed a high-fat diet plus ethanol (Yoshihara et al., 2010) (Table 5.2).
Dietary antioxiDants in the elDerly
specIAl Needs of the elderly ANd ImportANce of dIetAry ANtIoxIdANts
Old people tend to be neglected by both their families and the health-care system, and 
they sometimes live in isolation in their final stage of life. They are usually unable 
to shop and cook properly, and only a small fraction of them consume the recom-
mended levels of energy, essential trace elements, or vitamins A and D. Consumption 
of vegetables is usually low, and few of them manage to achieve the recommended 
five portions a day (Heinrich & Prieto, 2008). “Although health status has multiple 
contributing factors, nutrition is one of the major determinants of successful aging. 
taBle 5.2
recommended Dietary allowance, tolerable upper intake level, 









β-Carotene ND ND 1.2–50 mg 15.5 mg Daily or on 
alternate days
Vitamin A 900 μg 700 μg 3000 μg 400–7500 μg 1650 μg Daily
Vitamin C 90 mg 70 mg 2000 mg 60–2000 mg 450 mg Daily
Vitamin E 15 mg 15 mg 1000 mg 10–5000 mg 400 mg Daily or on 
alternate days
Selenium 55 μg 55 μg 400 μg 20–200 μg 87.5 μg Daily
Source: Bjelakovic, G., Nikolova, D., Gluud, L. L., Simonetti, R.G., and Gluud, C., Cochrane Datab Syst 
Rev 2, 2008.
Note: RDA, recommended dietary allowance; TUIL, tolerable upper intake level.
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Many older adults have at least one or more chronic health condition. Disparities 
in health are believed to be the result of complex interaction among genetic varia-
tions, environmental factors, and cultural and health behaviors. Inequities in access 
to health care, income, and poverty, as well as food security also contribute to health 
disparities among older adults” (Bernstein & Munoz, 2012).
Nowadays there is a trend to increase the lifespan, and research is generally 
focused on dietary traditions or interventions that allow healthy aging. The antioxi-
dant content of diet may play a pivotal role in the aging procedure and directly affect 
the appearance of neurodegenerative diseases (Heinrich & Prieto, 2008). The elderly 
life stage involves important physiological changes, including increased oxidative 
stress in tissues; thus, the antioxidant content of diets may decrease the impact of 
several pathophysiological processes (Zampelas, 2003; El Assar et al., 2013).
Vitamin A absorption is increased in the elderly; thus, the recommendations of 
800 mg and 1000 mg for women and men, respectively, adequately cover the needs of 
old age. Furthermore, for the fat-soluble vitamin E, there is no risk of inefficiency in 
old age because it is stored in the liver. On the contrary, in old age, there is an extended 
metabolism of vitamin C, especially in men. Men need 150 mg ascorbic acid daily 
for a normal plasma concentration of 1 mg/dL, while women need the recommended 
amount of 75–80 mg (Zampelas, 2003). According to the Dietary Reference Intakes 
(DRIs), the RDA for men >70 years old is 900 μg/day vitamin A (as RAE), 90 mg/day 
vitamin C, and 20 μg/day vitamin E (as α-tocopherol). For females >70 years old, the 
RDA is 700 μg/day vitamin A, 75 mg/day vitamin C, and 20 μg/day vitamin E (Food 
and Nutrition Board, Institute of Medicine, National Academies, 2011).
Recent scientific reports suggest that adherence to a balanced diet rich in antioxi-
dant components, such as the Mediterranean diet, could protect older adults from 
the progression of degenerative diseases. A balanced combination of antioxidant 
nutrients may be necessary to have a significant effect on the prevention of cognitive 
decline and dementia in the elderly. The Academy of Nutrition and Dietetics encour-
age older people to achieve intakes meeting the DRIs for antioxidant vitamins and 
minerals, and the recommendation of a multivitamin supplement only if food intake 
is low. High dietary intake of vitamins E and C was associated with a lower risk of 
Alzheimer’s disease, while decreased vitamin E levels have been associated with 
memory deficit in old people (Benfeito et al., 2012).
Research on antioxidant intakes at supplemental levels is inconclusive, and the 
conflicting results may be the result of various genetic factors and prior nutrient 
deficiencies. Furthermore, there is no evidence demonstrating the effective action of 
antioxidant supplements in doses higher than the DRIs in the elderly. On the con-
trary, the high consumption of vitamins A and E may induce toxicity in older adults 
due to the increased absorption of these antioxidant compounds (Gillette et al., 2007; 
Bernstein & Munoz, 2012).
dIetAry ANtIoxIdANt coNsumptIoN ANd dIseAse preveNtIoN IN the elderly
The increasing oxidative stress during aging is correlated with the progression of 
various disease pathophysiologies such as cataract, arteriosclerosis, Alzheimer’s dis-
ease, and Parkinson’s disease (Lau et al., 2005; Lloret et al., 2011; El Assar et al., 
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2013; Zampatti et al., 2014). Cataracts and age-related macular degeneration (AMD) 
are common diseases of older adults. Higher intakes of phytochemicals may help 
prevent or delay the development and progression of cataracts and AMD. Adequate 
intakes of flavonoids and carotenoids, especially lutein and zeaxanthin, through a 
diet rich in fruits and vegetables increase their serum concentrations and the macu-
lar pigment density, and may help in the prevention of AMD (Bernstein & Munoz, 
2012; Zampatti et al., 2014). A balanced diet containing antioxidant compounds is 
considered a basic parameter for enhancing endogenous stress responses and could 
be effective during the aging process, favoring a successful vascular aging; thus, it 
may reduce the risk for cardiovascular disease (El Assar et al., 2013).
Human brain and nervous system cells are particularly sensitive to oxidative 
stress because (i) the brain constitutes 2% of the total weight and consumes 20% of 
recruited oxygen; (ii) it is rich in polyunsaturated fatty acids, which are easily oxi-
dized; (iii) it contains large amounts of iron and ascorbate that catalyze lipid peroxi-
dation; (iv) many neurotransmitters are auto-oxidized and produce reactive oxygen 
species; (v) in specific brain areas, neuronal mitosis promotes oxidative damage; and 
(vi) via activation of genes such as Enos, IL-1β, TNF-α, and NF-κB, inflammatory 
processes may occur in nerve cells, thereby producing free radicals and cytokines. 
Therefore, the brain and nerve cells being prone to oxidative process may lead to the 
aging process and the emergence of diseases such as Alzheimer’s and Parkinson’s 
(Sun et al., 2002; Lau et al., 2005).
In recent years, many scientific studies, mainly in animals and humans, have 
suggested a possible beneficial effect of several food antioxidants in the decelera-
tion of aging process in the brain, which causes the neurodegenerative diseases of 
old age. Cognitive tests in mice with Alzheimer plaques showed that diet containing 
fruits and vegetables, which are rich in antioxidants, improved cognitive functions 
and increased the number of neuronal cells. Mice that ate fruits rich in polyphenols, 
such as berries, had increased memory, improved cognitive status, and showed pro-
liferation of neuronal cells, which are attenuated during aging, due to the increased 
expression of ERK genes in synaptosomes (Lau et al., 2005). The main mechanisms 
of action of antioxidants in neurological diseases include the possible influence on 
specific genes, antioxidant scavenging, and the regulation of cellular pathway mes-
saging (Sun et al., 2002; Lloret et al., 2011). For example, polyphenols have been 
found to inhibit free radicals in the brain, preventing the production of substances 
that promote neurological diseases, such as inflammatory cytokines and interleu-
kins, in microglia and peripheral nerves. They may also activate the factor NF-kB 
and remove iron, which is found in large concentrations in synaptosomes and mito-
chondria in the brain of patients with Alzheimer’s and Parkinson’s and has been 
linked to the pathogenesis of those diseases. Dietary antioxidants may reduce lipid 
peroxidation induced in the presence of iron in the mitochondria of mouse brain 
cells. They also form complexes with iron that reduce the in vitro production of 
aldehydes, a contributing factor in the production of reactive oxygen species and 
toxicity in the dopaminergic system (Sun et al., 2002; Esposito et al., 2003; Weinreb 
et al., 2004).
Alzheimer’s disease is a neurodegenerative process associated with oxidative 
stress. It is known that the intracellular amyloid β could play a pivotal role in the 
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pathophysiology of the disease. Amyloid β binds to heme groups in mitochondrial 
membranes, causing electron transport chain impairment and loss of respiratory 
function. Although many clinical trials have investigated whether antioxidants are 
beneficial in the treatment of Alzheimer’s, and there are some effective results from 
animal studies, there are no clear data confirming that antioxidants are an effective 
therapy; more research is necessary to clarify this point (Lloret et al., 2011). Findings 
from studies of antioxidant intake above RDA levels in subjects with diagnosed cog-
nitive impairment or Alzheimer’s disease demonstrated no difference in the delay of 
cognitive decline (Bernstein & Munoz, 2012).
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IntroduCtIon
Oxidative stress (OS) is a normal phenomenon in the body. The main contributors 
to OS, reactive oxygen species (ROS), are produced by living organisms as a result 
of normal cellular metabolism. Under normal conditions, physiologically important 
intracellular levels of ROS are maintained at low levels with various enzyme sys-
tems involved in redox homeostasis in vivo (Jakob and Reichmann 2013). At low to 
moderate concentrations, ROS function in normal cellular processes; however, at 
high concentrations, they produce undesirable changes in cellular components such 
as lipids, proteins, and DNA. The shift of the balance between oxidants/antioxidants 
is called “oxidative stress.” For the past two decades, OS has been one of the hottest 
topics among biological researchers worldwide.
Several reasons may be given to justify the importance of knowledge on ROS and 
reactive nitrogen species (RNS) production and metabolism: identification of biomark-
ers for oxidative damage, evidence for the occurrence of serious of chronic health 
problems due to OS, identification of different dietary antioxidants present in vegeta-
bles such as bioactive molecules, and so forth. OS contributes to many disease states, 
including cancer, neurological disorders, atherosclerosis, hypertension,  ischemia/ 
perfusion diabetes, acute respiratory distress syndrome, idiopathic pulmonary fibro-
sis, chronic obstructive pulmonary disease, and asthma (Da Costa et al. 2012).
Cigarette smoke is a highly complex aerosol consisting of several thousands of 
chemical substances, approximately 4700 of which are distributed between the gas 
and particle phases. It is divided into mainstream smoke (inhaled smoke) and side-
stream smoke. Mainstream smoke is divided into a solid particulate phase (tar) and 
a gas phase (toxic gases, volatile organic compounds, volatile organic compounds, 
free radicals [FRs], etc.) (Siasos et al. 2014, Wooten et al. 2006). Cigarette tar con-
tains extremely high concentrations of stable FRs (about 1017 spins g−1) with a very 
long lifetime. Sidestream smoke is divided into the solid and gas phases, and con-
tains higher concentrations of toxic and carcinogenic compounds and other volatile 
and semivolatile compounds. FRs and antioxidants in the gaseous phase are present 
in a stable state that is continuously formed and destroyed, and the concentration 
increases as the smoke ages. The gaseous phase is about 0.4–0.5 g/cigarette and 
contains 500 volatile organic and inorganic compounds. The particulate phase (tar) 
consists of fine and very fine particles (0.1–1.0 micron, aerodynamic diameter) that 
penetrate deep into the alveoli. Some of the soluble components of aqueous cigarette 
tar (ACT) can generate superoxide anion ( )O2
−  and then hydrogen peroxide (H2O2) 
and reactive hydroxyl radical (HO), which cause oxidative damage to cellular mem-
brane lipids, proteins, enzymes, and DNA (Romero et al. 2013). Sidestream smoke 
is composed of similar chemical components in solid and gaseous phases, and is 
also rich in short-lived and highly reactive FRs. Passive smoking (or environmental 
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tobacco [cigarette] smoke, ETS) has been shown to be a risk to the health of the 
nonsmoking population and contributes to major lung diseases (Widome et al. 2010, 
Wooten et al. 2006).
It is known that smoking is harmful to human health, from the results of many 
epidemiological studies linking smoking with high mortality from the onset of heart 
disease and cancer (Siasos et al. 2014). A large number of data on the composition of 
mainstream smoke have been published, and the matter has been examined in detail. 
The enormous complexity of cigarette smoke is the result of multiple thermolytic 
processes occurring during the combustion of the cigarette rod. These processes 
include distillation, pyrolysis, and combustion, and are influenced by factors includ-
ing the design of the cigarette and the composition of tobacco. Numerous chemi-
cal classes of organic compounds present in cigarette smoke include saturated and 
unsaturated hydrocarbons, alcohols, aldehydes, ketones, carboxylic acids, esters, 
phenols, nitriles, terpenoids, and alkaloids. As the composition of cigarette smoke is 
complex, some components of tobacco have been scrutinized more than others have, 
either because of their greater relative abundance in tobacco (which makes them 
easy to analyze), their known pharmacological properties, and/or because they are 
believed to be carcinogenic or potentially harmful to smokers.
InterrelatIonshIp between CIgarette 
smoke ChemIstry and os
There are a number of chemical classes of tobacco ingredients that have been 
reported to affect OS (Chalmers 1999). Owing to the complexity of cigarette smoke, 
it is impossible to be comprehensive, and much remains unknown. The components 
of smoke included in this chapter are compounds or metal ions that act as electro-
philes, FRs, reactive anions or metal ions that act as reducing agents (donate an 
electron), or FRs or metal ions that act as oxidizing agents (accept an electron). ROS 
and RNS are generated when mainstream cigarette smoke interacts with aqueous 
media or physiological fluids. Some components of tobacco are involved in OS only 
when chemically modified by metabolic processes in vivo. Also, it is possible to 
distinguish between an oxidant from the direct action of the components of cigarette 
smoke and secondary antioxidants that occur as a reaction to inflammation resulting 
from smoking-related OS.
Radicals in cigaRette taR
Free radicals (Frs)
Studies have shown that the FRs in cigarette smoke originate not only from the com-
bustion process but also from secondary reactions involving nitrogen oxide species 
(like nitric oxide [NO] and nitric dioxide [NO2]) following smoke generation. These 
species are involved in the generation of oxygen-centered radicals via the addition 
of nitrogen dioxide to unsaturated compounds (i.e., reactive double bonds). This may 
lead to the generation of carbon-centered radicals that subsequently react with atmo-
spheric oxygen to form oxygen-centered radicals (Wooten et al. 2006).
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Mainstream tobacco smoke contains up to 700 ppm NO that is produced from 
nitrogen-containing compounds (like proteins and alkaloids) in tobacco. This high 
concentration of NO is partially responsible for the generation of FRs in cigarette 
smoke. There is also indirect evidence that NO2 is involved in the generation of other 
radical species. By spin trapping the gas-phase FRs, the oxidation products derived 
from the corresponding spin trap can be clearly seen by electron paramagnetic reso-
nance (EPR) spectroscopy (Chalmers 1999).
Oxygen-centered FRs such as alkoxyls and peroxyls have also been identified in 
cigarette smoke by spin trapping, or by using a nonreductive scavenging method. 
However, the EPR spectra for O-centered radicals in the literature are usually weak 
and complex because they are mixed with C-centered radicals, which are formed 
first and are more stable. By employing 5-diethoxyphosphoryl-5-methyl-1-pyrroline-
N-oxide (DEPMPO), however, the lifetime of peroxyl radicals is increased by >15 
times (Zuo et al. 2014). In the literature, N-t-butyl-α-phenylnitrone and 5,5-dimethyl-
1-pyrroline-N-oxide have also been used as spin traps in cigarette smoke studies, 
although they are less suitable for O-centered radicals compared with DEPMPO. 
This work investigated some of the FRs in mainstream cigarette smoke in both the 
gas and particulate phases by combining spin-trapping techniques with EPR spec-
troscopy (Valavanidis et al. 2009).
Hydrogen peroxide is a naturally occurring by-product of OS, formed during 
normal breathing in living organisms by the catalytic disproportionation of super-
oxide by superoxide dismutase (SOD). Another enzyme, catalase, is very effective 
in converting H2O2 into “harmless products, water and molecular oxygen” (Wooten 
et al. 2006). If this cellular defense mechanism is overwhelmed, excess H2O2 can 
undergo disproportionation through the Fenton reaction to form hydroxyl radicals. 
The hydroxyl radicals from H2O2 are highly oxidizing species and are well known 
to cause oxidative damage to essential biomolecules, including DNA. H2O2 has been 
found in ACT and unbuffered aqueous solutions of catechin, a component of tobacco 
abundant in both ACT and total particulate matter (TPM). H2O2 concentration in 
smoke condensate has been shown to increase with age, temperature, and pH. H2O2 
found in cigarette smoke and H2O2 formed as a physiological response to smoke con-
stituents are considered to be a source of OS and/or damage to smokers.
Quinones
Quinones are easily formed by components of cigarette smoke that can undergo 
autoxidation. The toxicology of kinins has been studied extensively. Generally, the 
toxicity of quinones is believed to occur by two mechanisms: the mechanism of 
redox cycling, which produces excess ROS as by-products, and the formation of 
covalent bonds with the basic biological molecules (especially molecules containing 
thiol groups). Both mechanisms may contribute to the occurrence of OS (Valavanidis 
et al. 2009).
trace heavy metals
Tobacco plants carry the metal ions from the soil through the roots into the sheets. 
Trace amounts of heavy metals are accumulated on the sheets, and they are known 
to transfer in trace amounts from the treated and processed sheets to the inhaled 
87Smoking, Oxidative Stress, and Antioxidant Intake
tobacco smoke. These metals include cadmium, lead, mercury, arsenic, iron, copper, 
chromium, nickel, and selenium. Both redox-active and redox-inactive metals could 
potentially cause an increase in ROS in smokers (Valavanidis et al. 2009).
Radicals in gas Phase
The gas phase of cigarette smoke contains high concentrations of inorganic gases 
(O2, N2, CO, NO, HCN, H2S, and NH3), as well as various alkanes, alkenes, alcohols, 
and saturated and unsaturated aldehydes as volatile products of organic combustion. 
More specifically, the main gas-phase constituents are oxidative radicals, peroxyni-
trite, and glutathione.
oxidative radicals
Cigarette smoke contains abundant oxidants in the gas vapor. Even if the NO is 
from the same root, it is neither reactive nor particularly toxic. NO combines slowly 
with molecular oxygen in the air (for a period of seconds) to form the toxic oxidant 
and nitrating agent NO2. According to a proposed mechanism, NO2 reacts rapidly 
with other smoke constituents, such as isoprene and butadiene, to form nitrosocarbon-
centered radicals (Pryor et al. 1983). Atoms in the molecule are generally very reactive 
species. The gaseous-phase carbon in the molecule in tobacco reacts instantaneously 
with molecular oxygen to form peroxyl radicals that react with the NO gas phase of 
the smoke to form alkoxyl radicals and NO2, thus creating a continuous cycle. There 
are two interesting effects of the above reaction scheme (Jakob and Reichmann 
2013): (a) the oxidizing radicals in cigarette smoke are formed by reactions between 
the gas-phase constituents, and not primarily by pyrolysis or combustion reactions 
in the burning tobacco, and (b) the radicals collected inside an enclosed container 
of gas-phase smoke (Siasos et al. 2014) increase until the supply of NO· is depleted, 
persisting for several minutes.
peroxynitrite
Peroxynitrite RNS is formed by the reaction of NO and superoxide. Peroxynitrite 
is itself an FR, which is derived from two FRs, but it is also a strong oxidant that 
has been shown to induce failure in key biomolecules in physiological media. 
Peroxynitrite has been recognized as an OS-inducing compound in aqueous frac-
tions of cigarette smoke. After depletion of the intracellular reduced glutathione 
(GSH) content with electrophilic aldehydes, peroxynitrite interferes with specific 
target molecules, resulting in the activation of the stress associated with signal trans-
duction and gene expression in cells treated with cigarette smoke in vitro (Wooten 
et al. 2006).
glutathione depletion
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine, and is syn-
thesized and utilized in every organ of the body. It is abundant in the cytoplasm, 
nuclei, and mitochondria, and is the main water-soluble antioxidant in these cell 
compartments in millimolar concentrations. Amendments of intracellular GSH with 
electrophiles in the vapor phase of cigarette smoke were first reported decades before 
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it was reported that the concentration of protein sulfhydryl groups in plasma is about 
500 μM. After exposure to cigarette smoke, the concentration of protein sulfhy-
dryl groups decreased by about 60%. γ-Glutamylcysteine ligase is the rate-limiting 
enzyme involved in GSH synthesis, and its expression has been shown to be induced 
in response to cigarette smoke (Min et al. 2011). Cigarette smoke exposures evoke a 
powerful GSH adaptive response in the lung and systemically.
eFFeCts oF CIgarette smoke on os In humans
The acute effects of smoking (ACS) on OS markers have been mainly analyzed in 
exhaled air, bronchoalveolar lavage (BAL), and blood. Most studies have shown a 
direct increase in OS after ACS; however, in several studies, smoking had no effect 
(Wooten et al. 2006). Few studies have described the results of ACS in oxidative 
markers in exhaled breath condensate and air. In breath, the condensate 8-isopros-
tane, a product of lipid peroxidation, increased 15 min after ACS, and hydrogen 
peroxide increased 30 min after exposure. Smoke exhaled nitric oxide (eNO) was 
increased at 1 and 10 min but decreased 5 min after ACS in another study. This 
inconsistency probably reflects differences in eNO measurements and characteristics 
of individuals. No difference was observed in eNO at 15, 30, and 90 min after smok-
ing. Breath condensate nitrate levels increased at 30 min after ACS; however, nitrite 
and nitrotyrosine levels did not change.
Another study has investigated the effects of smoking on markers of OS in 
BAL, indicating increased superoxide release from BAL fluid (BALF) leukocytes 
and increased Trolox equivalent antioxidant capacity (TEAC). The latter surprising 
result can be explained by the fact that the studied subjects were all chronic smok-
ers already associated with high levels of BALF TEAC. No difference was found in 
intracellular GSH and oxidized glutathione (GSSG) in leukocytes, and thiobarbituric 
acid reactive substances (TBARS) in BALF and epithelial lining fluid.
Regarding peripheral blood, nitrate, nitrite, and cysteine levels were depressed 
for a short time just after smoking one cigarette (van der Vaart et al. 2004). No dif-
ference was observed in the production of reactive oxygen intermediates from neu-
trophils. Unlike in BALF, TBARS increased in plasma and plasma TEAC decreased 
1 h after smoking. Levels of F2-isoprostane, another product of lipid peroxidation, 
showed no change in plasma, possibly because all subjects in this study were chronic 
smokers and already have high F2-isoprostane levels.
Generally, acute smoking increases markers of OS in all experimental models—
human, animal, and in vitro (Rahal et al. 2014). NO and GSH are the only two 
parameters that have been investigated in all models. NO and its related substances 
increase within 24 h after smoke exposure. The GSH/GSSG ratio, reflecting the 
vital balance between oxidants and protecting antioxidants, decreased following 
acute smoke exposure in both animal and in vitro studies but not in the single study 
published in humans. This discrepancy can be explained by differences in species, 
smoke dose, or compartment (human BALF vs. animal lung homogenate).
Interestingly, ACS even results in damage of fatty acids in cell membranes, as 
measured by an increase in degradation products of lipid peroxidation in humans 
(exhaled air and plasma) and animals (BALF and lung tissue). No in vitro studies 
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investigating the acute smoke effects on lipid peroxidation products have been found. 
Because different time points within 24 h have been studied, it is possible to observe 
a time response of OS (van der Vaart et al. 2004). In humans, all oxidative markers 
increase within the first hour after ACS and most markers returned to normal within 
90 min. Exhaled air is the first compartment in which an increase in OS markers can 
be observed, followed by BALF and blood. In animals, most markers of OS change 
in the first 6 h after ACS and return to normal within 24 h. In all compartments (lung 
tissue, BALF, and blood), GSH or its derivatives are depressed in the same period, 
suggesting a generalized response to ACS.
As in humans, only a few time points have been studied in in vitro models. The 
initial depletion of GSH after ACS appeared to be followed by an increase in GSH 
24 h later, suggesting a protective mechanism of cells against OS from smoke. The 
importance of the GSH/GSSG balance was shown in several studies. When GSH 
was added to the experiment, the OS and inflammatory response induced by ciga-
rette smoke could be prevented. In summary, smoking immediately increases mark-
ers of OS in all models and even results in damage to the cell membrane.
InterrelatIonshIp between smokIng 
and antIoxIdant Intake
dietaRy antioxidants and smoking
A great number of epidemiological studies state that the consumption of antioxidant-
rich diets (fruits and vegetables) could reduce the risk of developing human degen-
erative diseases, by possibly protecting the organism more efficiently against OS (Da 
Costa et al. 2012). The most acceptable explanation was the presence of antioxidant 
nutrients, including vitamin C and E, carotenoids, flavonoids, selenium, etc., which 
protect against oxidative damage to the DNA, lipids, and proteins. Antioxidants are 
synthetic or natural substances, in low concentrations compared with the biomol-
ecules that they should protect. Their protective role is provided by their reaction 
with ROS and inhibition of the oxidation chain reactions, reducing their accumula-
tion and finally limiting the harmful effects of FRs (Romero et al. 2013). The human 
defense against OS includes endogenous and exogenous antioxidants. Endogenous 
antioxidants or endogenous radical scavengers, such as glutathione and coenzyme 
Q, are produced by the cell itself; however, the endogenous production is usually 
insufficient to inhibit OS (Kinnula 2005, Rahman et al. 2006). Exogenous antioxi-
dants, including nutrients and phytochemicals entering the organism through the 
diet (found in specific foods) or through supplements with antioxidant formulations 
and cofactors such as copper, zinc, manganese, iron, and selenium, can strengthen 
the organism and help combat diseases.
Endogenous and exogenous antioxidants play an important role in the regulation 
of ROS in a physiological manner (Table 6.1). In special conditions such as excessive 
FR production, their synergistic effect may be insufficient to prevent oxidative dam-
age (Figure 6.1). Furthermore, it is important to state that each person has a different 
capacity to defend against ROS and OS, which depends on the function of endog-
enous and exogenous antioxidant systems, their exposure to internal and external 
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table 6.1
examples of endogenous and exogenous (dietary) antioxidants
endogenous antioxidants exogenous (dietary) antioxidants
Enzymatic antioxidants Vitamins 
•	 Superoxide dismutase (SOD) •	 C (ascorbic acid)
•	 Glutathione peroxidase (GPx) •	 E (tocopherols, tocotrienols)
•	 Glutathione reductase (GRx) Carotenoids
•	 Catalase (CAT) •	  β-Carotene
Metabolic antioxidants (nonenzymatic) •	 Lutein
•	 Glutathione •	 Zeaxanthin
•	 Lipoic acid •	 Lycopene
•	 Uric acid •	  β-Cryptoxanthin
•	 Bilirubin Trace elements
•	 Melatonin •	 Selenium
•	 l-Arginine •	 Zinc
•	 Coenzyme Q10 Flavonols
•	 Metal-chelating proteins •	 Quercetin























Source: Da Costa, L.A. et al., Prog Mol Biol Transl Sci, 108, 179, 2012.
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stimuli (e.g., inflammation and smoking), and finally genetic variation (Comandini 
et al. 2010). The interaction of these factors may affect an individual’s ability to man-
age OS and determine antioxidant status.
Vitamins
Vitamin C
Vitamin C, also known as ascorbic acid or ascorbate, is the primary and one of the 
most abundant water-soluble dietary antioxidants. Experimental and epidemiologi-
cal evidence suggests that vitamin C is a powerful antioxidant, both in vivo and in 
vitro, in biological systems (Da Costa et al. 2012, Kelly 2003). Its health benefits 
refer to its anticarcinogenic, immunoregulatory, anti-inflammatory, and neuropro-
tector effects. It also plays an important physiological role as an electron donor, 
which explains its ability to neutralize FRs. Furthermore, it is an effective scavenger 
of the superoxide anion ( )O2
− , singlet oxygen (1O2), and hydroxyl radicals (OH−), and 
it protects lipids, proteins, and DNA from oxidative damage. However, vitamin C is 
Environment (exogenous
factors)
•  Chronic inflammation









•  Epithelial injury










FIgure 6.1 Interaction of reactive oxygen species (ROS), reactive nitrogen species (RNS), 
dietary and endogenous antioxidants, oxidative stress, and degenerative chronic disease. 
(From Da Costa, L.A. et al., Prog Mol Biol Transl Sci, 108, 179, 2012.)
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not an effective scavenger or neutralizer of hydrogen peroxide (H2O2) and may play 
an important role as a prooxidant in combination with redox-active metals such as 
iron (Romero et al. 2013). Vitamin C reacts with ROS and RNS to synthesize semi-
dehydroascorbate (ascorbate FR) and dehydroascorbate, which are reduced back to 
ascorbate by the actions of glutathione, NADH-dependent reductase enzymes, or 
thioredoxin. Vitamin C also participates in the regeneration of α-tocopherol from 
the α-tocopherol radical. The daily recommended doses of ascorbic acid are 75 mg/
day (for women) and 90 mg/day (for men). In the human body, the availability of 
ascorbic acid is between 1.2 and 2 g (20 mg/kg body weight) and its half-life ranges 
from 10 to 20 days.
Vitamin E
Vitamin E (α, β, γ, and δ tocopherols and α, β, γ, and δ tocotrienols), particularly 
α-tocopherol, acts as an intra- and extracellular liposoluble antioxidant; since it is 
a lipid-soluble molecule, its antioxidant functions are important in the protection 
of membrane lipids against peroxidation. Vitamin E is a chain-breaking antioxi-
dant that interrupts radical chain reactions produced by the lipid peroxy radicals 
(LOO−), thus preventing the propagation of damage to the biological membranes 
that give rise to FRs (Da Costa et al. 2012). Additionally, it directly scavenges 
superoxide radicals and singlet oxygen, which are thought to be initiators of oxida-
tion reactions. Its antioxidant activity is attributed to its chromanol rings, capable 
of donating hydrogen to ROS. In particular, the tocopherols concentrate on protect-
ing the polyunsaturated fatty acids of cell membrane phospholipids from cellular 
peroxidation, maintaining the integrity of biological membranes and other reac-
tive compounds (e.g., vitamins A and C) from oxidative damage. It also inhibits 
the peroxidation of low-density lipoproteins (LDLs), oxidizes the oxygen singlet, 
neutralizes peroxides, and captures the superoxide anion, converting it into less 
reactive forms (Kelly 2002a). In addition, tocopherols play an important role in 
cell respiration and in DNA and coenzyme Q biosynthesis. Regarding the dietary 
requirements of vitamin E, it is important to state that 1 international unit (IU) 
vitamin E is equal to 1 mg α-tocopherol, and 1 IU vitamin E is equal to 0.67 mg 
vitamin E. In adults specifically, the minimum daily requirement for vitamin E is 
15 mg/day, and the range between 200 and 600 mg/day is safe as it would not cause 
any disorder (Romero et al. 2013).
Vitamin A and Non–Provitamin A Carotenoids
Vitamin A is a family of essential liposoluble compounds, named retinoids, includ-
ing retinol, retinal, retinoic acid, and retinyl esters, which have a structural rela-
tionship and share their biological activity (Da Costa et al. 2012). In the human 
diet, the two different forms of vitamin A that are available are the preformed vita-
min A (retinol and its esterified form, retinyl ester) and provitamin A carotenoids 
(β-carotene [the most important form], α-carotene, and β-cryptoxanthin) (National 
Institutes of Health 2013). The most well-studied function of carotenoids is their role 
as precursors for vitamin A. This characterization applies only to the carotenes and 
cryptoxanthins, as lutein, zeaxanthin, and lycopene cannot be converted to retinol 
and are known as non–provitamin A carotenoids. Both retinyl esters and provitamin 
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A carotenoids are metabolized intracellularly to retinol, which is oxidized to retinal 
and then to retinoic acid, the active forms of vitamin A, to exert the vitamin’s impor-
tant biological functions.
Many roles have been proposed for carotenoids, including inhibition of tumor 
growth, protection against genotoxicity, and modulation of the immune system 
(Kelly 2002b). Vitamin A and carotenoids are characterized as antioxidant vitamins 
and are effective FR scavengers, inhibiting the activity of FR, protecting the DNA 
from their mutagenic action, and thus preventing cellular aging. Their oxygen sensi-
tivity is due to the large amount of double loops present in their structure.
As carotenoids are lipid soluble, their antioxidant properties may be particularly 
important for protection of lipids and may work synergistically with vitamin E to 
prevent lipid peroxidation. Their bioavailability increases with the presence of vita-
min E and other antioxidants. Carotenoids may also play an important role in the 
protection of DNA damage from ROS attack while additionally modulating DNA 
repair mechanisms. Particularly for lycopene, which is a non–provitamin A carot-
enoid (not converted into vitamin A in the human body), evidence supports their 
very high antioxidant properties. High consumption of lycopene has been related 
with the prevention of some cancer types, specifically that of the prostate (Romero 
et al. 2013).
Flavonoids
Flavonoids belong to an aromatic group, with heterocyclic pigments that contain 
oxygen, which can be found among plants and especially the majority of yellow, 
red, and blue fruits (Da Costa et al. 2012). Several properties have been attributed 
to flavonoids, such as anti-inflammatory, antimicrobial, antithrombotic, antiallergic, 
antitumor, anticarcinogenic, and antioxidant properties. The following are examples 
of flavonoids:




 5. Isoflavonoids, such as genestein and daidzein
 6. Kaempferol
 7. Proanthocyanidines
Flavonoids are easily oxidized substances; for this reason, a fundamental char-
acteristic of these substances responsible for many of their beneficial effects is their 
antioxidant capacity (Braun et al. 2011). Quercetin protects primary human osteo-
blasts exposed to cigarette smoke. Quercetins are characterized by their low toxicity, 
and they exert a protector effect of the vascular wall. They can also inhibit lipid 
peroxidation, have antimutagenic effects, and possess the capacity to inhibit diverse 
enzymes. The antioxidant function of flavonoids relies mainly on their capacity to 
sequester FRs; chelate transition metals such as Fe2+, Cu2+, or Zn2+; impede the cata-
lytic actions of FR; and they also act by inhibiting the enzyme systems related with 
vascular functionality (Braun et al. 2011, Romero et al. 2013). Furthermore, it has 
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been suggested that they also indirectly inhibit oxidative pathways, such as phospho-
lipase A2, while stimulating others with recognized antioxidant properties, such as 
catalase and SOD.
Among the >4000 varieties of flavonoids, quercetin is the natural flavonoid widely 
distributed in a healthy human diet that exerts an effective antioxidant function. It is 
present in five times higher amounts than vitamins A and C, and additionally is also 
hydrophilic like vitamin C. Flavonoids have been shown to exert antioxidant capacity 
by reducing OS-dependent damage and ROS formation, not only in vitro (e.g., ethanol-
treated primary human hepatocytes) but also in vivo in rats exposed to methyl-mercury. 
Furthermore, recent studies have shown that various flavonoids may positively influence 
the negative effects of cigarette-associated tissue damage in humans (Braun et al. 2011). 
Specifically, rutin (quercetin-3-β-d-rutinoside) has a synergic effect with all of the vita-
mins to which we have alluded. Ascorbic acid also reduces the oxidation of quercetin, 
allowing the flavonoids to maintain their functions for a longer time. Quercetin also pro-
tects vitamin E from oxidation. The flavonoids remove reactive oxygen, especially in 
the form of SOD, hydroxyl radicals, hydroperoxides, and lipid peroxides, inhibiting the 
harmful effects of these compounds on cells.
Some flavonoids, such as the anthocyanidines, cause low oxidation potentials (EP/2), 
which allow them to reduce Fe3+ and Cu2+, and thus they undergo autooxidation or 
become involved in the redox recycling pathway; acting in this manner, they work as 
pro-oxidant agents (Da Costa et al. 2012). Another potential mechanism is the autooxida-
tion of the aroxyl radical and generation of the superoxide anion ( )O2
−  that becomes the 
harmful hydroxyl radical (HO). The determinant of the antioxidant or prooxidant charac-
ter is the redox stability/lability of the radical compound that forms a part of the original 
flavonoid. The prooxidant actions are exerted when the flavonoid doses are very high.
minerals and trace elements
Minerals and trace elements such as copper, manganese, selenium, zinc, and iron 
may exert antioxidant properties. These substances act as potent antioxidant in a 
variety of metabolic processes and pathways in the human body (Da Costa et al. 
2012).
Zinc
Zinc is a trace element that takes part in >200 enzymatic reactions. In case of defi-
ciency, there is an increase in the production of oxidant species and OS (Romero et 
al. 2013).
Copper
Copper is a mineral that acts as an antioxidant through its participation in functions 
of the enzyme SOD, which eliminates the superoxide anion. Its antioxidant effect is 
exerted through the protection of cells from the toxic effects of FR and the facilita-
tion of calcium and phosphorous fixation (Da Costa et al. 2012).
Selenium
Selenium is a trace element that is involved in the process of the synthesis of enzymes 
related with oxidative function, including glutathione peroxidase. This enzyme 
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eliminates peroxide groups such as oxygen peroxide. Selenium is attached to pro-
teins, forming the denominated selenoproteins. With this action, it contributes to the 
prevention of cell damage (Da Costa et al. 2012).
Iron
Iron takes part in the organism’s antioxidant defense processes, as it intervenes in the 
elimination of the peroxide groups. Furthermore, its ability to change valence with 
ease (2+/3+) means that it can also be involved in the formation of FRs (Da Costa 
et al. 2012).
Interaction of smoking and dietary antioxidants
The reviewed literature proposes that smokers have lower circulating concentrations 
of many micronutrients, including ascorbic acid, β-carotene, α-carotene, and crypto-
xanthin (Vardavas et al. 2008). There is a complex relationship between smoking and 
the circulating concentrations of micronutrients, and scientific evidence is conflict-
ing concerning the antioxidant capacity of certain micronutrients, e.g., β-carotene. 
Taking into consideration that antioxidants may act as potential prooxidants, pos-
sible lower concentrations of antioxidants in smokers compared with nonsmokers 
may be a defensive adaptation to the pro-inflammatory environment in smokers’ tis-
sues. Furthermore, another explanation for these disparities may be the differences 
in dietary intakes.
case of natuRal antioxidants
Vitamin C
A great number of studies have shown that smoking reduces the plasma vitamin C 
level (Alberg 2002, Kelly 2003, Northrop-Clewes and Thurnham 2007). Specifically, 
one study that investigated the relationship between smoking status and serum and 
dietary micronutrient concentrations revealed that current smoking status affected 
the dietary nutrient intake (lower dietary intake) of vitamin C, but not of vitamin 
A and E (Vardavas et al. 2008). Epidemiological evidence also supports the idea 
that low-plasma vitamin C is a risk factor for coronary heart disease (May 2000, 
Northrop-Clewes and Thurnham 2007). The early and more recent research has sug-
gested that adverse changes in the intake, absorption, transport, utilization, turnover, 
and excretion of vitamin C are associated with exposure to cigarette smoke. Vitamin 
C status may also play a role in modulating the action and metabolism of compo-
nents of smoke and will be discussed in the following sections (Northrop-Clewes 
and Thurnham 2007).
Regarding the dietary intake of vitamin C and its interrelation with blood con-
centrations, some studies propose that the low concentrations of circulating vitamin 
C in smokers could be explained from alterations in the metabolism of this vitamin. 
Other studies suggest that this is due to low dietary intake of the nutrient. Most of 
the studies have shown that plasma and leukocyte concentrations of vitamin C are 
lower in smokers than in nonsmokers. Furthermore, it is stated that smokers have 
a nicotine-induced decrease in the efficiency of intestinal absorption, a decreased 
urinary excretion rate, and a higher metabolic turnover of vitamin C. Although 
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evidence suggests that administration of vitamin C can result in decreases in mark-
ers of OS, a recommended dietary allowance derived from a direct antioxidant func-
tion of vitamin C could not be calculated and proposed. This is due to the lack 
of a quantitative relationship between any antioxidant function and a health-related 
endpoint (Northrop-Clewes and Thurnham 2007). Concerning the turnover of vita-
min C, a great number of studies support the idea that there is increased turnover in 
response to the high and sustained oxidant load from smoking.
Vitamin e
In regard to vitamin E status, α-tocopherol concentrations usually do not differ in 
the serum of smokers and nonsmokers, in contrast to β-carotene and vitamin C, 
which are lower in cigarette smokers (Northrop-Clewes and Thurnham 2007). Older 
smokers may also have lower blood vitamin E concentrations than younger smok-
ers (Alberg 2002). In a cohort analysis study, it was found that higher α-tocopherol 
concentrations may be protective against pancreatic carcinogenesis in male smok-
ers (Stolzenberg et al. 2009). Furthermore, in one study, α-tocopherol concentration 
was negatively correlated with a smoking index (cigarettes/day × years of smoking). 
Pharmacokinetic data from different studies suggest that α-tocopherol metabolism 
might differ between smokers and nonsmokers (Bruno and Maret 2005).
With respect to the dietary intake of vitamin E, it is not clear whether the increase 
in vitamin E turnover is due to smoking-induced inflammatory changes or OS. It 
is also proposed that if the turnover of vitamin E is faster in smokers than in non-
smokers and, and if plasma concentrations are not adversely affected in smokers, 
the intake of vitamin E for smokers in industrialized countries should be adequate 
enough to enable them to deal with the added oxidative smoking-induced stress. 
Nicotine in cigarettes could cause the difference in vitamin E intake, which has an 
influence on taste and appetite (Northrop-Clewes and Thurnham 2007). However, 
the effects of smoking on appetite do not affect the intake of vitamin E–contain-
ing foods in the way and extent that smoking influences the intake of carotene and 
vitamin C.
Vitamin a and non–provitamin a Carotenoids
The serum retinol concentrations in smokers are usually similar to those of nonsmok-
ers. This suggests that the inflammation associated with smoking is not sufficient to 
disturb the normal homeostatic control of retinol in plasma. Also, the evidence on 
total dietary intake of vitamin A of smokers appears to be inconsistent, suggesting 
the need for further study (Alberg 2002, Northrop-Clewes and Thurnham 2007).
With respect to the β-carotene status of cigarette smokers and comparison of 
plasma/serum concentrations of β-carotene between heavy smokers (≥20 cigarettes/day 
or ≥10 years of smoking) and nonsmokers, the data revealed lower plasma β-carotene 
concentrations in smokers than in nonsmokers. The data also revealed that in heavy 
smokers, the increase in plasma β-carotene concentrations associated with higher 
intakes was smaller than in nonsmokers or light smokers (Northrop-Clewes and 
Thurnham 2007).
Regarding the dietary intake of β-carotene and its relationship with blood concen-
trations and disease, scientific evidence has shown that the concentration of plasma 
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β-carotene is mainly determined by dietary intake. Epidemiological evidence also 
proposes that cigarette smokers consume less fruit and vegetables than nonsmok-
ers. Low plasma β-carotene concentrations commonly found in smokers suggest that 
higher intakes of dietary carotenoids are probably needed to achieve optimal concen-
trations of plasma carotenoids in this population (Northrop-Clewes and Thurnham 
2007). In the case of carotenoids other than β-carotene, there are only small amounts 
in the diet and blood, and differences in intakes of vegetables and fruits may obscure 
the effects of smoking on both diet and blood concentrations.
Concerning lycopene, the major carotenoid present in tomato, its consumption 
may prevent smoke-induced cell damage; however, the mechanisms are still unclear. 
Beneficial effects of tomato lycopene on the risk of smoke-related diseases, includ-
ing cancer and cardiovascular injury, have been stated in epidemiological studies. 
However, the experimental basis for such health benefits is not fully understood 
(Alberg 2002).
Flavonoids
Results of meta-analyses of various studies revealed that total dietary flavonoids and 
several flavonoid subclasses were associated with reduced risks of smoking-related 
cancers (Hae and Jeongseon 2013). In only the case–control studies, flavones, flava-
nones, isoflavones, and flavonol quercetin (a natural flavonoid widely distributed in a 
healthy human diet) were inversely associated with the risk of smoking-related can-
cers. The beneficial effects of flavonoids on cancer risk were more prominent among 
smokers than nonsmokers. Although the protective effects of dietary flavonoids may 
differ by cancer site among the smoking-related cancers, the results of each flavo-
noid subclasses were similar. Total flavonols and flavonol quercetin may be the most 
powerful agents for smoking-induced carcinogenesis. Generally, it is proposed that 
smokers might benefit from a flavonoid-rich diet. Another study also found that quer-
cetin might be used not only in supporting bone regeneration in smokers but also 
in strengthening the bone metabolism in different pathogenesis (Braun et al. 2011).
Zinc
The reported differences in serum zinc concentrations between smokers and non-
smokers can reflect the duration and amount of smoking exposure. In one study, it 
was found that plasma zinc concentrations were unaffected by smoking; however, 
CuZn–SOD activity was higher in smokers. In another study, it was found that mean 
serum zinc was significantly lower in the smoking group than in the nonsmokers. In 
this study, it was suggested that lower serum zinc concentrations could reduce the 
zinc available for incorporation into CuZn–SOD and increase the risk of oxidative 
damage (Northrop-Clewes and Thurnham 2007).
Copper
Serum ceruloplasmin concentrations and erythrocyte CuZn–SOD activity are the two 
main indices of copper status that can be influenced by smoking. Scientific evidence 
has revealed that CuZn–SOD activity is consistently higher in smokers than nonsmok-
ers, and the increases may have been part of the body’s anti-inflammatory response 
to smoking. One explanation is that it has been shown to act as an acute-phase 
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protein with antioxidant and anti-inflammatory properties; however, it is not clear 
yet (Northrop-Clewes and Thurnham 2007).
selenium
The relationship between smoking and selenium status has not been studied exten-
sively, and generally, it was found that lower plasma concentrations are associated 
with increased cigarette use. Specifically, it has been suggested that the lower activ-
ity of erythrocyte GSHPx in smokers may occur due to the lower concentrations of 
plasma selenium. These low concentrations may be influenced by several other fac-
tors, such as the negative impact of cadmium, a toxic heavy metal found in tobacco, 
on the bioavailability of dietary selenium and the increased expression of inflam-
matory mediators such as interleukin-1 (IL-1), IL-2, IL-6, and IL-8 in response 
to smoking, which can have an effect on the concentrations of plasma selenium 
(Northrop-Clewes and Thurnham 2007). There is some evidence to suggest that the 
lower serum selenium concentrations are associated with inflammation.
Iron
There is scientific interest in the direction that high iron status may have an etiologi-
cal role in cardiovascular disease (CVD) and various cancers, since iron can promote 
the formation of FRs. Smoking appears to affect iron homeostasis mainly by causing 
changes in blood hemoglobin concentration. Serum iron, transferrin receptor (TfR), 
and ferritin concentrations are unaffected by smoking except in pregnancy, where 
there is evidence of increased erythropoiesis. Increased erythopoiesis causes lower 
iron saturation of plasma transferrin and probably results in lowering of iron stores 
(Northrop-Clewes and Thurnham 2007).
case of antioxidants in suPPlementation studies
Although observational studies have provided support for the potential health ben-
efits of antioxidants to smokers, we still have relatively little direct experimental evi-
dence from randomized trials. In this section, we present data from supplementation 
studies with antioxidants, alone or in combination.
Vitamin C supplementation studies
Several studies have demonstrated that a moderately large dose of vitamin C pre-
vents cigarette smoke–induced oxidative damage, inflammation, and apoptosis by 
reducing and thereby inactivating p-benzoquinone ( p-BQ) (Archita et al. 2012). 
Other studies in humans have looked at the effect of vitamin C supplementation on 
the ability of oxidation of LDLs, which is a risk factor for CVD. However, the supple-
mentation is often in combination with supplements of vitamin E or β-carotene. The 
study group in these studies includes smokers and nonsmokers, and a significant 
reduction in the ability of oxidation of LDLs has been revealed. However, because of 
the use of multiple nutrients in the supplements, it is difficult to clarify and quantify 
the contribution of vitamin C. Where vitamin C was the only given nutrient in sup-
plement dose, some studies found no effect while others found a significant reduction 
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in the ability of oxidation of LDLs. The conclusion is that supplementing smokers 
with vitamin C might provide some protection against atherosclerosis; however, no 
biomarker can be related to any health endpoint.
Vitamin e supplementation studies
According to the results from the ATBC (Alpha-Tocopherol Beta-Carotene Cancer 
Prevention) study, no reduction in lung cancer or major coronary events was found in 
male smokers receiving α-tocopherol. In another study, the HOPE (Heart Outcomes 
Prevention Evaluation) study, the subgroup analysis of data showed that vitamin E 
alone had no apparent effect on cardiovascular or myocardial infarction outcomes 
or deaths from coronary heart disease or stroke among smokers. In a meta-analysis 
studying the effects of vitamin E on myocardial infarction, stroke, or death from 
cardiovascular causes in smokers from four large trials: ATBC, CHAOS (Cambridge 
Heart Antioxidant Study), GISSI (Gruppo Italiano per lo Studio della Sopravvivenza 
nell’Infarto Miocardico), and HOPE, it was found that the overall relative risk (RR) 
was 0.97 (95% CI, 0.9–1.02) during a 4–6-year period of supplementation, and thus, 
there was little effect on the outcomes measured (Mondul et al. 2011). However, in 
another study, γ-tocopherol-rich supplementation in combination with smoking ces-
sation improved vascular endothelial function (Mah et al. 2013).
non–provitamin a Carotenoid supplementation studies
Scientific evidence suggests that lycopene may be protective against smoke-induced 
cell damage and has an important role in inflammatory processes. The results of 
one study with 2 μM lycopene indicated that this non–provitamin A carotenoid pre-
vented cigarette smoke extract–induced IL-8 production through the inactivation of 
nuclear factor-κB (Rossella et al. 2014).
Combined antioxidant supplementation studies
It has been stated that pharmacological interventions with nonselective antioxidants 
usually fail to be an effective strategy for the prevention and treatment of CVD 
caused by smoking; thus, a combined application of antioxidants may be needed 
(Bernhard and Wang 2007). Data from a study with combined α-tocopherol and 
ascorbic acid supplementation showed protective effects against smoking-induced 
lung lesions in ferrets (Kim et al. 2012). Another study showed that oral supplemen-
tation (with commonly available antioxidants, vitamins, and omega-3 fatty acids) 
induced metabolomic changes in cigarette smokers, and these effects were different 
between smokers and nonsmokers (Spitale et al. 2012).
selenium supplementation studies
Data from the Nutritional Prevention of Cancer Trial, a randomized clinical trial 
designed to evaluate the efficacy of selenium in preventing nonmelanoma skin can-
cer in the United States, stated that supplementation with 200 μg selenium daily was 
associated with a significantly lower risk of both total and prostate cancer incidence 
in former smokers; nonsignificantly lower risks were found in current and nonsmok-
ers who were supplemented (Northrop-Clewes and Thurnham 2007).
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ConClusIon
It is increasingly evident that a good diet influences the development and treatment of 
diseases. Furthermore, epidemiological studies have shown the association between 
moderate consumption of certain foods and reduced incidence of various diseases. 
These observations have attracted considerable interest in studying the properties of 
substances inherent in the chemical composition of food. Among the characteristics 
of these substances is their antioxidant activity, associated with the elimination of 
FRs and therefore with the prevention of the early stages that can trigger degen-
erative diseases. In this regard, it is important to continue the study of dietary anti-
oxidants concerning the activity they may have in human diseases, paying attention 
to the substances, primarily natural antioxidants of food, and the synthetic way to 
assess their protective effect on the body. Finally, a novel strategy for the prevention 
and treatment of diseases caused by smoking, relying on a combined application of 
antioxidants, substitution of important factors for human oxidant defense, and metal-
detoxifying agents, may be proposed.
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IntroductIon
Physical exercise is a cornerstone of good health, and it also plays a key role in the 
primary prevention of lifestyle-related diseases. Generation of reactive oxygen spe-
cies (ROS) is a constant process of normal cellular function. Oxidative stress, an 
imbalance of the generation of ROS and antioxidant defense capacity, and perturba-
tion of redox control of cellular events, is closely related to physiological aging and 
the pathophysiology of a wide range of diseases (Radak et al. 2013; Sen and Packer 
2000). During heavy physical exercise, the oxygen flux to active skeletal muscles is 
remarkably increased. Such acceleration in the oxidative metabolism is associated 
with increased production of ROS that are hazardous to living organisms. Oxidative 
insult is not only mediated by macromolecular oxidative damage but also through 
the disruption of the cellular redox homeostasis. At moderate concentrations, how-
ever, ROS and other related reactive molecules play an important role in the regu-
lation of cellular signaling. ROS act as secondary messengers to control a variety 
of vital processes. Therefore, many of the ROS-mediated responses protect against 
oxidative and metabolic stress and constitute a “redox homeostasis” (Sen 2001).
In biological systems, a variety of endogenous antioxidants have evolved to 
cope with oxidative stress, acting in concert to quench ROS and to maintain redox 
homoeostasis and tissue protection. This synergism between several endogenous and 
dietary antioxidants is essential for an effective protection. Although no solid sci-
entific evidence exists on the benefits of antioxidant supplementations to exercise 
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performance, multivitamins are widely used among athletes in hope that these agents 
may be effective (Atalay et al. 2006). The aim of this chapter is to briefly discuss 
the role of endogenous and exogenous antioxidants on physical exercise and human 
performance. Specifically, we will focus on the need, advantages, and disadvantages 
of antioxidant supplements for the physically active population and give a special 
emphasis on thiol antioxidants, which play a key role in cellular redox regulation.
AntIoxIdAnts And GenerAl HeAltH
There is a general consensus in the mechanistic and epidemiologic studies that an 
adequate and balanced intake of dietary antioxidants prevents the formation of ROS 
and contributes to lowering the risk of several common diseases. The frequent use 
of natural sources of antioxidant nutrients in the Mediterranean diet, together with 
unsaturated fats, low proportion of simple sugars, and high content of dietary fibers, 
appear to account for a lower risk of certain types of cancer as well as chronic heart 
disease (Castro-Quezada et al. 2014). Epidemiological evidence suggests protec-
tion of cardiovascular disease by dietary intake of flavonoids (Basu et al. 2010). 
Although several epidemiological studies have pointed out an inverse association 
between dietary intake of vitamin C, vitamin E, and β-carotene and cardiovascular 
disease (Whayne and Maulik 2012), the overall results of published trials of vitamin 
E and β-carotene supplementations have failed to confirm any protective effect on 
mortality. In agreement with previous reports, a meta-analysis of 68 randomized 
antioxidant supplement trials (a total of 232,606 human participants) concluded 
that dietary supplementation with β-carotene, vitamin A, and vitamin E above the 
recommended daily allowance (RDA) does not improve health outcomes and may 
increase mortality (Bjelakovic et al. 2007). In contrast, a recent meta-analysis of 
15 trials reporting data on 188,209 participants indicated that antioxidant vitamin 
supplementation as compared with placebo did not provide any overall protection 
against major cardiovascular events (Ye et al. 2013). Therefore, in contrast to the 
benefits of adequate antioxidant intake through a balanced and healthy diet, the 
use of antioxidant supplements may even exert a negative impact on general health.
need for AntIoxIdAnt supplementAtIon 
for pHysIcAlly ActIve IndIvIduAls
It is a common practice for athletes to use antioxidant supplements with the notion 
that they prevent the deleterious effects of exercise-induced oxidative stress, has-
ten the  recovery of muscle function, and improve performance (Atalay et al. 2006; 
Peternelj and Coombes 2011). Athletes may have ambiguous perceptions and receive 
misinformation about antioxidant supplementation in the public press: most of the 
physically active persons believe that they may have higher requirements of antioxidants 
than those who are sedentary. Therefore, physically active persons are more likely to 
use diverse antioxidant supplements compared with the overall prevalence in the 
general population (Rock 2007). In a recent study, 30% of athletes were reported to 
use more than two supplements (Tscholl et al. 2010). Most surprisingly, among elite 
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athletes aged 12 to 21 years, the average supplement use was even higher than what 
was observed in adult athletes with, on an average, 2.96 products used (Dascombe 
et al. 2010). Although a supplement may contain a dosage close to the RDA, the use 
of multiple supplements may result in cumulative, and sometimes an excess, intake 
of one or more nutrients. Despite the frequent use of antioxidant supplements among 
the physically active population, until now there has been no convincing scientific 
evidence to prove the presumption that antioxidant supplementations enhance sport 
performance, increase the health benefits of exercise, or decrease sports injuries. 
Furthermore, the obtained results are conflicting, and because of the diverse struc-
ture and biological effects of the antioxidant compounds, generalizing any individ-
ual supplementation result to all antioxidant supplements may be problematic. The 
reasons behind the null findings or inconsistent results among the studies employing 
simultaneous exercise and supplementation interventions could be explained by sev-
eral factors: differences in exercise protocols; characteristics of the subject popula-
tion, including sex, age, prior training, and physical activity status; dosage, form, 
duration, and timing of the supplementation; and the method used to assess the out-
comes of the intervention.
Up until now, there has been no solid evidence in the literature demonstrat-
ing a higher need for antioxidants in athletes. Most of the nutrition surveys in the 
United States indicate that athletes have adequate intake of vitamin C. The vitamin 
C consumption for male athletes ranges from 95 to 520 mg/day, whereas the con-
sumption range for females is from 55 to 230 mg/day (Lukaski 2004), while the 
current dietary reference intakes (DRIs) of vitamin C are 90 mg/day for males and 
75 mg/dL for females of different adult age groups (U.S. Department of Health and 
Human Services and the U.S. Department of Agriculture 2010). However, inade-
quate intake of vitamin C in certain athlete groups involved with heavy training load 
and exposed to physiologic stressors, including infection, cigarette smoke, high alti-
tude, and extreme environmental temperatures, increase requirements for vitamin C 
(Lukaski 2004). Nonetheless, there has not been any solid evidence to support the 
idea that regular exercise increases the requirement for vitamin C in athletes (Peake 
2003), and plasma vitamin C levels of athletes are usually within the normal ranges. 
Only a small fraction of athletes have plasma vitamin C values less than the lower 
limits or at the lower end of the range of normal values (Lukaski 2004). Regarding 
the vitamin E levels according to the National Health and Nutrition Examination 
Survey III (NHANES III) (Ford and Sowell 1999), mean intakes of α-tocopherol of 
the U.S. population meet and probably exceed the RDA of 15 mg/day when correc-
tions are applied for underreporting of food intake. Although physically active peo-
ple generally consume vitamin E within the limits of DRI or higher (Economos et al. 
1993), an early study showed that vitamin E intake was greater among athletes than 
sedentary people (Guilland et al. 1989). Nevertheless, a certain group of athletes 
having limitation of their food intake for esthetical purposes or competitive limita-
tions may have inadequate intake of vitamin E (Guilland et al. 1989; Lukaski 2004). 
Although physical activity and increased intake of polyunsaturated fatty acids may 
induce oxidative stress and increase the need for vitamin E, its deficiency is rare 
among the physically active population and athletes consuming balanced diets.
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endoGenous AntIoxIdAnts
Glutathione
The endogenous thiols, specifically glutathione (GSH), play a central role in the anti-
oxidant defenses that control cellular events and regulate protection against oxidative 
stress (Radak et al. 2013), a condition that alters normal redox control of cellular 
signaling, more specifically by disruption of thiol redox circuits (Jones 2006). In 
addition to its central role in supporting a large network of antioxidant defense, GSH 
has various biological functions, including regulation of receptors, enzyme activity, 
short-term storage of cysteine, protein structure, cell growth, proliferation, apoptosis, 
transcription factors, and ultimately redox-sensitive signal transduction (Sen 2000).
Glutathione (l-γ-glutamyl-l-cysteinylglycine) is the predominant intracellular 
thiol. GSH plays an essential role in antioxidant protection and provides an appropri-
ate reducing milieu inside the cell directly, and also by regenerating crucial exog-
enous antioxidants such as vitamins E and C from their respective oxidized forms 
(Radak et al. 2013). During strenuous physical exercise where the oxygen consump-
tion is increased many fold, when ROS is detoxified, GSH is oxidized, and, as a con-
sequence, the disulfide glutathione (GSSG) accumulates. The balance of oxidized to 
reduced glutathione (GSSG/GSH) acts as a “redox control node” to regulate “sul-
fur switches” for responses to acute exercise-induced oxidative stress, and also to 
develop adaptations of various defense mechanisms during regular physical training.
GSH can either directly scavenge ROS, or enzymatically via GSH peroxidases 
(GSHPx) and GSH transhydrogenases, while GSH itself is oxidized to GSSG. 
Intracellular GSSG, thus formed, may be reduced back to GSH by GSSG reductase, 
or released to the extracellular compartment (Sen 2000). Most of the GSHPx, but not 
all, are selenium dependent. Because selenium is a cofactor of most of the subtypes 
of GSHPx, it has gained considerable attention as a key antioxidant. Nevertheless, 
one has to keep in mind that selenium itself is not a potent antioxidant but only 
a component of GSH-dependent antioxidant defense. Supplementation of selenium 
and other trace minerals is not generally necessary in well-nourished populations; 
however, possible deficiencies of selenium should be avoided.
GSH is synthesized in the liver and also in skeletal muscle; however, intact GSH 
is usually not transportable to intracellular compartments, and therefore, strategies 
to increase tissue GSH levels through various administration protocols have ended 
in failures. Furthermore, data on the role of endogenous glutathione on exercise per-
formance, especially for the endurance capacity, are limited. In an early work of 
our group, we investigated the relative role of exogenous GSH and N-acetylcysteine 
(NAC), as well as endogenous GSH, on exercise-induced oxidative stress and exer-
cise performance in rats. Intraperitoneal administration of GSH neither affected 
tissue GSH levels nor reduced oxidative stress. Furthermore, GSH and NAC admin-
istration did not influence exercise performance measured as time to exhaustion dur-
ing treadmill running. In contrast, GSH depletion in rats decreased endurance time 
to exhaustion by half with concomitant increase of oxidative stress in all the tissues 
examined (Sen et al. 1994). Although there is a controversial report in the literature 
regarding the impact of GSH deficiency on prolonged swimming performance in 
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mice (Leeuwenburgh and Ji 1995), one may still postulate that endogenous GSH not 
only plays a critical role in the tissue protection against exercise-induced oxidative 
stress but also determines exercise performance.
ROS act as important mediators of the signal transduction pathways for several 
physiological functions, including immune response and inflammation. In several 
studies, cytokine response was represented with the commonly studied cytokine 
interleukin-6 (IL-6). In addition to inflammatory and immune modulatory func-
tions, IL-6 is also a skeletal muscle secreted myokine and tightly related with the 
skeletal muscle energy availability during strenuous exercise (Pedersen 2012). In an 
early study, antioxidant supplementation with vitamins E, A, and C, allopurinol, and 
NAC attenuated plasma IL-6 and other cytokine responses to exercise in humans 
(Vassilakopoulos et al. 2003). In agreement with these findings, we have observed 
that α-lipoic acid decreased hydrogen peroxide-induced IL-6 secretion from L6 
myoblasts (Atalay et al. unpublished observations). Hence, the blunting effect of 
antioxidants on IL-6 levels may not only be interpreted as an anti-inflammatory 
effect; instead, antioxidants can decrease energy availability to working muscle and 
may potentially decrease exercise performance. Similarly, excess availability of anti-
oxidants may suppress other adaptive responses of physical training, such as stress 
protein expression. Heat shock proteins (HSPs), a group of stress-regulated proteins 
that contribute to cellular protection and promote cell survival, are induced by vari-
ous stresses, including exhaustive physical exercise (Fehrenbach and Northoff 2001). 
A large number of studies showed that both acute exercise and endurance training 
induce HSP expression and enhance tissue protection (Atalay et al. 2004). Previous 
studies of our group and others showed that antioxidant supplementations blunt exercise- 
induced increases of HSPs (Khassaf et al. 2003; Oksala et al. 2006). Vitamin C 
supplementation increased baseline expression but attenuated acute exercise-induced 
HSP expression in humans (Khassaf et al. 2003). Co-supplementation of vitamins 
C and E attenuated moderately exercise-induced HSP72 expression in the elderly 
population (Simar et al. 2012).
lipoic acid
α-Lipoic acid is a natural thiol antioxidant and redox modulator that has been widely 
used as a therapeutic agent in many oxidative stress-associated diseases, including 
diabetes and diabetic complications. α-Lipoic acid plays an important role in anti-
oxidant defense; in addition to its potent antioxidant properties as a direct scavenger 
of various ROS, it also increases GSH synthesis and act together with vitamin C to 
contribute to the regeneration of vitamin E. As an essential coenzyme for pyruvate 
dehydrogenase and α-ketoglutarate dehydrogenase, α-lipoic acid plays a critical role 
in mitochondrial energy metabolism, ultimately resulting in the production of ade-
nosine triphosphate, ATP (Petersen Shay et al. 2008). The effects of α-lipoic acid 
on stress protein response were diverse in our studies using different animal models 
and different dosages of α-lipoic acid. In rats, high dosages of α-lipoic acid (150 mg/kg 
intragastrically) decreased the levels of skeletal muscle, liver, and kidney HSP72 
and of the antioxidant stress protein heme oxygenase-1 (HSP32, HO-1) in healthy as 
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well in diabetic rats (our unpublished observations); however, α-lipoic acid supple-
mentation increased hepatic HSP60 levels (Oksala et al. 2006). On the other hand, 
in regularly trained horses, 5-week supplementation of low-dose α-lipoic acid (25 
mg/kg body weight/day) enhanced the skeletal muscle HSP response (Kinnunen et 
al. 2009a). One can postulate that high doses of antioxidant supplementations may 
result in a decline in HSP response to exercise, which may impair tissue protection 
and increase tissue damage that ultimately reduces the health benefits of exercise.
Despite the reported unfavorable effects of antioxidant supplementations to 
decrease health benefits and adaptations of exercise training, we observed benefi-
cial effects of low-dose α-lipoic acid supplementation (25 mg/kg body weight/day) 
on performance and exercise-induced muscle damage in horse (Kinnunen et al. 
2009b). As a result of 5-week α-lipoic acid supplementation, we found a decreased 
rate of lactate formation during exercise and simultaneously increased skeletal mus-
cle citrate synthase activity, a key indicator of muscle oxidative metabolism. These 
observations may be explained by the impact of α-lipoic acid on the enzymes of oxi-
dative metabolism in mitochondria: by improving their cofactor availability, which, 
in turn, may increase oxidative capacity of the skeletal muscle and lead to improved 
performance in endurance events (Sen and Packer 2000). However, our group has 
previously reported that intragastrically supplemented high doses of α-lipoic acid 
(150 mg/kg) did not increase the levels of lipoyllysine in rat skeletal muscle (Khanna 
et al. 1998). Lipoyllysine is the bound form of α-lipoic acid and a cofactor of pyru-
vate dehydrogenase and α-ketoglutarate dehydrogenase in skeletal muscle (Khanna 
et al. 1998). On the other hand, α-lipoic acid enhances glucose uptake by the muscle 
cells by increasing glucose transporters in the plasma membrane (Sen and Packer 
2000). Enhanced glucose metabolism, in turn, may increase pyruvate availability for 
the tricarboxylic acid cycle and result in increased oxidative capacity of the muscles 
(Savitha et al. 2005). In addition, low-dose α-lipoic acid supplementation attenu-
ated plasma creatine kinase levels after exercise and during recovery, which indi-
cates a less exercise-induced muscle damage (Kinnunen et al. 2009b). In addition, 
α-lipoic acid supplementation attenuated exercise-induced oxidative stress as evident 
by directly measured lower free radical signals and also by lower lipid peroxidation 
by-products in horses (Kinnunen et al. 2009b) and in humans (Zembron-Lacny et 
al. 2007).
On the other hand, in another study (Matsumoto et al. 2012), the effects of 
14  weeks of cosupplementation of α-lipoic acid with α-tocopherol and treadmill 
exercise on myocardial and vascular endothelium gene expression were investigated 
in rats. Antioxidant supplementation upregulated and exercise downregulated the 
expression of the RAS homolog gene family member A (RhoA), a gene involved in 
cardiovascular disease progression. The combination of supplementation and exer-
cise abolished the exercise-mediated downregulation of RhoA expression. These 
findings pointed out an unfavorable effect of antioxidant supplementation on exercise-
induced cardiovascular protection. Consistent with these findings, antioxidant sup-
plementation of vitamins C and E and α-lipoic acid reversed the beneficial effect of 
6 weeks of knee-extensor exercise training that had reduced systolic blood pressure 
and also blunted training-induced improvements in vascular function, measured as 
flow-mediated vasodilation (Wray et al. 2009).
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Furthermore, in a recent study, the therapeutic role of α-lipoic acid supplemen-
tation in combination with moderate-intensity aerobic exercise on metabolic distur-
bances was examined in obese subjects with impaired glucose tolerance (McNeilly et 
al. 2011). Surprisingly, a 12-week supplementation period with a relatively high dose 
of α-lipoic acid (1 g/day) increased low-density lipoprotein (LDL) oxidation, which 
indicates increased atherogenesis. Nevertheless, exercise training and α-lipoic acid 
in combination attenuated LDL oxidation. Therefore, apart from the general trend of 
results that antioxidants diminish the health benefits of exercise, in this study, exercise 
training offset the adverse effect of antioxidant supplementation on LDL atherogenic-
ity. However, because there was no exercise training group independent of antioxidant 
supplementation, one cannot make any conclusion whether α-lipoic acid supplemen-
tation blunted or potentiated the health benefits of exercise training (McNeilly et al. 
2011). In addition, the same study found no impact of α-lipoic acid alone or in combi-
nation with exercise training on glycemic control, which is in total disagreement with 
previous studies that have pointed out the beneficial role of α-lipoic acid on glucose 
transport and consequently on glycemic regulation (Estrada et al. 1996).
In early animal studies, allopurinol has been found to attenuate the exercise-
induced increase of XO activity and ROS formation, which was associated with a 
decreased activation of mitogen-activated protein kinases (MAPKs) and blunted 
DNA-binding of nuclear factor kappa B (NF-κB) (Gomez-Cabrera et al. 2006). 
MAPKs regulate cell development and survival in response to extracellular stimuli, 
including oxidative stress. The transcription factor NF-κB is not only implicated 
in the regulation of inflammatory responses and innate immune response, but also 
control the enzymes such as Mn-superoxide dismutase (Mn-SOD) and nitric oxide 
synthases (eNOS and iNOS). Therefore, impairing the effects of exercise training 
by antioxidant supplementation on MAPKs and NF-κB would affect these positive 
benefits. Consistent with these assumptions, administration of allopurinol before 
a marathon race suppressed the exercise-induced increase of antioxidant enzyme 
expression in humans (Gomez-Cabrera et al. 2006).
exoGenous AntIoxIdAnts
Vitamins c and e
The antioxidants vitamins C and E are among the most commonly consumed supple-
ments (Kennedy et al. 2013), and often taken in large doses by athletes in belief of 
their potential protective effect against muscle damage. In the body, vitamins C and 
E act synergistically, with vitamin E acting as the primary antioxidant; the result-
ing vitamin E radical is regenerated back to vitamin E at the expense of vitamin C. 
Although vitamin C can decrease indices of oxidative stress taken at doses of 200 
to 1000 mg/day (Braakhuis 2012), there is no convincing supporting evidence for a 
role of vitamin C and/or vitamin E in protecting against muscle damage (McGinley 
et al. 2009).
It could be speculated that higher intakes of vitamin C for short periods, such as 
onset of illness or during training camps, may provide health benefit for improved 
immunity. Indeed, a recent meta-analysis supports the notion that to reduce the 
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incidence of colds, at least 200 mg of vitamin C per day may be useful for people 
exposed to brief periods of severe physical exercise (Hemila and Chalker 2013).
Antioxidant supplementation with vitamins C and E has shown to prevent the 
induction of molecular regulators of insulin sensitivity and endogenous antioxidant 
defense by physical exercise (Ristow et al. 2009). At large doses, e.g., ≥1000 mg/day, 
vitamin C appears to reduce training-induced adaptations by reducing mitochon-
drial biogenesis (Ristow et al. 2009), indicating that the exercise-induced increase 
in ROS is necessary for physiological adaptations. In a recent study by Paulsen et al. 
(2014), a combination of vitamin C and E supplementation ingested shortly before 
and after exercise training hampered cellular adaptions in the exercised muscles. 
Although this did not translate to changes in the physical performance outcomes, the 
authors advocate caution when considering antioxidant supplementation combined 
with endurance exercise. Although high doses of vitamin C have not been shown 
to result in impaired exercise performance outcomes (Roberts et al. 2011), there is 
growing evidence of the negative effects of antioxidant supplementation on exercise 
performance (Nikolaidis et al. 2012). It is likely that a smaller dose of about 200 to 
500 mg/day vitamin C may be sufficient to reduce oxidative stress without hamper-
ing mitochondrial training adaptations (Braakhuis 2012; Yfanti et al. 2010).
As discussed by Nikolaidis et al. (2012), the inherent complexity of redox bio-
chemistry signifies the difficulty in providing unidirectional predictions after anti-
oxidant supplementation; thus, a permanent intake of supraphysiological dosages of 
vitamin C and/or E cannot be recommended to healthy, exercising individuals.
FlaVonoids
Flavonoids (plant polyphenols) are well-established antioxidants, with direct ROS-
scavenging and chain-breaking properties. Current evidence indicates that the pro-
tective actions of polyphenols are mainly through the modulation of cellular signaling 
cascades by binding to specific target proteins and less via their potent antioxidant 
properties (Quideau et al. 2011). Among a large number of flavonoids, quercetin 
has been recognized with its several purported physiological benefits to health. 
Quercetin is not only a cardioprotective, anticarcinogenic, antioxidant, and antiapop-
totic agent, but has also been proposed to exhibit ergogenic properties. On the other 
hand, human studies examining the effects of quercetin on exercise performance do 
not indicate a high level of efficacy. A recent meta-analysis indicated that quercetin 
supplementation in human subjects actually exerts a favorable effect on endurance 
capacity (calculated as combining VO2max and endurance exercise performance). 
However, the ergogenic effect was small and corresponded to an approximately 3% 
improvement over placebo. In subgroup meta-analysis, no significant difference was 
found for the effects of quercetin on endurance exercise performance and VO2max. 
Furthermore, meta-regression analyses showed that variation in the study effect size 
was not significantly associated with subjects’ fitness level or plasma quercetin con-
centration (Kressler et al. 2011).
Sirtuins comprise a family of NAD+-dependent deacylases that promote longev-
ity and mediate many of the beneficial effects of calorie restriction. Recently, sirtu-
ins have been postulated as redox-dependent metabolic sensors (Radak et al. 2013). 
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Among the polyphenolic compounds, resveratrol has been identified as the most potent 
inducer of sirtuin-1 (SIRT1) and AMP-activated protein kinase (AMPK), and reported 
to increase the lifespan of organisms via a wide range of processes, including suppres-
sion of apoptosis and inflammation or enhancing DNA repair (Hubbard and Sinclair 
2014). Animal studies provided evidence that resveratrol has effects similar to those 
observed with exercise training: increases mitochondrial mass, increases endurance 
capacity, and induces muscle fiber shift to red type with greater aerobic capacity (Price 
et al. 2012). In human studies, the effect of resveratrol is controversial; in a recent study 
with healthy aged subjects, resveratrol did not elicit metabolic improvements but, in 
contrast, impaired the observed exercise training–induced improvements in the mark-
ers of inflammation and oxidative stress in skeletal muscle (Olesen et al. 2014).
conclusIons
Compelling evidence indicates that exercise-induced ROS production is crucial to 
develop training response and adaptations by promoting the expression of numerous 
skeletal muscle proteins, including antioxidant and HSP defenses, and regulating 
glucose homeostasis and mitochondrial function. Although epidemiological evi-
dence suggests that adequate intakes of antioxidant micronutrients may help protect 
against life-threatening diseases, the general trend of published studies does not sup-
port the notion that antioxidant supplementation over a balanced diet rich in fruits 
and vegetables is beneficial to human health.
Despite a perceived need of antioxidant supplements to attenuate exercise-induced 
oxidative damage, a number of studies pointed out that excess antioxidant intake 
through antioxidant supplementation generally does not improve physical perfor-
mance or potentiate health outcomes of physical exercise. In contrast, supraphysi-
ological dosages of antioxidant supplementations may interfere with ROS-mediated 
cell signaling and blunt the positive effects of exercise. According to current knowl-
edge, a nutritional approach of adequate intake of antioxidant nutrients through a 
healthy diet remains to be the safest strategy to minimize exercise-induced oxidative 
insult and sustain high performance.
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8 Coronary Heart 
Disease and Stroke
Antonis Zampelas and Ioannis Dimakopoulos
IntroductIon
Noncommunicable diseases (NCDs) or chronic diseases generally progress slowly 
and have a long duration (World Health Organization [WHO] 2013a). NCDs account 
for 64% of all annual deaths (WHO 2013a). The four major types of NCDs are 
cardiovascular diseases (CVDs), cancer, chronic respiratory diseases, and diabetes. 
CVD is the number one cause of death globally (WHO 2011a). CVDs are a group 
of disorders that include coronary heart disease (CHD), cerebrovascular disease, 
peripheral arterial disease (PAD), rheumatic heart disease, congenital heart disease, 
deep vein thrombosis, and pulmonary embolism (WHO 2013b).
The majority of CVDs result from complications of atherosclerosis (Singh et al. 
2005). Atherosclerosis is a disease in which plaque (fatty deposits) builds up inside 
the arteries and blood vessels and thus narrowing them, making it more difficult for 
blood to pass through and therefore limiting oxygen supply to the organs as well as 
other parts of the body (American Heart Association [AHA] 2013b). Heart attacks 
and strokes are acute events mainly caused by a blood clot that blocks the blood sup-
ply to the heart or brain, respectively (WHO 2013b). Of the 17.3 million people that 
have died globally due to CVD, 7.3 million died due to CHD and 6.2 million due to 
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stroke (WHO 2011a), and it is estimated that by 2030 this number will increase to 
23.3 million deaths annually (WHO 2011b).
CHD occurs when plaque builds up in the coronary arteries that supply oxygenated 
blood to the heart muscle, therefore limiting blood supply (National Institutes of Health 
2013). This is called ischemia and can be chronic, caused by narrowing of the coronary 
artery, or it can be acute as a result of a plaque that suddenly ruptures (AHA 2013a).
The most common type of stroke is ischemic stroke, which occurs when a blood 
vessel that supplies the brain is blocked and when blood supply to a part of the brain 
is shut off, leading to the death of brain cells (AHA 2013b). On the other hand, a 
hemorrhagic stroke occurs when a blood vessel within the brain bursts (AHA 2013b). 
Stroke remains the second leading cause of death globally and the most common 
cause of disability in adults in most regions (Chen et al. 2013a). Every year, 795,000 
people experience a new or recurrent stroke and, on average, every 40 s, someone in 
the United States has a stroke and dies of one approximately every 4 min (Go et al. 
2013). In Europe, CVD is responsible for nearly half of all deaths each year, and due 
to its high mortality and morbidity CVD is estimated to cost the European Union 
€190 billion a year (Allender et al. 2008).
Risk FactoRs associated with chd and stRoke
There is a multitude of risk factors associated with CHD and stroke that can be differenti-
ated to modifiable and nonmodifiable risk factors. The most important modifiable risk 
factors are the following: unhealthy diet, physical inactivity, smoking, and harmful use of 
alcohol (WHO 2013b). The effects that risk factors can exert on CVD may be shown via 
the so-called intermediate risk factors such as hypertension, increased levels of blood glu-
cose and/or lipids, and increased body weight (WHO 2013b). Changes in health behavior 
associated with those risk factors (e.g., maintaining a healthy body weight, increasing 
physical activity levels, consumption of fruits and vegetables, and smoking cessation) 
have been shown to reduce the risk of CVD (WHO 2013b). In addition to modifiable 
risk factors, there are nonmodifiable risk factors, including family history, ethnicity, and 
being postmenopausal for women and age older than 45 years for men, that also exert an 
effect on CVD (AHA 2013b; World Heart Federation [WHF] 2013).
As a risk factor, diet plays an important role in the maintenance of optimal cardio-
vascular health, and there is consistent evidence from observational cohort studies 
showing that increased consumption of fruits and vegetables, as well as other plant 
foods, is associated with lower overall mortality rates and lower death rates from 
CVD (He et al. 2006, Dauchet et al. 2009, WHO 2013b). Furthermore, according 
to estimates, if an individual increases fruit and vegetable intake to 600 g/day, the 
global burden of disease could be reduced by 31% for ischemic heart disease and 
19% for ischemic stroke (Lock et al. 2005). In addition, it is estimated that 74% of 
coronary events among nonsmokers might have been prevented by eating a healthy 
diet, maintaining a healthy body weight, exercising regularly for ≥30 min/day, and 
consuming a moderate amount of alcohol (Hu and Willett 2002). However, the dif-
ficulty of individuals to reduce and maintain a normal body weight, as well as make 
healthier food choices in the long term, made the hypothesis of counteracting this 
with antioxidants, among other nutrients, attractive (Traber 2007).
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antioxidant hypothesis
Evidence for the association between CVD and fruit and vegetable consumption has 
led to the hypothesis that specific components of fruits and vegetables are responsible 
for the health benefits observed, although it is not yet known which molecules found 
in fruits and vegetables contribute more to their cardioprotective effect (Chong-Han 
2010). One very popular hypothesis is that antioxidant nutrients prevent atheroscle-
rosis via their beneficial effect against reactive oxygen species (ROS) (Stanner et 
al. 2004). ROS include free radicals, oxygen ions, and peroxides, both organic and 
inorganic (Taverne et al. 2013). They are produced as a by-product of oxidative phos-
phorylation but can also be produced through physiological biochemical reactions 
(Taverne et al. 2013).
Physiologically, ROS are found in low levels and this enables them to function as 
messengers in signal transduction for vascular homeostasis and cell signaling (Taverne 
et al. 2013). When ROS are excessively produced, when they are not controlled, or 
when antioxidants are depleted, they can damage lipids, proteins, and DNA (Taverne 
et al. 2013). This imbalance between oxidation and reduction is called oxidative stress 
and can contribute to the development as well as progression of CVD (Taverne et 
al. 2013). In addition, common characteristics of CVD risk factors, such as obesity, 
dyslipidemia, insulin resistance, and hypertension are the elevated levels of oxidative 
stress (Griendling and FitzGerald 2003a,b). Therefore, as the majority of CVDs are 
a result of atherosclerosis (Taverne et al. 2013), and oxidative damage contributes to 
atherosclerosis (Ozkanlar and Akcay 2012), antioxidant supplementation could be an 
important step toward the prevention and treatment of CVD. It has been shown that 
antioxidants can protect against atherosclerosis by blocking low-density lipoprotein 
(LDL) oxidation, positively influencing plaque stability, vasomotor function, and ten-
dency for thrombosis, among other possible protective mechanisms (Bin et al. 2011). 
The oxidative modification hypothesis (Figure 8.1) supports the idea that the oxida-
tion of LDL is a crucial step in atherogenesis (Maiolino et al. 2013). In fact, a series of 
biological properties of oxidized LDLs that are thought to promote atherosclerosis are 
the following: recruitment/activation and proliferation of monocytes/macrophages 
in the arterial wall, increased production of growth factors, stimulation of collagen 
production, cytotoxic activity in vascular cells, promotion of apoptosis, and stimula-
tion of platelet adhesion and aggregation (Maiolino et al. 2013). However, although 
the oxidized LDL hypothesis of atherogenesis seems plausible, human observational 
studies have shown conflicting results (Maiolino et al. 2013). Furthermore, research-
ers believe that LDL oxidation alone does not explain the complex mechanism of 
atherosclerosis and other mechanisms have also been proposed, like, for example, 
a mechanism involving oxidized LDL and nitric oxide (Ozkanlar and Akcay 2012). 
It has also been shown that plasma vitamin E is inversely correlated with mortality 
from ischemic heart disease (Gey et al. 1991), and therefore supplemental intake of 
antioxidants might be a treatment option for CVD (Taverne et al. 2013).
In contrast to the available evidence from animal studies and data from prospec-
tive human studies for fruits and vegetables, data from randomized controlled trials 
(RCTs) have not reported consistent benefit from the use of antioxidant supplements 
on CVD risk (Bhupathiraju and Tucker 2011), and some trials have reported harm 
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with high doses of antioxidant supplements. In addition, the effects of different anti-
oxidants to CVD are further perplexed, as there is lack of knowledge with regard 
to the optimal dose. For example, oral supplementation of some antioxidants like 
vitamin C can decrease its bioavailability, and lack of clinical improvement in RCTs 
might be a result of the characteristics of the population being studied (Taverne et al. 
2013). In addition, in many RCTs, participants have been diagnosed with CVD, and 
this might be the reason why a beneficial effect is not observed with supplementation.
AntIoxIdAnts
Antioxidants are molecules that interact with and protect the body from free radi-
cals, the molecules that induce oxidative stress, thus preventing them from causing 
damage (National Cancer Institute 2013). The major dietary antioxidants include 
the following: vitamin E, vitamin C, carotenoids, flavonoids, selenium, polyphenols, 
resveratrol, and lycopene.
Vitamin e
Vitamin E is a lipid-soluble vitamin with the ability to inhibit lipid peroxidation by 
















































FIGure 8.1 Putative pathway of oxidized low-density lipoprotein (OxLDL) in the athero-
genetic process according to the oxidative hypothesis of atherosclerosis. SMC, smooth mus-
cle cell; MMPs, matrix metalloproteinases; NOS, nitric oxide synthase; G-CSF, granulocyte 
colony stimulating factor; M-CSF, macrophage colony stimulating factor; MCP-1, monocyte 
chemoattractant protein-1; PDGF, platelet derived growth factor; bFGF, basic fibroblast growth 
factor. (From Maiolino, G. et al., Mediators Inflamm 2013, 1, 2013.)
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In vitro studies have proposed that antioxidants, including vitamin E, reduce lipid 
peroxidation and the damage by free radicals, therefore postponing the development 
of atherosclerosis (Bleys et al. 2006).
In addition, some observational epidemiological evidence suggests that increased 
consumption of dietary or supplementary vitamin E has a protective effect against 
CHD (Rimm et al. 1993, Stampfer and Rimm 1995). This might partly explain the 
fact that before the availability of evidence from RCTs, about 25% of adults were 
taking vitamin E supplements in the United States (Eidelman et al. 2004). However, 
findings from observational studies are inconsistent (Knekt et al. 2004, Ye and Song 
2008). This might have occurred owing to the few CHD cases reported in some of 
the studies detecting associations, not controlling for confounding factors, inability 
to investigate subpopulations, and misclassification of antioxidants taken (Knekt et 
al. 2004). Given these limitations, meta-analyses of prospective cohort studies were 
conducted to examine the effects of vitamin E on CVD.
A meta-analysis of nine prospective cohort studies suggests that dietary intake of 
antioxidant vitamins was only weakly related to reduced CHD risk and that supple-
mental vitamin E intake is not significantly related to CHD (Knekt et al. 2004). 
Another meta-analysis of 15 prospective cohort studies, of >7000 incident CHD 
cases and 370,000 participants, reported that increased vitamin E is significantly 
associated with reduced CHD risk irrespective of study size, sex, duration of follow-
up, and type of vitamins taken (dietary or supplemental) (Ye and Song 2008). It 
also suggests that each 30 IU/day increase in vitamin E could decrease CHD risk 
by 4% (Ye and Song 2008). However, due to limitations in the included prospective 
cohort studies (e.g., inability to adjust for some confounding factors) as well as the 
limitations associated with observational studies in general, it is suggested that the 
observed relationship still needs careful consideration (Ye and Song 2008). To illus-
trate this last point, further participants taking supplements might also have other 
healthy habits that have an effect on CVD risk factors, therefore confounding the 
relationship (Ye and Song 2008).
Apart from laboratory and observational studies, several RCTs (Table 8.1) and 
meta-analyses of RCTs (Eidelman et al. 2004, Shekelle et al. 2004, Bleys et al. 2006, 
Schurks et al. 2010, Bin et al. 2011, Myung et al. 2013, Ye et al. 2013) have been con-
ducted to examine the effect of vitamin E intake on CVD outcomes.
A recent meta-analysis, of 13 RCTs that included 166,282 participants, was con-
ducted by Bin et al. (2011) to evaluate the role of vitamin E supplementation in the 
prevention of stroke. The pooled results showed no significant benefit in the vitamin 
E group with respect to any type of stroke—hemorrhagic stroke, ischemic stroke, 
fatal stroke, and nonfatal stroke (Bin et al. 2011).
This discrepancy between studies evaluating the association of increased fruit 
and vegetable consumption vs. studies evaluating supplemental intake with regard 
to risk of stroke might be explained by the fact that supplemental intake and diet are 
different types of intake of antioxidants, and their effects on CVD might be different 
(Bin et al. 2011). In addition, although observational studies usually involve healthy 
participants whereas RCTs mostly study participants at high risk of macrovascular 
disease or who are diseased, in a subanalysis of healthy participants in three RCTs, 
performed by Bin et al. (2011), the pooled result showed similar effects.
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An earlier meta-analysis on the effects of vitamin E on stroke subtypes concluded 
that vitamin E increases the risk of hemorrhagic stroke by 22% and reduces the risk 
of ischemic stroke by 10%, results that are obscured when examining total stroke 
(Schurks et al. 2010). Owing to the small risk reduction of ischemic stroke and the 
increased risk of hemorrhagic stroke, as noted in the meta-analysis by Schurks et 
al. (2010), widespread use of vitamin E is not suggested. Furthermore, apart from 
vitamin E supplementation, there are other strategies that can effectively and sub-
stantially reduce the risk of stroke, such as antihypertensive or lipid-lowering med-
ication, as well as cessation of smoking, maintaining a healthy weight, having a 
healthy diet, and regularly exercising (Schurks et al. 2010).
A very recent meta-analysis that included 50 RCTs concluded that there was no 
evidence to support the use of vitamin and antioxidant supplements for the preven-
tion of CVD irrespective of the type of prevention, type of vitamins and antioxidants, 
type of CVD outcomes, study design, methodological quality, duration of treatment, 
funding source, provider of supplements, type of control, number of participants in 
each trial, and supplements given singly or in combination with other supplements 
(Myung et al. 2013). In addition, another meta-analysis of RCTs has shown that there 
is no effect of vitamin–mineral supplementation on the progression of atherosclero-
sis (Bleys et al. 2006). This is in agreement with previous meta-analyses that also 
report that there is good evidence that vitamin E supplementation does not have an 
effect on CVD (Vivekananthan et al. 2003, Shekelle et al. 2004).
Overall, the evidence does not support the long-term use of vitamin E for CVD 
prevention or progression of atherosclerosis.
Vitamin c
Vitamin C, also known as ascorbic acid, is a hydrophilic vitamin and acts as an anti-
oxidant in hydrophilic media (Wang et al. 2012). Vitamin C regenerates tocopheryl 
from its oxidized form (Wang et al. 2012). As described previously, vitamin C may 
have a beneficial effect on atherogenesis as it is a strong antioxidant and has been 
shown to decrease the oxidation of LDL, inhibit proliferation of smooth muscle cells, 
and protect membranes from peroxidation (Chen et al. 2000, 2013a).
Similar to vitamin E, vitamin C has also been extensively investigated with 
regard to its effect on CVD outcomes (Ye and Song 2008); however, results are 
inconsistent. Meta-analysis of nine prospective cohort studies suggested a reduced 
incidence of major CHD events at high supplementation of vitamin C in men and 
women, whereas dietary vitamin C intake was not related to CHD incidence (Knekt 
et al. 2004). In more detail, participants in the highest quintile of vitamin C intake 
had 24% lower risk compared with those in the lowest quintile, and a dose–response 
association was observed. Adjustment for confounding factors did not affect the 
association. Although the results of this meta-analysis suggest the use of vitamin C 
supplementation to reduce CHD incidence, as the effects of high antioxidant vitamin 
intake are not fully understood, there is no adequate support for recommending high 
doses of vitamin C supplementation.
In contrast, a later meta-analysis of 15 prospective cohort studies suggests that 
dietary vitamin C has an inverse association with CHD risk, whereas supplement use 
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of vitamin C is not significantly associated with the risk of CHD (Ye and Song 2008). 
Given the inconsistencies observed in prospective cohort studies and the limitations 
associated with their study design, RCTs have been conducted to evaluate the effect of 
vitamin C on CVD outcomes.
A meta-analysis of RCTs concluded that antioxidant vitamin supplementation 
(including vitamin C) does not affect major CVD events such as myocardial infarc-
tion, stroke, CVD mortality, CHD, angina, congestive heart failure, and revascu-
larization (Ye et al. 2013). Furthermore, the authors found that subgroup analysis 
also supported the same conclusions. These results have also been replicated in 
other meta-analyses of RCTs (Chen et al. 2013a, Myung et al. 2013). Another meta-
analysis has also shown that there is no evidence of a protective effect of antioxidant 
vitamin supplementation, including vitamin C, on the progression of atherosclerosis 
(Bleys et al. 2006). In contrast, dietary vitamin C is significantly and inversely asso-
ciated with the risk of stroke in a dose–response manner (Chen et al. 2013a).
Apart from the examined effect of vitamin C on CVD outcomes, RCTs have 
also been conducted to examine the effect of vitamin C on intermediate risk factors 
such as blood pressure. A recent meta-analysis of RCTs about the effects of vitamin 
C supplementation on blood pressure showed that in short-term trials, vitamin C 
significantly reduced systolic and diastolic blood pressure (Juraschek et al. 2012) by 
−3.84 mm Hg and −1.48 mm Hg, respectively; however, there is lack of long-term 
clinical trial evidence. The authors of this meta-analysis also note that the included 
trials were small, and there was significant heterogeneity of effects across studies, 
which leads to the conclusion that additional trials are needed, with larger sample 
sizes and with attention to the quality of blood pressure assessment.
In summary, vitamin C supplementation is not recommended for the prevention 
or treatment of CVD.
caRotenoids
There are 600 naturally occurring carotenoids; however, six carotenoids (lutein, 
lycopene, zeaxanthin, β-cryptoxanthin, β-carotene, and α-carotene) represent >95% 
of carotenoids in plasma and are associated with health benefits (Wang et al. 2013). 
Table 8.2 provides an overview of observational studies of dietary and supplemental 
intake of carotenoids and their association with major CVD outcomes.
Most of the observational studies of dietary carotenoid intake have examined the 
effect of β-carotene on CVD outcomes. In the Nurses’ Health Study, dietary α- and 
β-carotene were inversely associated with coronary artery disease; the same was not 
observed for intake of other carotenoids (Osganian et al. 2003). In addition, in the 
Health Professionals’ Follow-up Study, current and former smokers had significantly 
lower CHD risk; however, the same was not observed for nonsmokers (Rimm et al. 
1993). In the same cohort study, only lutein was shown to be inversely associated 
with the risk of stroke (Ascherio et al. 1999).
A meta-analysis of nine prospective cohort studies suggested that the risk reduc-
tion of carotenoids was only weakly associated with major CHD events (Knekt et al. 
2004). In more detail, significant inverse associations were observed between dietary 
α-carotene, β-carotene, lutein, and β-cryptoxanthin with the incidence of all major 
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CHD events in the pooled population not taking vitamin supplements; after adjustment 
for confounding factors, only lutein was significantly and inversely associated with 
CHD incidence. However, because the associations observed with lutein disappeared 
after further exclusion of cases during the first 2 years of follow-up, the authors 
concluded that none of the carotenoids, when consumed in usual dietary quantities, 
can predict reduced incidence of CHD. These conclusions are further replicated in a 
more recent meta-analysis of 15 prospective cohort studies that examined the effect 
of β-carotene on CHD (Ye and Song 2008), whereas an earlier meta-analysis of 
RCTs suggested that β-carotene supplementation should be actively discouraged as it 
was found to be associated with a small but significant excess of all-cause and CVD 
mortality (Vivekananthan et al. 2003).
Table 8.1 presents the available randomized controlled trials that examine the 
effect of β-carotene, either alone or in combination with other antioxidants, on major 
CVD outcomes. The vast majority of studies produced nonsignificant results. The 
study that showed a significant association was the ATBC (Alpha-Tocopherol Beta-
Carotene) trial in which a population of male smokers was examined (Rapola et al. 
1997, Virtamo et al. 1998, Leppala et al. 2000). In fact, a meta-analysis of RCTs 
concluded that there is no evidence to support antioxidant vitamin supplements 
(including β-carotene supplements) for the primary or secondary prevention of vari-
ous diseases (Bjelakovic et al. 2012), and this finding has also been replicated in 
more recent meta-analyses of RCTs (Myung et al. 2013, Ye et al. 2013). In addition, 
a meta-analysis of RCTs concluded that there was no evidence of a protective effect 
of β-carotene on the progression of atherosclerosis (Bleys et al. 2006).
In conclusion, there is no evidence to support a role of carotenoid supplementation 
for the prevention or treatment of CVD.
selenium
Selenium is an essential trace element that is involved in the protection against oxi-
dative damage (Rayman 2000). The main sources of selenium include plant foods, 
meat, and seafood; however, the selenium content of foods varies according to 
the soil, water concentrations, and selenium-containing fertilizers (Flores-Mateo 
et al. 2006), and this is the reason why dietary assessment methods are irrelevant 
in the study of selenium status; instead, toenail, blood, erythrocyte, or serum and 
plasma selenium concentrations are used (Longnecker et al. 1996, Satia et al. 2006). 
Observational studies investigating the association between low selenium concentra-
tion with CVD outcomes and RCTs investigating supplemental selenium and CHD 
have been inconclusive.
Flores-Mateo et al. (2006) appraised the evidence with regard to the association 
of selenium and CHD, and the meta-analysis suggests that there is a statistically 
significant inverse association between selenium concentration in several tissues 
and CHD outcomes in observational studies; a 50% increase was associated with 
24% reduced risk of coronary events. However, given the experience from observa-
tional studies of other antioxidants, this validity is uncertain, as RCTs might show 
a different result. RCTs examining selenium supplementation are few, and selenium 
has been administered in combination with other antioxidants (Table 8.1). Another 
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meta-analysis of RCTs that examined vitamin–mineral supplementation and the pro-
gression of atherosclerosis reached a similar conclusion (Bleys et al. 2006).
In addition, a Cochrane collaboration review by Rees et al. (2013), which included 
19,715 participants, found no statistically significant effects of selenium supplemen-
tation on all-cause mortality, CVD mortality, nonfatal CVD events, and all CVD 
events, and therefore suggests that selenium supplements do not prevent the occur-
rence of major CVDs. They also suggest that taking selenium supplements is nei-
ther beneficial nor harmful for CVD, but is probably unnecessary for those who are 
already well nourished and who take their selenium from natural foods.
polyphenols
A vast number of molecules has a polyphenol structure; thousands have been identi-
fied in higher plants and several hundred in edible plants, and they can be classified 
according to the number of phenol rings that they contain as well as the structural 
rings that bind these rings together (Manach et al. 2004). Polyphenols can be found 
in a wide range of fruits and vegetables, as well as in other foods/beverages (e.g., tea, 
wine, and soy milk), and include phenolic acids, flavonoids, stilbenes and lignans, 
and flavonoids, which may be further subdivided to six subclasses: flavonols, fla-
vones, isoflavones, flavanones, anthocyanidins, and flavanols (Manach et al. 2004). 
Polyphenols in plants act as a defense system against infection and protect against 
ultraviolet radiation, pathogens, and physical damage (Davidson and Duchen 2007).
During the last few decades, researchers became interested in polyphenols, and 
the main reason for this was the recognition of the antioxidant properties of polyphe-
nols (Manach et al. 2004). Apart from their antioxidant properties, polyphenols also 
have several other specific biological actions that are yet poorly understood (Manach 
et al. 2004). With regard to in vivo studies, one can find many experimental studies 
in the literature that show that polyphenols have many effects in animal models; 
they act as free radical scavengers, regulate nitric oxide, decrease leukocyte immo-
bilization, induce apoptosis, inhibit cell proliferation and angiogenesis, and exhibit 
phytoestrogenic activity (Arts and Hollman 2005). However, results from animal 
studies cannot be extrapolated to humans as the bioavailability and metabolism of 
polyphenols vary between animals; consequently, human studies are needed before 
moving on to making recommendations (Chong et al. 2010).
As noted earlier, for other antioxidants, increased fruit and vegetable consump-
tion has been associated with beneficial effects on CVD. However, fruits and veg-
etables contain an array of antioxidant substances, such as vitamins and nonnutrient 
phytochemicals like carotenoids and polyphenols, and the contribution of each of 
these substances in cardioprotection is not very clear (Chong et al. 2010). Although 
no information on causality can be obtained, researchers have suggested that poly-
phenols may explain part of the beneficial effect of fruit and vegetable consumption 
on CVD (Arts and Hollman 2005).
Up to date, most studies in humans have explored the associations of polypheno-
lic-rich beverages like tea, cocoa, and red wine, and intervention studies examining 
fruits are few (Chong-Han 2010). In addition, there is lack of studies examining hard 
outcomes. In a review by Chong-Han (2010) where fruit polyphenols were examined 
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in relation to CVD risk (platelet function, hypertension, lipid metabolism, and vascu-
lar function), it was concluded that there is some supportive evidence for the benefi-
cial effects of fruit polyphenols on CVD risk; however, the literature is limited and 
the study design often varies.
Table 8.2 provides an overview of observational studies that have examined the 
effects of polyphenols on CVD risk. As Wang et al. (2013) noted, accurate estima-
tion of polyphenol intake is critical for the investigation of their association with 
CVD outcomes, and it was only after 2003 that the U.S. Department of Agriculture 
released the first flavonoids databases, which included 26 flavonoids. This database 
was also updated in 2013. In addition, another database of polyphenol content of 
foods was recently published (Neveu et al. 2010). Owing to the limitation mentioned 
with regard to the availability of nutrition data on polyphenol content of foods, stud-
ies conducted after the release of the databases have shown a significant inverse 
association with CVD outcomes (Wang et al. 2013).
A meta-analysis of six prospective cohort studies that examined the association 
between flavonol intake and stroke risk concluded that a high intake of dietary fla-
vonols compared with a low intake is associated with 20% lower stroke incidence 
(Hollman et al. 2010). However, the authors also note that owing to the small number 
of studies and an indication for publication bias, results should be interpreted with 
caution. Similar findings have also been reported in a meta-analysis that examined 
the relationship between flavonol intake and CHD mortality (Huxley and Neil 2003).
Currently, there is no clinical trial available examining the effects of polyphenols 
on major CVD outcomes; however, observational studies suggest a beneficial asso-
ciation. Some researchers have even suggested that polyphenols could be expected 
to have a “pleiotropic effect” similar to that of statins in the prevention of atheroscle-
rosis (Kishimoto et al. 2013).
ResVeRatRol
Resveratrol is a polyphenol found in grape skin/seed, a variety of berries, peanuts, 
red wine, and the root of Polygonum cuspidatum, a traditional Chinese and Japanese 
medicinal material (Smoliga et al. 2011, Wang et al. 2012). Owing to red wine’s rich 
resveratrol content, it has been hypothesized to be an important factor in the French 
paradox (Liu et al. 2007). Cross-sectional evidence shows that 69.8% of women and 
64.1% of men that are long-term consumers of multiple dietary supplements take 
supplemental resveratrol (Block et al. 2007).
A number of studies have proposed that it has many properties that can confer, 
among others, CVD benefit (Wang et al. 2012). In vivo evidence suggests that resve-
ratrol has some beneficial effects in rodent models of stress and disease (Baur and 
Sinclair 2006). Moreover, the effects of resveratrol on isolated tissues or organs, 
many of which are associated with oxidative stress, are well documented (Opie and 
Lecour 2007).
Resveratrol can act as a radical-scavenging antioxidant and an anti-inflammatory 
agent, has been shown to induce platelet apoptosis, activate antiaging genes and 
facilitate extending lifespan in organisms like yeasts and worms, prevent the pro-
liferation and differentiation of preadipocytes, promote fat mobilization in white 
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adipocytes, trigger lipolysis, and protect mice against diet-induced obesity (Wang et 
al. 2012). In vivo studies also suggest that dietary resveratrol is hypolipidemic, with 
a tendency for antitumor growth and antimetastasis effects observed in hepatoma-
bearing rats (Miura et al. 2003). In addition, resveratrol has some beneficial anti-
oxidant activity related to LDL oxidation (Fremont et al. 1999). Other metabolic 
roles of resveratrol include statin-like effects; furthermore, resveratrol treatment has 
been observed to elevate high-density lipoprotein (HDL) levels as well as promote 
the capacity of HDL to mediate cholesterol efflux (Wang et al. 2012). Moreover, it 
has been suggested that resveratrol has beneficial effects on glucose metabolism and 
insulin sensitivity, endothelial function, and cardiovascular remodeling (Wang et al. 
2012). It also seems that resveratrol directly improves the function of a failing heart 
(Wang et al. 2012).
In contrast to the above, the complexity of resveratrol’s effects in vivo presents a 
major challenge in human studies (Smoliga et al. 2011). Although resveratrol seems 
to have many potential beneficial effects on CVD, its effects in vivo as well as its 
effective dose in animals cannot be generalized to humans (Reagan-Shaw et al. 
2008). Many clinical trials that aim to decipher the safety, effective dose, and the 
effects of resveratrol are currently ongoing (Wang et al. 2012). Some skepticism 
exists with regard to resveratrol’s very low bioavailability (Smoliga et al. 2011), as 
effects seen in vivo may not be replicated in humans because of its rapid metabolism 
(Goldberg et al. 2003). In addition, resveratrol’s bioavailability from supplements is 
highly variable (Smoliga et al. 2011).
lycopene
Lycopene is a carotenoid and is the pigment that gives tomatoes their distinctive 
red color (Ried and Fakler 2011). In addition, owing to its chemical structure, lyco-
pene is a powerful antioxidant and free radical scavenger; however, it has also been 
hypothesized to reduce cholesterol levels and increase LDL degradation (Ried and 
Fakler 2011). In vitro evidence suggests that lycopene protects against oxidation, and 
it is considered to be the most effective quencher of LDL and human lymphoid cells; 
however, evidence in humans is limited (Chen et al. 2013b).
Observational studies have suggested that increased consumption of foods rich in 
lycopene has an inverse relationship with CVD and cancer (Rao and Agarwal 2000). 
However, lycopene metabolism is not yet fully understood, and, as with other anti-
oxidants, its effects in vitro might differ from its effects in vivo (Chen et al. 2013b).
There is a lack of RCTs examining the relationship between long-term lyco-
pene intake/supplementation and major CVD outcomes. However, a meta-analysis 
by Chen et al. (2013b) that pooled results from 13 RCTs revealed no statistically 
significant difference in the LDL lag time between the lycopene treatment group 
and the control group. In contrast, a meta-analysis of another three trials within the 
same publication suggests that lycopene significantly increases DNA tail length. The 
authors conclude that the effect of lycopene supplementation remains unconfirmed 
and its efficiency as an antioxidant in vivo needs further investigation. They also 
report that consumption of natural carotenoid-rich fruits and vegetables is preferable 
to lycopene supplementation. Another recent meta-analysis suggests that lycopene 
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taken in doses of ≥25 mg daily is effective in reducing LDL cholesterol by approxi-
mately 10% in patients with slightly elevated cholesterol levels.
A meta-analysis by Ried and Fakler (2011) suggests that lycopene is effective in 
reducing LDL and total serum cholesterol if taken in doses of >25 mg daily, and in 
reducing systolic blood pressure in individuals with hypertension.
concLusIon
In contrast to the observational evidence showing that increased consumption of 
fruits and vegetables is inversely associated with reduced CVD risk, prospective 
studies and RCTs of antioxidants have failed to show a consistent effect on CVD 
outcomes. Therefore, antioxidant supplement administration is not advisable for 
reducing the risk of developing CHD or stroke. In addition, there are no guidelines 
with regard to which fruits and vegetables contribute most to the risk reduction and, 
therefore, consuming a variety would be advisable. Further studies that examine 
which fruits and vegetables contribute more to the CVD risk reduction, as well as 
other chronic diseases, seen in observational studies are needed to make more spe-
cific recommendations.
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IntroductIon
Diabetes mellitus—a noncommunicable disease that has reached the dimensions 
of an epidemic—affects more than 370 million people nowadays, mainly due to a 
worldwide explosion of obesity [1].
For many years, the pathophysiology of type 2 diabetes remained obscure, and 
insulin resistance was thought to be the leading cause of metabolic dysregulation. 
However, in recent years, a feedback loop that operates to ensure integration of glu-
cose homeostasis and maintenance of glucose concentration in a narrow range has 
been recognized [2]. This feedback loop relies on a crosstalk between β-cells and 
peripheral tissues. Insulin released following β-cell stimulation mediates uptake of 
substrates—glucose, amino acids, and fatty acids—by insulin-sensitive tissues. In 
turn, peripheral tissues signal to islet cells according to their insulin needs. The 
whole process probably includes interaction between the brain and the humoral 
system. When insulin resistance is present, as in people with obesity and a seden-
tary lifestyle, β-cells increase insulin secretion to maintain euglycemia. However, if 
β-cells are defective, dysglycemia develops [3].
The combination of genes and environmental factors mediates insulin resistance 
and β-cell dysfunction. Even the in utero environment could result in epigenetic 
and gene expression changes that increase the risk of development of obesity and 
type 2 diabetes for the offspring later in life [4]. Diabetes mellitus is a complex 
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and multifactorial disease presenting with dysregulation in glucose homeostasis, and 
lipid and protein metabolism.
The metabolic derangement associated with diabetes causes secondary patho-
physiologic changes in multiple organ systems that impose a heavy burden of mor-
bidity and mortality from macrovascular and microvascular complications [5]. 
Moreover, metabolic syndrome and type 2 diabetes are related to chronic systemic 
inflammation and increased oxidative stress. Prolonged hyperglycemia alters intra-
cellular metabolism and induces cumulative long-term changes in the structure and 
function of macromolecules like lipids, carbohydrates, proteins, and nucleic acids 
[6]. Oxidative stress also plays an important role in chronic diabetic complications 
and is considered to be associated with increased lipid peroxidation [7].
Under normal physiological conditions, there is a critical balance in the generation 
of oxygen free radicals and antioxidant defense systems used by organisms to deac-
tivate the former and protect themselves against free radical toxicity [8]. Impairment 
in this equilibrium increases oxidative stress. Formation of lipid peroxides by the 
action of free radicals on unsaturated fatty acids has been implicated in the patho-
genesis of atherosclerosis [9]. Other mechanisms that contribute to increased oxida-
tive stress in diabetes may include increased advanced glycation and autoxidative 
glycosylation, metabolic stress resulting from changes in energy metabolism, altera-
tions in the sorbitol pathway, increased inflammatory mediators, disturbed status of 
antioxidant defense systems, and localized tissue damage as a result of hypoxia and 
ischemic reperfusion injury. Advanced oxidation protein products accelerate athero-
sclerosis through promoting oxidative stress and inflammation [7,10,11].
Antioxidants are reducing agents that, by being oxidized themselves, stop the 
oxidation reaction that can lead to the creation of free radicals, and provoke oxida-
tive stress and the damage and even the death of cells [12]. Hyperglycemia causes the 
generation of reactive oxygen species (ROS), which, in case endogenous antioxidants 
such as vitamins C and E, catalase, glutathione, and superoxide dismutase are miss-
ing, can lead to the generation of DNA alterations whose gene products can damage 
cells and tissues [13,14]. Oxidative stress, in turn, elevates the level of glycosylated 
hemoglobin (ΗbΑ1c) [15], increases insulin resistance, and decreases β-cell secre-
tory capacity [16,17]. As a result, the idea that antioxidants can contribute to glyce-
mic control in diabetes mellitus type 2 is reasonable but under question.
AntIoxIdAnts And dIAbetes
Antioxidants can be provided through food or may be synthesized within the body 
[18] and are divided into two categories: hydrophilic antioxidants such as ascorbic 
acid (vitamin C), glutathione, lipoic acid, uric acid, and bilirubin, and lipophilic ones 
such as carotenes, oxy-carotenoid (vitamin A), tocopherol (vitamin E), and ubiquinol 
(coenzyme Q) [12].
Antioxidants act in three ways to prevent oxidant-induced cell damages. They can 
limit the generation of ROS, scavenge them, or eliminate and correct the damage 
that they can induce [19].
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Vitamin E
Tocopherol (vitamin E) is a lipophilic reducing agent that scavenges ROS and thus 
prevents oxidant-induced cell damage [20]. The intake of vitamin E, which can be 
through fruits, vegetable oils, green vegetables, and nuts [21], is inversely related to 
the risk of type 2 diabetes, according to a 23-year population-based study involv-
ing 4304 middle-aged individuals from Finland [22]. Approximately 12.7% of the 
adult population in the United States take vitamin E as a dietary supplement [23]. 
Many studies have tried to describe exactly the way vitamin E acts to control the 
levels of plasma glucose and decrease oxidative stress [24]. Vitamin E inhibits the 
formation of advanced glycosylation end products, and interrupts glycosylation at 
an early step in the Maillard reaction [25], thus decreasing the glucosylation of 
hemoglobin [26]. On the other hand, it limits the apoptosis of pancreatic β-cells 
[27,28] and decreases, as the majority of antioxidants do, the creation of ROS 
and their disposal on β-cells [14]. It is also found that vitamin E is beneficial for 
nonalcoholic steatohepatitis, although in particularly high doses [29]. According 
to observational cohorts, high serum vitamin E level corresponds to a lower risk 
of diabetes. Case–control trials demonstrated that vitamin E supplementation 
improves glycemic control and reduces fasting glucose [30] and fasting insulin 
[31] in diabetic subjects. However, some RCTs [32] and other studies [33] showed 
no association between the risk of type 2 diabetes and vitamin E supplementation. 
Future large-scale, randomized trials are needed to demonstrate the actual effect 
of vitamin E supplementation on glycemic control [34], as the findings are contro-
versial thus far.
Vitamin C
Ascorbic acid (vitamin C) is a hydrophilic antioxidant that resets tocopherol in the 
phase it was in before being oxidized [35]. It is a cofactor in several enzymatic reac-
tions whose deficiency causes symptoms of scurvy. In healthy people, ascorbate 
blood levels range from 61 to 80 μmol/L; however, in people who have increased 
oxidative stress, these levels are lower than 45 μmol/L [36]. The levels of vitamin 
C are related in a larger extent to the consumption of fruits and vegetables than do 
vitamin E or carotenoids [37]. According to previous findings, people with diabetes 
have lower levels of vitamin C in their blood [38]. Thus, in persons with diabetes, 
this deficiency may lead to an increased risk of oxidative tissue damage. This may 
be explained by the fact that in diabetic individuals, (i) hyperglycemia may reduce 
renal reabsorption of vitamin C, (ii) blood glucose may compete with vitamin C for 
uptake into several cells and tissues, and (iii) increased oxidative stress may result 
in consumption antioxidant vitamin C. However, other studies sustain that although 
higher intake of antioxidants such as vitamin E, α-tocopherol, γ-tocopherol, 
δ-tocopherol, β-tocotrienol, and β-cryptoxanthin was inversely related to the risk 
for type 2 diabetes, intake of vitamin C as a supplement indicated no association to 
that risk [22].
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CarotEnoids
Carotenoids are lipophilic antioxidants that exist in chloroplasts and chromoplasts 
of plants and some photosynthetic bacteria and fungi. They exist in fruits and vege-
tables [39–41] and are responsible for their color (orange, red, and yellow). In nature, 
more than 600 carotenoids exist, 40 of which can be provided through diet; 90% of 
these are represented by α-carotene, β-carotene, lycopene, lutein, and cryptoxanthin 
[42]. Particularly, α-carotene and β-carotene exist in fruits; yellow–orange vegeta-
bles provide α-cryptoxanthin, tomatoes provide lycopene [39,43], whereas lutein can 
be found in egg yolks [40]. Despite the general belief that serum retinol and carot-
enoids may battle chronic disease pathogenesis through their antioxidative proper-
ties [41,42], randomized controlled trials have not indicated any relation between 
β-carotene supplements and the risk of type 2 diabetes [43–46]. In addition, obser-
vational studies have shown ambiguous results [47–56].
sErum rEtinol
Levels of serum retinol may positively relate to impaired glucose metabolism 
[57–59]. In two National Health and Nutrition Examination Surveys (NHANES) 
analyses—NHANES III (1988–1994) [56] and NHANES 2001–2006 [47]—hyper-
glycemia and insulin resistance did not relate to serum retinol, despite its association 
to the metabolic syndrome. The BioCycle Study (2005–2007), a prospective cohort 
of 259 healthy premenopausal women, indicated that retinol was positively asso-
ciated with HOMA-IR (homeostasis model assessment of insulin resistance), and 
that this relationship was driven by insulin. Retinol was inversely associated with 
sex hormone–binding globulin (SHBG); the relation between serum carotenoids and 
HOMA-IR was not significant; whereas β-carotene was positively related to SHBG 
and β-cryptoxanthin was inversely associated with fasting glucose [60]. This is also 
in agreement with recent findings indicating a positive association of retinol-binding 
protein-4 with the presence and severity of coronary artery disease in people with or 
without overt diabetes [61].
lyCopEnE
Lycopene is the most efficient biological carotenoid singlet in oxygen quenching 
[62]. With reference to its relation to the risk of type 2 diabetes, the results remain 
controversial. In the first phase of NHANES, Ford et al. [47] found that type 2 
diabetic subjects and people with glucose intolerance had lower serum lycopene 
than the healthy population and a negative relation to fasting plasma insulin. Coyne 
et al. [52] described a reduction of serum lycopene as age or physical inactivity 
increased.
According to a cohort of the women’s health study conducted by Wang et al. [63], 
no relation between type 2 diabetes and lycopene intake was found. The CARDIA 
cohort study showed that people who had several risk factors for diabetes had higher 
concentration of lycopene in their blood [64]. Case–control studies also found 
decreased lycopene levels in persons with diabetes [65].
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sElEnium
In 1957, selenium was recognized as an essential nutrient for animals and 15 years 
later cellular glutathione peroxidase (GPX1) was identified to be the first selenium-
dependent enzyme [66]. Although GPX1 was shown to induce type 2 diabetes in 
mice, human studies have shown that low selenium intake increases the risk of type 2 
diabetes, and there seems to be an association between low whole-blood GPx activ-
ity and higher measures of general and central adiposity [67,68].
A number of correlative epidemiological studies showed that in serious chronic 
diseases such as diabetes, there is a deficiency in serum levels of selenium [69]. On 
the contrary, in randomized, blinded, controlled prospective trials in humans, and a 
meta-analysis, the supplementation of selenium has not indicated a reduction in the 
incidence of diabetes and did not decrease mortality [70].
Gao et al. [71], through a recently published cohort study of 1925 Swedish men 
who were 50 years old and did not have diabetes, showed that dietary selenium does 
not play a role in glucose values, metabolism, or diabetes risk. On the other hand, 
Sarmento et al. [72], in a systematic review, indicated that although in patients with 
diabetes type 2, selenium levels lower than 14.1 μmol/L were associated with an 
increased risk for cardiovascular disease (RR 1.70; 95% CI 1.21–2.38), further pro-
spective studies are needed to prove the proliferative role of selenium supplementa-
tion in cardiovascular disease in patients with diabetes.
polyphEnols
Polyphenols are the most abundant antioxidants in the diet. Their dietary intake 
is 1 g/day, which is much higher than intake of other dietary antioxidants [73,74]. 
Polyphenols can be found in fruits and vegetables, green tea, coffee, red wine, 
chocolate, olives, herbs, spices, nuts, and extra olive virgin oil [75]. They include 
two main classes: hydroxybenzoic acid derivatives (gallic acid, p-hydroxybenzoic 
acid, and protocatechuic acid) and hydroxycinnamic acid derivatives (chlorogenic 
acid, coumaric acid, caffeic acid, ferulic acid, and sinapic acid) [75]. Flavonoids 
are the most abundant polyphenols in the human diet. There exist six subclasses of 
flavonoids: anthocyanins (in red wine, black grape, strawberry), flavonols (in onions, 
blueberries, and broccoli), flavanols, flavanones, flavones, and isoflavones (in soy-
beans, soy products). Dietary polyphenols are found to have antiallergic, anticar-
cinogenic, anti-inflammatory, free radical scavenging, antiviral, and antimicrobial 
properties, through their modulation of important signaling cell pathways, such 
as the activator protein-1 DNA binding, phosphoinositide 3 kinase/protein kinase 
B, nuclear factor-κB, mitogen-activated protein kinases, nuclear factor erythroid 2 
related factor 2, and extracellular signal-regulated protein kinase [76].
Studies in vitro, animal models, and clinical trials have been conducted to determine 
the impact of polyphenols on glucose metabolism and homeostasis [77]. Polyphenols 
inhibit α-glucosidase and α-amylase, which are responsible for the transformation of 
dietary carbohydrates to glucose [78–80]. Some polyphenols, such as ferulic, chlo-
rogenic, caffeic, and tannic acids, can inhibit glucose absorption by interacting with 
sodium-dependent glucose cotransporters, SGLT1 and SGLT2, in the gut [81,82]. 
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Some studies have shown that polyphenols reduce insulin resistance and induce the 
production of glucose-dependent insulinotropic polypeptide GIP and glucagon-like 
polypeptide-1 (GLP-1), both known for their beneficial role on glucose metabolism 
[83,84]. Studies in mice also indicated that ferulic acid induces glucokinase activity 
and hepatic production of glycogen and increased insulin sensitivity [85]. They also 
showed that hesperidin and naringin, except for inducing gluconeogenesis in the liver, 
also decrease the activity of glucose-6-phosphatase and phosphoenolpyruvate car-
boxykinase, and in that way improve glycemic control [86,87]. In vitro studies showed 
that polyphenolic compounds such as resveratrol or quercetin promote glucose translo-
cation in adipose and muscle cells through GLUT4 transporters, and through inducing 
the AMP-activated protein kinase pathway [88,89]. They may also induce phosphati-
dylinositide 3-kinase, which can lead to increase in glucose uptake [90].
Some polyphenolic compounds protect β-cells from glucotoxicity and oxida-
tive stress (Figure 9.1) [91]. Resveratrol is also found to improve glucose tolerance, 
reduce oxidative stress in β-cells, and inhibit their apoptosis [92,93]. As a conclu-
sion, polyphenols have a good impact on carbohydrate metabolism, insulin secretion, 
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FIGure 9.1 Dietary polyphenols as potential nutraceuticals in management of diabetes: a 
review. (From Bahadoran Z et al., J Diabetes Metab Disord, 12, 43, 2013.)
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dIet versus PIlls: And the WInner Is…
Numerous studies have assessed the dilemma of whether the supplementation of 
antioxidants is noninferior to the ingestion of natural antioxidants through diet. The 
market share of supplements is tremendous, and the actual effectiveness or safety of 
a long-term supranutritional supplementation of antioxidants remains obscure. For 
instance, a number of studies suggest a neutral or a negative effect of supplements 
on metabolism. Wang et al. [95] recently demonstrated that selenium supplementa-
tion to a mouse model of type 2 diabetes exhibited conflicting actions on glucose 
regulation. On the one hand, it increased β-cell mass and insulin secretion, thus 
lowering blood glucose; on the other hand, subsequent hyperinsulinemia reduced 
antioxidant defense capacity and exacerbated fatty liver degeneration, inducing insu-
lin resistance.
A systematic review and meta-analysis of randomized control trials showed that 
vitamin E and/or C supplementation improved endothelial function in nonobese dia-
betic patients but had no impact in obese or overweight ones [96]. Another system-
atic review assessing the effect of supplement consumption of vitamin E, vitamin C, 
coenzyme Q10, α-lipoic acid, l-carnitine, ruboxistaurin, and diabetes management 
concluded there is no established benefit for antioxidant use in the management of 
diabetic complications [97].
More specifically, in biological systems, vitamin C may exert antioxidant, anti-
inflammatory, enzyme cofactor, or prooxidant activity, depending on the specific 
tissue context. Commonly in clinical trials, vitamin C is assumed to act as an anti-
oxidant or an anti-inflammatory factor without actual measurements of antioxidant 
capacity or oxidative stress to prove the latter [98].
Suksomboon et al. [99], in another systematic review for vitamin E supplementa-
tion, suggests no actual benefit for glycemic control in diabetic subjects in general, 
but implies a positive effect in a subgroup with low serum levels of the antioxidant 
component. The latter again points out the need for an individual approach.
De Leeuw et al. [100] has shown that intensive supplementation of magnesium 
in Mg-depleted patients with type 1 diabetes did not improve antioxidant capacity 
or the rate of LDL oxidation, although it increased magnesium concentration within 
erythrocytes.
Study designs and potential residual confounding with diet and lifestyle patterns 
may account for the conflicting results. For example, individuals who use nutrient 
supplements are also more likely to eat sophisticated or healthier diets, exercise 
more, and smoke fewer cigarettes. Although nutritional supplements are at the peak 
of dietetic therapies, the consumption of several specific foods (fatty fish, vegetables 
and fruits, nuts, etc.) with bioactive components within a balanced diet is a promising 
approach to manage dysmetabolic manifestations.
conclusIon
It is now well established that the risk of the development of diabetes and its complica-
tions, as well as the management of the metabolic disorder itself, are highly amelio-
rated when the ingestion of antioxidants through a diet rich in fruits and vegetables is 
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increased. The same has not been proven concerning the consumption of supplements. 
The results in the literature are highly controversial, indicating that even serum levels 
of antioxidants might represent a marker of the derangement and not a direct causative 
effect. On the other hand, supplementation of antioxidants present with either ben-
eficial or detrimental effects on metabolism, which in turn might have controversial 
effects on target tissues and clinical implications. Antioxidant supplements should be 
considered as medicinal products and undergo sufficient evaluation before market-
ing. Until there is enough evidence for their safety and efficacy, it is advisable that 
people with diabetes and related disorders should follow the European Association for 
the Study of Diabetes/American Diabetes Association and American Association of 
Clinical Endocrinologists nutritional guidelines and consume a diet rich in a variety 
of natural antioxidants in combination with an overall healthy lifestyle.
reFerences
 1. International Diabetes Federation. IDF Diabetes Atlas, update 2012, 5th edn. 
International Diabetes Federation, Brussels, Belgium.
 2. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: 
Perspectives on the past, present, and future. Lancet, 2014.383:1068–83.
 3. Stancakova A, Javorsky M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M. Changes 
in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 
6414 Finnish men. Diabetes, 2009.58:1212–21.
 4. Guenard F, Deshaies Y, Cianflone K, Kral JG, Marceau P, Vohl M-C. Differential meth-
ylation in glucoregulatory genes of off spring born before vs. after maternal gastrointes-
tinal bypass surgery. Proc Natl Acad Sci U S A, 2013.110:11439–44.
 5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. 
Diabetes Care, 2005.28:37–42.
 6. Sheetz MJ, King GL. Molecular understanding of hyperglycemia’s adverse effects for 
diabetic complications. JAMA, 2002.288:2579–88.
 7. Pasupathi P, Chandrasekar V, Kumar US. Evaluation of oxidative stress, enzymatic and 
non-enzymatic antioxidants and metabolic thyroid hormone status in patients with dia-
betes mellitus. Diab Metab Syndr Clin Res Rev, 2009.3:160–5.
 8. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and 
in cell culture: How should you do it and what do the results mean? Br J Pharmacol, 
2004.142:231–55.
 9. Donald DH. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol, 
2005.26:689–95.
 10. Mahboob M, Rahman MF, Grover P. Serum lipid peroxidation and antioxidant enzyme 
levels in male and female diabetic patients. Singapore Med J, 2005.46:322–4.
 11. Xi LS, Fan HF, Jian GZ et al. Advanced oxidation protein products accelerate athero-
sclerosis through promoting oxidative stress and inflammation. Arterioscler Thromb 
Vasc Biol, 2006.26:1156–62.
 12. Sies H. Oxidative stress: Oxidants and antioxidants. Exp Physiol, 2007.82(2):291–5.
 13. Fardoun RZ. The use of vitamin E in type 2 diabetes mellitus. Clin Exp Hypertens, 
2007.29(3):135–48.
 14. Paolisso G, Esposito R, D’Alessio MA, Barbieri M. Primary and secondary prevention 
of atherosclerosis: Is there a role for antioxidants? Diabetes Metab, 1999.25:298–306.
 15. Madian AG, Myracle AD, Diaz-Maldonado N, Rochelle NS, Janle EM, Regnier FE. 
Differential carbonylation of proteins as a function of in vivo oxidative stress. J Proteome 
Res, 2011.10:3959–72.
159Diabetes
 16. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in 
pancreatic islet beta cells in diabetes. J Biol Chem, 2004.279:42351–4.
 17. Robertson RP, Harmon JS. Diabetes, glucose toxicity, and oxidative stress: A case of 
double jeopardy for the pancreatic islet beta cell. Free Radic Biol Med, 2006.41:177–84.
 18. Vertuani S, Angusti A, Manfredini S. The antioxidants and pro-antioxidants network: 
An overview. Curr Pharm Des, 2004.10(14):1677–94.
 19. Vassort G, Turan B. Protective role of antioxidants in diabetes-induced cardiac dysfunc-
tion. Cardiovasc Toxicol, 2010.10(2):73–86.
 20. Schurks M, Glynn RJ, Rist PM, Tzourio C, Kurth T. Effects of vitamin E on stroke sub-
types: Meta-analysis of randomised controlled trials. BMJ, 2010.341:c5702.
 21. Clarke MW, Burnett JR, Croft KD. Vitamin E in human health and disease. Crit Rev 
Clin Lab Sci, 2008.45:417–50.
 22. Montonen J, Knekt P, Järvinen R, Reunanen A. Dietary antioxidant intake and risk of 
type 2 diabetes. Diabetes Care, 2004.27(2):362–6.
 23. Radimer K, Bindewald B, Hughes J, Ervin B, Swanson C, Picciano MF. Dietary sup-
plement use by US adults: Data from the National Health and Nutrition Examination 
Survey 1999–2000. Am J Epidemiol, 2004.160(4):339–49.
 24. Paolisso G, D’Amore A, Galzerano D et al. Daily vitamin E supplements improve meta-
bolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care, 
2003.16:1433–7.
 25. Xu R, Zhang S, Tao A, Chen G, Zhang M. Influence of vitamin E supplementation 
on glycaemic control: A meta-analysis of randomised controlled trial. PLoS One, 
2014.9(4):e95008.
 26. Minamiyama Y, Takemura S, Bito Y et al. Supplementation of alpha-tocopherol 
improves cardiovascular risk factors via the insulin signalling pathway and reduction 
of mitochondrial reactive oxygen species in type II diabetic rats. Free Radic Res, 2008. 
42:261–71.
 27. Pazdro R, Burgess JR. The role of vitamin E and oxidative stress in diabetes complica-
tions. Mech Ageing Dev, 2010.131:276–86.
 28. Jin L, Xue HY, Jin LJ, Li SY, Xu YP. Antioxidant and pancreas-protective effect of aucu-
bin on rats with streptozotocin-induced diabetes. Eur J Pharmacol, 2008.582:162–7.
 29. Bell LN, Wang J, Muralidharan S et al. Relationship between adipose tissue insulin 
resistance and liver histology in nonalcoholic steatohepatitis: A pioglitazone versus 
vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic 
steatohepatitis trial follow-up study. Hepatology, 2012.56(4):1311–8.
 30. Tütüncü NB, Bayraktar M, Varli K. Reversal of defective nerve conduction with 
vitamin E supplementation in type 2 diabetes: A preliminary study. Diabetes Care, 
1998.21(11):1915–8.
 31. Paolisso G, Tagliamonte MR, Barbieri M et al. Chronic vitamin E administration 
improves brachial reactivity and increases intracellular magnesium concentration in 
type II diabetic patients. J Clin Endocrinol Metab, 2000.85(1):109–15.
 32. Manzella D, Barbieri M, Ragno E, Paolisso G. Chronic administration of pharmacologic 
doses of vitamin E improves the cardiac autonomic nervous system in patients with type 
2 diabetes. Am J Clin Nutr, 2001.73(6):1052–7.
 33. Liu S, Lee IM, Song Y et al. Vitamin E and risk of type 2 diabetes in the women’s health 
study randomized controlled trial. Diabetes, 2006.55(10):2856–62.
 34. Economides PA, Khaodhiar L, Caselli A et al. The effect of vitamin E on endothelial 
function of micro- and macrocirculation and left ventricular function in type 1 and type 
2 diabetic patients. Diabetes, 2005.54(1):204–11.
 35. Chen K, Suh J, Carr AC, Morrow JD, Zeind J, Frei B. Vitamin C suppresses oxidative 
lipid damage in vivo, even in the presence of iron overload. Am J Physiol Endocrinol 
Metab, 2000.279(6):E1406–12.
160 Antioxidants in Health and Disease
 36. Schorah CJ, Downing C, Piripitsi A et al. Total vitamin C, ascorbic acid, and dehy-
droascorbic acid concentrations in plasma of critically ill patients. Am J Clin Nutr, 
1996.63(5):760–5.
 37. Block G, Norkus E, Hudes M, Mandel S, Helzlsouer K. Which plasma antioxidants are 
most related to fruit and vegetable consumption? Am J Epidemiol, 2001.154(12):1113–8.
 38. Will JC, Byers T. Does diabetes mellitus increase the requirement for vitamin C? Nutr 
Rev, 1996.54:193–202.
 39. Mangels AR, Holden JM, Beecher GR, Forman MR, Lanza E. Carotenoid contents of 
fruits and vegetables: An evaluation of analytical data. J Am Diet Assoc, 1993.93:284–96.
 40. Johnson EJ. The role of carotenoids in human health. Nutr Clin Care, 2002.5(2):47–9.
 41. Agarwal S, Rao AV. Carotenoids and chronic diseases. Drug Metab Drug Interact, 
2000.17(1–4):189–210.
 42. Gerster H. The potential role of lycopene for human health. J Am Coll Nutr, 
1997.16:109–26.
 43. Ong ASH, Tee ES. Natural sources of carotenoids from plants and oils. Methods 
Enzymol, 1992.213:142–67.
 44. Liu S, Ajani U, Chae C, Hennekens C, Buring JE, Manson JE. Long-term β-carotene 
supplementation and risk of type 2 diabetes mellitus: A randomized controlled trial. 
J Am Med Assoc, 1999.282(11):1073–5.
 45. Czernichow S, Couthouis A, Bertrais S et al. Antioxidant supplementation does not 
affect fasting plasma glucose in the Supplementation with Antioxidant Vitamins and 
Minerals (SU.VI.MAX) study in France: Association with dietary intake and plasma 
concentrations. Am J Clin Nutr, 2006.84(2):395–9.
 46. Kataja-Tuomola M, Sundell JR, Männistö S et al. Effect of α-tocopherol and β-carotene 
supplementation on the incidence of type 2 diabetes. Diabetologia, 2008.51(1):47–53.
 47. Ford ES, Will JC, Bowman BA, Narayan KMV. Diabetes mellitus and serum carot-
enoids: Findings from the Third National Health and Nutrition Examination Survey. Am 
J Epidemiol, 1999.149(2):168–76.
 48. Beydoun MA, Shroff MR, Chen X, Beydoun HA, Wang Y, Zonderman AB. Serum 
antioxidant status is associated with metabolic syndrome among U.S. adults in recent 
national surveys. J Nutr, 2011.141(5):903–13.
 49. Wang L, Liu S, Pradhan AD et al. Plasma lycopene, other carotenoids, and the risk of 
type 2 diabetes in women. Am J Epidemiol, 2006.164(6):576–85.
 50. Ylönen K, Alfthan G, Groop L, Saloranta C, Aro A, Virtanen SM. Dietary intakes and 
plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism 
in subjects at high risk of type 2 diabetes: The Botnia Dietary Study. Am J Clin Nutr, 
2003.77(6):1434–41.
 51. Coyne T, Ibiebele TI, Baade PD, McClintock CS, Shaw JE. Metabolic syndrome and 
serum carotenoids: Findings of a cross-sectional study in Queensland, Australia. Br J 
Nutr, 2009.102(11):1668–77.
 52. Coyne T, Ibiebele TI, Baade PD et al. Diabetes mellitus and serum carotenoids: 
Findings of a population-based study in Queensland, Australia. Am J Clin Nutr, 
2005.82(3):685–93.
 53. Czernichow S, Vergnaud AC, Galan P et al. Effects of long-term antioxidant supple-
mentation and association of serum antioxidant concentrations with risk of metabolic 
syndrome in adults. Am J Clin Nutr, 2009.90(2):329–35.
 54. Suzuki K, Ito Y, Nakamura S, Ochiai J, Aoki K. Relationship between serum carot-
enoids and hyperglycemia: A population-based cross–sectional study. J Epidemiol, 
2002.12(5):357–66.
 55. Suzuki K, Ito Y, Inoue T, Hamajima N. Inverse association of serum carotenoids with 
prevalence of metabolic syndrome among Japanese. Clin Nutr, 2011.30(3):369–75.
161Diabetes
 56. Ford ES, Mokdad AH, Giles WH, Brown DW. The metabolic syndrome and antioxidant 
concentrations: Findings from the Third National Health and Nutrition Examination 
Survey. Diabetes, 2003.52(9):2346–52.
 57. Graham TE, Yang Q, Blüher M et al. Retinol-binding protein 4 and insulin resistance in 
lean, obese, and diabetic subjects. N Engl J Med, 2006.354(24):2552–63.
 58. Yang Q, Graham TE, Mody N et al. Serum retinol binding protein 4 contributes to insu-
lin resistance in obesity and type 2 diabetes. Nature, 2005.436(7049):356–62.
 59. Kowalska I, Straczkowski M, Adamska A et al. Serum retinol binding protein 4 is 
related to insulin resistance and nonoxidative glucose metabolism in lean and obese 
women with normal glucose tolerance. J Clin Endocrinol Metab, 2008.93(7):2786–9.
 60. Blondin SA, Yeung EH, Mumford SL et al. Serum retinol and carotenoids in associa-
tion with biomarkers of insulin resistance among premenopausal women. ISRN Nutr, 
2013.2013:619516.
 61. Lambadiari V, Kadoglou NP, Stasinos V et al. Serum levels of retinol-binding protein-4 
are associated with the presence and severity of coronary artery disease. Cardiovasc 
Diabetol, 2014.13(1):121.
 62. Di Mascio P, Kaiser S, Sies H. Lycopene as the most efficient biological carotenoid 
singlet oxygen quencher. Arch Biochem Biophys, 1989.274(2):532–8.
 63. Wang L, Liu S, Manson JE, Gaziano JM, Buring JE, Sesso HD. The consumption of 
lycopene and tomato-based food products is not associated with the risk of type 2 diabe-
tes mellitus in women. J Nutr, 2006.136:620–5.
 64. Hozawa A, Jacobs DR, Steffes MW, Gross MD, Steffen LM, Lee DH. Associations of 
serum carotenoid concentrations with the development of diabetes and with insulin con-
centration: Interaction with smoking. The Coronary Artery Risk Development in Young 
Adults (CARDIA) study. Am J Epidemiol, 2006.163:929–37.
 65. Polidori MC, Mecocci P, Stahl W et al. Plasma levels of lipophilic antioxidants in very 
old patients with type 2 diabetes. Diabetes Metab Res Rev, 2000.16:15–9.
 66. McClung JP, Roneker CA, Mu W et al. Development of insulin resistance and obe-
sity in mice overexpressing cellular glutathione peroxidase. Proc Natl Acad Sci U S A, 
2004.101:8852–7.
 67. Pepper MP, Vatamaniuk MZ, Yan X, Roneker CA, Lei XG. Impacts of dietary sele-
nium deficiency on metabolic phenotypes of diet-restricted GPX1-overexpressing mice. 
Antioxid Redox Signal, 2011.14:383–90.
 68. Wang X, Vatamaniuk MZ, Roneker CA et al. Knockouts of SOD1 and GPX1 exert dif-
ferent impacts on murine islet function and pancreatic integrity. Antioxid Redox Signal, 
2011.14:391–401.
 69. Stranges S, Marshall JR, Natarajan R et al. Effects of long-term selenium supple-
mentation on the incidence of type 2 diabetes: A randomized trial. Ann Intern Med, 
2007.147:217–23.
 70. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements 
for prevention of mortality in healthy participants and patients with various disease. 
Cochrane Database Syst Rev, 2012.3:CD007176. doi:10.1002/14651858.CD007176 
.pub2.
 71. Gao H, Hägg S, Sjögren P, Lambert PC, Ingelsson E, van Dam RM. Serum selenium in 
relation to measures of glucose metabolism and incidence of type 2 diabetes in an older 
Swedish population. Diabet Med, 2014.31(7):787–93.
 72. Sarmento RA, Silva FM, Sbruzzi G, Schaan BD, Almeida JC. Antioxidant micronutri-
ents and cardiovascular risk in patients with diabetes: A systematic review. Arq Bras 
Cardiol, 2013.101(3):240–8.
 73. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. J Nutr, 
2000.130:2073S–85S.
162 Antioxidants in Health and Disease
 74. D’Archivio M, Filesi C, Varì R, Scazzocchio B, Masella R. Bioavailability of the poly-
phenols: Status and controversies. Int J Mol Sci, 2010.11(4):1321–42.
 75. Am Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: Food 
sources and bioavailability. Am J Clin Nutr, 2004.12:727–47.
 76. Han X, Loa T. Dietary polyphenols and their biological significance. Int J Mol Sci, 
2007.12:950–88.
 77. Hanhineva K, Törrönen R, Bondia-Pons I et al. Impact of dietary polyphenols on carbo-
hydrate metabolism. Int J Mol Sci, 2010.12:1365–402.
 78. Iwai K. Antidiabetic and antioxidant effects of polyphenols in brown alga Ecklonia sto-
lonifera in genetically diabetic KK-A(y) mice. Plant Foods Hum Nutr, 2008.12:163–9.
 79. Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea—A review. J Am Coll 
Nutr, 2006.12:79–99.
 80. Tadera K, Minami Y, Takamatsu K, Matsuoka T. Inhibition of alpha-glucosidase and 
alpha-amylase by flavonoids. J Nutr Sci Vitaminol (Tokyo), 2006.12:149–53.
 81. Kobayashi Y, Suzuki M, Satsu H et al. Green tea polyphenols inhibit the sodium-
dependent glucose transporter of intestinal epithelial cells by a competitive mechanism. 
J Agric Food Chem, 2000.12:5618–23.
 82. Johnston K, Sharp P, Clifford M, Morgan L. Dietary polyphenols decrease glucose 
uptake by human intestinal Caco-2 cells. FEBS Lett, 2005.12:1653–7.
 83. Johnston KL, Clifford MN, Morgan LM. Coffee acutely modifies gastrointestinal hor-
mone secretion and glucose tolerance in humans: Glycemic effects of chlorogenic acid 
and caffeine. Am J Clin Nutr, 2003.2:728–33.
 84. Dao TM, Waget A, Klopp P et al. Resveratrol increases glucose induced GLP-1 secre-
tion in mice: A mechanism which contributes to the glycemic control. PLoS One, 
2011.12:e20700.
 85. Jung EH, Kim SR, Hwang IK, Ha TY. Hypoglycemic effects of a phenolic acid frac-
tion of rice bran and ferulic acid in C57BL/KsJ-db/db mice. J Agric Food Chem, 
2007.12:9800–4.
 86. Jung UJ, Lee MK, Jeong KS, Choi MS. The hypoglycemic effects of hesperidin and 
naringin are partly mediated by hepatic glucose-regulating enzymes in C57BL/KsJ-db/
db mice. J Nutr, 2004.12:2499–503.
 87. Jung UJ, Lee MK, Park YB, Kang MA, Choi MS. Effect of citrus flavonoids on lipid 
metabolism and glucose-regulating enzyme mRNA levels in type-2 diabetic mice. Int J 
Biochem Cell Biol, 2006.12:1134–45.
 88. Zhang B, Kang M, Xie Q et al. Anthocyanins from Chinese bayberry extract protect 
β-cells from oxidative stress-mediated injury via HO-1 upregulation. J Agric Food 
Chem, 2011.12:537–45.
 89. Park CE, Kim MJ, Lee JH et al. Resveratrol stimulates glucose transport in C2C12 myo-
tubes by activating AMP-activated protein kinase. Mol Med, 2007.12:222–9.
 90. Kumar R, Balaji S, Uma TS, Sehgal PK. Fruit extracts of Momordica charantia potenti-
ate glucose uptake and up-regulate Glut-4, PPAR gamma and PI3K. J Ethnopharmacol, 
2009.12:533–7.
 91. Yin P, Zhao S, Chen S et al. Hypoglycemic and hypolipidemic effects of polyphenols 
from burs of Castanea mollissima Blume. Molecules, 2011.12:9764–74.
 92. Szkudelski T, Szkudelska K. Anti-diabetic effects of resveratrol. Ann N Y Acad Sci, 
2011.12:34–9.
 93. Szkudelski T. Resveratrol inhibits insulin secretion from rat pancreatic islets. Eur J 
Pharmacol, 2006.12:176–81.
 94. Bahadoran Z, Mirmiran P, Azizi F. Dietary polyphenols as potential nutraceuticals in 
management of diabetes: A review. J Diabetes Metab Disord, 2013.12:43.
163Diabetes
 95. Wang C, Yang S, Zhang N et al. Long-term supranutritional supplementation with sele-
nate decreases hyperglycemia and promotes fatty liver degeneration by inducing hyper-
insulinemia in diabetic db/db mice. PLoS One, 2014.9:e101315.
 96. Montero D, Walther G, Stehouwer CD, Houben AJ, Beckman JA, Vinet A. Effect of 
antioxidant vitamin supplementation on endothelial function in type 2 diabetes mel-
litus: A systematic review and meta-analysis of randomized controlled trials. Obes Rev, 
2014.15:107–16.
 97. Golbidi S, Ebadi SA, Laher I. Antioxidants in the treatment of diabetes. Curr Diabetes 
Rev, 2011.7:106–25.
 98. Michels AJ, Frei B. Myths, artifacts, and fatal flaws: Identifying limitations and oppor-
tunities in vitamin C research. Nutrients, 2013.5:5161–92.
 99. Suksomboon N, Poolsup N, Sinprasert S. Effects of vitamin E supplementation on gly-
caemic control in type 2 diabetes: Systematic review of randomized controlled trials. 
J Clin Pharm Ther, 2011.36:53–63.
 100. De Leeuw I, Engelen W, Aerts P, Schrans S. Effect of intensive magnesium supplemen-
tation on the in vitro oxidizability of LDL and VLDL in Mg-depleted type 1 diabetic 







Free Radicals and Their Contribution to Cancer Development ............................. 166
Antioxidants ........................................................................................................... 166
Cancer and Folic Acid ....................................................................................... 167
Cancer and Selenium......................................................................................... 170
Cancer and Vitamin C ....................................................................................... 172
Antioxidant Supplementation and Prevention of Cancer .................................. 174
Dilemma of Taking Antioxidant Supplements while Having Cancer ............... 177
Foods Rich in Antioxidants ............................................................................... 179
Prevention .............................................................................................................. 179
Cancer and Fruits and Vegetables ..................................................................... 179
Intake Recommendations ............................................................................. 181
Cruciferous Vegetables ...................................................................................... 181
Iodine and Thyroid Function and Cruciferous Vegetables ................................ 182
Intake Recommendations ............................................................................. 182
Cancer and Legumes ......................................................................................... 182
Dry Beans, Peas, and Lentils ........................................................................ 182
Prostate Cancer ............................................................................................. 182
Cancer and Soy ................................................................................................. 183
Prostate Cancer ............................................................................................. 183
Breast Cancer ............................................................................................... 183
Intake Recommendations ............................................................................. 183
Cancer and Whole Grains ................................................................................. 184
Intake Recommendations ............................................................................. 184
Cancer and Carotenoids .................................................................................... 184
Food Sources ................................................................................................ 184
β-Carotene and α-Carotene .......................................................................... 185
β-Cryptoxanthin............................................................................................ 185
Lycopene ...................................................................................................... 185
Lutein and Zeaxanthin .................................................................................. 186
Curcumin ...................................................................................................... 186
Cancer and Curcumin ........................................................................................ 187
Colorectal Cancer and Fiber.............................................................................. 188
166 Antioxidants in Health and Disease
IntroduCtIon
Antioxidants are chemicals that obstruct the action of other chemicals known as 
free radicals. Free radicals are highly reactive and have the potential to cause dam-
age to cells, including damage that may lead to cancer. Free radicals are produced 
naturally in the body. Additionally, some environmental toxins may contain high 
levels of free radicals or encourage the body’s cells to produce more free radicals 
(Higdon, 2007).
Although some antioxidants are made naturally by the body, others can only 
be obtained by external (exogenous) sources, including the diet and dietary sup-
plements. Laboratory and animal research has shown that exogenous antioxidants 
can help prevent the free radical damage associated with the development of cancer 
(Higdon and Drake, 2011).
Free radICals and theIr ContrIbutIon 
to CanCer development
Free radicals are produced when an atom or a molecule either gains or losses an 
electron. Free radicals are formed naturally in the body and play an important role in 
many normal cellular processes. Nevertheless, at high concentrations, free radicals 
can be harmful to the body and hurt all major components of cells, including DNA, 
proteins, and cell membranes. The damage to cells caused by free radicals may cause 
the progression of cancer and other health conditions (Diplock et al., 1998; Valko 
et al., 2007).
Unusually high concentrations of free radicals in the body can be caused by expo-
sure to ionizing radiation and other environmental toxins. When ionizing radiation 
hits an atom or a molecule in a cell, an electron may be misplaced, resulting to the 
formation of a free radical. The fabrication of oddly high levels of free radicals is the 
mechanism by which ionizing radiation kills cells. Furthermore, some environmen-
tal toxins (i.e., cigarette) may include large amounts of free radicals or encourage the 
cells to produce more free radicals.
Free radicals that contain the element oxygen are the most common type of 
free radicals produced in living tissue, also called reactive oxygen species (ROS) 
(Diplock et al., 1998; Valko et al., 2007).
antIoxIdants
Antioxidants (“free radical scavengers”) are chemicals that work together with and 
neutralize free radicals, hence preventing them from causing damage.
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167Cancer
The body makes some of the antioxidants it uses to neutralize free radicals, 
known as endogenous antioxidants. Nevertheless, the body relies on external 
(exogenous) sources, primarily the diet, to obtain the rest of the antioxidants 
it needs, known as dietary antioxidants. Fruits, vegetables, and grains are rich 
sources of dietary antioxidants (Bouayed and Bohn, 2010). Examples of dietary 
antioxidants include folic acid, β-carotene, lycopene, and vitamins A, C, and E 
(α-tocopherol). The mineral element selenium is often thought to be a dietary anti-
oxidant, the antioxidant effects of selenium are most likely due to the antioxidant 
activity of proteins in which it is an essential component, and not to selenium itself 
(Davis et al., 2012).
CanCer and FoliC aCid
Cancer is thought to arise from DNA damage in excess of ongoing DNA repair and/or 
the inappropriate expression of critical genes. Because of the important roles played 
by folate in DNA and RNA synthesis and methylation, it is possible for folate intake 
to affect both DNA repair and gene expression with the consumption of at least five 
servings of fruits and vegetables per day, which it is associated with a diminished 
incidence of cancer. Fruits and vegetables are excellent sources of folate and contrib-
ute positively to the anticarcinogenic effect. Observational studies have found that a 
decreased folate status in human nutrition is associated with cancers of the cervix, 
colon and rectum, lung, esophagus, brain, pancreas, and breast. Intervention trials in 
humans have been conducted mainly with respect to cervical and colorectal cancer. 
The results in cervical cancer have been inconsistent (Choi and Mason, 2000), but 
with more relevant randomized intervention trials regarding colorectal cancer there 
is a different point of view (Gravo et al., 1998; Kim et al., 2001).
•	 Colorectal	cancer: The role of folate in preventing colorectal cancer pro-
vides an example of the complexity of the interactions between genetics 
and the nutritional environment. In general, observational studies have 
found relatively low folate intake and high alcohol intake to be associ-
ated with increased incidence of colorectal cancer (Food and Nutrition 
Board, Institute of Medicine, 1998; Su and Arab, 2001; Terry et al., 2002). 
Alcohol interferes with the absorption and metabolism of folate (Herbert, 
1999). In a prospective study of more than 45,000 male health profession-
als, an intake of more than two alcoholic drinks per day doubled the risk 
of colon cancer. The combination of high alcohol and low folate intake 
yielded an even greater risk of colon cancer. However, increased alcohol 
intake in individuals who consumed 650 μg or more of folate per day was 
not associated with an increased risk of colon cancer (Giovannucci et al., 
1995). In some studies, individuals who are homozygous for the C677T 
MTHFR polymorphism (T/T) have been found to be at decreased risk for 
colon cancer when folate intake is adequate. However, when folate intake 
is low and/or alcohol intake is high, individuals with the (T/T) genotype 
have been found to be at an increased risk of colorectal cancer (Ma et al., 
1997; Slattery et al., 1999).
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•	 Breast	cancer: A number of prospective studies have found that even mod-
erate alcohol intake is associated with an increased risk of breast cancer 
in women. Recently, the results of three prospective studies suggested that 
increased folate intake may reduce the risk of breast cancer in women who 
regularly consume alcohol (Zhang et al., 1999b; Rohan et al., 2000; Sellers 
et al., 2001). A prospective study of more than 88,000 nurses found no rela-
tionship between folic acid intake and breast cancer in women who con-
sumed less than one alcoholic drink per day. However, in those women 
consuming at least one alcoholic drink per day, folic acid intake of at least 
600 μg daily resulted in about half the risk of breast cancer compared with 
women who consumed less than 300 μg of folic acid daily (Zhang et al., 
1999b).
Table 10.1 presents the current recommended dietary allowance (RDA) for folate 
as micrograms (μg) of dietary folate equivalents (DFEs). The Food and Nutrition 
Board (FNB) developed DFEs to reflect the higher bioavailability of folic acid than 
that of food folate. At least 85% of folic acid is estimated to be bioavailable when 
taken with food, whereas only about 50% of folate naturally present in food is bio-
available. On the basis of these values, the FNB defined DFE as follows:
•	 1 μg DFE = 1 μg food folate
•	 1 μg DFE = 0.6 μg folic acid from fortified foods or dietary supplements 
consumed with foods
•	 1 μg DFE = 0.5 μg folic acid from dietary supplements taken on an empty 
stomach
According to the Dietary Guidelines for Americans, moderate alcohol consump-
tion is defined as having up to one drink per day for women and up to two drinks 
per day for men. This definition is referring to the amount consumed on any single 
day and is not intended as an average over several days. The Dietary Guidelines 
also state that it is not recommended that anyone begin drinking or drink more 
frequently on the basis of potential health benefits because moderate alcohol intake 
is also associated with increased risk of breast cancer, violence, drowning, and 
injuries from falls and motor vehicle crashes. For men, heavy drinking is typically 
defined as consuming 15 drinks or more per week; significant alcohol intake is con-
sidered >140 g/week in men and >70 g/week in women. For women, heavy drinking 
is typically defined as consuming eight drinks or more per week (U.S. Department 
of Agriculture [USDA] and U.S. Department of Health and Human Services, 2010).
A standard drink in the United States is equal to 14.0 g (0.6 oz) of pure alcohol. 
Generally, this amount of pure alcohol is found in
•	 12 oz of beer (5% alcohol content)
•	 8 oz of malt liquor (7% alcohol content)
•	 5 oz of wine (12% alcohol content)
•	 1.5 oz or a “shot” of 80-proof (40% alcohol content) distilled spirits or 
liquor (e.g., gin, rum, vodka, and whiskey)
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table 10.1
Food sources of Folate and Folic acid
Food μg dFe per serving % dva
Beef liver, braised, 3 oz 215 54
Spinach, boiled, 1/2 cup 131 33
Black-eyed peas (cowpeas), boiled, 1/2 cup 105 26
Breakfast cereals, fortified with 25% of the DVb 100 25
Rice, white, medium-grain, cooked, 1/2 cupb 90 23
Asparagus, boiled, 4 spears 89 22
Spaghetti, cooked, enriched, 1/2 cupb 83 21
Brussels sprouts, frozen, boiled, 1/2 cup 78 20
Lettuce, romaine, shredded, 1 cup 64 16
Avocado, raw, sliced, 1/2 cup 59 15
Spinach, raw, 1 cup 58 15
Broccoli, chopped, frozen, cooked, 1/2 cup 52 13
Mustard greens, chopped, frozen, boiled, 1/2 cup 52 13
Green peas, frozen, boiled, 1/2 cup 47 12
Kidney beans, canned, 1/2 cup 46 12
Bread, white, 1 sliceb 43 11
Peanuts, dry roasted, 1 oz 41 10
Wheat germ, 2 tablespoons 40 10
Tomato juice, canned, 3/4 cup 36 9
Crab, Dungeness, 3 oz 36 9
Orange juice, 3/4 cup 35 9
Turnip greens, frozen, boiled, 1/2 cup 32 8
Orange, fresh, 1 small 29 7
Papaya, raw, cubed, 1/2 cup 27 7
Banana, 1 medium 24 6
Yeast, baker’s, 1/4 teaspoon 23 6
Egg, whole, hard-boiled, 1 large 22 6
Vegetarian baked beans, canned, 1/2 cup 15 4
Cantaloupe, raw, 1 wedge 14 4
Fish, halibut, cooked, 3 oz 12 3
Milk, 1% fat, 1 cup 12 3
Ground beef, 85% lean, cooked, 3 oz 7 2
Chicken breast, roasted, 1/2 breast 3 1
Source: U.S. Department of Agriculture, Agricultural Research Service. 2012. USDA National 
Nutrient Database for Standard Reference, Release 25. Available at: http://www.nal 
.usda.gov/fnic/foodcomp/search/.
a DV = daily value. The Food and Drug Administration (FDA) developed DVs to help consum-
ers compare the nutrient contents of products within the context of a total diet. The DV for 
folate is 400 μg for adults and children aged 4 years and older. However, the FDA does not 
require food labels to list folate content unless a food has been fortified with this nutrient. 
Foods providing 20% or more of the DV are considered to be high sources of a nutrient.
b Fortified with folic acid as part of the folate fortification program.
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CanCer and Selenium
There is a lot of evidence that selenium supplementation at high levels reduces the 
incidence of cancer in animals. In fact, in animal models of spontaneous, viral, and 
chemically induced cancers, selenium supplementation greatly reduced tumor inci-
dence (Rayman and Clark, 2000). The evidence indicated that the methylated forms 
of selenium were the active species against tumors, and these methylated selenium 
compounds were produced at the greatest amounts with excess selenium intakes. 
Selenium deficiency did not appear to make animals more susceptible to developing 
cancerous tumors (Combs and Gray, 1998).
Various studies have shown a tendency for population that reside in areas with 
low soil selenium and have relatively low selenium intakes to have higher cancer 
mortality rates. Food sources of selenium depends from the soil content of selenium 
(Table 10.2). Results of epidemiologic studies of cancer incidence in groups with 
less variable selenium intakes have been less consistent, but also show a trend for 
individuals with lower selenium levels (blood and nails) to have a higher incidence 
of several different types of cancer. This trend is less pronounced in women. Chronic 
infection with viral hepatitis B or C significantly increases the risk of liver cancer. 
In a study of Taiwanese men with chronic viral hepatitis B or C, decreased plasma 
selenium concentrations were associated with an even greater risk of liver cancer 
(Yu et al., 1999). A case–control study within a prospective study of more than 9000 
Finnish men and women examined serum selenium levels in 95 individuals conse-
quently found to have lung cancer and 190 matched controls (Knekt et al., 1998). 
Lower serum selenium levels were related with an enlarged risk of lung cancer, 
and the association was more prominent in smokers. Additionally, a case–control 
study within a prospective study of more than 50,000 male health professionals in 
the United States found a significant inverse relationship between toenail selenium 
content and risk of prostate cancer in 181 men with advanced prostate cancer and 
181 matched controls (Yoshizawa et al., 1998).
Toenail selenium concentration has been proposed as a long-term (6–12 months) 
indicator of human selenium status. In the analysis of covariance, the best predictors 
of toenail selenium concentration were selenium intake from supplements and food, 
and among supplement users also dietary β-carotene (Ovaskaimen et al., 1993). In 
persons whose toenail selenium substance was consistent with an average intake 
of 159 μg/day, the possibility of progressive prostate cancer was only 35% of those 
whose toenail selenium content was consistent with an intake of 86 μg/day. In a 
prospective study of more than 9000 Japanese–American men, a case–control study 
that examined 249 established cases of prostate cancer and 249 matched controls 
found the risk of developing prostate cancer to be 50% lower in men with serum 
selenium levels in the highest quartile paralleled with those in the lowest quartile 
(Nomura et al., 2000). Moreover, another case–control study found that men with 
prediagnostic plasma selenium levels in the lowest quartile were four to five times 
more prone to progress to prostate cancer than those in the highest quartile (Brooks 
et al., 2001). On the other hand, a case–control study indicated an important inverse 
association between toenail selenium and the risk of colon cancer, but found no 
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table 10.2




Brazil nuts, 1 oz (6–8 nuts) 544 777
Tuna, yellowfin, cooked, dry heat, 3 oz 92 131
Halibut, cooked, dry heat, 3 oz 47 67
Sardines, canned in oil, drained solids with bone, 3 oz 45 64
Ham, roasted, 3 oz 42 60
Shrimp, canned, 3 oz 40 57
Macaroni, enriched, cooked, 1 cup 37 53
Beef steak, bottom round, roasted, 3 oz 33 47
Turkey, boneless, roasted, 3 oz 31 44
Beef liver, pan fried, 3 oz 28 40
Chicken, light meat, roasted, 3 oz 22 31
Cottage cheese, 1% milk fat, 1 cup 20 29
Rice, brown, long-grain, cooked, 1 cup 19 27
Beef, ground, 25% fat, broiled, 3 oz 18 26
Egg, hard-boiled, 1 large 15 21
Puffed wheat ready-to-eat cereal, fortified, 1 cup 15 21
Bread, whole-wheat, 1 slice 13 19
Baked beans, canned, plain or vegetarian, 1 cup 13 19
Oatmeal, regular and quick, unenriched, cooked with 
water, 1 cup
13 19
Spinach, frozen, boiled, 1 cup 11 16
Milk, 1% fat, 1 cup 8 11
Yogurt, plain, low fat, 1 cup 8 11
Lentils, boiled, 1 cup 6 9
Bread, white, 1 slice 6 9
Spaghetti sauce, marinara, 1 cup 4 6
Cashew nuts, dry roasted, 1 oz 3 4
Corn flakes, 1 cup 2 3
Green peas, frozen, boiled, 1 cup 2 3
Bananas, sliced, 1 cup 2 3
Potato, baked, flesh and skin, 1 potato 1 1
Peaches, canned in water, solids and liquids, 1 cup 1 1
Carrots, raw, 1 cup 0 0
Lettuce, iceberg, raw, 1 cup 0 0
Source: U.S. Department of Agriculture, Agricultural Research Service. 2010. USDA Database for the 
Oxygen Radical Absorbance Capacity (ORAC) of Selected Foods, Release 2. Available at: 
http://www.orac-info-portal.de/download/ORAC_R2.pdf.
a DV = daily value. DVs were developed by the FDA to help consumers compare the nutrient contents of 
products within the context of a total diet. The DV for selenium is 70 μg for adults and children aged 
4 years and older. Foods providing 20% or more of the DV are considered to be high sources of a nutrient. 
1 oz = 28.350 g.
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associations between toenail selenium and the risk of breast cancer or prostate 
cancer (Ghadirian et al., 2000).
An intervention trial commenced among a general population of more than 
130,000 individuals in five townships of Qidong, China, a high-risk area for viral 
hepatitis B infection and liver cancer, which provided table salt enriched with 
sodium selenite to the population of one township (almost 21,000 people), with the 
other four areas designated as controls. Throughout an 8-year follow-up period, the 
average frequency of liver cancer was condensed by 35% in the selenium-enhanced 
population, while no decline was uncovered in the control populations. In a clinical 
trial in the identical area, 226 persons with sign of chronic hepatitis B infection were 
supplemented with either 200 μg of selenium in the form of selenium-enhanced yeast 
tablet or a placebo yeast tablet daily. Throughout the 4-year follow-up period, 7 of 
113 individuals receiving placebo advanced to primary liver cancer, while none of 
the 113 subjects supplemented with selenium presented liver cancer (Yu et al., 1997).
Furthermore, a double-blind, placebo-controlled study in the United States of 
1250 older people with a history of skin cancer discovered that 200 μg/day of selenium-
enhanced yeast for an average of 7.4 years did not influence the reappearance of skin 
cancers (Clark et al., 1996). Nevertheless, selenium supplementation was related to 
a 52% reduction in prostate cancer frequency and a 33% reduction in total cancer 
in men. The protective outcome of selenium supplementation was highest in those 
with lesser pretreatment plasma selenium levels. Selenium supplementation did not 
decrease the probability of cancer in women, who were 25% of the participants 
(Rayman and Clark, 2000).
The mechanisms for the protective effect of selenium are the maximized activity 
of antioxidant selenoenzymes and improved antioxidant status, improved immune sys-
tem function, distressed metabolism of carcinogens, and increased levels of selenium 
metabolites that prevent tumor cell growth. The nutritional quantity of 40–100 μg/
day selenium in adults maximizes antioxidant selenoenzyme activity and probably 
enhances immune system function and carcinogen metabolism. At supranutritional 
levels of 200–300 μg/day selenium in adults, the formation of selenium metabolites, 
especially methylated forms of selenium, may also exert anticarcinogenic effects 
(Combs and Gray, 1998).
CanCer and Vitamin C
A large number of studies have shown that increased consumption of fresh fruits 
and vegetables is associated with a reduced risk for most types of cancer (Steinmetz 
and Potter, 1996) (Table 10.3). These studies are the core for dietary guidelines 
recognized by the USDA and the National Cancer Institute, which endorse at least 
five servings of fruits and vegetables per day. A number of case–control studies 
have investigated the role of vitamin C in cancer prevention. Most have shown that 
higher intakes of vitamin C are associated with decreased incidence of cancers of the 
mouth, throat and vocal chords, esophagus, stomach, colon–rectum, and lung (Carr 
and Frei, 1999). Because the possibility of bias is greater in case–control studies, 
prospective studies are generally given more weight in the evaluation of the effect of 
nutrient intake on disease. In general, prospective studies in which the lowest intake 
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group consumed more than 86 mg of vitamin C daily have not found differences in 
cancer risk, while studies finding significant cancer risk reductions found them in 
people consuming at least 80–110 mg of vitamin C daily (Carr and Frei, 1999).
A prospective study of 870 men for a period of 25 years established that those 
who had an intake of more than 83 mg of vitamin C daily had a 64% reduction in 
lung cancer compared with those who received less than 63 mg/day (Kromhout, 
1987). Although most large prospective studies found no association between 
breast cancer and vitamin C intake, two studies found dietary vitamin C intake to 
be inversely associated with breast cancer risk in certain subgroups. In the Nurses’ 
Health Study, premenopausal women with a family history of breast cancer who 
consumed an average of 205 mg/day of vitamin C from foods had a 63% lower risk 
of breast cancer than those who consumed an average of 70 mg/day (Zhang et al., 
1999a). In the Swedish Mammography Cohort, women who were overweight and 
consumed an average of 110 mg/day of vitamin C had a 39% lower risk of breast 
table 10.3
Food sources of vitamin C
Food milligrams (mg) per serving percent (%) dva
Red pepper, sweet, raw, 1/2 cup 95 158
Orange juice, 3/4 cup 93 155
Orange, 1 medium 70 117
Grapefruit juice, 3/4 cup 70 117
Kiwifruit, 1 medium 64 107
Green pepper, sweet, raw, 1/2 cup 60 100
Broccoli, cooked, 1/2 cup 51 85
Strawberries, fresh, sliced, 1/2 cup 49 82
Brussels sprouts, cooked, 1/2 cup 48 80
Grapefruit, 1/2 medium 39 65
Broccoli, raw, 1/2 cup 39 65
Tomato juice, 3/4 cup 33 55
Cantaloupe, 1/2 cup 29 48
Cabbage, cooked, 1/2 cup 28 47
Cauliflower, raw, 1/2 cup 26 43
Potato, baked, 1 medium 17 28
Tomato, raw, 1 medium 17 28
Spinach, cooked, 1/2 cup 9 15
Green peas, frozen, cooked, 1/2 cup 8 13
Source: U.S. Department of Agriculture, Agricultural Research Service. 2011. USDA National 
Nutrient Database for Standard Reference, Release 24. Available at: http://www.ars.usda 
.gov/ba/bhnrc/ndl.
a DV = daily value. DVs were developed by the FDA to help consumers compare the nutrient con-
tents of products within the context of a total diet. The DV for vitamin C is 60 mg for adults and 
children aged 4 years and older. The FDA requires all food labels to list the percent DV for vita-
min C. Foods providing 20% or more of the DV are considered to be high sources of a nutrient.
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cancer compared with overweight women who consumed an average of 31 mg/day 
(Michels et al., 2001). A number of observational studies have found increased 
dietary vitamin C intake to be associated with decreased risk of stomach cancer, 
and laboratory experiments indicate that vitamin C inhibits the formation of car-
cinogenic compounds in the stomach. Infection with the bacterium Helicobacter	
pylori is known to increase the risk of stomach cancer and also appears to lower 
the vitamin C content of stomach secretions. Although two intervention studies 
did not find a decrease in the occurrence of stomach cancer with vitamin C supple-
mentation, more recent research suggests that vitamin C supplementation may be 
a useful addition to standard H.	pylori eradication therapy in reducing the risk of 
gastric cancer (Feiz and Mobarhan, 2002).
antioxidant Supplementation and preVention oF CanCer
In laboratory and animal studies, the presence of increased levels of exogenous 
antioxidants has been shown to prevent the types of free radical damage that have 
been associated with cancer development. Therefore, researchers have investigated 
whether taking dietary antioxidant supplements can help lower the risk of developing 
or dying from cancer in humans.
Many observational studies, including case–control studies and cohort studies, 
have been conducted to investigate whether the use of dietary antioxidant supple-
ments is associated with reduced risks of cancer in humans. Overall, these studies 
have yielded mixed results (Patterson et al., 1997). Because observational studies 
cannot adequately control for biases that might influence study outcomes, the results 
of any individual observational study must be viewed with caution.
Randomized controlled clinical trials, on the other hand, lack most of the biases 
that limit the reliability of observational studies. As a result, randomized trials are 
deemed to present the most powerful and reliable evidence of the benefit and/or 
harm of a health-related intervention. To date, nine randomized controlled trials of 
dietary antioxidant supplements for cancer prevention have been conducted world-
wide. Many of the trials were sponsored by the National Cancer Institute, and some 
of them are presented below.
•	  α-Tocopherol/β-Carotene	 Cancer	 Prevention	 Study	 (ATBC): This trial 
investigated whether the use of α-tocopherol and/or β-carotene supplements 
for 5–8 years could help reduce the incidence of lung and other cancers in 
middle-aged male smokers in Finland. Initial results of the trial, reported 
in 1994, showed an increase in the incidence of lung cancer among the 
participants who took β-carotene supplements (20 mg/day); in contrast, 
α-tocopherol supplementation (50 mg/day) had no effect on lung cancer 
incidence (The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study 
Group, 1994). Later results showed no effect of β-carotene or α-tocopherol 
supplementation on the incidence of urothelial (bladder, ureter, or renal pel-
vis), pancreatic, colorectal, renal cell (kidney), or upper aerodigestive tract 
(oral/pharyngeal, esophageal, or laryngeal) cancers (Rautalahti et al., 1999; 
Albanes et al., 2000; Virtamo et al., 2000; Wright et al., 2007).
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•	 Carotene	and	Retinol	Efficacy	Trial	(CARET): This U.S. trial examined the 
effects of daily supplementation with β-carotene and retinol (vitamin A) on 
the incidence of lung cancer, other cancers, and death among people who 
were at high risk of lung cancer because of a history of smoking or exposure 
to asbestos. The trial began in 1983 and ended in late 1995, 2 years earlier 
than originally planned. Results reported in 1996 showed that daily supple-
mentation with both 15 mg β-carotene and 25,000 international units (IU) 
retinol was associated with increased lung cancer and increased death from 
all causes (all-cause mortality) (Omenn et al., 1996). A 2004 report showed 
that these adverse effects persisted up to 6 years after supplementation ended, 
although the elevated risks of lung cancer and all-cause mortality were no 
longer statistically significant (Goodman et al., 2004). Additional results, 
reported in 2009, showed that β-carotene and retinol supplementation had 
no effect on the incidence of prostate cancer (Neuhouser et al., 2009).
•	 Women’s	Health	Study	(WHS): This trial investigated the effects of β-carotene 
supplementation (50 mg every other day), vitamin E supplementation (600 IU 
every other day), and aspirin (100 mg every other day) on the incidence of 
cancer and cardiovascular disease in U.S. women ages 45 years and older. 
The results, reported in 1999, showed no benefit or harm associated with 
2 years of β-carotene supplementation (Lee et al., 1999). In 2005, similar 
results were reported for vitamin E supplementation (Lee et al., 2005).
•	 Heart	Outcomes	Prevention	Evaluation—The	Ongoing	Outcomes	(HOPE-
TOO)	Study: This international trial examined the effects of α-tocopherol 
supplementation on cancer incidence, death from cancer, and the incidence 
of major cardiovascular events (heart attack, stroke, or death from heart dis-
ease) in people with cardiovascular disease or diabetes. The results, reported 
in 2005, showed no effect of daily supplementation with α-tocopherol 
(400 IU) for a median of 7 years on any of the outcomes (Lonn et al., 2005).
•	 Selenium	 and	Vitamin	 E	Cancer	 Prevention	 Trial	 (SELECT): This U.S. 
trial investigated whether daily supplementation with selenium (200 μg), 
vitamin E (400 IU), or both would reduce the incidence of prostate cancer 
in men ages 50 years and older. The study began in 2001 and was stopped 
in 2008, approximately 5 years earlier than originally planned. Results 
reported in late 2008 showed that the use of these supplements for a median 
duration of 5.5 years did not reduce the incidence of prostate or other can-
cers (Lippman et al., 2009). Updated findings from the study, reported in 
2011, showed that, after an average of 7 years (5.5 years on supplements 
and 1.5 years off supplements), there were 17% more cases of prostate 
cancer among men taking vitamin E alone than among men taking a pla-
cebo (Klein et al., 2011). No increase in prostate risk was observed for men 
assigned to take selenium alone or vitamin E plus selenium compared with 
men assigned to take a placebo (Lippman et al., 2009).
•	 Physicians’	Health	 Study	 II	 (PHS	 II): This trial examined whether sup-
plementation with vitamin E, vitamin C, or both would reduce the inci-
dence of cancer in male U.S. physicians ages 50 years and older. The results, 
reported in 2009, showed that the use of these supplements (400 IU vitamin 
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E every other day, 500 mg vitamin C every day, or a combination of the two) 
for a median of 7.6 years did not reduce the incidence of prostate cancer or 
other cancers, including lymphoma, leukemia, melanoma, and cancers of 
the lung, bladder, pancreas, and colon and rectum (Gaziano et al., 2009).
Overall, the nine randomized controlled clinical trials did not provide evidence that 
dietary antioxidant supplements are beneficial in primary cancer prevention. In addition, 
a systematic review of the available evidence regarding the use of vitamin and mineral 
supplements for the prevention of chronic diseases, including cancer, conducted for the 
U.S. Preventive Services Task Force likewise found no clear evidence of a benefit in 
preventing cancer (Fortmann et al., 2013). A review of almost 80 randomized clinical 
studies on antioxidant use (vitamins A, C, E; β-carotene; and selenium) for preventing 
disease-related death provides evidence that further challenges the widely claimed ben-
efits of antioxidants. Collectively, the studies included a total of almost 300,000 men and 
women (described as both “healthy” and with diseases in a “stable phase”). Significantly 
more deaths were observed in men and women taking vitamin E, β-carotene, or doses of 
vitamin A that exceed the RDA, which are 700 μg for women and 900 μg for men. These 
findings led the authors to caution against the use of antioxidant supplements for both the 
general population and in those with various diseases (Bjelakovic et al., 2012).
The lack of benefit in clinical studies can be explained by differences in the 
effects of the tested antioxidants when they are consumed as purified chemicals as 
opposed to when they are consumed in foods, which contain complex mixtures of 
antioxidants, vitamins, and minerals (Bouayed and Bohn, 2010). Therefore, obtain-
ing a more inclusive information of the antioxidant content of individual foods, how 
the various antioxidants and other substances in foods interact with one another, and 
factors that influence the uptake and distribution of food-derived antioxidants in the 
body are active areas of ongoing cancer prevention research.
The measure of antioxidant capacity (AC) considers the cumulative action of 
all the antioxidants present in plasma and body fluids, thus providing an integrated 
parameter rather than the simple sum of measurable antioxidants. The capacity 
of known and unknown antioxidants and their synergistic interaction is therefore 
assessed, giving an insight into the delicate balance in	vivo between oxidants and 
antioxidants. Measuring plasma AC may help in the evaluation of physiological, 
environmental, and nutritional factors of the redox status in humans. Determining 
plasma AC may help identify conditions affecting oxidative status in	vivo (e.g., expo-
sure to reactive oxygen species and antioxidant supplementation) (Ghiselli, 2000). 
The term “antioxidant” refers mainly to nonnutrient compounds in foods, such as 
polyphenols, which have AC in	vitro and so provide an artificial index of antioxidant 
strength—the ORAC measurement. Oxygen radical absorbance capacity (ORAC) is 
a method of measuring antioxidant capacities in biological samples in	vitro. Values 
are expressed as the sum of the lipid-soluble (e.g., carotenoid) and water-soluble 
(e.g., phenolic) antioxidant fractions (i.e., “total ORAC”) reported as in micromoles 
Trolox equivalents per 100 g sample, and are compared with assessments of total 
polyphenol content in the samples. These values are considered biologically irrel-
evant by the European Food Safety Authority (EFSA) and USDA (EFSA Panel on 
Dietetic Products, Nutrition and Allergies, 2010).
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Many common foods are good sources of antioxidants. In the list of foods given 
below, “rich in antioxidants” usually means at least an ORAC rating of 1000 per 
100 g. A typical apple or pear weighs around 200 g, and hence 200 g can be consid-
ered as the serving size.
Spices, herbs, and essential oils are rich in antioxidant properties in the plant 
itself and in	vitro; however, the serving size is too small to supply antioxidants via 
the diet. Typical spices high in antioxidants (confirmed in	vitro) are clove, cinnamon, 
oregano, turmeric, cumin, parsley, basil, curry powder, mustard seed, ginger, pep-
per, chili powder, paprika, garlic, coriander, onion, and cardamom. Typical herbs are 
sage, thyme, marjoram, tarragon, peppermint, oregano, savory, basil, and dill weed.
Dried fruits are a good source of antioxidants by weight/serving size as the water 
has been removed, making the ratio of antioxidants higher. Typical dried fruits are 
pears, apples, plums, peaches, raisins, figs, and dates. Dried raisins are high in poly-
phenol. Red wine is high in total polyphenol, which supplies antioxidant quality that 
is unlikely to be conserved following digestion (see the next section).
Deeply pigmented fruits like cranberries, blueberries, plums, blackberries, raspber-
ries, strawberries, blackcurrants, figs, cherries, guava, oranges, mango, grape juice, 
and pomegranate juice also have significant ORAC scores (Table 10.4) (USDA, 2012).
With nearly all vegetables, conventional boiling can reduce the ORAC value by 
up to 90%, while steaming retains more of the antioxidants.
dilemma oF taking antioxidant SupplementS while haVing CanCer
Several randomized controlled trials, some including only small numbers of patients, 
have investigated whether taking antioxidant supplements during cancer treatment 
alters the effectiveness or reduces the toxicity of specific therapies (Lawenda et al., 
2008). Although these trials had mixed results, some found that people who took 
antioxidant supplements during cancer therapy had worse outcomes, especially if 
they were smokers.
Additional large randomized controlled trials are needed to provide clear scien-
tific evidence about the potential benefits or harms of taking antioxidant supplements 
during cancer treatment. Until more is known about the effects of antioxidant supple-
ments in cancer patients, these supplements should be used with caution.
Antioxidants prevent the chemical process of oxidation. However, oxidation helps 
the body kill off bad cells like cancer cells, as well as healthy cells. Different parts 
of the body have their own unique ways of developing cancer. Similarly, one organ 
responds differently to nutrients than another; thus, the supplement that helps lower 
your risk for one cancer could raise your risk of another.
Studies also suggest that taking antioxidant supplements such as vitamin C during 
chemotherapy may not be a good idea. In one study, large doses of vitamin C supple-
ments reduced the effectiveness of several anticancer drugs including methotrexate, 
doxorubicin, and imatinib, resulting in 30–70% fewer cancer cells killed. The authors 
concluded that vitamin C may actually be helping cancer cells survive by protecting 
the cells’ power source (Heaney et al., 2008). In another study, the antioxidants vitamin 
C and N-acetylcysteine (often sold under the name “NAC”) significantly reduced the 
effectiveness of anticancer drugs vinblastine and cisplatin (Fukumura et al., 2012).
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Antioxidant supplements have not been found to diminish the risk of cancer in 
most studies. In effect, for people with a higher than normal risk of cancer (smokers 
and people who have already survived one cancer) and those being treated for cancer 
with chemotherapy, antioxidant supplements were found to be destructive. Dietary 
supplements are intended to be used when the body is not receiving certain nutrients 
in the right amounts; however, like drugs, they can have unplanned adverse effects 
and therefore should only be taken as recommended.
Consequently, some established strategies that can help reduce the risk of cancer 
are as follows:
•	 Maintain a healthy weight by limiting the high-calorie foods you eat and 
getting regular physical activity.
•	 Eat foods rich in antioxidants (rather than use supplements).
•	 Eat plenty of fruits and vegetables every day (fruits and vegetables should 
cover half of the plate).
table 10.4
Food oraC scores
rank Food Item serving size
total antioxidant Capacity
per serving size
1 Small red bean (dried) Half cup 13,727
2 Wild blueberry 1 cup 13,427
3 Red kidney bean (dried) Half cup 13,259
4 Pinto bean Half cup 11,864
5 Blueberry (cultivated) 1 cup 9019
6 Cranberry 1 cup (whole) 8983
7 Artichoke (cooked) 1 cup (hearts) 7904
8 Blackberry 1 cup 7701
9 Prune Half cup 7291
10 Raspberry 1 cup 6058
11 Strawberry 1 cup 5938
12 Red delicious apple 1 whole 5900
13 Granny Smith apple 1 whole 5381
14 Pecan 1 oz 5095
15 Sweet cherry 1 cup 4873
16 Black plum 1 whole 4844
17 Russet potato (cooked) 1 whole 4649
18 Black bean (dried) Half cup 4181
19 Plum 1 whole 4118
20 Gala apple 1 whole 3903
Source: U.S. Department of Agriculture, Agricultural Research Service. 2010. USDA Database for 
the Oxygen Radical Absorbance Capacity (ORAC) of Selected Foods, Release 2. Available 
at: http://www.orac-info-portal.de/download/ORAC_R2.pdf
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•	 Limit the amount of red meat and processed meat (hot dogs, sausages, 
bologna, etc.) eaten.
•	 Eat foods made of whole grains.
FoodS riCh in antioxidantS
Antioxidants are plentiful in fruits and vegetables, nuts, grains, and some meats, 
poultry, and fish. The list below describes food sources of common antioxidants.
•	  β-Carotene is found in many foods that are orange in color, including sweet 
potatoes, carrots, cantaloupe, squash, apricots, pumpkin, and mangoes. 
Some green leafy vegetables, including collard greens, spinach, and kale, 
are also rich in β-carotene.
•	 Lutein, best known for its association with healthy eyes, is abundant in 
green, leafy vegetables such as collard greens, spinach, and kale.
•	 Lycopene is a potent antioxidant found in tomatoes, watermelon, guava, 
papaya, apricots, pink grapefruit, blood oranges, and other foods. Estimates 
suggest that 85% of the American dietary intake of lycopene comes from 
tomatoes and tomato products.
•	 Selenium is a mineral, not an antioxidant nutrient. However, it is a compo-
nent of antioxidant enzymes. Plant foods like rice and wheat are the major 
dietary sources of selenium in most countries. The amount of selenium in 
soil, which varies by region, determines the amount of selenium in the foods 
grown in that soil. Animals that eat grains or plants grown in selenium-rich 
soil have higher levels of selenium in their muscle. In the United States, 
meats and bread are common sources of dietary selenium. Brazil nuts also 
contain large quantities of selenium.
•	 Vitamin	A is found in three main forms: retinol (vitamin A1), 3,4-didehydro-
retinol (vitamin A2), and 3-hydroxy-retinol (vitamin A3). Foods rich in 
vitamin A include liver, sweet potatoes, carrots, milk, egg yolks, and moz-
zarella cheese.
•	 Vitamin	C is also called ascorbic acid, and can be found in high abundance 
in many fruits and vegetables and is also found in cereals, beef, poultry, 
and fish.
•	 Vitamin	E, also known as α-tocopherol, is found in almonds; in many oils 
including wheat germ, safflower, corn, and soybean oils; and also in man-
goes, nuts, broccoli, and other foods.
preventIon
CanCer and FruitS and VegetableS
Many studies discovered a physically powerful link between eating fruits and veg-
etables and protection against cancer. The results of the case–control studies indicate 
that eating a diet rich in fruits and vegetables decreases the risk of developing several 
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different types of cancer, particularly cancers of the digestive tract (oropharynx, 
esophagus, stomach, colon, and rectum) and lung (Block et al., 1992; World Cancer 
Research Fund, 1997). The balanced combinations of fruits and vegetables decreases 
the risk of cancer (Ohigashi and Murakami, 2004). The results of these studies are 
the foundation for the National Cancer Institute’s “five-a-day” program, which is 
aimed at increasing the fruit and vegetable consumption of the American public to 
a minimum of five servings daily. In contrast to the results of case–control studies, 
many prospective cohort studies have found little or no association between total 
fruit and vegetable intake and the risk of various cancers (Michels et al., 2000; Smith-
Warner et al., 2001, 2003; Flood et al., 2002; Michaud et al., 2002; McCullough et 
al., 2003; Hung et al., 2004; Key et al., 2004; Lin et al., 2005; Sato et al., 2005; 
Tsubono et al., 2005; Van Gils et al., 2005). There is some reasoning for this. Case–
control studies, in which the past diets of people with a particular type of cancer are 
compared with the diets of those without cancer, are more susceptible to bias in the 
selection of participants and dietary recall than prospective cohort studies, which 
collect information on the diets of large cohorts of patients over time. Although pro-
spective cohort studies provide weak support for an association between total fruit 
and vegetable consumption and cancer risk, they provide some evidence that high 
intakes of certain classes of fruits or vegetables are associated with a reduced risk of 
individual cancers. Higher intakes of fruits were associated with modest but signifi-
cant reductions in lung cancer risk in a pooled analysis of eight prospective cohort 
studies (Smith-Warner et al., 2003). In men, higher intakes of cruciferous vegetables 
were associated with significant reductions in the risk of bladder cancer, and higher 
intakes of tomato products were associated with significant reductions in the risk of 
prostate cancer (Higdon, 2007).
Cohort studies, which follow large groups of initially healthy individuals for 
years, generally provide more reliable information than case–control studies because 
they do not rely on information from the past. Furthermore, data from cohort studies 
have not consistently shown that a diet rich in fruits and vegetables prevents cancer 
in general. For example, in the Nurses’ Health Study and the Health Professionals 
Follow-up Study, during a 14-year period, men and women with the highest intake of 
fruits and vegetables (8+ servings a day) were just as likely to have developed cancer 
as those who ate the fewest daily servings (<1.5) (Hung et al., 2004).
A more likely possibility is that some types of fruits and vegetables may protect 
against certain cancers. A massive report by the World Cancer Research Fund and 
the American Institute for Cancer Research suggests that nonstarchy vegetables—
such as lettuce and other leafy greens, broccoli, bok choy, cabbage, as well as garlic, 
onions, and the like—and fruits “probably” protect against several types of cancers, 
including those of the mouth, throat, voice box, esophagus, and stomach; fruits prob-
ably also protect against lung cancer (World Cancer Research Fund, 2007).
Specific components of fruits and vegetables may also be protective against 
cancer. For example, a line of research stemming from a finding from the Health 
Professionals Follow-up Study suggests that tomatoes may help protect men against 
prostate cancer, especially aggressive forms of it (Giovannucci et al., 2007). One 
of the pigments that give tomatoes their red hue, lycopene, could be involved in 
this protective effect. Although several studies other than the Health Professionals 
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Study have also demonstrated a link between tomatoes or lycopene and prostate 
cancer, others have not or have found only a weak connection (Kavanaugh et al., 
2007). Taken as a whole, however, these studies suggest that increased consumption 
of  tomato-based products (especially cooked tomato products) and other lycopene-
containing foods  may reduce the occurrence of prostate cancer (World Cancer 
Research Fund, 2007). Lycopene is one of several carotenoids (compounds that the 
body can turn into vitamin A) found in brightly colored fruits and vegetables, and 
research suggests that foods containing carotenoids may protect against lung, mouth, 
and throat cancer (World Cancer Research Fund, 2007). However, more research is 
needed before we know the exact relationship between fruits and vegetables, carote-
noids, and cancer.
Intake recommendations
The National Cancer Institute recommends a range of five to nine servings of fruits 
and vegetables daily. Specifically, adolescent and adult women should aim for seven 
daily servings, whereas adolescent and adult men should aim for nine daily servings. 
The 2010 Dietary Guidelines for Americans are similar with respect to fruit and 
vegetable intake recommendations; however, they are tied to energy (caloric) intake 
rather than age and sex. Daily consumption of 2 cups (4 servings) of fruit and 2.5 cups 
(5 servings) of vegetables are recommended for people who consume 8368 kJ/day 
(2000 kcal/day), whereas 1.5 cups of fruit (3 servings) and 2 cups (4 servings) of veg-
etables are recommended for people who consume 6693.4 kJ/day (1600 kcal/ day). 
In both cases, consumption of a variety of different fruits and vegetables is rec-
ommended, including dark green, red, orange, yellow, blue, and purple fruits and 
vegetables, as well as legumes (peas and beans), onions, and garlic (Higdon, 2007).
CruCiFerouS VegetableS
Cruciferous or Brassica vegetables are plants in the family known as Cruciferae	
(Brassicaceae). Many commonly consumed cruciferous vegetables come from the 
Brassica genus, including broccoli, Brussels sprouts, cabbage, cauliflower, collard 
greens, kale, kohlrabi, mustard, rutabaga, turnips, bok choy, and Chinese cabbage 
(Kristal and Lampe, 2002). Arugula, horseradish, radish, wasabi, and watercress 
are also cruciferous vegetables. Cruciferous vegetables are exceptional as they are 
good sources of glucosinolates, sulfur-containing compounds that are responsible 
for their pungent aromas and spicy (or bitter) taste. The hydrolysis (breakdown) of 
glucosinolates by a class of plant enzymes called myrosinase results in the formation 
of biologically active compounds, such as indoles and isothiocyanates. Myrosinase 
is physically separated from glucosinolates in intact plant cells. However, when 
cruciferous vegetables are chopped or chewed, myrosinase comes in contract with 
glucosinolates and catalyzes their hydrolysis. Scientists are currently investigating 
the potential for high intakes of cruciferous vegetables and several glucosinolate 
hydrolysis products to prevent cancer.
Akin to most other vegetables, cruciferous vegetables are good sources of a vari-
ety of nutrients and phytochemicals that may work synergistically to help prevent 
cancer. One challenge in studying the relationships between cruciferous vegetable 
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intakes and cancer risk in humans is sorting out the benefits of diets that are gener-
ally rich in vegetables from those that are specifically rich in cruciferous vegetables. 
One characteristic that sets cruciferous vegetables apart from other vegetables is 
their high glucosinolate content. Glucosinolate hydrolysis products could help pre-
vent cancer by enhancing the elimination of carcinogens before they can damage 
DNA or by altering cell signaling pathways in ways that help prevent normal cells 
from being transformed into cancerous cells. Some glucosinolate hydrolysis prod-
ucts may alter the metabolism or activity of hormones like estrogen in ways that 
inhibit the development of hormone-sensitive cancers (Higdon, 2007).
iodine and thyroid FunCtion and CruCiFerouS VegetableS
Very high intakes of cruciferous vegetables, such as cabbage and turnips, have been 
found to cause hypothyroidism in animals (Fenwick et al., 1983). Two mechanisms 
have been identified to explain this effect. The hydrolysis of some glucosinolates 
found in cruciferous vegetables (e.g., progoitrin) may yield a compound known as 
goitrin, which has been found to interfere with thyroid hormone synthesis. The 
hydrolysis of another class of glucosinolates, known as indole glucosinolates, results 
in the release of thiocyanate ions, which can compete with iodine for uptake by the 
thyroid gland. Increased exposure to thiocyanate ions from cruciferous vegetable 
consumption or, more commonly, cigarette smoking does not appear to increase 
the risk of hypothyroidism unless accompanied by iodine deficiency. One study 
in humans found that the consumption of 150 g/day (5 oz/day) of cooked Brussels 
sprouts for 4 weeks had no adverse effects on thyroid function (Higdon, 2007).
Intake recommendations
Although many organizations, including the National Cancer Institute, recommend 
the consumption of five to nine servings (2.5–4.5 cups) of fruits and vegetables 
daily, separate recommendations for cruciferous vegetables have not been estab-
lished. Much remains to be learned regarding cruciferous vegetable consumption 
and cancer prevention; however, the results of some prospective cohort studies sug-
gest that adults should aim for at least five weekly servings of cruciferous vegetables 
(Michaud et al., 1999).
CanCer and legumeS
dry beans, peas, and lentils
Dry beans, peas, and lentils are rich in several compounds that could decrease the 
risk of certain cancers (Mathers, 2002).
prostate Cancer
There is limited evidence from observational studies that legume intake is inversely 
related to the risk of prostate cancer. In a 6-year prospective study of more than 
14,000 Seventh Day Adventist men living in the United States, those with the high-
est intakes of legumes (beans, lentils, or split peas) had a significantly lower risk of 
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prostate cancer (Mills et al., 1989). A prospective study of more than 58,000 men 
in the Netherlands found that those with the highest intakes of legumes had a risk 
of prostate cancer that was 29% lower than those with the lowest intakes. Similarly, 
in a case–control study of 1619 North American men with prostate cancer and 1618 
healthy men matched for age and ethnicity, those with the highest legume intakes 
had a risk of prostate cancer that was 38% lower than those with the lowest intakes 
(Kolonel et al., 2000). Excluding the intake of soy foods from the analysis did not 
weaken the inverse association between legume intake and prostate cancer, sug-




Although there is substantial scientific interest in the possibility for soy products to 
prevent prostate cancer, evidence that higher intakes of soy foods can reduce the risk 
of prostate cancer in humans is limited. Only two out of six case–control studies 
found that higher intakes of soy products were associated with significantly lower 
prostate cancer risk. In the largest case–control study, North American men who 
consumed an average of at least 1.4 oz of soy foods daily were 38% less likely to have 
prostate cancer than men who did not consume soy foods. A much smaller case– 
control study of Chinese men found that men who consumed at least 4 oz of soy foods 
daily were only half as likely to have prostate cancer as those who consumed less 
than 1 oz daily. A 6-year prospective cohort study of more than 12,000 Seventh Day 
Adventist men in the United States found that those who drank soy milk more than 
once daily had a risk of prostate cancer that was 70% lower than those who never 
dark soy milk; however, a 23-year study of more than 5000 Japanese American men 
found no association between tofu consumption and prostate cancer risk (Nomura 
et al., 2004).
breast Cancer
At least 15 epidemiological studies have assessed the relationship between soy food 
intake and the risk of breast cancer. One out of four prospective studies found that 
higher intakes of soy food were associated with a significant reduction in breast can-
cer risk. In that 9-year study of more than 21,000 Japanese women, higher intakes of 
miso soup (no other soy foods) were inversely associated with breast cancer risk. Most 
case–control studies did not find that women with higher soy intakes were at lower risk 
of breast cancer, except for women who had higher soy intakes during adolescence 
(Shannon et al., 2005). Two case–control studies, one of Chinese women and one of 
Asian American women, found that women with higher soy intakes during adoles-
cence were significantly less likely to develop breast cancer later in life (Higdon, 2007).
Intake recommendations
Substituting beans, peas, and lentils for foods that are high in saturated fat or refined 
carbohydrates is likely to help lower the risk of type 2 diabetes mellitus (DM) and 
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cardiovascular disease. Soybeans and foods made from soybeans (soy foods) are 
excellent sources of protein. In fact, soy protein is a complete protein, meaning it 
provides all of the essential amino acids in adequate amounts for human health 
(Messina, 1999). As with beans, peas, and lentils, soy foods are also excellent sub-
stitutes for protein sources that are high in saturated fat like red meat or cheese. In 
the 2010 Dietary Guidelines of Americans, an intake of three cups (six servings) of 
legumes weekly is recommended for people who consume 8368 kJ/2000 kcal/day. 
A serving of legumes is equal to one-half cup of cooked beans, peas, lentils, or tofu.
CanCer and whole grainS
Even if the protecting effects of whole grains against various types of cancer are 
not as well known as those against diabetes and cardiovascular disease, numerous 
case–control studies have found inverse associations between various measures of 
whole-grain intake and cancer risk (La Vecchia et al., 2003). A meta-analysis of 
40 case–control studies examining 20 different types of cancer found that those with 
high whole-grain intakes had an overall risk of cancer that was 34% lower than those 
with low whole-grain intakes. Elevated intakes of whole grain were most constantly 
associated with decreased risk of gastrointestinal tract cancers, including cancers 
of the mouth, throat, stomach, colon, and rectum. A prospective cohort study that 
followed more than 61,000 Swedish women for 15 years found that those who con-
sumed more than 4.5 servings of whole grain daily had a risk of colon cancer that 
was 35% lower than those who consumed less than 1.5 servings of whole grain daily. 
Higher fiber intakes are known to speed up the passage of stool through the colon, 
allowing less time for potentially carcinogenic compounds to stay in contact with 
cells that line the inner surface of the colon. Lignans in whole grains are phytoestro-
gens and may affect the development of hormone-dependent cancers.
Phenolic compounds in whole grains may modify signal transduction pathways 
that promote the development of cancer or bind potentially damaging free metal ions 
in the gastrointestinal tract (Higdon, 2007).
Intake recommendations
Whole-grain intakes approaching three servings daily are associated with significant 
reductions in chronic disease risk in populations with relatively low whole-grain 
intakes. The 2010 Dietary Guidelines for Americans recommend consuming three 
or more servings of whole-grain products daily (U.S. Department of Agriculture and 
U.S. Department of Health and Human Services, 2010). Whole-grain foods should 
be substituted for refined carbohydrates whenever possible.
CanCer and CarotenoidS
Food sources
The most common dietary carotenoids in typical Western diets are β-carotene, 
α-carotene, β-cryptoxanthin, lycopene, lutein, and zeaxanthin. Carotenoids in foods 
are mainly in the all-trans form, although cooking may result in the formation of 
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other isomers. The relatively low bioavailability of carotenoids from most foods 
compared with supplements is partly because they are associated with proteins in 
the plant matrix. Chopping, homogenizing, and cooking disrupt the plant matrix, 
increasing the bioavailability of carotenoids. The bioavailability of lycopene from 
tomatoes is substantially improved by heating tomatoes in oil (Gartner et al., 1997).
β-Carotene and α-Carotene
β-Carotene and α-carotene are provitamin A carotenoids; that is, they can be con-
verted by the body to vitamin A. The vitamin A activity of β-carotene in foods is 
1/12 that of retinol (preformed vitamin A). Thus, it would take 12 μg of β-carotene 
from foods to provide the equivalent of 1 μg of retinol. The vitamin A activity of 
α-carotene from foods is 1/24 that of retinol, so it would take 24 μg of α-carotene 
from foods to provide the equivalent of 1 μg of retinol. Orange and yellow vegetables 
like carrots and winter squash are rich sources of β- and α-carotene. Spinach is 
also a rich source of β-carotene, although the chlorophyll in spinach leaves hides 
the  yellow–orange pigment. Some foods that are good sources of α-carotene and 
β-carotene are listed in Tables 10.5 and 10.6, respectively.
β-Cryptoxanthin
Like β- and α-carotene, β-cryptoxanthin is a provitamin A carotenoid. The vitamin A 
activity of β-cryptoxanthin from foods is 1/24 that of retinol, so it would take 24 μg 
of β-cryptoxanthin from food to provide the equivalent of 1 μg of retinol. Orange and 
red fruits and vegetables, like sweet red peppers and oranges, are particularly rich 
sources of β-cryptoxanthin.
lycopene
Lycopene gives tomatoes, pink grapefruit, watermelon, and guava their red color. 
It has been estimated that 80% of the lycopene in the diet of the U.S. population 
table 10.5
α-Carotene Content of selected Foods
Food serving α-Carotene (mg)
Pumpkin, canned 1 cup 11.7
Carrot juice, canned 1 cup (8 fl oz) 10.2
Carrots, cooked 1 cup 5.9
Carrots, raw 1 medium 2.0
Mixed vegetables, frozen cooked 1 cup 1.8
Winter squash, baked 1 cup 1.4
Plantains, raw 1 medium 0.8
Pumpkin pie 1 piece 0.7
Collards, frozen cooked 1 cup 0.2
Tomatoes, raw 1 medium 0.1
Tangerines, raw 1 medium 0.08
Peas, frozen, cooked 1 cup 0.08
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comes from tomatoes and tomato products like tomato sauce, tomato paste, and cat-
sup (ketchup) (Clinton, 1998). Lycopene is not a provitamin A carotenoid, meaning 
the body cannot convert lycopene to vitamin A.
lutein and Zeaxanthin
Although lutein and zeaxanthin are different compounds, they are both from the 
class of carotenoids known as xanthophylls. They are not provitamin A carotenoids. 
Some methods used to quantify lutein and zeaxanthin in foods do not separate the 
two compounds, so they are typically reported as lutein and zeaxanthin or lutein + 
zeaxanthin. Lutein and zeaxanthin are present in a variety of fruits and vegetables. 
Dark green leafy vegetables like spinach and kale are particularly rich sources of 
lutein and zeaxanthin. Some foods that are good sources of lutein and zeaxanthin 
are listed in Table 10.7.
Curcumin
Turmeric is a spice derived from the rhizomes of Curcuma	longa, which is a mem-
ber of the ginger family (Zingiberaceae) (Aggarwal et al., 2005). Curcumin is the 
principal curcuminoid found in turmeric and is generally considered its most active 
constituent (Sharma et al., 2005).
The ability of curcumin to induce apoptosis in cultured cancer cells by several 
different mechanisms has generated scientific interest in the potential for curcumin 
to prevent some types of cancer (Sharma et al., 2005). Oral curcumin administration 
has been found to inhibit the development of chemically induced cancer in animal 
models of oral (Krishnaswamy et al., 1998; Li et al., 2002), stomach (Huang et al., 
1994; Ikezaki et al., 2001), liver (Chuang et al., 2000), and colon cancer (Rao et al., 
1995; Pereira et al., 1996; Kawamori et al., 1999). ApcMin/+ mice have a mutation in 
the adenomatous	polyposis	coli (Apc) gene similar to that in humans with familial 
adenomatous polyposis, a genetic condition that is characterized by the development 
table 10.6
β-Carotene Content of selected Foods
Food serving β-Carotene (mg)
Carrot juice, canned 1 cup (8 fl oz) 22.0
Pumpkin, canned 1 cup 17.0
Sweet potato, baked 1 medium 16.8
Spinach, frozen, cooked 1 cup 13.7
Carrots, cooked 1 cup 13.0
Collards, frozen, cooked 1 cup 11.6
Kale, frozen, cooked 1 cup 11.5
Turnip greens, frozen, cooked 1 cup 10.6
Pumpkin pie 1 piece 7.4
Dandelion greens, cooked 1 cup 6.2
Winter squash, cooked 1 cup 5.7
Cantaloupe, raw 1 cup 3.2
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of numerous colorectal adenomas (polyps) and a high risk for colorectal cancer. Oral 
curcumin administration has been found to inhibit the development of intestinal ade-
nomas in ApcMin/+ mice (Mahmoud et al., 2000; Perkins et al., 2002).
CanCer and CurCumin
The ability of curcumin to induce apoptosis in a variety of cancer cell lines in culture 
and its low toxicity have led to scientific interest in its potential for cancer therapy as 
well as cancer prevention (Karunagaran et al., 2005). To date, most of the controlled 
clinical trials of curcumin supplementation in cancer patients have been phase I tri-
als. Phase I trials are clinical trials in small groups of people, aimed at determining 
bioavailability, optimal dose, safety, and early evidence of the efficacy of a new 
therapy (National Institutes of Health, 2005). A phase I clinical trial in patients with 
advanced colorectal cancer found that doses up to 3.6 g/day for 4 months were well 
tolerated, although the systemic availability of oral curcumin was low (Sharma et al., 
2004). When colorectal cancer patients with liver metastases took 3.6 g/day of cur-
cumin orally for 7 days, trace levels of curcumin metabolites were measured in liver 
tissue; however, curcumin itself was not detected (Garcea et al., 2004). In contrast, 
curcumin was measured in normal and malignant colorectal tissue after patients 
with advanced colorectal cancer took 3.6 g/day of curcumin orally for 7 days (Garcea 
et al., 2005). These findings suggest that oral curcumin is more likely to be effective 
as a therapeutic agent in cancers of the gastrointestinal tract than other tissues. Phase 
II trials are clinical trials designed to investigate the effectiveness of a new therapy 
in larger numbers of people and to further evaluate the short-term adverse effects 
and safety of the new therapy. Phase II clinical trials of curcumin in patients with 
advanced pancreatic cancer are currently under way, and phase II trials of curcumin 
for colorectal cancer have been recommended (Sharma et al., 2005).
table 10.7
lutein + Zeaxanthin Content of Foods
Food serving lutein + Zeaxanthin (mg)
Spinach, frozen, cooked 1 cup 29.8
Kale, frozen, cooked 1 cup 25.6
Turnip greens, frozen cooked 1 cup 19.5
Collards, frozen, cooked 1 cup 18.5
Mustard greens, cooked 1 cup 8.3
Dandelion greens, cooked 1 cup 4.9
Summer squash, cooked 1 cup 4.0
Peas, frozen, cooked 1 cup 3.8
Winter squash, baked 1 cup 2.9
Broccoli, frozen, cooked 1 cup 2.8
Pumpkin, cooked 1 cup 2.5
Brussels sprouts, frozen, cooked 1 cup 2.4
Sweet yellow corn, boiled 1 cup 1.6
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ColoreCtal CanCer and Fiber
Most case–control studies conducted before 1990 found the incidence of colorec-
tal cancer to be lower in people with higher fiber intakes. In contrast, most 
prospective cohort studies conducted more recently have not found significant 
associations between measures of dietary fiber intake and colorectal cancer risk. 
Three controlled clinical trials also failed to demonstrate a protective effect of 
fiber consumption on the recurrence of colorectal adenomas (precancerous pol-
yps). The rate of recurrence of colorectal adenomas during a 4-year period was 
not significantly different between those who consumed 33 g/day of fiber from 
a fruit- and vegetable-rich, low-fat diet and those in a control group who con-
sumed 19 g/day. In another trial, there was no significant difference in the rate 
of colorectal adenoma recurrence during a 3-year period between those supple-
mented with 13.5 g/day of wheat bran fiber and those supplemented with 2 g/day. 
Surprisingly, supplementation with 3.5 g/day of psyllium for 3 years resulted in 
a significant increase in adenoma recurrence compared with placebo (Bonithon-
Kopp et al., 2000).
The reasons for the discrepancies between the findings of early case–control 
studies with those of most prospective cohort studies and recent interventions 
trials have generated considerable debate among scientists. Potential reasons for 
the lack of a protective effect by dietary fiber observed in these studies include 
the possibility that the type or the amount of fiber consumed by most people in 
these studies was inadequate to prevent colorectal cancer, or that other dietary 
factors like fat may interact with fiber, influencing its effects on colorectal cancer 
(Higdon, 2007).
breaSt CanCer
Although several early case–control studies found significant inverse associations 
between dietary fiber intake and breast cancer incidence, most prospective cohort 
studies have not found dietary fiber intake to be associated with significant reduc-
tion in breast cancer risk. The only exception was a prospective cohort study in 
Sweden, which found that women with the highest fiber intakes (averaging 26 g/
day) had a risk of breast cancer that was 40% lower than women with the low-
est fiber intakes (averaging 13 g/day) (Mattisson et al., 2004). Those women with 
the highest fiber and lowest fat intakes had the very lowest risk of breast cancer. 
The results of small short-term intervention trials in premenopausal and post-
menopausal women suggest that low-fat (10–25% of energy), high-fiber (25–40 
g/day) diets could decrease circulating estrogen levels by increasing the excre-
tion of estrogens and promoting the metabolism of estrogens to less estrogenic 
forms. Nevertheless, it is not known whether fiber-associated effects on endog-
enous estrogen levels have a clinically significant impact on breast cancer risk 
(Institute of Medicine, 2002). At present, the available evidence does not support 





In light of consistent evidence from prospective cohort studies that fiber-rich 
diets are associated with significant reductions in cardiovascular disease risk, 
the FNB of the Institute of Medicine established its first recommended intake 
levels for fiber in 2001. The adequate intake (AI) recommendations for total fiber 
intake are based on the findings of several large prospective cohort studies that 
dietary fiber intakes of 14 g/4184 kJ (1000 kcal) of energy were associated with 
significant reductions in the risk of coronary heart disease, as well as type 2 DM 
(Salmeron et al., 1997). For adults who are 50 years of age or younger, the AI 
for total fiber intake is 38 g/day for men and 25 g/day for women. For adults >50 
years of age, the recommendation is 30 g/day for men and 21 g/day for women. 
The AI recommendations for males and females of all ages are presented in 
Table 10.8.
Eating a large amount of fiber in a short period can cause intestinal gas (flatu-
lence), bloating, and abdominal cramps. This usually goes away once the natu-
ral bacteria in the digestive system get used to the increase in fiber in the diet. 
Adding fiber gradually to the diet, instead of all at one time, can help reduce gas or 
diarrhea.
Too much fiber may interfere with the absorption of minerals such as iron, zinc, 
magnesium, and calcium. However, this effect usually does not cause too much con-
cern because high-fiber foods are typically rich in minerals.
table 10.8
u.s. Institute of medicine adequate Intake recommendation for 
total Fiber
life stage age males (g/day) Females (g/day)
Infants 0–6 months ND ND
Infants 7–12 months ND ND
Children 1–3 years 19 19
Children 4–8 years 25 25
Children 9–13 years 31 26
Adolescents 14–18 years 38 26
Adults 19–50 years 38 25
Adults 51 years and older 30 21
Pregnancy All ages – 28
Breastfeeding All ages – 29
Source: Institute of Medicine. Dietary,	Functional,	and	Total	Fiber.	Dietary	Reference	
Intakes	for	Energy,	Carbohydrate,	Fiber,	Fat,	Fatty	Acids,	Cholesterol,	Protein	
and	Amino	Acids. Washington, DC: National Academies Press; 2002: 265–334.
Note: ND, not determined.
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CanCer and FlaVonoidS
Although various flavonoids have been found to inhibit the development of chemi-
cally induced cancers in animal models of lung, oral, esophageal, stomach, colon, 
skin, prostate, and breast cancer, epidemiological studies do not provide convinc-
ing evidence that high intakes of dietary flavonoids are associated with substantial 
reductions in human cancer risk. Most prospective cohort studies that have assessed 
dietary flavonoid intake using food frequency questionnaires have not found flavo-
noid intake to be inversely associated with cancer risk (Higdon, 2007).
Two prospective cohort studies in Finland, where average flavonoid intakes are 
relatively low, found that men with the highest dietary intakes of flavonols and fla-
vones had a significantly lower risk of developing lung cancer than those with the 
lowest intakes. When individual dietary flavonoids were analyzed, dietary querce-
tin intake, mainly from apples, was inversely associated with the risk of lung can-
cer, and myricetin intake was inversely associated with the risk of prostate cancer 
(Higdon, 2007).
There is limited evidence that low intakes of flavonoids from food are associated 
with increased risk of certain cancers; however, it is not clear whether these findings 
are related to insufficient intakes of flavonoids or other nutrients and phytochemicals 
in flavonoid-rich foods.
Food sources
Although some subclasses of dietary flavonoids like flavonols are found in many 
different fruits and vegetables, others are not as widely distributed (see Table 10.9). 
Total flavonoid intakes in Western populations appear to average 150–200 mg/day. 
table 10.9
subclasses of Common dietary Flavonoids and some Common Food sources
Flavonoid subclass dietary Flavonoids some Common Food sources
Anthocyanins Cyanidin, delphinidin, malvidin, 
pelargonidin, peonidin, petunidin
Red, blue, and purple berries; red 
and purple grapes; red wine
Flavanols
– Monomers Catechin, epicatechin, epigallocatechin, 
epicatechin gallate, epigallocatechin 
gallate
Teas (green and white), chocolate, 
grapes, berries, apples
– Polymers Theaflavins, thearubigins, 
proanthocyanidis
Teas (black and oolong), chocolate, 
apples, berries, red grapes, red 
wine
Flavanones Hesperetin, naringenin, eriodictyol Citrus fruits and juices
Flavonols Quercetin, kaempferol, myricetin, 
isorhamnetin
Yellow onions, scallions, kale, 
broccoli, apples, berries, teas
Flavones Apigenin, luteolin Parsley, thyme, celery, hot peppers
Isoflavones Daidzein, genistein, glycitein Soybeans, soy foods, legumes
Source: DeVries, JW, Proc	Nutr	Soc, 62, 37, 2003.
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Information on the flavonoid content of some flavonoid-rich foods is presented in 
Table 10.10. These values should be considered approximate because several factors 
may affect the flavonoid content of foods, including agricultural practices, environ-
mental factors, ripening, processing, storing, and cooking (Higdon, 2007).
Nutrition in cancer care embodies prevention of disease, treatment, cure, or sup-
portive palliation. Caution should be exercised when considering alternative or 
unproven nutritional therapies during all phases of cancer treatment and supportive 
palliation, as these diets may prove harmful. Patient nutritional status plays an integral 
role in determining not only risk of developing cancer but also risk of therapy-related 
toxicity and medical outcomes. Whether the goal of cancer treatment is cure or pal-
liation, early detection of nutritional problems and prompt intervention are essential.
Optimal nutritional status is an important goal in the management of individuals 
with cancer. Although nutrition therapy recommendations may vary throughout the 
continuum of care, maintenance of adequate intake is important. Therefore, a waiver 
from most dietary restrictions observed during religious holidays is granted for those 
undergoing active treatment. Individuals with cancer are encouraged to speak to 
their religious leaders regarding this matter before a holiday.
table 10.10
Flavonoid Content of 100 g or 100 ml of selected Foods by Flavonoid 
subclass














Blackberry 89–211 13–19 6–47 – 0–2 –
Blueberry 67–183 1 88–261 – 2–16 –
Grapes, red 25–92 2 44–76 – 3–4 –
Strawberry 15–75 – 97–183 – 1–4 –
Red wine 1–35 1–55 24–70 0 2–30 –
Plum 2–25 1–6 106–334 0 1–2 –
Onion, red 13–25 – – 0 4–100 –
Onion, 
yellow
– 0 – 0 3–120 –
Green tea – 24–216 – 0–1 3–9 –
Black tea – 5–158 4 0 1–7 –
Chocolate, 
dark
– 43–63 90–332 – – –
Parsley, 
fresh
– – – 24–634 8–10 0
Grapefruit 
juice
– – – 0 0 10–104
Source: DeVries, JW, Proc	Nutr	Soc, 62, 37, 2003.
a Per 100 g (fresh weight) or 100 mL (liquids); 100 g is equivalent to ~3.5 oz; 100 mL is equivalent to 
~3.5 fl oz.
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Whether patients are undergoing active therapy, recovering from cancer therapy, 
or in remission and striving to avoid cancer recurrence, the benefit of optimal caloric 
and nutrient intake is well documented.
The goals of nutrition therapy are to accomplish the following:
•	 Prevent or reverse nutrient deficiencies
•	 Preserve lean body mass
•	 Help patients better tolerate treatments
•	 Minimize nutrition-related adverse effects and complications
•	 Maintain strength and energy
•	 Protect immune function, decreasing the risk of infection
•	 Aid in recovery and healing
•	 Maximize quality of life
Patients with advanced cancer can receive nutritional support even when nutri-
tion therapy can do little for weight gain. Such support may help accomplish the 
following:
•	 Lessen adverse effects
•	 Reduce risk of infection (if given enterally)
•	 Reduce asthenia
•	 Improve well-being
In individuals with advanced cancer, the goal of nutrition therapy should not be 
weight gain or reversal of malnutrition, but rather comfort and symptom relief.
Nutrition continues to play an integral role for individuals whose cancer has been 
cured or who are in remission. A healthy diet helps prevent or control comorbidities 
such as heart disease, diabetes, and hypertension. Following a healthful nutrition 
program might help prevent another malignancy from developing.
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Neurodegeneration
Truth or Myth?
Francisco Capani, George Barreto, 
Eduardo Blanco Calvo, and Christopher Horst Lillig
Redox ContRol and ReaCtive oxygen 
SpeCieS/ReaCtive nitRogen SpeCieS
The cell signaling theory was developed from the analysis of signal transduction 
from extracellular signals to intracellular effector molecules via G-protein coupled 
receptors by Rodbell [1] and Gilman [2]. First, an extracellular signal activates a 
receptor protein or protein complex. Then, this activation promotes the release of 
second messenger molecules. These molecules might act on transducer proteins, e.g., 
protein kinases, activate the production or release of third messenger molecules, or 
directly activate effector molecules.
The activities of the enzymes that catalyze the generation of the signals and the 
modifications of the effector molecules determine the transduction of the infor-
mation, and the action of protein kinases and phosphatases in signal transduction 
pathways.
Redox signaling requires the active adjustment of the levels of redox activity of the 
second messengers in response to the activation of a receptor or sensor molecule [3,4]. 
The key compounds, i.e., the metabolites that hold the potential to induce reversible 
posttranslational redox modifications on proteins, are H2O2, NO•, and peroxynitrite/
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peroxynitrous acid (ONOO−/ONOOH). These compounds are produced enzymati-
cally, either as primary products of specialized enzymes, for instance NO• produced 
by nitric oxide synthase (NOS), or as by-products of enzymes, such as superoxide 
O2
−( )  produced by complex I of the inner mitochondrial membrane and a number 
of other enzymes. The decay of these compounds is controlled by other independent 
enzymes; for instance, H2O2 and ONOOH are reduced by glutathione peroxidases 
and peroxiredoxins. The levels of these redox-active second messengers are thus 
enzymatically regulated on both the production and the elimination side, similar 
to, e.g., adenylate cyclases and phosphodiesterases whose combined activities deter-
mine the level of the second messenger molecule cAMP.
The thioredoxin protein family (Trxs) is involved in this function in different 
ways through their thiol groups. Two protein thiols can be oxidized to a disulfide, 
forming a strong inter- or intramolecular bridge. A single protein thiol may also form 
a disulfide with GSH, termed glutathionylation, or free cysteine, termed cysteinyl-
ation or thiolation. Cysteinyl thiols may also react with hydrogen sulfide (H2S) to 
form persulfides, reactive oxygen species (ROS), or reactive nitrogen species (RNS) 
to form sulfenic acids, or nitric oxide resulting in nitroso thiols, a process named 
S-nitrosylation. Not every surface-exposed, cysteinyl residue can undergo any or all 
of these oxidative modifications. It was repeatedly demonstrated that distinct thiol 
groups undergo specific modifications, such as glutathionylation, S-nitrosylation, or 
sulfenylation, in response to specific oxidants [5].
thioRedoxin Family pRoteinS in the BRain
Trxs are a class of enzymes that utilize the thiol groups of cysteinyl residues for the 
catalysis of thiol-disulfide exchange and peroxidatic reactions. This family includes 
the thioredoxins (Trxs), glutaredoxins (Grxs), and peroxiredoxins (Prxs) [6–8], 
which are all characterized by a common structural motif known as the thioredoxin 
fold [9].
Trxs were first described as hydrogen donors for ribonucleotide reductase from 
Escherichia coli [10]. However, during the previous decade, these proteins were rec-
ognized as key regulators of cellular functions in the response to redox signals, for 
instance by the modulation of various signaling pathways, transcription factors, 
and the immune response [8]. Although the Trxs include more than 10 proteins, 
the major Trx isoforms are the cytosolic Trx1 and the mitochondrial Trx2. Trxs 
are thought to be tightly connected to thioredoxin reductases (TrxR). TrxR is an 
NADPH-dependent homodimer with one FAD cofactor per subunit and a cysteine– 
selenocysteine active site that reduces the disulfide in the active site of oxidized Trx 
[11,12]. In addition, TrxR1 can directly reduce the number of substrates, in particular 
lipid hydroperoxides and H2O2 [13–17].
Glutathione (GSH) constitutes the major intracellular redox buffer in cells [18]. 
GSH is synthesized in the cytosol in two steps. First, the enzyme γ-glutamylcysteine 
synthetase (γ-GCS) catalyzes the formation of l-γ-glutamyl-l-cysteine [19–21]. The 
glycine residue of the GSH tripeptide is added in the second step by glutathione 
synthetase. Cellular GSH exists predominantly in a reduced form; however, small 
amounts of the oxidized disulfide form GSSG can also be detected. GSSG is reduced 
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by glutathione reductase (GR) at the expense of NADPH. The GSH/GSSG ratio is 
often taken as an indicator of the cellular redox status. Changes in this ratio have 
been associated with the modulation of transcription of a wide variety of genes 
implied in multiple cellular processes such as growth, differentiation, and cell death 
[22–24]. To date, four Grx isoforms have been found in mammals [24]: the cytosolic 
dithiol Grx1; the mainly mitochondrial Grx2 (Grx2a); testicular cells and some can-
cer cells express two additional cytosolic/nuclear isoforms of the protein, Grx2b and 
Grx2c; the cytosolic multidomain monothiol Grx3; and the mitochondrial monothiol 
Grx5 [8,24]. Unlike in the Trx system, electrons in the Grx system are transferred 
from the NADPH-dependent glutathione reductase to glutathione (GSH), which, in 
turn, reduces oxidized glutaredoxin [24].
Peroxiredoxins are a heterogeneous family of thiol-dependent peroxidases pres-
ent in all kingdoms of life. Prxs execute enzymatic degradation of H2O2, organic 
hydroperoxides, and peroxynitrite [25]. Unlike Trxs that possess the active double-
cysteine region forming an intramolecular disulfide bond when oxidized, Prxs can 
form intermolecular disulfide bonds. By the number of active Cys residues, mam-
malian peroxiredoxins fall into three groups: typical two-cysteine Prxs (Prx1–Prx4) 
that contain both N- and C-terminal Cys residues, atypical two-cysteine Prxs (Prx5) 
that contain the N-terminal conserved Cys but require an additional Cys for their 
peroxidase activity, and single-cysteine Prxs (Prx6) that contain only the N-terminal 
Cys [22,26]. Prxs are present in all subcellular compartments: Prx1, Prx2, and Prx5 
are found in the cytoplasm and nuclei, Prx4 and Prx6 in the cytoplasm and secreted, 
and Prx3 and Prx5 in mitochondria [23,26].
The brain is more susceptible to oxidative damage than most other organs 
because of its high oxygen utilization, high iron content, presence of unsaturated 
fatty acids, and decreased activities of detoxifying enzymes such as superoxide dis-
mutase (SOD), catalase, and GR [27–29]. Molecular oxygen is the central component 
in energy production in mammalians, and the drop in oxygen supply to neuronal tis-
sue has serious consequences for cell fate and survival. Ischemia–reperfusion injury 
induces serious oxidative stress and, as consequence, a multitude of spatially and 
temporally regulated responses, ranging from changes in the gene expression pat-
tern to biochemical alterations and, ultimately, cell death. The disturbance of redox 
homeostasis, low levels of GSH, and an increased production of ROS and peroxyni-
trite have been described for a number of central nervous system (CNS) disorders, 
for instance perinatal asphyxia [30–32], stroke [22], focal traumatic brain injury 
[33], and numerous neurodegenerative disorders including Alzheimer’s disease, 
Parkinson’s disease, multiple sclerosis, and amyotrophic lateral sclerosis [34,35]. 
Ischemic brain injuries, resulting either from global or focal decreases in perfusion, 
are among the most common and important causes of disability and death worldwide 
after heart infarction and cancer [36,37].
Recently, we described the cellular localization of Trxs in the CNS [38]. We have 
observed several remarkable differences in both abundance and regional distribution 
of Trx-immunopositive cells that point to a complex interplay and crosstalk between 
the proteins of this family. Most of the Golgi type I neurons in the different ische matic- 
sensitive areas showed strong staining for Trx1, Trx2, TrxR1, TrxR2, Txnip, Grx1, 
Grx2, Grx3, Grx5, γ-GCS, Prx1, Prx2, Prx3, Prx4, Prx5, and Prx6. In addition, one 
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of the most striking localizations was in hippocampal astrocytes stained with Trx2 
(Figure 11.1). These data strongly support the concept that Trxs, Grxs, and Prxs are 
involved in various steps during the oxidative stress response induced by CNS dis-
ease [39–52] (for more details, see the next section).
pathologieS involved in neuRodegeneRation
Perinatal asPhyxia
Perinatal asphyxia (PA)-induced brain injury is one of the most common causes of 
morbidity and mortality in term and preterm neonates, accounting for 23% of neona-
tal deaths globally [53]. Following PA, approximately 45% of newborns die and 25% 
have permanent neurological deficits, including cerebral palsy, mental retardation 
and developmental delay, learning disabilities, and different issues in school readi-
ness [54]. Neonatal stroke, a cerebrovascular event that occurs between 28 weeks’ 
gestation and 1 month postnatal age, may be either hemorrhagic or hypoxia-ischemia 
(HI) in origin and has been associated with consequences including cerebral palsy 
and behavioral abnormalities [55,56].
Brain injury that occurs early during development results in significant and per-
sistent decreases in cortical and hippocampal volumes. The type and distribution 
of human brain lesions differ markedly between premature and term babies, likely 
attributed to the stage of brain maturation and regional vulnerability, as described 
elsewhere [57–59]. Atrophy of both gray and white matter is also obvious in models 
FiguRe 11.1 Hippocampal astrocytes expressing Trx2. Scale bar, 10 μm.
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of perinatal HI. This atrophy is attributed to both loss of ischemic infarcted tissue 
and impaired development of the surrounding tissue over time [59,60]. The imma-
ture brain is considerably more resistant to hypoxia presumably because of the lower 
density of axons and dendrites over which a membrane gradient must be maintained. 
Therefore, obtaining a similarly sized injury between age groups requires different 
durations of hypoxia–ischemia [60]. Moreover, different mechanisms of injury are 
activated in the immature brain versus the adult, the most obvious difference being 
that apoptotic mechanisms are several-fold more pronounced in immature animals 
[60]. It is becoming increasingly recognized that the developing brain shows marked 
susceptibility to both oxidative stress and neuronal apoptosis, which may underlie 
this age-dependent injury vulnerability [61–65].
The mechanisms that cause neurological damage after PA are divided schemati-
cally into three metabolic phases [66,67]. Hypoxia leads to primary energy failure 
(phase 1); then, a short time after reoxygenation, aerobic metabolism and cell func-
tions are reestablished (phase 2). However, as a result of a cascade of cellular mecha-
nisms [68,69], after this “latent phase” of 6–24 h, mitochondrial energy production 
again begins to fail. This secondary energy failure (phase 3) lasts for 24–48 h after 
the hypoxic event. The damage that occurs during this phase is considerable [70]. 
In addition, the reoxygenation part of the hypoxia is necessary but also induces the 
most damage after AP: during the reoxygenation period, extracellular glutamate lev-
els are increased, enhancing the activation of Na+/ATPase, increasing further ATP 
consumption. Extracellular glutamate levels override the buffer capacity of astro-
cytes, resulting in sustained overactivation of glutamate receptors, mainly of the 
N-methyl-d-aspartate (NMDA) increasing Ca2+ conductance. All these changes acti-
vate molecular and cell cascades, prolonging the energy deficit and oxidative stress 
associated with further cell damage and apoptotis or necrosis.
Oxidative stress is inherent to reoxygenation, resulting in overactivation, but also 
inactivation of a number of enzymes, mainly those modulating the activity of mito-
chondria [29,31]. In the clinical situation, resuscitation may even imply hyperoxemia, 
leading to further production of free radicals and oxidative stress, worsening brain 
injury [30,31,71–73].
Parkinson’s Disease
Parkinson’s disease (PD) manifests itself in most patients with prominent move-
ment abnormalities, including a 4–6 Hz tremor at rest, muscular rigidity, slow-
ness of movement (bradykinesia), and a failure of movement initiation (akinesia). 
Several environmental factors may have an impact on the occurrence of the disease. 
Living in rural areas, drinking well water, pesticide exposure, and head trauma are 
associated with an increased risk of developing PD, while caffeine consumption, 
taking nonsteroidal anti-inflammatory medications, and smoking appear to protect 
against it.
The prominent motor abnormalities in PD appear to arise in large part from degen-
eration of neurons in the substantia nigra (SNc), with resulting loss of dopamine in 
the basal ganglia. Degenerating dopaminergic cells leave characteristic eosinophilic 
inclusions in their wake, the so-called Lewy neurites and Lewy bodies [74].
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Most cases of PD are “sporadic” and appear to arise from a combination of 
genetic predisposition and environmental or toxic factors. Purely genetic forms of 
the disease probably account for less than 10% of cases; however, the risk of family 
members of an affected patient to develop PD is significantly increased even in spo-
radic PD. Cells in the SNc are among the most vulnerable cells in the brain due to 
a relative deficiency in neuroprotective factors, such as the antioxidant glutathione, 
and because they are exposed to a high level of oxidative stress due to the presence 
of dopaminergic metabolism and other factors.
This environment may induce these neurons particularly vulnerable to nonspe-
cific genetic or environmental insults that, by themselves, would not be sufficient 
to induce cell death in other cells. Interestingly, many of the factors known to be 
involved in neuronal damage in PD appear to interfere with the cell’s ability to 
eliminate damaged or mutated proteins through the ubiquitin proteasome system 
[74]. One example of a genetically determined form of parkinsonism, which results 
directly in degeneration of dopaminergic neurons, are mutations of the gene cod-
ing for α-synuclein [75]. Mutated α-synuclein tends to aggregate as the result of a 
conformational change of the molecule from its usual unfolded, soluble form into a 
β-pleated sheath. Aggregated α-synuclein is a prominent component of Lewy bodies.
A number of genetic mutations have been associated with autosomal recessive 
juvenile Parkinson’s disease. The most frequent of these is the gene PARK2, coding 
for parkin, which accounts for about half of patients with juvenile onset, below the 
age of 40 years. Parkin is an E3 ubiquitin ligase that is necessary for ubiquitination 
of proteins for their subsequent degradation in proteasomes. Loss of function of the 
mutated enzyme may result in failure to direct its substrates to the proteasome sys-
tem for degradation [76]. However, the mechanism involved in Parkinson disease is 
not well known.
alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia among older adults, 
affecting more than 4 million people in the United States and almost 30 million 
worldwide [77]. AD is the most common form of dementia and characterized by 
deposition of amyloid-β (Aβ) plaques, neurofibrillary tangles, and progressive neuro-
degeneration. AD manifests as progressive memory loss and cognitive impairments 
[77,78]. This syndrome results from abnormalities associated with dysfunction and 
death of the neurons involved in memory and cognition [78]. Genetic evidence indi-
cates that the inheritance of mutations in several genes causes autosomal dominant 
familial AD (fAD), while the presence of certain alleles of ApoE4 are significant risk 
factors for putative sporadic disease [79,80].
Multiple lines of evidence have implicated oxidative stress and free radical dam-
age to the pathogenesis and possible etiology of AD. Such damage found in AD 
includes advanced glycation end products [81–83], nitration [82], lipid peroxidation 
adduction products [78], and carbonyl-modified neurofilament protein and free car-
bonyls [84]. The cytopathological significance of oxidative damage is seen by the 
upregulation of antioxidant enzymes. Heme oxygenase-1 (HO-1) is among the most 
sensitive and selective indicators of the cellular oxidative stress response [85,86]. 
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However, the most crucial aspects of the cellular oxidative damage in AD pathogen-
esis appear to be the cytoskeletal modifications in neurons susceptible to AD, which 
in turn play a key role in the irreversible cellular dysfunction that ultimately leads 
to neuronal death [87]. The neuropathological hallmarks of AD are senile plaques 
and neurofibrillary tangles [88,89]. Evidence of an increased oxidation of macromol-
ecules (lipids, carbohydrates, proteins, and DNA) and oxidative stress products has 
been found in senile plaques and neurofibrillary tangles [90]. Biomarkers of these 
forms of oxidation have been observed not only in AD brains but also in peripheral 
tissues (e.g., blood cells) and biological fluids (e.g., urine) of individuals affected by 
AD [91–95].
Signaling pathwayS in CnS diSeaSeS: Role oF 
the thioRedoxinS pRotein Family
Oxidative stress and a misbalance in the production or free radicals have been impli-
cated in different diseases of the CNS. Since Trxs are key proteins related to the 
regulation of redox signaling, it is logical to think that they might be involved in 
the pathogenesis of CNS disorders. Regarding thioredoxins (Trx1), using amyloid-β 
treatment in an AD model led to oxidation of Trx1 in the neuroblastoma cell line 
SH-SY5Y [96]. Overexpression of Trx1 protected SH-SY5Y cells against amyloid-
β-induced cell death [96]. Trx1 expression was suppressed in a rat pheochromocy-
toma cell line (PC12) after treatment with 1-methyl-4-phenylpyridinium (MPP+), 
an active metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) that 
causes parkinsonism [97]. Trx1 is also induced after cerebral ischemia induced by 
middle cerebral artery occlusion [98], and mice overexpressing Trx1 showed attenu-
ation of apoptosis and thereby neuroprotection after both permanent and transient 
focal ischemia [99].
Although proper mitochondrial function is crucial for the progression of most 
neurological diseases, almost nothing is known about the role of the mitochondrial 
Trx2, except for the finding that Trx2 levels were increased in the hippocampus 
of gerbils after ischemia–reperfusion [100]. Treatment of rat primary hippocampal 
neurons with TrxR1 attenuated amyloid-β-mediated toxicity. In AD patients, TrxR1 
activity was generally enhanced compared with controls [101], whereas TrxR1 levels 
in cerebrospinal fluid and blood of multiple sclerosis patients were decreased [102].
In relation to glutaredoxins, overexpression of Grx1 protected SH-SY5Y cells 
against amyloid-β-induced cell death [96]. Several proteins have been described to 
be involved in PD development and progression. The expression of one of these 
proteins, DJ-1 [98], correlates with the expression of Grx1 [103,104]. In a mouse 
model for PD based on MPTP toxicity, loss of dopaminergic neurons was associated 
with inactivation of mitochondrial complex I, a hallmark of the disease. Recovery 
of complex I activity correlated with an increase of Grxs activity following MPTP 
treatment. Whereas knockout of both Grx1 and Grx2 inhibited this recovery [105], 
over expression of Grx2 diminished MPTP-induced neuronal apoptosis via decreased 
complex I activity [106]. After induction of focal ischemia in rat brains, Grx1 lev-
els decreased parallel to the rate of neuronal damage. In AD brain tissue, Grx1 
was upregulated in healthy neurons of the hippocampus and the frontal cortex but 
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downregulated in degenerating neurons [96]. Deglutathionylation/glutathionylation, 
specifically catalyzed by Grxs, is associated with several aspects of neurodegenera-
tion, like apoptosis, mitochondrial function, and plaque formation, summarized for 
instance in Ref. [107].
Several other studies demonstrated the important role of GSH in pathologies of 
the CNS. Amyloid-β treatment of SH-SY5Y cells decreased the total cellular GSH 
amount [96]. In the substantia nigra of PD patients, total GSH levels were not only 
decreased, but GSH was also virtually absent. This loss of GSH is one of the first 
signs of the disease. Knockdown of GSH synthesis in PC12 cells, rat dopaminergic 
N27 cells, as well as in mice by catecholaminergic neuron-specific downregulation 
of γ-glutamyl cysteine ligase, the rate-limiting enzyme in the de novo glutathione 
synthesis, resulted in inhibition of complex I activity [108,109]. These data highlight 
the importance of the GSH/Grx system in maintenance of mitochondrial function in 
the early onset of PD.
Finally, some functions have been attributed to Prxs in CNS disease. In amyloid-
β-resistant clones of the PC12 cell line, Prx1, Prx2, and Prx6 expression was sig-
nificantly increased. PC12 cells and primary neurons overexpressing Prx1 exhibited 
attenuated amyloid-β and MPP+/MPTP toxicity [110]. Treatment with 6-hydroxy-
dopamine (6-OHDA) led to an oxidation of Prx1. Increased levels of Prx1 and Prx2 
protected dopaminergic cells in vitro and in vivo against 6-OHDA-induced apopto-
sis, whereas silencing of Prx1 sensitized the cells [111]. In addition, elevated Prx2 
levels protected against amyloid-β toxicity in a transgenic mouse model for AD 
[112]. In whole brain samples, the expression levels of Prx1 and Prx2 were elevated 
in AD patients [113]. Two other studies, however, could not confirm a higher Prx1 
expression in AD brains [114]. Prx2 levels were also increased in the hippocampus 
and the frontal cortex of AD patients [114] and in the substantia nigra of PD patients 
[115]. Prx3 expression was decreased in the brains of AD patients [116]. In addition, 
Prx6 was upregulated in astrocytes of AD patients [117]. In PD patients, peroxidase 
activity of Prx2 was inhibited by S-nitrosylation [118,119] and phosphorylation [114]. 
The redox states of Prx2 and Prx6 were more oxidized in the brains and serum 
of AD patients [120]. In circulating endothelial progenitor cells of ischemia stroke 
patients, Prx1 was 10-fold more highly expressed than in healthy controls [121]. Prx2 
in rat brains was downregulated after cerebral ischemia [122] and protected against 
stroke-related insults, such as ischemia and glutamate treatment in vitro and in vivo 
[99]. Prx3 was increased in the hippocampus of gerbils after cerebral ischemia–
reperfusion and protected against ischemic damage [123,124].
phaRmaCologiCal appRoaCheS
A body of studies have been published about antioxidant properties; however, they 
have not had a positive effect on clinical studies [117]. Since Trx family proteins 
show specific alterations in various pathological conditions, including changes in 
protein expression, enzymatic activity, tissue distribution, and intra- and extracel-
lular localization, they have been used as therapeutic tools in different experimental 
models. For instance, ebselen, reviewed in Ref. [119], a chemical mimic of glutathi-
one peroxidase that was shown to reduce hydrogen peroxide levels and oxidize Trx 
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[120], was analyzed as potential drug, e.g., for cerebral ischemia [121] and stroke 
[122]. Two drugs, nipradilol and timolol, used in glaucoma therapy increase the pro-
tein levels of Prx2 and thereby protect cells of the trabecular meshwork, the tissue 
surrounding the base of the cornea, against hydrogen peroxide–induced apoptosis 
[123]. Another potential target in the clinic is Prx6. Overexpression of the peroxidase 
could be used to prevent the progression of hypoxia-dependent disorders, such as 
glaucoma [124]. These studies suggest Trxs as a promising tool for a new therapeutic 
approach.
ConCluSion
The importance of redox signaling is increasingly recognized despite the highly 
transient nature of the redox modifications that makes them very difficult to investi-
gate deeply. The various redox modifications are highly target specific and site spe-
cific, and the Trx protein family systems are key players in redox signal transduction 
both as transducers and regulators of second messenger levels.
Thus far, neuroprotective treatment may limit the secondary neuron damage. 
New knowledge about cellular repair mechanisms can also pave the way for types of 
treatment that not merely limit damage but can also repair defects. Therefore, redox 
signaling studies will be able to answer several questions about the functions of oxi-
dative stress contributing to the development of new clinical applications.
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Preface
Oxidative stress, defined as a persistent imbalance between the formation of pro- 
oxidant molecules and antioxidant defenses, in favor of the former, has recently emerged 
as a key factor contributing to the development and progression of inflammation-based 
gastrointestinal diseases. Considerable evidence from both human and animal studies 
support that the consequences of oxidative stress, including the peroxidation of cellu-
lar constituents, disruption of intracellular signaling pathways, and perpetuation of the 
inflammatory response, induce intestinal damage and contribute to intestinal pathol-
ogy. There is also a limited number of reports testing the use of antioxidants as a part 
of the management of various gastrointestinal disorders; however, their preliminary 
data cannot support a definite therapeutic advantage thus far. The present chapter pro-
vides an overview of the role of oxidative stress in the pathogenesis of inflammation-
based gastrointestinal tract diseases, namely celiac disease and inflammatory bowel 
diseases, as well as the potential role of antioxidants in their prevention and treatment.
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celiac Disease
IntroductIon
Celiac disease, also defined as gluten-sensitive enteropathy, is a multiorgan, chronic 
inflammatory disorder induced by permanent intolerance to gluten, a protein found 
in cereal grains, namely wheat, barley, and rye (Troncone et al. 2008b; Hall et al. 
2009; Ferretti et al. 2012). Alcohol extraction of gluten produces a soluble frac-
tion, the prolamins (gliadin in wheat, secalin in rye, and hordein in barley), and 
an insoluble fraction, the glutenins, which are both toxic for patients with celiac 
disease and consist the environmental stimuli responsible for the development of 
the intestinal damage (Ciclitira et al. 1984). The disease is characterized by histo-
pathological damage mainly located in the proximal small intestine, including villus 
atrophy, crypt hyperplasia, flattened mucosa, and increased epithelial lymphocytic 
infiltration (Stojiljkovic et al. 2009; Ferretti et al. 2012). It affects approximately 
0.5–1% of the worldwide population; however, more than half of the patients remain 
undetected.
Although celiac disease can have its onset at any age, it is usually first diagnosed 
in adulthood (Troncone et al. 2008b; Hall et al. 2009). Typical clinical manifesta-
tions of celiac disease include chronic diarrhea, weight loss, abdominal distension, 
lassitude, and malaise. However, a significant proportion of patients experience other 
extradigestive symptoms, such as anemia, skin lesions, isolated hypertransaminas-
emia, osteopenia, infertility, dermatitis herpetiformis, ataxia, or polyneuropathia. It 
is important that there are also patients with no or atypical symptoms (silent celiac 
disease), resulting in underdiagnosis of the disease (Troncone et al. 2008a,b).
Celiac disease is associated with serious consequences on health, such as mal-
absorption of nutrients, osteoporosis, gastrointestinal malignancies, and the onset 
of other autoimmune diseases, such as diabetes mellitus, making it a serious public 
health problem, which needs to be treated. The cornerstone of the disease treatment 
is the lifelong adherence to a gluten-free diet (GFD), which has been associated with 
clinical and histological recovery, a better quality of life, and the prevention of dis-
ease complications (Troncone et al. 2008a; Hall et al. 2009).
Although the exact mechanisms by which gluten and its fractions (prolamins 
and glutenins) cause intestinal damage remain unclear, it seems that an interaction 
of genetic, environmental, and immunological factors occurs. Celiac disease has a 
genetic basis, indicated by a concordance in monozygotic twins and an increased 
prevalence in first-degree relatives. The determinants of genetic heritability are the 
human leukocyte antigen (HLA) class II DQA and DQB genes located in the major 
histocompatibility complex on chromosome 6. The combination of HLA-DQA1*0501 
and DQB1*0201 alleles encode the HLA-DQA2 class II protein, which is respon-
sible for prolamins’ presentation to positive T-cell receptors of CD4 lymphocytes. 
However, these alleles are critical but not sufficient for celiac disease development 
(Ferretti et al. 2012). The proposed theory is that gluten and its fractions, as well as 
other environmental factors, trigger the inflammatory injury and the development of 
intestinal damage, by activating various pathological immune responses in geneti-
cally susceptible individuals (Troncone et al. 2008b).
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oxIdatIve StreSS and celIac dISeaSe
Evidence acquired during the last decade suggests that most of the cytotoxic, inflam-
matory, and immunogenic effects of gluten peptides on the intestinal epithelium 
are mediated by increased oxidative stress. Some gluten peptides have the ability to 
penetrate cells in celiac disease patients. Then, they accumulate in lysosomes and 
trigger the activation of some signal transduction pathways, leading to an overpro-
duction of free radicals (reactive oxygen species [ROS] and reactive nitrogen spe-
cies [RNS]). In turn, free radicals disturb the pro-oxidant/antioxidant balance in the 
intestinal mucosa, by increasing levels of lipid peroxidation products and oxidized 
(GSSG)/reduced (GSH) glutathione ratio (oxidative stress markers), and decreas-
ing protein-bound sulfhydryl groups (which are involved in the cell regulation of 
ROS levels together with antioxidants). The altered oxidative balance leads to the 
activation of pro-inflammatory transcription protein complex of the nuclear factor-
kappa B (NF-κB), which results in the transcription of pro-inflammatory cytokines 
like tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), and interferon-γ (IFN-γ), 
and enzymes such as cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase 
(iNOS). Consequently, prostaglandins and nitric oxide (NO) metabolites are pro-
duced, which further contribute to oxidative stress, perpetuating a vicious cycle as 
illustrated in Figure 12.1. The increased oxidative stress also downregulates the pro-
duction of peroxisome proliferator-activated receptor gamma, mediated by tissue 
transglutaminase, leading equally to NF-κΒ activation. As a result, the epithelial 
barrier dysfunction and the intestinal permeability increase and gluten peptides pass 
through the enterocytes, activating various immune responses, which further lead to 
cell damage and villous atrophy in celiac disease patients (Ferretti et al. 2012).
Data from several studies assessing the oxidative or antioxidant status of patients 
with celiac disease also support the involvement of oxidative stress in the disease 
pathogenesis and have been recently reviewed (Ferretti et al. 2012). As reported 
in this review, it seems that celiac disease patients demonstrate increased markers 
of oxidative stress and damage (e.g., increased iNOS expression in intestine and 
NO metabolite levels in plasma) and decreased levels of antioxidant enzymes (e.g., 
decreased glutathione peroxidase activity in the intestine and in blood, respectively) 
and nuclear factors in intestinal cells and biological fluids, compared with healthy 
controls (Ferretti et al. 2012).
antIoxIdantS and celIac dISeaSe rISk
Celiac disease patients’ dietary habits, in terms of macro- and micronutrient intake, 
have been thus far explored in many studies, with most of the data suggesting that 
both newly diagnosed and long-term patients are characterized by inadequate 
dietary vitamin and mineral intake. Reasons for the observed nutritional inadequa-
cies include habitual poor food choices in addition to inherent deficiencies in the 
GFD, as well as the lack of a proper dietary counseling (Shepherd and Gibson 2013; 
Wierdsma et al. 2013). However, studies exploring the relationship between dietary 
antioxidants intake and the risk of celiac disease are currently unavailable. On the 
other hand, few cross-sectional studies have assessed the antioxidant body content 
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of patients with celiac disease and reported decreased levels of antioxidant vitamin E 
(α-tocopherol) in both patients’ circulating cells and plasma (Stojiljkovic et al. 2007; 
Szaflarska-Poplawska et al. 2010), as well as low serum selenium levels (Yuce et al. 
2004). Nevertheless, the above-mentioned decreased levels of antioxidants are prob-
ably the result of intestinal malabsorption, rather than inadequate dietary intake. 
Given the fact that cross-sectional studies do not provide a good basis for estab-
lishing causality, the conduction of prospective studies in genetically predisposed 
individuals is clearly needed, to assess the relationship between dietary antioxidant 
intake and the risk of celiac disease development.
Despite the lack of strong evidence regarding the role of specific antioxidants in 
celiac disease risk, it is worth mentioning that current theories support the important 
role of selenium in celiac disease development and severity for two main reasons. 
Oxidative stress
Increased formation of pro-oxidant molecules (ROS
and RNS) and decreased antioxidant defense
Intestinal damage
Stimulation of inflammatory
cells and increased expression






the intestine and activation




Increased production of pro-inflammatory cytokines,
such as TNF-α, IL-1β, IL-6, and IFN-γ
fiGUre 12.1 Schematic illustration of the interaction between oxidative stress and inflam-
mation in the pathophysiology of inflammatory-based gastrointestinal (GI) tract diseases. As 
depicted, oxidative stress contributes to intestinal inflammation by (i) increasing intestinal 
permeability and the exposure of intestinal cells to harmful stimuli (gluten in the case of 
celiac disease or intestinal pathogens in the case of inflammatory bowel diseases), and 
(ii) stimulating signaling pathways, especially the redox-sensitive transcription factor nuclear 
factor kappa B (NF-κB), which in turn promotes the production of inflammatory cytokines, 
such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and 
interferon-γ (IFN-γ). On the other hand, inflammation augments oxidative stress by stimu-
lating the expression of inflammatory cells’ reactive oxygen and nitrogen species (ROS and 
RNS) generating systems, such as lipoxygenase (LOX), cycloxygenase-2 (COX-2), NAD(P)H 
oxidases (NOXs), inducible-nitric oxide synthase (i-NOS), and myeloperoxidase (MPO).
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First, selenium is a part of glutathione peroxidase, one of the strongest antioxidant 
enzymes in the human body, which is involved in the protection of intestinal cells 
against oxidative damage. Second, selenium deficiency seems to be associated with 
the development of autoimmune thyroid diseases (AITDs), a common extraintestinal 
complication of celiac disease, since selenoproteins are necessary for the biosynthe-
sis and activity of thyroid hormones and the maintenance of normal thyroid gland 
function. Given the aforementioned, selenium malabsorption in celiac disease has 
recently emerged as a key factor directly leading to both thyroid and intestinal dam-
age. Under this scope, the correction of selenium deficiency, possibly via selenium 
supplementation, should be considered in patients with celiac disease in parallel 
with the adoption of GFD, to prevent both further oxidative stress–induced intestinal 
damage and the development of AITDs (Stazi and Trinti 2010).
antIoxIdantS and treatment of celIac dISeaSe
There is much evidence that dietary antioxidants, such as plant polyphenols, carot-
enoids, and vitamins have the potential to modulate predisposition to intestinal 
chronic inflammatory diseases. They act through a plethora of mechanisms, includ-
ing the decrease of inflammatory mediator production through effects on cell signal-
ing and gene expression, the reduction of damaging oxidants production, and the 
promotion of gut barrier function and anti-inflammatory responses (Calder et al. 
2009).
Data investigating the role of antioxidants in celiac disease treatment are scarce. 
Perhaps one reason explaining this fact is that during the past decades, scientific 
interest has focused on the effectiveness of GFD, which remains the cornerstone of 
disease treatment (Hall et al. 2009). Thus far, there is no human clinical trial avail-
able investigating the effect of antioxidant intake on celiac disease treatment. There 
is, however, only one study in a mouse model of celiac disease with unexpected 
results, concerning the role of retinoic acid (metabolite of vitamin A) in gliadin toler-
ance and inflammation. According to this study, retinoic acid promoted rather than 
prevented inflammatory cellular responses in a stressed intestinal environment and 
worked together with interleukin-15 (IL-15) to drive pro-inflammatory responses 
against gliadin (De Paolo et al. 2011).
Most of the data regarding the potential role of antioxidants in celiac disease 
management come from in vitro studies. Previously, one study reported that syn-
thetic (pyrrolidine dithiocarbammate) and natural (genistein and tyrphostin) anti-
oxidants inhibited the iNOS gene expression in a mouse monocyte/macrophage 
RAW 264.7 cell line, which were stimulated by gliadin and IFN-γ (De Stefano et 
al. 2006). iNOS production significantly increased in the stimulated cells; however, 
in the presence of the above-mentioned antioxidants, this response was attenuated. 
One year later, members of the same research team found that lycopene (carotenoid), 
quercetin (flavonoid), and tyrosol (polyphenol) decreased iNOS and COX-2 gene 
expression induced by gliadin and IFN-γ in RAW 246.7 macrophages (De Stefano 
et al. 2007). These results suggest that antioxidants may control the genes encod-
ing pro-inflammatory cytokines that are involved in celiac disease pathogenesis. In 
another recent in vitro study, the addition of vitamin C (ascorbate) to a culture of 
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gliadin-challenged, duodenal biopsy extracts from treated celiac disease patients (for 
a minimum of 6 months on GFD) blocked the secretion of nitrites and pro-inflammatory 
cytokines (IFN-α, IFN-γ, TNF-α, and IL-6), and inhibited the expression of IL-15 
triggered by gliadin, compared with samples from a non-ascorbate-supplemented 
 culture (Bernardo et al. 2012). The authors suggested in their conclusions that vita-
min C supplementation might be beneficial for patients with celiac disease and can 
be considered as a future treatment option. The conclusions of one recent review are 
also promising, suggesting that flavonoids such as epigallocatechin gallate, genis-
tein, myricetin, and quercetin have a protective effect on intestinal intracellular tight 
junction (Tj) barrier function. The Tjs play an important role in the transport of glu-
ten through enterocytes and in the function of the intestinal barrier. Oxidative stress 
and pro-inflammatory cytokines causes dysfunction of Tjs in celiac disease patients, 
and the aforementioned flavonoids have been suggested to protect their function 
(Suzuki and Hara 2011).
concluSIonS
To sum up, oxidative stress seems to be involved in celiac disease pathogenesis and 
celiac patients are characterized by a low antioxidant status. According to the afore-
mentioned studies, dietary antioxidants (antioxidant vitamins and phytochemicals) 
may have a role in the nutritional treatment of celiac disease, by exerting protective 
effects against toxic gluten fractions on intestinal cells (Figure 12.2). However, the 
benefits of antioxidants observed in cell cultures must also be confirmed in ani-
mal and human studies, to clarify the conclusions that remain ambiguous until now. 
Further research should also focus on the optimal dosage of antioxidant intake and 
on the possible differences between dietary sources of antioxidants and supplements. 
Until then, GFD remains the only step of treatment after the diagnosis of the disease.
Antioxidant vitamins (e.g., vitamin C)







Intestine of a genetically susceptible individual
fiGUre 12.2 Potential beneficial effect of dietary antioxidant vitamins and phytochemi-
cals on celiac disease patients. Dietary antioxidants may attenuate the toxic effects of gluten 




Inflammatory bowel diseases (IBDs) represent a group of chronic idiopathic intes-
tinal diseases, with Crohn’s disease (CD) and ulcerative colitis (UC) being the two 
major phenotypes. Although both pathological conditions are characterized by 
intestinal inflammation, the site, nature, and extent of intestinal involvement differ 
significantly among them. CD usually involves the terminal ileum and the colon; 
however, it can practically affect any part of the gastrointestinal tract from the mouth 
to the anus in a segmental way (skip lesions), while inflammation is transmural. By 
contrast, UC always affects the rectum and can spread proximally up to the cecum 
in an uninterrupted retrograde pattern (continuous areas of inflammation and ulcer-
ation with no segments of normal tissue), while inflammation is typically confined 
to the mucosa (Assadsangabi and Lobo 2013). According to epidemiological data, 
the highest prevalence of IBD is reported in westernized nations (Europe and North 
America) and their incidence appears to be gradually increasing in different regions 
worldwide, indicating their emergence as global diseases imposing great health and 
economic burdens (Molodecky et al. 2012).
IBDs can occur anytime in life; however, they usually have an onset in early 
adulthood and a lifelong impact characterized by periods of remission and periods 
of active disease. The onset and active phases of IBD usually involve symptoms of 
abdominal and/or rectal pain and diarrhea (with blood or mucus in UC), frequently 
accompanied by other manifestations such as anorexia, weight loss, nausea and 
vomiting, arthralgia, and fever. Patients with IBD are at a high risk of developing 
intestinal cancer (mostly colorectal cancer in UC), while both CD and UC are also 
associated with several extraintestinal manifestations, including cutaneous lesions, 
ophthalmologic and joint disorders, biliary and liver complications, osteoporosis, 
and anemia. The primary end points of active IBD therapy include induction and 
maintenance of remission, as well as management of IBD-related complications. 
Currently, therapeutic options include salicylates, corticosteroids, immunosuppres-
sants, immunomodulators, and biologic agents; however, if these treatments fail, the 
surgical removal of the highly affected intestinal parts remains the only available 
therapeutic choice (Engel and Neurath 2010).
It has been proposed that IBD occurs due to inappropriate inflammatory and 
immune response to luminal pathogens and the resulting host–microbe interactions 
in genetically susceptible individuals; however, the exact pathogenetic mechanisms 
responsible for their development remain partly elucidated. In brief, data thus far 
suggest that genetic factors, gut microbiota disorders, defects in the intestinal bar-
rier function that lead to increased intestinal permeability and increased exposure to 
pathogens, dysregulated innate and adaptive immune system response resulting in 
an increased secretion of pro-inflammatory cytokines, and the presence of various 
types of potentially cytotoxic autoantibodies represent the most important determi-
nants of IBD pathogenesis (Fries and Comunale 2011; Zhang and Li 2014). Among 
the mediators of the dysfunctional immunoregulation of the gut, oxidative stress is 
considered as a potential etiological and/or triggering factor for IBD.
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oxIdatIve StreSS and IBdS
Current theories on IBD pathogenesis suggest that interactions among various 
genetic, environmental, and immune factors lead to an uncontrolled, dysregulated 
immune response in the intestinal mucosa. Underlying mechanisms are not entirely 
clear; however, substantial evidence suggests that chronic intestinal inflammation is 
associated with enhanced production of ROS and RNS, which in turn contributes to 
the initiation and perpetuation of the abnormal immune response (Zhu and Li 2012).
There is much direct evidence that a state of increased oxidative stress is pres-
ent in human and experimental IBD. Several studies have demonstrated that com-
pared with controls, both CD and UC patients and animals with experimental IBD 
exhibit increased formation of ROS/RNS and excessive levels of oxidized molecules 
(lipid and DNA oxidation markers), both in blood and in the gastrointestinal tract 
(Thomson et al. 1998; Rezaie et al. 2007). The intestinal epithelium contains mul-
tiple antioxidant systems, such as antioxidant enzymes (i.e., superoxide dismutase, 
catalase, glutathione peroxidase, myeloperoxidase, and glutathione reductase) and 
low molecular-weight antioxidant molecules (i.e., reduced glutathione and metallo-
thionein), all of which are involved in protecting the intestinal cells against oxidative 
stress. In line with the augmented formation of oxidized molecules, both human and 
in vivo studies have reported an imbalance (either increase or decrease) in blood 
and intestinal mucosa concentrations of the aforementioned antioxidants in IBD 
(Thomson et al. 1998; Rezaie et al. 2007). This suggests either an induction of their 
synthesis in response to the oxidative molecules produced during the inflammatory 
response or their depletion due to severe persistent oxidative stress.
Oxidative stress is considered to contribute both to the development and the pro-
gression of IBD. It has been proposed that the augmented formation of ROS/RNS 
may occur at the very early stage of the disease process or even before the disease 
onset, suggesting a possible causative role of oxidative stress in the genesis of IBD. 
This notion is largely supported by several in vivo studies, recently reviewed by Zhu 
and Li (2012), showing that the direct inoculation of ROS/RNS to the intestine of 
experimental animals leads to intestinal inflammation and the development of coli-
tis. Moreover, the chemical or genetic depletion of endogenous antioxidants (e.g., 
glutathione or glutathione peroxidase) has been shown to lead to spontaneous devel-
opment of experimental colitis, while both the administration of exogenous antioxi-
dants and the chemical or genetic amplification of endogenous antioxidants, such as 
superoxide dismutase, have been proven to attenuate the progression of chemically 
induced colitis in mice (Zhu and Li 2012). Regarding IBD progression, overpro-
duction of ROS/RNS via various sources, especially the activated neutrophils and 
macrophages, can cause direct damage to intestinal cells via interacting with cellular 
constituents, including lipids. The subsequent formation of lipid peroxidation prod-
ucts, such as reactive aldehydes, has been shown to induce the infiltration and activa-
tion of inflammatory cells, leading to additional mucosal injury and the perpetuation 
of the inflammatory response (Kumagai et al. 2004; Trevisani et al. 2007).
It is still unclear whether oxidative stress precedes or follows intestinal inflam-
mation. ROS/RNS can disintegrate the intestinal epithelium and increase intestinal 
permeability, leading to an increased exposure to intestinal pathogens and induction 
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of the inflammatory response. Moreover, oxidative stress can lead to the activation 
of NF-κB, a pro-inflammatory redox-sensitive transcription factor that is known to 
result in a further overexpression of pro-inflammatory cytokines, hence contributing 
to the perpetuation of intestinal inflammation in IBD. On the other hand, inflamma-
tion can result in oxidative stress by stimulating ROS/RNS-generating systems. The 
increased activity of infiltrating immune cells in IBD patients is known to result in 
an increased production of pro-inflammatory cytokines, such as TNF-α, IL-1β, and 
IFN-γ, which in turn lead to an increased formation of ROS/RNS by phagocytic cells 
accumulating within the gastrointestinal tract, during times of active inflammation 
(Abraham and Cho 2009; Jena et al. 2012). It is therefore obvious that oxidative stress 
and intestinal inflammation consist of two closely related mechanistic aspects, both 
implicated in the development and the progression of IBD, as shown in Figure 12.1.
antIoxIdantS and IBd rISk
As previously described, oxidative stress plays an important role in IBD pathogen-
esis. Several studies have thus far attempted to investigate any potential relationship 
between dietary antioxidant intake or blood circulating antioxidant levels and IBD 
risk, which are presented and discussed in detail below.
Dietary antioxidant intake and iBD risk
Although genetic and immune factors are the most important determinants of IBD 
development, nutrition has also been proposed as a potential environmental factor 
affecting IBD risk. For instance, it has been hypothesized that dietary components 
could influence the risk of intestinal inflammation through several mechanisms, 
including a direct contact with the colonic mucosa, changes in the chemical compo-
sition of mucosal cell membranes, or even an effect on the balance of intestinal flora. 
Indeed, several studies have thus far explored potential associations between long-
term dietary habits, in terms of nutrients and foods or food groups, and IBD risk. 
According to a recent review of prospective cohorts, mainly including middle-aged 
Europeans, a diet high in protein from meat and fish has been consistently found to 
increase the risk of both CD and UC development, while an increased intake of lin-
oleic acid and a decreased intake of omega-3 polyunsaturated fatty acids seem to be 
associated with increased UC risk (Andersen et al. 2012). Retrospective case–control 
studies also demonstrate a positive association between the dietary intake of total 
polyunsaturated fatty acids and omega-6 fatty acids, as well as the consumption of 
meat and the likelihood of both CD and UC, while they also provide limited data on 
food groups rich in antioxidants; in specific, a high consumption of fruits has been 
associated with a lower likelihood of CD, while a high consumption of vegetables 
has been associated with a lower likelihood of UC (Hou et al. 2011).
Regarding dietary antioxidants, given the involvement of oxidative stress in IBD 
pathogenesis, one could speculate that an increased dietary antioxidant intake could 
protect against the development of IBD; however, such evidence is currently limited. 
Thus far, only one prospective study provided results regarding the potential asso-
ciations between specific dietary antioxidants and UC risk (Hart et al. 2008). In this 
nested case–control study within a European prospective investigation, 260,686 men 
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and women aged 20–80 years residing in the United Kingdom, Sweden, Denmark, 
Germany, and Italy, selected from the European Prospective Investigation into 
Cancer and Nutrition (EPIC) Study cohort, provided information on their dietary 
habits through country-specific food-frequency questionnaires and were followed for 
the development of UC. According to the study’s results, no significant association 
between dietary vitamin C, vitamin E, carotene, and retinol intake and UC risk was 
observed. Prospective studies testing associations between dietary antioxidants and 
CD risk are currently unavailable. Evidence regarding the potential role of dietary 
antioxidants in IBD development is also available through some case–control stud-
ies, comparing the dietary habits of either newly diagnosed or long-term IBD patients 
with those of healthy individuals (Reif et al. 1997; Geerling et al. 1998, 2000a; 
Sakamoto et al. 2005; Filippi et al. 2006; Rosman-Urbach et al. 2006; Kawakami et 
al. 2007; Sousa Guerreiro et al. 2007). Most of the data support that both CD and UC 
patients tend to report lower vitamin C intake, compared with controls, while data on 
other dietary antioxidants, such as vitamin A or vitamin E, are largely conflicting. 
Moreover, in most studies, patients with CD exhibit a higher frequency of inadequate 
dietary antioxidant intake (defined as a dietary intake below the country-specific 
recommended intake) compared with healthy individuals.
Prospective studies undoubtedly provide the most reliable data regarding disease 
risk. Given the lack of such studies evaluating the association between dietary anti-
oxidants and IBD risk, a definite conclusion cannot be drawn. On the other hand, 
case–control studies can provide valuable information regarding the role of dietary 
antioxidants in IBD development, given that the interval between the diagnosis and 
participants’ recruitment into the study is short, so that the prediagnosis diet is accu-
rately reported. However, it should be mentioned that they also present many meth-
odological limitations, mainly due to being largely susceptible to recall bias, while 
their retrospective design does not allow the reporting of causal associations between 
dietary antioxidant intake and IBD risk, as does a prospective design. Particularly, 
case–control studies on long-term IBD patients are of little value, since patients’ 
dietary habits are most probably already influenced by the disease itself. It has been 
reported that patients with IBD in remission modify their dietary habits to prevent a 
possible disease relapse; food groups usually avoided or completely excluded include 
fruits, vegetables, legumes, pulses, and whole grains (Zallot et al. 2013), which are 
among the most important dietary sources of antioxidants. In addition, IBD patients 
are usually advised to follow a low-fat diet to prevent symptoms of diarrhea resulting 
from fat malabsorption due to intestinal inflammation (Brown et al. 2011). This pos-
sibly contributes to a decreased intake of the fat-soluble antioxidants vitamins A and 
E. Given the aforementioned, the low antioxidant intake of IBD patients observed in 
case–control studies could actually reflect disease-associated dietary modifications 
rather than dietary habits contributing to IBD development.
Blood antioxidant levels and iBD risk
Evidence regarding the association between antioxidants and IBD is also available 
through studies exploring the blood antioxidant status of patients with CD and UC 
in comparison with healthy subjects (Ringstad et al. 1993; Ramakrishna et al. 1997; 
Bousvaros et al. 1998; D’Odorico et al. 2001; Koutroubakis et al. 2004; Rezaie et 
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al. 2007). Briefly, patients with IBD tend to exhibit lower total plasma antioxidant 
capacity and lower plasma vitamin C, vitamin A, and vitamin E levels compared 
with healthy individuals; however, not all studies confirm these differences between 
patients and controls. Interestingly, some studies have also reported lower serum 
selenium levels both in adults and children with IBD compared with healthy con-
trols, as well as an inverse association between serum selenium levels and disease 
extent. Given that patients with IBD have an increased risk of intestinal cancer and 
that selenium may inhibit intestinal carcinogenesis through multiple mechanisms 
(e.g., by protecting cellular membranes against oxidative damage, by reducing the 
mutagenicity of cancer-causing chemicals, or by affecting carcinogen metabolism) 
(Meplan and Hesketh 2012), reduced selenium levels may be of special importance 
in patients with IBD.
Although it is clear that IBD patients present an imbalance in blood antioxidant 
levels, this observation could be a result of the established disease rather than a 
preceding phenomenon. For instance, low blood antioxidant levels could reflect a 
poor dietary antioxidant intake, caused by IBD patients’ strict dietary modifications 
to prevent and/or manage gastrointestinal symptoms or prevent disease relapse as 
previously mentioned. Most important, decreased blood levels of antioxidants could 
be the result of IBD patients’ general state of malnutrition. It is estimated that mal-
nutrition occurs in up to 85% of patients with CD and up to 60% of patients with 
UC both in active phases of the disease and in periods of remission. Nutritional 
deficiencies are prevalent, particularly in relation to anemia and osteoporosis, but 
also vitamin and mineral deficiencies, and result from extensive intestinal inflam-
mation leading to nutrient malabsorption, poor appetite leading to low energy intake 
and consequent weight loss, gastrointestinal symptoms including nausea, vomiting 
and diarrhea, intestinal surgery complications, or medication-related adverse effects 
(Lomer 2011).
antIoxIdantS and treatment of IBdS
Given the strong involvement of oxidative stress in IBD pathogenesis and progres-
sion, antioxidant supplementation has been proposed as a potential alternative thera-
peutic option combined with established pharmacological treatment for IBD patients. 
In fact, the oldest and most commonly used drug for the treatment of patients with 
IBD, mesalazine, also known as 5-aminosalicylic acid, has shown ROS scaveng-
ing capabilities, as well as a synergistic interaction with other antioxidants, such as 
α-tocopherol (Rezaie et al. 2007).
Thus far, only few interventional studies have been conducted to examine the effi-
cacy of specific antioxidants in patients with IBD, which are briefly presented in Table 
12.1. The main antioxidants studied are vitamins C and E, β-carotene, and selenium 
(Geerling et al. 2000b; Aghdassi et al. 2003; Trebble et al. 2004, 2005; Seidner et 
al. 2005; Mirbagheri et al. 2008; Wiese et al. 2011), while two other studies inves-
tigated the role of curcumin in IBD treatment (Holt et al. 2005; Hanai et al. 2006). 
Curcumin (plant name Curcuma longa) is the principal natural polyphenolic com-
pound found in the Indian spice, turmeric, and seems to exert strong anti-inflammatory 
and antioxidant properties (Holt et al. 2005). Thus far, the studies’ results are quite 
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promising, suggesting that antioxidants may be a therapeutic option in IBD treat-
ment. However, they also present various limitations, such as the low dose of admin-
istered antioxidants, small sample size, short duration, and no or short follow-up 
period. In addition, in five of the above-mentioned studies (Geerling et al. 2000b; 
Trebble et al. 2004; Seidner et al. 2005; Trebble 2005; Wiese et al. 2011), the supple-
ment given to IBD patients, apart from antioxidants, also contained other dietary 
components such as fish oil, vitamins, and minerals; hence, the effect of antioxidants 
per se on IBD activity and severity is largely unclear.
Despite the lack of interventional studies in humans with IBD, most of the data 
assessing the effectiveness of antioxidants in the treatment of IBD comes from animal 
or in vitro studies. Several animal studies in rodent models of IBD (mainly experi-
mental colitis and models of intestinal inflammation) have shown that vitamin E or 
selenium supplementation alone or in combination can significantly reduce markers 
of disease activity or severity, inflammation, and/or oxidative damage (Ademoglu 
et al. 2004; Tirosh et al. 2007; Bitiren et al. 2010; Tahan et al. 2011). In addition, 
there is much evidence that pure polyphenol molecules, such as quercetin, apigenin, 
genistein, resveratrol, and epigallocatechin-3-gallate, as well as natural polypheno-
lic extracts, such as extracts from green tea leaves and red wine, are capable of 
attenuating IBD severity and activity, by reducing immune cell infiltration in the 
intestine, intestinal inflammation, and oxidative stress markers (Romier et al. 2009). 
Interesting enough are the beneficial effects of curcumin on IBD treatment, shown 
in several in vivo studies (Jian et al. 2005; Camacho-Barquero et al. 2007; Deguchi 
et al. 2007; Mouzaoui et al. 2012), while only two of the aforementioned human 
trials have reproduced these data (Holt et al. 2005; Hanai et al. 2006). In brief, the 
main mechanisms proposed behind the observed effects of curcumin include free 
radical scavenging, the increase in the antioxidant enzymes, the suppression of pro-
inflammatory enzymes (e.g., COX-2) and inflammatory cytokines (e.g., TNF-α, like 
ΙNF-γ), and the modulation of signal transduction and transcription factors, includ-
ing NF-κB. In addition, apart from curcumin’s potent anti-inflammatory properties, 
its potential chemopreventive effects on carcinogenesis are currently being investi-
gated (Baliga et al. 2012). Subsequently, limited in vitro studies also indicate that 
pure polyphenols and plant polyphenolic extracts could exert anti-inflammatory 
properties via the modulation of intracellular signaling cascades in the intestinal 
cell. However, other in vitro studies have produced contradictory results, making it 
difficult to draw definite conclusions (Romier et al. 2009).
Undoubtedly, further research is needed through well-designed human random-
ized controlled trials to elucidate the applicability of antioxidants in IBD treatment. 
In addition, more in vitro and in vivo studies are also required to understand the 
complex mechanisms regarding the actions of antioxidants on IBD pathogenesis and 
progression.
concluSIonS
Although mounting evidence supports the involvement of oxidative stress in 
IBD pathogenesis and progression, data regarding the role of specific antioxi-
dants on IBD risk and management remain thus far limited and do not allow 
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the development of evidence-based recommendations on dietary antioxidant 
intake for these diseases. Nevertheless, given that current dietary guidelines for 
patients with both CD and UC suggest vitamin and mineral supplementation for 
all patients, or at least in those with malnutrition or those exhibiting reduced oral 
intake (Brown et al. 2011), the selection of supplements that also contain antioxi-
dant compounds should be considered, to improve patients’ nutritional and blood 
antioxidant status.
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13 Antioxidants in Obesity 
and Inflammation
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IntroductIon
The development of obesity is characterized by an increased number and size of fat 
cells due to enhanced processes of adipocyte proliferation and differentiation, which 
are regulated by interacting genetic, metabolic, pharmacological, environmental, 
and nutritional factors. The key abnormality in obesity is an energy imbalance pro-
moting excess energy storage in adipose tissue, which becomes progressively hyper-
trophic, hyperplastic, and dysfunctional, and is characterized by severe metabolic 
stress and disrupted energy metabolism.
Obesity is strongly associated with increased risk for type 2 diabetes mellitus 
(T2DM) and cardiovascular disease (CVD), mainly due to concomitant chronic sub-
clinical inflammation and oxidative stress (Dali-Youcef et al., 2013; Vincent and Taylor, 
2006), providing the rationale for testing the short- and long-term effectiveness of 
several antioxidant and anti-inflammatory pharmacological and dietary interventions 
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for the prevention and treatment of obesity and its cardiometabolic complications. 
Experimental data from animal and in vitro studies as well as small-scale observa-
tional studies in humans suggest beneficial effects of specific antioxidant compounds on 
obesity-related conditions. However, it is important to note that randomized controlled 
clinical trials assessing the long-term safety and efficacy of antioxidant supplementation 
in obese humans are currently limited, inconsistent, and raise a number of methodologi-
cal issues that warrant a cautious interpretation and critical appraisal of their findings.
obesIty as an Inflammatory condItIon
Low-grade systemic inflammation is a prominent characteristic of obesity and is 
defined as a modest upregulation of circulating indicators of inflammation such as 
leukocyte count and concentrations of acute-phase proteins, pro-inflammatory cyto-
kines, chemokines, soluble adhesion molecules, and prothrombotic mediators. In 
obese humans, systemic concentrations of pro-inflammatory mediators are consis-
tently higher than in lean individuals, and promote cardiometabolic dysregulation 
by increasing the risk for insulin resistance and atherosclerosis (Calder et al., 2011). 
Obesity has been mechanistically linked to low-grade inflammation through the 
concept that adipose tissue synthesizes and secretes into the circulation a number 
of biologically active molecules such as hormones, growth factors, inflammatory 
mediators, and immune system effectors. White adipose tissue is no longer viewed as 
an inert energy storage organ, but is rather perceived as the largest endocrine gland 
of the human body. The secretory products of adipose tissue are collectively termed 
adipokines, and represent the mediating link between local and systemic inflam-
mation in the context of obesity (Tilg and Moschen, 2006). Some adipokines are 
produced exclusively by adipocytes (leptin, adiponectin), while others are produced 
by both adipocytes and other cell populations of the stromovascular fraction of adi-
pose tissue, predominantly the resident macrophages that infiltrate the hypertrophic 
adipose tissue (Weisberg et al., 2003). The anatomical localization of adipose tissue 
is of paramount importance for determining its physiological function, especially 
with regard to lipid handling (lipolysis and lipogenesis), gene expression patterns, 
insulin sensitivity, and profile of secreted adipokines. Central fat accumulation in 
the thorax and abdomen has been associated with increased systemic inflammation 
and cardiometabolic risk, whereas peripheral fat distribution is considered metaboli-
cally benign (Peppa et al., 2013). Obesity-related chronic low-grade inflammation 
can be further aggravated by hyperglycemia, which is commonly prevalent in obese 
humans owing to their concomitant peripheral insulin resistance (Calder et al., 2011).
assocIatIon of obesIty wIth oxIdatIve stress
Oxidative stress is one of the unifying mechanisms underlying the development of 
obesity-related comorbidities, mainly T2DM and CVD. In obesity, multiple con-
tributing factors may promote increased oxidative stress, including hyperglycemia, 
hyperleptinemia, increased tissue lipid availability leading to lipotoxicity, inad-
equate antioxidant capacity, and chronic subclinical inflammation (Vincent and 
Taylor, 2006). Data from cross-sectional studies provide solid evidence for increased 
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systemic oxidative stress in obesity. Markers of systemic lipid peroxidation (plasma 
malondialdehyde levels, thiobarbituric acid reactive substances) are increased in 
obese humans, and low-density lipoprotein (LDL) cholesterol is oxidized much 
faster, promoting atherosclerosis (Van Gaal et al., 1998). Urinary isoprostane excre-
tion rates are higher in obese subjects and correlate positively with body mass index 
(BMI), as shown in the Framingham offspring cohort (Keaney et al., 2003). Plasma 
isoprostane levels have been also shown to correlate positively with BMI and total 
and visceral fat mass (Urakawa et al., 2003). Biomarkers of oxidative stress are pres-
ent in several tissues of obese humans, including plasma, skeletal muscle, and eryth-
rocytes. The strong association between obesity and oxidative stress is highlighted 
by the finding that measures targeted at reducing body weight, such as physical activ-
ity, caloric restriction, and surgical interventions, have been shown to substantially 
improve biomarkers of oxidative stress in obese humans (Vincent and Taylor, 2006).
defectIve antIoxIdant defense In obesIty
Antioxidants can be either nonenzymatic (dietary antioxidants and endogenous coen-
zyme Q) or enzymatic (antioxidant enzymes). Dietary antioxidants mainly comprise 
vitamins (C, E, β-carotene), antioxidant minerals (zinc, copper, selenium, manganese), 
and phytochemicals (phenols, flavonoids, lycopene, hydroxytyrosol), while the major 
antioxidant enzymes include superoxide dismutase (SOD), glutathione peroxidase 
(GPX), and catalase. The collective antioxidant capacity can be measured by total 
antioxidant status, representing free radical inhibition attained by all the antioxidants 
listed above in a tissue sample such as serum or plasma (Vincent and Taylor, 2006).
In the healthy state, endogenous and exogenous antioxidants work cooperatively 
to maintain the pro-oxidant/antioxidant balance and prevent tissue damage. An ade-
quate combination of enzymatic and nonenzymatic antioxidants is indeed critical to 
secure cellular homeostasis. In obesity, total antioxidant defense from both endog-
enous and exogenous (dietary) sources is insufficient (Figure 13.1). A low dietary 
intake of protective antioxidants and phytochemicals has been reported in obese 
humans, since these individuals tend to consume relatively low amounts of antiox-
idant-rich foods such as fruit, vegetables, whole grains, legumes, wine, olive oil, 
seeds, and nuts (Vincent et al., 2010). This distinct dietary behavior leads to reduced 
serum levels of vitamins (C, E, β-carotene) and trace minerals such as selenium and 
zinc, which are important cofactors for proper antioxidant enzyme function (Ozata 
et al., 2002; Wallström et al., 2001). As a result of poor antioxidant intake, obese 
humans face an antioxidant deficit, independent of the external metabolic stressors 
imposed on their body. Beyond that, it has been suggested that dietary antioxidants 
are more rapidly depleted in obese humans to effectively combat the excessive pro-
oxidant processes, leaving them ultimately less defended against free radical toxic-
ity (Vincent and Taylor, 2006). Furthermore, the activity of all major antioxidant 
enzymes appears to be impaired in obesity. In obese humans, erythrocyte antioxi-
dant enzyme activities (SOD, GPX) are markedly lower compared with their lean 
counterparts (Olusi, 2002). Of note, all the above data refer to long-standing obesity. 
Interestingly, it has been proposed that in the early stages of obesity, there might be 
a transient upregulation of total radical–scavenging capacity to counteract increased 
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oxidative stress, which is, however, followed by progressive depletion of all available 
antioxidants, a process induced by prolonged obesity (Vincent et al., 2001).
In summary, the combination of inadequate dietary and enzymatic antioxidants 
with increased production of reactive oxygen species (ROS) leads to an imbalance 
that favors lipid and protein oxidation in obesity. The available antioxidant capacity 
is “overpowered” by excessive uncontrolled ROS formation in obese humans, shift-
ing the pro-oxidant/antioxidant balance toward oxidative stress.
clInIcal and experImental evIdence on the 
effects of exogenous antIoxIdants In obesIty
The term phytochemicals is used to describe naturally occurring, plant-derived, 














fIgure 13.1 Mechanisms for reduced antioxidant defense capacity in human long-standing 
obesity. Low dietary intake of protective antioxidants (vitamins, trace minerals, phytochemi-
cals), rapid depletion of available antioxidants to confront excessive radical production, and 
impaired activity of antioxidant enzymes all contribute to insufficient antioxidant defense 
mechanisms in chronically obese humans, shifting the pro-oxidant/antioxidant balance toward 
increased oxidative stress. GPX, glutathione peroxidase; ROS, reactive oxygen species; SOD, 
superoxide dismutase.
237Antioxidants in Obesity and Inflammation
of chronic metabolic and inflammatory disorders, including obesity. Dietary poly-
phenols are considered the leading phytochemicals and comprise catechins, antho-
cyanins, curcumin, and resveratrol, which are discussed in detail below. These 
compounds may modulate physiological and molecular pathways involved in energy 
metabolism, and their antiobesity effects have been demonstrated in cell cultures, 
animal models of obesity, and clinical/epidemiological studies (Meydani and Hasan, 
2010).
Green Tea CaTeChins
Green tea has been extensively studied for its putative disease-preventing effects and 
is rich in polyphenolic flavonoids known as catechins (Sae-tan et al., 2011). A typical 
brewed green tea beverage (2.5 g green tea in 250 mL hot water) contains 240–
320 mg catechins, including epicatechin (EC), epigallocatechin (EGC), epicatechin-
3-gallate (ECG), and epigallocatechin-3-gallate (EGCG), which is considered the 
most abundant and well-studied green tea polyphenol, accounting for approximately 
30–50% of total green tea catechin (GTC) content. As summarized in Table 13.1, the 
main mechanisms suggested to be involved in the antiobesity effects of GTCs have 
been demonstrated in in vitro studies and include (Moon et al., 2007) (i) inhibition 
of dietary fat absorption resulting in increased fecal lipid excretion due to inhibition 
of pancreatic lipase and changes in lipid emulsification properties of gastric and 
duodenal fluids, leading to impaired capacity of pancreatic lipase to digest dietary fat 
(Nakai et al., 2005); (ii) modulation of lipid metabolism in liver and adipose tissue in 
the direction of decreased de novo lipogenesis and enhanced fat oxidation and ther-
mogenesis in brown adipose tissue (Lee et al., 2009; Park et al., 2011); (iii) activation 
of the nutrient-sensing enzyme adenosine monophosphate (AMP)-dependent protein 
kinase (AMPK), which prevents fat accumulation and favors fat oxidation and glu-
cose utilization (Murase et al., 2009); and (iv) modulation of mitogenic, endocrine, 
and metabolic function of adipocytes (Lin and Lin-Shiau, 2006).
table 13.1
main mechanisms suggested to be Involved in the antiobesity effects of 
dietary polyphenols such as green tea catechins, resveratrol, and 
curcumin
Reduced dietary fat digestion, absorption, and transportation
Decreased lipogenesis in liver and adipose tissue
Increased catecholamine-mediated thermogenesis in brown adipose tissue
Activation of adenosine monophosphate-dependent protein kinase (AMPK)
Increased fat oxidation in the liver and muscle
Inhibition of adipocyte proliferation and differentiation
Suppressed angiogenesis in adipose tissue
Improvement of peripheral glucose uptake
Reduced inflammation in liver and adipose tissue
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In more detail, EGCG or EGCG-containing green tea extracts have been shown 
to reduce food intake, lipid digestion, absorption and transportation, and increase 
energy expenditure by stimulating thermogenesis in brown adipose tissue through 
a synergistic interaction with norepinephrine, enhancing fatty acid oxidation in 
liver and muscle, increasing muscle glucose uptake through glucose transporter-4 
(GLUT4) translocation, and promoting fecal lipid excretion (Bose et al., 2008; Klaus 
et al., 2005). In adipose tissue, EGCG exerts antimitogenic and antilipogenic effects. 
The antimitogenic effects of EGCG on preadipocytes are mediated by downregulated 
activities of cell cycle control kinases such as extracellular signal-regulated kinases 
1/2 (ERK 1/2) and cyclin-dependent kinase 2 (CDK2), leading to suppressed adipo-
cyte proliferation and differentiation (Lin and Lin-Shiau, 2006). Beyond inhibiting 
preadipocyte maturation, EGCG may also induce apoptosis in mature adipocytes 
(Lin et al., 2005). EGCG exerts its antilipogenic effects through inhibited expres-
sion and activity of multiple lipogenic enzymes such as acetyl-coA carboxylase 
(rate-limiting step in fatty acid synthesis), fatty acid synthase, glycerol-3-phosphate 
dehydrogenase (rate-limiting step in triglyceride biosynthesis), and stearoyl-coA-
desaturase 1 (rate-limiting enzyme in monounsaturated fatty acid synthesis) (Ahmad 
and Mukhtar, 1999; Ikeda et al., 2005; Lee et al., 2009).
Animal data suggest that supplementation of a high-fat diet (HFD) with EGCG 
results in lower weight gain due to reduced fat absorption from the gut (Bose et al., 
2008). In addition to decreasing intestinal fat absorption, EGCG may prevent diet-
induced obesity in mice by enhancing fat oxidation and augmenting norepinephrine-
mediated sympathetic stimulation of thermogenesis in brown adipose tissue (Klaus et 
al., 2005). It has been also suggested that long-term green tea supplementation in animal 
models of obesity may exert beneficial metabolic effects, leading to a significant decline 
in fasting glucose and insulin levels and improved insulin sensitivity (Wu et al., 2004).
With regard to clinical data, not all epidemiological studies provide clear-cut 
evidence that green tea consumption is linked to body weight. A cross-sectional 
study conducted in Taiwan reported an association of habitual green tea consump-
tion with lower body fat mass (Wu et al., 2003), in line with a longitudinal study from 
the Netherlands showing that green tea consumption is associated with lower BMI 
(Hughes et al., 2008). However, other studies found no association of green tea with 
adiposity measures, but only with an improved lipoprotein profile, which is beneficial 
for the overall obesity-associated atherosclerotic risk. In one of these studies, green 
tea consumption was associated with reduced total and LDL cholesterol but not with 
body weight (Tokunaga et al., 2002). In another study performed in male subjects 
over the age of 40 years, green tea consumption again displayed no correlation with 
body weight, but was associated with increased high-density lipoprotein (HDL) cho-
lesterol and decreased LDL cholesterol and triglycerides (Imai and Nakachi, 1995). 
Thus, the epidemiological (cross-sectional and prospective) data remain inconsistent. 
Similarly controversial are the data regarding the effects of GTCs on energy expen-
diture and fat oxidation in humans. In one study comparing an EGCG-containing 
green tea extract enriched with 50 mg caffeine against caffeine alone, the green tea 
extract formulation was significantly more potent in stimulating 24-h energy expen-
diture, fat oxidation, and urinary norepinephrine excretion in healthy male humans 
(Dulloo et al., 1999). In contrast with these data, in another study in overweight 
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and moderately obese male and female subjects, green tea extracts rich in EGCG 
and caffeine consumed for 13 weeks were not associated with maintenance of body 
weight lost after a very-low-calorie diet, indicating no effects of GTCs on fat oxida-
tion and energy homeostasis (Kovacs et al., 2004). With regard to controlled clinical 
intervention trials, they suggest overall that long-term consumption of green tea at 
high doses may be effective in reducing body weight and fat mass in humans (Sae-
tan et al., 2011), particularly when combined with physical activity (Venables et al., 
2008). In a clinical study, it was shown that an EGCG-rich green tea extract reduced 
body weight and waist circumference by 4.5% in moderately obese patients after 
3 months of treatment (Chantre and Lairon, 2002). In the same direction, daily 
ingestion of one bottle of tea rich in GTCs (690 mg) for 12 weeks resulted in lower 
body weight, waist circumference, and total and subcutaneous fat, compared with 
a bottle of tea with a lower amount of GTCs (22 mg) (Nagao et al., 2005). The het-
erogeneity of data presented above must be acknowledged and is possibly related to 
differences in the treatment protocols employed, the purity of extracts tested, the 
percentage of concomitant caffeine enrichment, the duration of intervention, and 
the distinct physiological characteristics of the studied participants.
anThoCyanins and BlueBerries
Anthocyanins are the major active component of blueberries, which are fruit rich in 
bioactive polyphenolic compounds such as hydroxycinnamic acid, flavonoids, proan-
thocyanidines, and anthocyanins. Blueberry juice can be biotransformed within the 
gut by Serratia vaccinii bacteria, increasing its polyphenolic content and quadru-
pling its antioxidant activity (Meydani and Hasan, 2010).
In animal studies, it has been shown that supplementation of an HFD with puri-
fied anthocyanins extracted from blueberries has no marked effects on body weight, 
hepatic steatosis, and food intake, but exerts beneficial metabolic effects on serum 
lipids, fasting glucose, leptin levels, and β-cell function (Prior et al., 2009). Of note, 
the same effects are not accomplished with administration of blueberry extracts, sug-
gesting that the absorption and bioavailability of anthocyanins from the gut may be 
hindered by the concomitant presence of carbohydrates and lipids contained in whole 
blueberry extracts (Prior et al., 2008). In a mouse model of obesity and diabetes, 
chronic administration of anthocyanins failed to reduce body weight, but decreased 
fasting glucose and increased adiponectin (Vuong et al., 2009). In another animal 
study, supplementation of an HFD with whole blueberry powder again showed no 
effects on body weight, but improved insulin sensitivity and glucose homeostasis 
due to inhibition of macrophage infiltration in adipose tissue (DeFuria et al., 2009).
In summary, anthocyanins and blueberry extracts seem to have no beneficial 
effects on obesity per se, but may favorably impact obesity-associated conditions 
such as insulin resistance and inflammation, thus promoting cardiometabolic health.
CurCumin
Curcumin is the major, low-molecular, bioactive polyphenol found in the spice tur-
meric and possesses a great number of biological properties such as antioxidant, 
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anti-inflammatory, anticancer, antiangiogenetic, chemopreventive, and chemothera-
peutic effects. Cell culture and animal studies suggest that curcumin may modu-
late energy metabolism, ameliorate inflammation, and suppress angiogenesis, which 
might also account for its anticancer effects (Strimpakos and Sharma, 2008). With 
regard to obesity, curcumin has been shown to inhibit the expression of several 
growth factors in adipose tissue such as vascular endothelial growth factor, fibroblast 
growth factor, epidermal growth factor, and angiopoietin, leading to reduced angio-
genesis in adipose tissue and thus preventing its expansion (antiadipogenic effect) 
(Gururaj et al., 2002). Of note, the antiobesity effects of curcumin have been mainly 
studied in animal experiments, whereas intervention studies in humans are mainly 
focused on its anti-inflammatory and anticancer properties.
In HFD-fed mice, curcumin supplementation reduced the density of microvessels 
in adipose tissue, providing direct evidence for suppressed angiogenesis (Ejaz et 
al., 2009). In addition, it activated AMPK, downregulated lipogenic gene expres-
sion, and enhanced fat oxidation. In hamsters, supplementation of an HFD with cur-
cumin reduced blood lipids, leptin levels, and insulin resistance (Jang et al., 2008). 
Furthermore, in a mouse model of obesity and insulin resistance, a generous amount 
of curcumin in the diet significantly improved glycemic control and reduced hepatic 
and adipose tissue inflammation, in addition to lowering body weight and fat mass as 
measured by magnetic resonance imaging (Weisberg et al., 2008).
resveraTrol
Resveratrol is a well-studied polyphenol, which is present, among other foods, in grapes, 
red wine, peanuts, and ground nuts, and is considered protective against CVD, T2DM, 
aging, cancer, and obesity through its pluripotent antioxidant and anti-inflammatory 
properties. Studies in animal models have shown that resveratrol induces biological 
effects similar to those observed after caloric restriction, such as increased longevity 
and prevention of age-associated cardiometabolic abnormalities (Barger et al., 2008). It 
acts by stimulating AMPK activity, thus leading to enhanced fat oxidation and periph-
eral glucose uptake through GLUT4 translocation (Zang et al., 2006). It has also been 
suggested that it may upregulate sirtuin 1 activity, which deacetylates and activates a 
critical transcription factor related to mitochondrial biogenesis (peroxisome prolifer-
ator-activated receptor γ co-activator 1a), leading to increased oxidative phosphory-
lation capacity and reduced lipid accumulation (Lagouge et al., 2006). In vitro data 
from cell cultures and gene microarray analyses have shown that resveratrol inhibits 
adipogenesis and enhances lipolysis in isolated human adipocytes, and downregulates 
the expression of lipogenic genes in hepatic tissue (Ahn et al., 2008). Through its potent 
antioxidant activity, resveratrol may also prevent oxidative damage related to impaired 
glucose metabolism, thus preventing the pathogenesis of diabetic complications.
Resveratrol treatment has been shown to significantly reduce total and regional 
body fat in both genetic and diet-induced animal models of adiposity (Meydani 
and Hasan, 2010). In humans, a double-blinded, placebo-controlled, randomized, 
cross-over clinical trial showed that resveratrol treatment for 30 days (150 mg/day) 
improved adipose tissue function in healthy obese men, by decreasing adipocyte 
size and upregulating intracellular pathways related to lysosomal and phagosomal 
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processes, suggesting autophagy as an alternative mechanism of resveratrol-induced 
lipid breakdown (Konings et al., 2013).
Despite compelling evidence from molecular, cell culture, and animal studies that 
resveratrol may contribute to the prevention of obesity, epidemiological and random-
ized clinical trials are needed to substantiate its effects on humans.
Coenzyme Q
Coenzyme Q (CoQ) is the only nonenzymatic antioxidant synthesized by humans and 
the single lipid component of the mitochondrial electron transport chain, regulating 
mitochondrial membrane permeability and activity of uncoupling proteins at a sub-
cellular level (Turunen et al., 2004). CoQ is at the crossroad between oxidative stress 
and mitochondria, which are thought to play a crucial role in adipocyte differentiation 
and energy metabolism in obesity. A strong negative correlation between CoQ con-
tent in adipose tissue and obesity markers in rodents and humans has been found. In 
mice, HFD-induced obesity depletes CoQ from subcutaneous adipose tissue, whereas 
a long-term increase in CoQ content by gene overexpression related to its synthesis 
inhibits adipogenesis, suggesting CoQ as a potent antiadipogenic factor (Bour et al., 
2011). In obese humans, adipose tissue CoQ levels are markedly reduced and a criti-
cal threshold of CoQ content in adipose tissue has been identified, below which all 
rodents and humans develop an obese phenotype (species-conserved threshold value) 
(Bour et al., 2011). In the clinical setting, CoQ treatment for 8–9 weeks has been asso-
ciated with a clear body weight reduction in obese humans (Van Gaal et al., 1984).
α-lipoiC aCid
α-Lipoic acid (ALA) is a naturally occurring short-chain fatty acid, which serves 
as an essential cofactor for enzymes of the mitochondrial respiratory chain. It is a 
powerful antioxidant and widely used as a nutrient supplement due to its antioxidant 
properties. It has been shown that ALA supplementation may prevent lipid peroxi-
dation and oxidative DNA damage in obese rats, suppress ad libitum food intake, 
increase whole-body energy expenditure, reduce body weight and visceral fat mass, 
and additionally decrease blood glucose and insulin levels (Kim et al., 2004). Since 
ALA was effective after both intraperitoneal and intracerebrovascular administra-
tion in animal studies, the central nervous system appears as the primary site of its 
anorexigenic effects, which are particularly mediated by suppressed hypothalamic 
AMPK activity (Kim et al., 2004). In humans, the antiobesity effects of ALA supple-
mentation are less prominent. In a double-blinded, placebo-controlled, randomized 
clinical trial in a large number of overweight and obese subjects with comorbidities, 
ALA treatment for 20 weeks led to minimal weight loss (2.1%) only at the highest 
dosage (1800 mg/day) (Koh et al., 2011).
FruiTs, leGumes, and nuTs
A nutritional intervention study in obese men and women comparing two energy-
restricted diets enriched or not in fruits for 8 weeks showed that both diets led to 
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significant weight loss, but only the fruit-enriched diet resulted in an additional 
decrease of oxidized LDL cholesterol and increase of total serum antioxidant capac-
ity (Crujeiras et al., 2006). Legumes are also a significant dietary source of polyphe-
nolic compounds, including flavonoids, isoflavones, phenolic acids, and lignans. In a 
nutritional intervention study, soya consumption increased total plasma antioxidant 
capacity in obese postmenopausal women (Azadbakht et al., 2007), while more com-
mon legumes such as beans, lentils, and chickpeas have been shown to improve 
cardiovascular risk factors and biomarkers of oxidative stress in obese humans. 
Consumption of four servings of legumes per week within a weight reduction pro-
gram followed for 8 weeks led to more significant weight loss compared with a diet 
without frequent legume consumption, and furthermore improved plasma antioxi-
dant capacity and decreased circulating proatherogenic cholesterol levels (Crujeiras 
et al., 2007). Additional metabolic benefits of legumes are their satiety-promoting 
effects and their potential to alleviate the negative effects induced by hypocaloric 
diets on lean body mass and basal metabolic rate (Abete et al., 2008).
Nuts represent one more “functional” food with multiple bioactive compounds. 
The American Heart Association has recommended regular nut consumption since 
2000 (Krauss et al., 2000). Their mono- and polyunsaturated fat content relates to 
their lipid-lowering effects, while their rich concentration of copper, magnesium, 
tocopherols, squalene, and phytosterols accounts for their strong antioxidant capac-
ity (Alexiadou and Katsilambros, 2011). The concern that they might promote weight 
gain due to their high energy density is not evidence-based, since it has been shown 
that subjects who consume nuts more than 2 times per week have a lower risk of pro-
spective weight gain than those who eat rarely or no nuts, after adjusting for several 
obesity-related factors (Bes-Rastrollo et al., 2007).
safety concerns and open QuestIons
In observational and laboratory studies, high doses of EGCG have been asso-
ciated with hepatotoxicity (hepatic necrosis and inflammation) (Lambert et al., 
2010). In humans, a limited number of controlled clinical trials have been con-
ducted to determine the maximum tolerated dose of GTCs administered via diet 
or in alternative formulations such as pills or capsules. To date, no large-scale 
human intervention study has reported any serious adverse effects with GTCs. 
Mild adverse effects have been reported in a few cases of resveratrol treatment in 
humans (Cottart et al., 2009), while in animal studies high doses of resveratrol 
supplementation have been associated with anemia, nephrotoxicity, hepatotoxic-
ity, increased homocysteine, and reduced HDL cholesterol levels (Crowell et al., 
2004; Noll et al., 2009).
Beyond the underexplored safety issues related to long-term antioxidant supple-
mentation in humans, there is also a number of aspects that have not been adequately 
addressed yet. The primary molecular and cellular targets of action of dietary anti-
oxidants, their dose-response relationships, their threshold dose, and, most impor-
tant, the translation of animal and in vitro data to human intervention studies remain 
relevant unresolved questions. Of note, the major proposed mechanisms of action 
are based on in vitro studies and occur only at high concentrations of the tested 
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compounds. Owing to the absence of compelling in vivo evidence supporting these 
mechanisms, their in vivo relevance still remains uncertain. Furthermore, it has been 
intriguingly suggested that antioxidant supplements beyond critical concentrations 
may not only fail to accomplish the desired effects but also lead to opposite results 
from those anticipated (Spanou et al., 2010). For all the above reasons, the positive 
study findings with antioxidant supplementation in humans should be viewed and 
interpreted with caution.
recommendatIons
At present, there is no sufficient evidence to support the long-term use of exogenous 
antioxidant supplements as a safe and effective measure for the prevention and treat-
ment of obesity and its concomitant state of low-grade inflammation. The routine 
supplementation of diet with antioxidants and vitamins is therefore not considered 
necessary (Katsilambros et al., 2006). Nevertheless, the integration of healthy foods 
containing bioactive compounds in the context of a balanced energy-restricted 
dietary pattern can help maintain a normal body weight and prevent obesity-related 
cardiometabolic complications.
Finally, coffee, which also possesses antioxidant properties, may also be included 
as part of a healthy, heart-friendly diet. A recent review of the currently available 
evidence on the effects of habitual coffee intake on cardiometabolic outcomes 
has clearly demonstrated that a moderate daily consumption of two to three cups 
of coffee (300 mg caffeine) is safe, harmless, and associated with neutral to 
beneficial health outcomes for the general public (O’Keefe et al., 2013). In the 
same lines, there is evidence that green coffee extract may also exert a beneficial 
effect on weight, although the existing data are still not unequivocal (Onakpoya 
et al., 2011).
concludIng remarks and perspectIves
Despite uncertainties, nutritional intervention remains the safest and most cost-
effective treatment and prevention option for obesity and the metabolic syndrome. 
Although antioxidant supplementation should be viewed with caution, consumption 
of foods with anti-inflammatory and antioxidant properties should be considered an 
important component of a dietary approach against obesity and CVD. A diet rich 
in antioxidant compounds may enhance the benefits of weight loss, especially in 
patients with metabolic syndrome and high cardiovascular risk.
Further in vivo studies examining the primary molecular and cellular mechanisms 
of action of dietary antioxidants, and their temporal and dose-response relationships, 
are warranted. As to safety issues, the therapeutic index of all suggested antioxidant 
agents must be established, not only when these compounds are delivered through 
the diet, but especially when they are converted to a bolus formulation such as a pill 
or capsule (pharmacokinetic studies). Only with complete understanding of all pos-
sible effects and side effects of antioxidant interventions can their potential benefits 
for the prevention and treatment of obesity and obesity-related comorbidities be fully 
unraveled and critically appraised.
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IntroductIon
Healthy living is the best way to prevent disease. Environmental pollution, sunlight 
exposure, and many other influences favor radical stress, leading to an increasing 
number of oxidative stress–associated inflammatory diseases. Cardiovascular dis-
ease, cancer, neurological disorders, diabetes, ischemia/reperfusion, or even normal 
aging processes are characterized by an imbalance between radical generation and 
neutralization (Dalle-Donne et al., 2006; Dhalla et al., 2000; Jenner, 2003). Free 
radicals, like reactive oxygen species (ROS) or reactive nitrogen species (RNS), lead 
to oxidation and nitration of biomolecules, which can subsequently result in destruc-
tion of whole cellular compartments (Kovacic and Jacinto, 2001). To protect from 
radical damage, cells are equipped with a variety of enzymatic and nonenzymatic 
antioxidant systems. Exogenous antioxidants derived from diet or medications are 
suggested to support these protective mechanisms; however, excessive antioxidant 
intake may also lead to adverse effects. In this chapter, we will focus on the interfer-
ence of antioxidants with immune response and discuss possible consequences of 
unconsidered high-dose antioxidant supplementation.
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small redox molecules and redox HomeostasIs
In a redox reaction, electrons are transferred from one molecule to another. One 
agent becomes reduced by receiving electrons from the reaction partner, which will 
be oxidized. Such reactions are crucial for life; however, aberrant or excessive oxida-
tion of biomolecules can become damaging for the cell (Davies, 1995).
Free radicals are defined as molecules with one or more unpaired electrons. An 
unpaired electron extremely raises the reactivity of a molecule. Among the many 
small redox-active molecules, in particular ROS and RNS, were intensively investi-
gated because of their important roles as both deleterious and beneficial molecules 
(Valko et al., 2006). Cells continuously produce radicals such as superoxide anion 
( )O2
−  or nitric oxide (NO•), which react to a variety of ROS/RNS, such as hydroxyl 
radical (HO•), hydrogen peroxide (H2O2), hypochlorite (OCl−), and peroxynitrite 
(ONOO−) or nitrogen dioxide ( )NO2
  (Dröge, 2002; Wink et al., 2011).
Despite the variable structure of redox molecules, they share common mecha-
nisms that harm cells and tissues through damage of proteins, DNA, or lipids (Valko 
et al., 2007). All components of the DNA, the purine and pyrimidine bases as well 
as the deoxyribose backbone, were shown to be targets of, e.g., HO• (Halliwell and 
Gutteridge, 1999). Polyunsaturated fatty acid residues of phospholipids are extremely 
sensitive to oxidation and are easily attacked by ROS (Siems et al., 1995). Also, the 
side chains of all amino acid residues of proteins, in particular cysteine and methio-
nine residues, are susceptible to RNS/ROS attacks (Stadtman et al., 2004).
Various mechanisms to counteract ROS have been described: (i) endogenous anti-
oxidant enzymes such as catalase (CAT), glutathione reductase (GSR), or superoxide 
dismutase (SOD), as well as (ii) nonenzymatic systems such as glutathione (GSH), 
urate, and coenzyme Q. In addition, other various free amino acids, peptides, and 
proteins serve as low molecular weight antioxidants (Valko et al., 2006). All these 
enzymes and molecules have the ability to transform ROS/RNS into more stable, and 
thus harmless, compounds via redox-based mechanisms.
Production of high levels of ROS/RNS during respiratory burst reaction is an 
important strategy in the defense against invading pathogens (Decoursey et al., 
2005). However, at such high concentrations, free radicals can be hazardous and dam-
age not only target cells but also host cells in the inflamed tissue. Thus, ROS/RNS 
generation, release, and neutralization has to be tightly regulated during immune 
response. At low concentrations, ROS/RNS play an important role in many signaling 
processes as regulatory mediators. Stress response signaling, detoxification, and sev-
eral immunobiochemical pathways can be activated by ROS/RNS-derived signals in 
a dose-dependent manner (Gostner et al., 2013; Valko et al., 2007; Wink et al., 2011). 
Small redox molecules are also involved in the induction and maintenance of cell 
growth and differentiation. Thus, the cellular redox status is an intrinsic indicator of 
cellular and systemic homeostasis.
Normally, redox reactions are balanced and a dynamic equilibrium of radical generation 
and scavenging free radicals exists, called “redox homeostasis.” A disturbed equilibrium 
of pro-oxidant/antioxidant reactions, misbalance between enzymatic and nonenzymatic 
antioxidant systems in the body, but also an overdose of antioxidant intake, can be rea-
sons for a shift of the redox state, possibly leading to pathological consequences.
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There are numerous studies that extrapolate the potential of ROS to trigger spe-
cific disease conditions and, in these, immune responses play a major role. An imbal-
anced redox homeostasis and oxidative stress was described to be associated with 
diseases that are accompanied by chronic immune activation such as infections, 
allergies, autoimmune disorders, neurodegenerative diseases, several malignancies, 
or the normal aging process (Dalle-Donne et al., 2006; Murr et al., 2005; Sayre 
et al., 2001). Elevated oxidative stress levels are suggested to be involved in the 
development and progression of chronic diseases. To support the cellular antioxidant 
machinery in detoxification and neutralization of ROS/RNS, uptake of antioxidant 
therapeutics and supplements, but also an antioxidant-rich diet, was suggested to be 
beneficial.
However, for several pathologies, it is questionable if oxidative stress is caus-
ative for disease onset or if it is an accompanying factor due to sustained inflam-
mation. Thus, antioxidant treatment would only be helpful in reducing symptoms, 
but not the disease causes. Unreflected neutralization of reactive species may even 
cause shortage of RNS/ROS within the cell, which means that no more free radicals 
can perform their regulatory mechanisms of redox-regulated pathways and further 
pathologies could develop. Poor or even adverse outcomes of an antioxidant therapy 
in clinical studies support the view that further/other therapeutic approaches should 
be considered for such diseases (Bjelakovic et al., 2004; Dotan et al., 2009; Gerss 
and Köpcke, 2009; Kris-Etherton et al., 2004).
ProductIon of cellular ros/rns
Under normal conditions, the main intracellular source of ROS is O2
−, resulting 
as a by-product from the mitochondrial respiratory chain (Dröge 2002; LeBras 
et al., 2005); however, xanthine oxidase (McNally et al., 2003), lipid peroxi-
dases (Zhang et al., 2002), cytochrome P450 enzymes (Fleming et al., 2001), 
and uncoupled NO synthases (Vásquez-Vivar et al., 1998) also produce ROS as 
secondary products.
NADPH oxidases (NOX) produce ROS as their primary and sole function. NOX 
are membrane-bound enzyme complexes composed of a catalytic transmembrane 
spanning subunit and several regulatory proteins (Altenhöfer et al., 2012). The main 
reaction of NOX is to reduce molecular oxygen to O2
− (Altenhöfer et al., 2012; Rossi 
and Zatti, 1964). Phagocyte NOX was first identified to be responsible for the high 
amounts of O2
− and H2O2 released during the respiratory burst reaction. Excessive 
stimulation of NOX can become a major source of free radicals (Keisari et al., 1983).
Oxygenation of l-arginine in the presence of NADPH by nitric oxide synthase 
(NOS) leads to the formation of NO•, NADP+, and l-citrulline (McNeill and 
Channon, 2012). NO• is commonly known to be a regulator of the vasomotor tone. 
NO• is able to diffuse through cell membranes and can initiate a variety of sig-
naling cascades in a dose-dependent manner (Vignais, 2002; Wink et al., 2011). 
There exist three types of NOS isoforms: (i) neuronal NOS (nNOS), (ii) endothelial 
NOS (eNOS), and (iii) inducible NOS (iNOS). nNOS is involved, e.g., in the regula-
tion of synaptic signaling and in the control of muscle contractility and local blood 
flow, while eNOS is involved in vasodilation, inhibition of platelet aggregation, and 
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leukocyte adhesion, and controls vascular smooth muscle proliferation and endo-
thelial progenitor cell activation (Förstermann and Sessa, 2012). iNOS has effects 
on vascular functions under conditions of sepsis, and is an important mediator of 
inflammation. nNOS and eNOS are calcium dependent, while iNOS can act inde-
pendently. Many tissues express one or more of these isoforms. Low amounts of NO•, 
at nanomolar concentrations, are normally produced by the constitutively expressed 
eNOS and nNOS (Mariotto et al., 2004), while iNOS expression is inducible in 
macrophages, after stimulation with, e.g., lipopolysaccharide (LPS), cytokines like 
interferon-gamma (IFN-γ), or other proinflammatory stimuli, and NO• levels can 
increase up to micromolar concentrations (Thomas et al., 2008). Such large amounts 
of NO• can have cytostatic effects. Excessive NO• production by iNOS can also con-
tribute to chronic inflammatory pathologies and plays a crucial role in septic shock 
(Förstermann and Sessa, 2012).
ROS and RNS production during the respiratory burst reaction is conducted in 
the phagosome to minimize damage to cells. The regulation of phagosomal pH and 
O2
−  production in neutrophils, macrophages, and dendritic cells follows distinct pro-
grams due to differences in NOX localization and phagosomal NO• concentrations 
(Savina and Amigorena, 2007). The interaction of NO• and O /ROS2
−  can lead to 
the formation of nitrite (NO2
− ), nitrogen dioxide (NO2
 ), and also nitrogen trioxide 
(N2O3). The ROS/RNS balance is important in orchestrating immunomodulatory 
mechanisms. However, both oxidative and nitrosative stress can interfere with intra-
cellular redox buffer systems and thus result in a decrease of antioxidant ability 
(Wink et al., 2011).
antIoxIdant systems
Various enzymatic and nonenzymatic antioxidant defense systems protect cells 
against ROS/RNS attacks (Cadenas, 1997), and further preventive and repair mecha-
nisms contribute to the overall protection.
SOD, CAT, and glutathione peroxidase (GPX) are the primary antioxidant enzymes 
that counteract ROS damage. SODs dismutate O2
− to H2O2 or molecular oxygen. CAT 
catalyzes the composition of H2O2 to water and molecular oxygen. GPX requires 
GSH as an electron donor and converts H2O2 very efficiently to water (Valko et al., 
2007).
The primary intracellular nonenzymatic systems are GSH, cysteine/cystine (Cys/
CySS) couples, and thioredoxins (TRXs). GSH is the major intracellular redox buf-
fer in mammalian cells. GSH acts as a cofactor for several detoxifying enzymes 
and as a free radical scavenger. It is able to regenerate important antioxidants, like 
vitamins, back into their active forms. The capacity to regenerate important antioxi-
dants is linked with the redox state of the glutathione/glutathione-disulfide couple 
(GSH/GSSH). GSH/GSSH couples are located in the cytoplasm, nucleus, mitochon-
dria, plasma, or other organelles, but at different concentrations and different redox 
potentials (Kemp et al., 2008). Upon secretion of GSH, most of it is cleaved into its 
components and the resulting cysteines will fill the extracellular Cys/CySS pool, 
which is the major thiol/disulfide extracellular redox buffer system (Kemp et al., 
2008). The GSH/GSSG ratio is a good measure to detect oxidative stress within 
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the cell (Jones et al., 2000; Nogueira et al., 2004). TRXs are low molecular weight 
proteins that contain a conserved dithiol at the active site. They are mostly found in 
the cytoplasm and nuclei in mammalian cells, and possess cytokine-like properties 
(Kemp et al., 2008). All thiol/disulfide buffers share similarities in their mode of 
action; however, each system has its own and unique function and is able to sup-
port the reduction of different subsets of proteins (Kemp et al., 2008; Lillig and 
Holmgren, 2007).
The intracellular redox balance is primarily held by the thiol/disulfide buffers. 
Under oxidative stress, not only the GSSG content increases but, in parallel, the con-
tent of protein mixed disulfides also augments (Valko et al., 2007). Thiol-containing 
signaling proteins such as receptors, protein kinases, and some transcription factors 
can be altered in their function by the formation of mixed disulfides. Thus, thiol/
disulfide buffers represent an important element for various signal transduction net-
works, e.g., for the activation and differentiation of T cells but also for several other 
immunological mechanisms (Kesarwani et al., 2013).
Besides cellular antioxidant systems, antioxidant substances can be absorbed 
from dietary intake. Many food compounds exhibit antioxidative properties such as 
vitamins; phytochemicals can also be potential antioxidants, e.g., carotenoids like 
lutein and zeaxanthin, polyphenols, and flavonoids or stilbenes such as resveratrol 
have been shown to modulate redox homeostasis in vitro (Butt and Sultan, 2009; 
Santhakumar et al., 2014; Zaknun et al., 2012). Many of these compounds are con-
tained in so-called healthy food, especially in fruits or vegetables or in beverages 
such as red and white wine, cacao and tea, and they are considered to play a major 
role in preventing disease and improving health (Heidemann et al., 2008). Thus, 
in the last years, ascorbic acid (vitamin C), carotenes (vitamin A), melatonin, glu-
tathione, tocopherols, and tocotrienols (vitamin E) were in the focus of research 
because of their antioxidant capacities as potent agents for nutritional supplementa-
tion (Balsano and Alisi, 2009; Zaknun et al., 2012).
Although a clear demonstration of beneficial effects of the use of antioxidant sup-
plements in disease prevention is not yet available (Stanner et al., 2006), such prepa-
rations are already widely used, sometimes also without any medical indication. 
Besides that many clinical trials could not associate a connection between antioxi-
dant supplementation and disease prevention, high-dose (single) antioxidants could 
even increase the risk of disease as was reported, e.g., for age-related diseases or 
cardiovascular disorders (Bjelakovic et al., 2007; Jha et al., 1995; Myung et al., 2013; 
Zheng Selin et al., 2013). There is also evidence accumulating that high vitamin sup-
plementation in early life increases the risk of an allergy later in life (Hyppönen et 
al., 2004; Milner et al., 2004). Furthermore, excess of vitamin uptake can cause neu-
rotoxicity; however, vitamin deficiency may lead to neurological defects (Lanska, 
2010; Snodgrass, 1992).
Of note, in daily life antioxidant uptake is often not recognized as such and many 
people do not even know which substances can act as antioxidants, as it is the case 
for several food additives such as preservatives and colorants but also for vitamins. 
Addition of antioxidants to food or beverage has increased, to stabilize them for 
transport and storage, to maintain color, or because of potential beneficial health 
implications, and an overexposure is not easy to avoid.
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Extra-high-dose antioxidant uptake might not only support the development 
of allergy but could also disturb the successful execution of an immune response. 
Cytocidal products like ROS or RNS are necessary as a defense strategy, and their 
shortage may not only counteract pathogen eradication but also interfere with neg-
ative feedback loops of antiproliferative mechanisms, which regulate control and 
limit immune reactions. Thus far, several studies have investigated the influence of 
antioxidants on Th1-type immune response by focusing on tryptophan breakdown 
(Jenny et al., 2011).
tH1-tyPe Immune resPonse
Various cell types act in cooperation for an effective immune response, whereby they 
cross-regulate each other. A coordinated interplay between innate and adaptive 
immune system is necessary for an efficient defense.
If an antigen enters the body, it will be presented on major histocompatibility 
complexes of antigen-presenting cells to T cells. There it will be recognized by the 
T-cell receptor and the presence of additional costimulatory signals such as protein 
ligand B7 and cluster of differentiation 28 (CD28) interaction ensures that T cells get 
activated (Balakrishnan and Adams, 1995). Antigen-mediated signals and stimuli 
from the microenvironment, such as cytokines, are critically involved in T cell dif-
ferentiation into different effector subtypes.
Activated Th1-type cells secrete cytokines and thus activate T effector cells, like 
cytotoxic T cells or nonspecific effector cells such as natural killer cells and macro-
phages. They represent an important subpopulation of T helper cells that are char-
acterized by the release of interleukin (IL)-2 and IFN-γ. Other cytokines like IL-4, 
IL-5, IL-6, and IL-13 are secreted by the subpopulation Th2-type cells and favor the 
Th2-type immune response (Romagnani, 2006). The classical division of Th1- and 
Th2-type cells has been extended as additional Th cell subtypes were identified in 
recent years. T-cell differentiation into Th1- and Th2-type cells is suggested to cru-
cially depend on the redox environment, where oxidative conditions favor Th1 devel-
opment and “antioxidative stress” leads to a shift in allergic Th2 responses (Gostner 
et al., 2013; Zaknun et al., 2012) (Figure 14.1).
Th17-type cells, which combine the innate and adaptive immunity, were found 
to be involved in the defense against extracellular fungi or bacteria (Yu and Gaffen, 
2008). The Th9-type subset controls growth and activation (Schmitt et al., 2014), and 
follicular helper T (Tfh) cells are involved in B-cell maturation (Zhou et al., 2009). 
Another type of T-helper cells—the regulatory T (Treg) cells—are responsible for 
the maintenance of self-tolerance (Hori et al., 2003) and can limit the potential of 
collateral tissue damage (Hori et al., 2003; Zhou et al., 2009).
During defense against intracellular pathogens, Th1-type cells release the most 
prominent pro-inflammatory cytokine, IFN-γ. It is probably the most important 
inducer of antimicrobial and antitumoral defenses, and stimulates the production 
of ROS in macrophages (Nathan et al., 1983; Nathan, 1987). These high amounts 
of ROS further triggers redox-sensitive signaling cascades, e.g., mitogen-activated 
protein kinase, transcription factor nuclear factor-κB (NF-κB), and activator protein 
(AP)-1-dependent signaling cascades. NF-κB is a central inflammation mediator that 
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regulates the expression of pro-inflammatory cytokines, chemokines, and adhesion 
molecules (Aggarwal, 2004). Morever, NF-κB coordinates the expression of differ-
ent subsets of genes; thus, NF-κB signaling is not only involved in the initiation but 
also in the maintenance and resolution of immune responses.
IFN-γ induces biochemical pathways such as GTP-cyclohydrolase (GCH1), 
indoleamine 2,3-dioxygenase 1 (IDO1), and iNOS (Werner et al., 2011; Widner et al., 
2000). IDO is the rate-limiting enzyme in the conversion of the essential amino acid 
tryptophan into kynurenine. IDO1 is expressed in various cells such as macrophages, 
microglia, neurons, and astrocytes (Guillemin et al., 2007), and its activation plays 
an essential role as an antiproliferative strategy for pathogens and malignant cells 
but also as a negative feedback loop in the control of Th1-type immune response 
(Samelson-Jones and Yeh, 2006). Tryptophan metabolism is implicated in a vari-
ety of physiological and pathophysiological processes like antimicrobial, antitumor 
defense, neuropathology, and immunoregulation. Also, antioxidant activities have 
been described for IDO owing to the utilization of O2
− both as a substrate and as 
cofactor (Thomas and Stocker, 1999).
Activation of GCH1 leads to the formation of neopterin, a pteridine derivate, and 
of 5,6,7,8-tetrahydrobiopterin (BH4). Neopterin has been identified as a biomarker 
for oxidative stress (Murr et al., 2002). BH4 is an essential cofactor for several mono-
oxygenases, such as iNOS (Werner et al., 2011). Of note, BH4 is stabilized by several 
antioxidants to guarantee proper function. Owing to a relative deficiency of human 




















fIGure 14.1 Owing to the cross-regulation between Th1- and Th2-type immune responses, 
high doses of antioxidants can suppress Th1-type responses and favor the development of 
allergy or asthma. During Th1-type immune response, macrophages produce large amounts 
of reactive oxygen species (ROS) to protect the cell against pathogens. In parallel, signaling 
cascades such as transcription factor nuclear factor-κB (NF-κB) and activator protein (AP)-
1-dependent pathways are induced. Antioxidants can exhibit anti-inflammatory properties 
by suppressing ROS production. Excessive antioxidants shift the balance towards Th2-type 
reactions that are associated with a risk for allergy development.
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produced. The NO• output in humans is probably generated by the proper function-
ing of NOS in other cell types, such as endothelial cells, rather than by inducible 
NOS (iNOS) of macro phages. BH4-deficient NOS produce O2
− instead of NO• and 
can promote further reactions to form RNS or ROS such as H2O2 or ONOO−. Of 
note, NO• can act as an anti-inflammatory agent by directly inhibiting IDO enzyme 
function.
Neopterin derivatives are to be able to interfere with several redox-regulated 
pathways, such as NF-κB signaling and iNOS expression. High neopterin levels 
have been shown to be associated with a strong release of H2O2 (Nathan, 1986). 
Furthermore, higher neopterin levels were found to be associated with lower levels 
of antioxidants in human serum (Murr et al., 2009). Thus, neopterin can be used as 
a sensitive indirect marker for oxidative stress during immune activation (Murr et 
al., 1999).
The Th1-type immune response is involved in the pathogenesis of several inflam-
matory disorders like autoimmune syndromes, cardiovascular diseases, malignant 
tumor diseases, or neurodegenerative disorders (Romagnani, 2004; Schroecksnadel 
et al., 2006, 2007). Several in vitro studies confirmed the  association of altered 
neopterin levels and IDO activity in patients with infectious disease, including 
HIV, cardiovascular disease, malignancies, neurodegenerative disorders, or nor-
mal aging processes (Capuron et al., 2011; DeRosa et al., 2011; Fuchs et al., 1992; 
Schroecksnadel and Fuchs, 2006).
Neopterin is a stable biomarker that can be measured in body fluids like urine, 
blood, and cerebrospinal fluid with enzyme-linked immunosorbent assays (Fuchs et 
al., 1992; Murr et al., 2002). IDO activation can be estimated by the calculation of the 
kynurenine-to-tryptophan ratio, which can be measured by using high-performance 
liquid chromatography (Widner et al., 1997). Thus, neopterin formation and trypto-
phan breakdown are robust readouts to evaluate the immune activation status.
monItorInG Immune resPonse In VItro
Peripheral blood mononuclear cells (PBMCs) isolated via density centrifugation 
from blood of healthy donors can be used as in vitro model to measure the immuno-
modulatory influences of various substances on Th1-type immune response (Jenny 
et al., 2011). PBMCs comprise lymphocytes, mainly T cells but also B cells and natu-
ral killer cells, and monocytes/macrophages. T cells can be stimulated with mitogens 
such as phytohemagglutinin (PHA) to produce IFN-γ, which activates monocytes 
and initiates Th1-type pathways. When analyzing for GCH1 and IDO activity, neop-
terin, tryptophan, and kynurenine concentrations can be measured in cell superna-
tants after 2 days of incubation. With PHA stimulation, an artificial inflammatory 
milieu is generated, and different substances can be tested concerning whether they 
can influence immunobiochemical pathways (Figure 14.2).
Several drugs that are known to possess antioxidant activities, like aspirin, sali-
cylic acid, atorvastatin, or vitamin A or C but also phytocompounds and botanical 
extracts, were shown to suppress tryptophan breakdown and neopterin produc-
tion in PHA-stimulated PBMCs in a dose-dependent manner (Becker et al., 2014; 
Jenny et al., 2011).
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A central target of antioxidants is NF-κB signaling. NF-κB is highly inducible by 
ROS and mediates pro-inflammatory cytokine expression (Asehnoune et al., 2004). 
A close relationship between NF-κB activation, production of neopterin, and deg-
radation of tryptophan was demonstrated in the human myelomonocytic cell-line 
THP1-Blue in vitro (Schroecksnadel et al., 2010). This reporter cell line expresses an 
alkaline phosphatase reporter upon activation of NF-κB/AP-1 signaling, allowing a 
colorimetric readout of NF-κB activity in the cell supernatant.
antIoxIdants—a two-edGed sword
The anti-inflammatory properties of antioxidants might be helpful during a situation 
of an overwhelming immune activation. Still, there is a question of dosage and the 
timepoint of intervention with antioxidant therapeutics or high-dose supplements 
during the course of infection or disease.
However, excessive antioxidant uptake presents a potential risk for unwanted 














fIGure 14.2 The in vitro model for cellular (Th1-type) immune response employs human 
peripheral blood mononuclear cells (PBMCs) and mimics the T-cell/macrophage interplay 
during immune activation. This model represents a convenient testing system to measure 
immunomodulatory effects of drugs, chemicals, and botanical extracts in vitro. T cells are 
activated upon stimulation with phytohemagglutinin (PHA) and release large amounts of 
the pro-inflammatory cytokine interferon-γ (IFN-γ), which induces monocyte differentiation 
and activates several enzymatic cascades. GTP-cyclohydrolase (GCH) produces the oxidative 
stress marker neopterin; in parallel, indoleamine 2,3-dioxygenase (IDO) converts tryptophan 
(TRP) into kynurenine (KYN). Furthermore, NADPH oxidase (NOX) produces reactive oxy-
gen species (ROS), and the activated transcription factor nuclear factor-κB (NF-κB) induces 
the expression of pro-inflammatory cytokines.
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the immune defense may result in inefficient pathogen clearance, and the risk of an 
infection can increase. Other adverse effects can be due to the interference with the 
cross-regulation of Th1 and Th2 immune responses, where a suppression of Th1-
type response can favor Th2-type activation and can increase the risk of allergy or 
asthma. The typical Th2-type immune reaction after an allergen exposure result in 
the production of specific cytokines like IL-4, IL-5, and IL-13; whenever another 
allergen is met, a stronger immune response occurs. Under an antioxidant stress 
condition, the allergic response is suggested to be stronger and the sensitivity for 
allergens is enhanced.
conclusIon
Antioxidants may have a beneficial influence on human health when administered 
as an anti-inflammatory agent under certain conditions characterized by high levels 
of oxidative stress. However, excessive antioxidant uptake may increase allergy risks 
via the modulation of immune reactions toward a Th2-type pattern. Interestingly, 
the increase in allergy development is in line with the large-scale introduction of 
antioxidants in foods in the Western world.
Of note, for several antioxidant molecules, their direct antioxidant activity is not 
their sole function; the indirect effects mediated by these compounds should also 
be taken into consideration (Dinkova-Kostova and Talalay, 2008). The origin of the 
antioxidant may also play a role, especially when evaluating a high-dose uptake of 
single antioxidants in comparison to antioxidant-rich nutrition.
In general, a well-functioning human being does not need further supplementa-
tion of antioxidants; a balanced diet together with regular physical exercises will 
keep the body healthy and balanced.
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Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) 
remains one of the most important public health challenges worldwide, especially 
in low- and middle-income countries. According to the World Health Organization 
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people globally were living with the HIV infection in 2010. Also in the same year, 
2.7 million new HIV infections, including 390,000 among children less than 15 
years old, and an annual death rate of 1.8 million people was reported [1]. In sub-
Sahara Africa, where two-third (22.6 million) of the HIV-infected people live, more 
than 6800 new infections and more than 5700 persons were dying from HIV in 2010 
[2,3]. After sub-Sahara Africa, the regions with the highest rate of infection are the 
Caribbean, Eastern Europe, and Central Asia [3].
TypEs of HiV infEcTion
Two types of HIV infections are known, HIV-1 and HIV-2. Both strains of HIV 
are retroviruses and causative agents of AIDS. Although both viruses are similar 
in terms of basic gene arrangement, mode of transmission, intracellular replication 
pathway, and clinical consequence, important differences exist between infections 
caused by both viruses (Table 15.1; Refs. [4–6]).
HiV Transmission
HIV can be transmitted through a multitude of routes. In Africa, about 90% of HIV 
transmission in adults occurs through sexual contact. In industrialized countries, 
it has been observed that the prevalence of HIV among men who have sex with 
men is consistently higher than that in the general population [7]. Another path 
for HIV transmission is HIV from mother-to-child transmission (MTCT). MTCT 
tABLe 15.1
differences between HIV-1 and HIV-2
characteristic HIV-1 HIV-2
Origin SIV cpz SIV smm
Epidemiology Extends worldwide Largely confined in West Africa and 
communities in Europe with 
socioeconomic links to West Africa, 
e.g., Portugal 
Clinical progression Progression to immunodeficiency 
is faster
Progression to immunodeficiency is 
slower; hence, individuals are mostly 
long-term nonprogressors
Pathological processes Progression occurs at lower CD4 
counts
Progression occurs at higher CD4 
counts
Virology Rate of DNA replication is higher, 
leading to higher viral load
Rate of DNA replication about 
100-fold lower, leading to lower viral 
load
Cellular response Less polyfunctional and produce 
less IL-2
More polyfunctional and produce more 
IL-2
Source: Nyamweya S et al., Rev. Med. Virol., 23, 221, 2013; Martinez-Steele E et al., AIDS, 21, 317, 
2007; Sharp PM and Hahn BH, Cold Spring Harbor Perspect. Med., 1, a006841, 2011.
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is responsible for about 630,000 pediatric infection annually, with more than 90% 
of these children living in sub-Sahara Africa [1,8]. HIV can also be transmitted 
through contaminated blood during blood transfusion or objects. Chen and cowork-
ers discovered that the natural history of AIDS was caused by blood transfusion [9].
PAtHomecHAnIsm of HIV
cd4 cElls and HiV
The HIV virus affects various cells of the immune system. Besides mononuclear 
phagocytes (monocytes and macrophages), studies in vivo show that CD4 lympho-
cytes are the most affected by HIV-1. To measure the state of the immune system and 
the degree of immune suppression due to HIV infection, the concentration of CD4 
(cluster of differentiation 4) cells in plasma is used. The higher the CD4 cell count, 
the better the condition and prognosis of the individual (Table 15.2; Ref. [10]).
CD4 cells act as receptors for the entry of HIV virus into the cells. CCR5 (human 
C–C chemokine receptor 5), expressed on immune receptor cells and antigen-
presenting cells, together with CD4 cells, are the primary receptors used by HIV 
for viral entry. Specific molecules that bind to CCR5 include MIP-1α, MIP-1β, and 
RANTES. These molecules play an important role in the homing and migration 
of effector and memory T cells during acute infections. Activation of CCR5 cells 
tABLe 15.2













<500 cells/μl Early 
symptomatic 
phase





<350 cells/μl Late 
symptomatic 
phase
Damage is severe 
and patient is 
officially diagnosed 




<50 cells/μl Infection is 
advanced and 
damage may be 
irreparable
Viral load >100.000 copies 







Source: Nielsen K and Bryson YJ, Pediatr. Clin. North Am., 47, 39, 2000.
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by chemokine leads to T-cell migration to the site of inflammation and immune 
response to antigen [11].
Viral load and HiV
HIV viral load is one of the main surrogate indicators used for monitoring and man-
aging HIV disease progression and treatment success in adults and children world-
wide [12]. Viral load represents the number of copies of HIV virus per milliliter of 
blood and measures the speed with which the infection is progressing. The higher 
the viral load, the faster the progression. HIV patients are required to test their CD4 
count and viral load regularly since these values will help the clinician determine the 
appropriate time to initiate the antiretroviral therapy. However, in many resource-
limited areas, it is difficult to systematically monitor HIV progression through HIV 
viral load. This difficulty is due to the high cost of testing in big cities and the lack 
of equipment and technology in rural areas, where most of the infected persons live. 
For this reason, CD4 count or CD4% are now frequently used to monitor HIV-1 
disease progression in both children and adults.
The progressive depletion of CD4 and increase in viral load are the hallmarks 
for HIV infection. Although the mechanism by which the HIV virus causes CD4 
depletion is not well known, evidence exist that the depletion of CD4 is caused by 
an indirect mechanism. The most acceptable mechanism, supported by in vivo stud-
ies, includes the consequences of HIV interaction with resting CD4 lymphocytes, 
which cannot support viral replication. The binding of the HIV virus to resting CD4 
cells in the lymphoid tissues leads to the upregulation of the lymph node homing 
receptors (L-selectin and Fas) [12]. When these HIV-signaled CD4 cells return to the 
blood, they home very rapidly back to peripheral lymph nodes and axial bone mar-
row. Their disappearance from the blood is likely due to their leaving the circulatory 
system. Most of the cells that have been induced by HIV to home on lymph nodes are 
subsequently induced into apoptosis during the process of trans-endothelial migra-
tion when secondary signals are received through various homing receptors [13]. The 
more CD4 cells are being activated, the higher the number of homing receptors (signs 
of CD4 destruction by apoptosis), and consequently the higher the HIV-1 viral load.
HIV/AIds And mALnutrItIon
Despite the major advances in understanding the biology of the HIV infection and 
important progress in the HIV/AIDS therapy, the basic role of the patients’ nutrition 
in the pathogenesis of HIV infection is still a subject of great interest. Malnutrition 
and HIV are intricately interrelated with one another. Evidence exists that malnutri-
tion increases the rate of disease progression as well as the rate of transmission of 
infection from mother to child. Also, HIV infection enhances malnutrition through 
its impact on nutrient intake, absorption, and utilization. However, it is still unclear 
which specific nutritional deficiencies contribute to poor clinical outcomes. With the 
increased global HIV/AIDS pandemic, coupled with the limited HIV drug availabil-
ity, especially in developing countries, nutritional strategies to correct micronutrient 
deficiencies are gaining interest. Micronutrient deficiency during an HIV infection is 
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provoked by body metabolism changes and opportunistic conditions such as mouth 
sores, pain in the mouth, swallowing problems, anorexia, fever, diarrhea, vomiting, 
or loss of appetite, which, in turn, lead to reduced food intake and visible weight 
loss. These conditions lead to deficiencies of vitamins and minerals (vitamins A, C, 
and E; selenium; zinc, etc.) that are required to enhance the immune system [14,15]. 
Studies indicate that micronutrient supplements reduce plasma HIV RNA viral load, 
improve CD4+ cell counts, and reduce the incidence of opportunistic infections [16].
HIV And nutrItIon
Recently, the importance of nutrition in human health is receiving increasing atten-
tion. Also, the assessment and improvement of the nutritional status in HIV infection 
has been recognized as an important part of comprehensive care of HIV-infected 
persons [17]. The use of nutritional supplements as well as natural food has been 
used to investigate its effects in various health conditions, including HIV/AIDS.
During an HIV infection, a long-term practice of adequate nutrition would com-
pensate for energy lost due to HIV infection and would help the body resist further 
infections. To achieve this goal, the body has to be fed with relevant nutrients that 
can boost the immune system. Examples of such nutrients are micronutrients, includ-
ing antioxidants such as vitamins A, C, and E; selenium; zinc; etc. These antioxi-
dants are known in clinical interventions to positively influence the nutritional status 
and immunological parameters of HIV/AIDS patients. Besides nutritional supple-
ments, a wide range of natural foods such as fruits, vegetables, cereals, etc., are rich 
sources of micronutrients [18,19]. The WHO recommends the “five-a-day” intake of 
fruits and vegetables, which can cover the required daily allowance of antioxidants. 
Environmental and epidemiological studies indicate that a high intake of fruit and 
vegetables is associated with a reduced risk of cancer, cardiovascular diseases, and 
oxidative stress [20]. Meanwhile, the health benefits of a high fruit and vegetable 
intake has been attributed to their high antioxidant content.
HIV/AIds And oxIdAtIVe stress
During HIV infection, oxidative stress occurs through the activation of reactive oxy-
gen species (ROS), produced after the activation of phagocytic cells (macrophages 
and neutrophils). ROS are also produced as by-products during electron mitochon-
drial transport of aerobic respiration, oxidoreductase catalysis, and metal-catalyzed 
oxidation. ROS are thus highly reactive and capable of causing significant damages 
to cell structure and function. Common ROS are the hydroxyl radical, hydrogen 
peroxide, and superoxide anion. ROS are known to play a critical role in the induc-
tion of oxidative stress and the degradation of immune cells [21]. Excess produc-
tion of ROS can attack double bonds in polyunsaturated fatty acids, inducing lipid 
peroxidation that may result in more oxidative cellular stress. Oxidative stress is a 
condition when the balance between pro-oxidants and antioxidants is upset, causing 
an overproduction of ROS [22]. Oxidative stress promotes the replication of the virus 
by upregulating the activation of NF-kappa B (NF-κB), a transcriptional promoter 
of proteins involved in the inflammatory and acute-phase response. NF-κB is bound 
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to I-κB in the cytoplasm in its inactive form. However, tumor necrosis factor-α and 
ROS can cause the activation of NF-κB from I-κB. NF-κB then translocates to the 
nucleus and binds to the DNA, promoting transcription of HIV-1 [23,24]. To prevent 
such damages, adequate amounts of neutralizing antioxidants to act as scavenger of 
free radicals are required.
AntIoxIdAnts And HIV/AIds
Antioxidants are nutrients who protect cells and tissues against ROS, produced as 
a result of immune activation to eradicate pathogens. Antioxidants occur endoge-
nously in the body and also naturally in foods such as fruits and vegetables [25]. 
Common endogenous antioxidants include superoxide dismutase (catalyzes the con-
version of two superoxide anions into a molecule each of hydrogen peroxide and 
oxygen), catalase (catalyzes the conversion of hydrogen peroxide to water and oxy-
gen), and glutathione peroxidase (catalyzes the degradation of hydrogen peroxides 
and other organic peroxides to alcohols). They are known for their beneficial effects 
on free radicals in biological systems, reducing oxidative stress on immune cells 
and reducing the replication of the HIV virus [26]. Common exogenous antioxidants 
include ascorbic acid, α-tocopherol, carotenoids, polyphenolic flavonoids, selenium, 
and zinc, which can be obtained directly from the diet.
ViTamin a
Of all the known vitamins, the role of vitamin A has been studied most extensively. 
Studies show that vitamin A has an effect on the immune system through the action 
of all-trans retinoic acid, which supports robust antibody responses by promot-
ing Th2 (type 2 helper) cell development [27]. Th2 produces cytokines (IL-4, IL-5, 
and IL-10) that are responsible for strong antibody production as well as activation 
of eosinophils and inhibition of several macrophage functions, hence providing a 
phagocyte-independent protective response [28]. Hoag et al. observed a profound 
reduction in Th2 cells in vitamin A–deficient mice, accounting for their depressed 
T-dependent antibody responses [29]. Providing vitamin A or its active metabolites 
reversed this defect. Vitamin A deficiency is a result of a low serum level of vitamin 
A due to reduced dietary intake following the HIV-related conditions already men-
tioned [30]. Vitamin A deficiency can also be a result of increased urinary excretion 
due to acute infections [31]. Visser and coworkers also observed, in resource-poor 
settings in South Africa, an association between advanced disease and/or weight 
loss and lowered blood concentrations of vitamin A [32]. Vitamin A deficiency can 
lead to pathological changes in the mucosal surfaces, impaired antibody responses, 
decreased CD4 cell population, and altered T- and B-cell functions.
Previous studies have shown that low vitamin A levels are also associated with 
increased risk of transmission of HIV from mother to child [33]. Fawzi and cowork-
ers proposed that advanced HIV disease may suppress the release of vitamin A from 
the liver, leading to low levels of vitamin A in the plasma (despite the body hav-
ing enough vitamin A liver stores) and, correspondingly, an increase in the risk of 
MTCT [34].
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Recently, another researcher observed no improvement in vitamin A level, CD4 
counts, and viral load after supplementing HIV-positive patients with a fortified sor-
ghum meal. The conclusion was made that the major differences between these trials 
of multiple micronutrient supplements in HIV-infected adults—including: variations 
in the characteristics of study participants, composition and doses of the supple-
ments, study duration, and other differences—could explain these contradictory 
findings [35].
β-caroTEnE
Carotenoids are among the most important dietary antioxidants found in human 
plasma. Their concentrations in plasma are considered to be the most accurate indi-
cator of dietary carotenoid intake. Many epidemiologic studies have associated high 
carotenoid intake with a decrease in the incidence of chronic disease. However, the 
biological mechanisms for such protection are currently unclear. β-Carotene, among 
other carotenoids, is known to have antioxidant properties; however, the antioxidant 
activity of these compounds can shift into a pro-oxidant effect, depending on fac-
tors such as oxygen tension or carotenoid concentration. Mixtures of carotenoids 
alone or in association with other antioxidants can increase their activity against 
lipid peroxidation [36]. Although some clinical trials found no benefit of supple-
menting β-carotene on CD4 counts [37], others indicate its beneficial effects on HIV 
disease progression [38]. Baeten and coworkers observed in a multivariate analy-
sis that β-carotene concentrations below the median were associated with elevated 
C-reactive protein (>10 mg/l) and higher HIV-1 plasma viral load. The authors sug-
gest that low β-carotene concentrations primarily reflect a more active HIV infec-
tion, rather than true deficiency amenable to intervention [39].
ViTamin c
Vitamin C, also known as ascorbic acid, is synthesized in the liver of most mammalian 
species but not by humans. Like most antioxidants, studies indicate an increased utili-
zation of vitamin C in HIV-infected persons compared with healthy controls [31,40]. 
Increased use coupled with low dietary intake of vitamin C can lead to vitamin defi-
ciency during HIV infection. Previous studies already confirmed that massive doses of 
vitamin C can suppress the symptoms of HIV disease and significantly reduce the occur-
rence of secondary infections [41]. Later, Fawzi and coworkers observed that supplemen-
tation of vitamin C in combination with vitamin E may provide protection to red blood 
cells against being destroyed by free radicals [34]. Recent studies indicate that increased 
intakes of vitamin C during HIV infection can lead to mild increase of CD4 counts, help 
prevent oxidative damage, and enhance normal immune function and survival [42].
ViTamin E
Studies disclose the presence of low vitamin E levels in the plasma of HIV-infected 
persons [31,43]. This can be a result of increased utilization of vitamin E in quench-
ing free radicals, thus reducing the peroxidation of polyunsaturated fatty acids [44]. 
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Vitamin E deficiency in HIV patients can also be due to poor dietary intake, poor 
absorption, diarrhea, and impairment of the recycling mechanism of vitamin E 
through vitamin C [45]. Studies have shown an association between higher vita-
min E intake and lower risk of progression to AIDS [32,43]. Other studies indi-
cate the possibility for the supplementation of vitamin E to influence the production 
of RANTES, an important antiviral chemokine. In a small supplementation study, 
500 mg α-tocopherol given once daily for 2 months reduced RANTES production 
and increased the expression of CCR5 on the surface of CD4 cells of HIV-1-infected 
persons. Endogenous production of antiviral factors like RANTES may significantly 
affect HIV-1 replication and the pace of disease progression.
sElEnium
Selenium is an important part of glutathione peroxidase, which is a very impor-
tant enzyme in the metabolism of erythrocytes. Selenium plays an important role 
in the selenoenzyme glutathione peroxidase, which protects cells against free radi-
cal damage and oxidative stress [46]. Evidence exists that the utilization of sele-
nium increases in HIV patients, leading to low plasma selenium levels. Low serum 
selenium level exacerbates the oxidative stress induced by HIV, increasing the risk 
of mortality and the occurrence of AIDS-related opportunistic infections [30,47]. 
Previous studies showed an increase in lipid peroxidation (oxidative stress) in HIV-
positive individuals with lower plasma concentrations of selenium. Further studies 
illustrated that supplementation with selenium in HIV-positive patients led to higher 
glutathione peroxidase levels [48]. These studies do not indicate an improvement in 
CD4 cells. Meanwhile, Hurwitz and coworkers observed a suppression of the viral 
load in HIV patients after supplementation with selenium. However, since most stud-
ies on selenium are small and observational studies, confounding could be a possible 
justification for conflicting results [15].
Zinc
Zinc is a vital mineral known to affect a multitude of enzymes involved in the syn-
thesis and metabolism of carbohydrates, lipids, proteins, nucleic acids, alcohol and 
membrane stabilization, etc. Zinc deficiency in humans could be a result of the 
intake of diets poor in zinc and animal proteins, and rich in inhibitors of zinc absorp-
tion such as phytic acid and inorganic calcium salts. Studies indicate an association 
between zinc deficiency and impaired immune function and increasing infection risk 
[49,50]. Zinc is involved in the growth, development, and function of neutrophils, 
macrophages, natural killer cells, and T and B lymphocytes. Studies also show that 
zinc supplementation can reduce the rate of diarrheal diseases, reduce acute lower 
respiratory tract infections, and increase CD4 cells [51]. Abrams and coworkers, in a 
related study, also indicated a positive relationship between CD4 counts and dietary 
intake of zinc, although no relation between dietary intake of zinc and HIV disease 
progression was evident [52]. However, the reported relationships of zinc and HIV-
related outcomes have not been consistent across studies. A possible explanation for 
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this contradictory observation could be confounding due to the small size of studies 
and study design, as already mentioned above.
polypHEnols
Polyphenols are a class of bioactive secondary plant substances that are widespread in 
plants, including sorghum, millet, barley, dry beans, peas, and other legumes; fruits such 
as apples, blackberries, cranberries, grapes, oranges, pears, plums, raspberries, and straw-
berries; and vegetables such as cabbage, celery, onion, and parsley. Phenolic compounds 
are also present in tea and wine. They are known to exert strong antioxidant and anti-
inflammatory effects in vitro [24,53]. Polyphenols are known to boost immune function 
in HIV-infected persons by their ability to counteract oxidative stress [54]. Some studies, 
however, show no effect of polyphenols on CD4 and viral load after supplementation 
with fruit juices, although plasma antioxidant capacity is increased [55]. Both previous 
and recent studies indicate increased antioxidant capacity and increased intracellular 
glutathione in T cells (an indication of reduced intracellular oxidative stress), increased 
proliferation of CD4 cell count, decreased viral load in the subgroups with advanced 
immunodeficiency, after treatment with polyphenol-rich antioxidants [26,56]. Despite 
the positive effects of polyphenols on lymphocyte proliferation and apoptosis, it will 
be profitable to further research in this area, considering larger sample sizes and longer 
duration. Also, a variety of polyphenols should be taken into consideration.
N-acETyl cysTEinE (nac)
NAC has been in clinical practice for several years and has been used for the treat-
ment of several disorders, including HIV/AIDS. NAC has been proven beneficial 
in patients with the autoimmune disorder systemic lupus erythematosus. In these 
patients, the mechanism underlying NAC activity was ascribed to a blockade of the 
mammalian target of rapamycin (mTOR) in T lymphocytes. Activation of mTOR 
occurs upon glutathione (GSH) depletion or after exposure to nitric oxide (NO), 
which causes mitochondrial hyperpolarization. This can lead to a downregulation 
of the transcription factor for knead box P3 and, subsequently, to a decline in CD4. 
NAC blocks the activation of mTOR and increases the number of T lymphocytes 
[57]. NAC can cross the epithelial cell membrane and sustain the synthesis of glu-
tathione (GSH), which is the ubiquitous source of the thiol pool in the body and an 
important antioxidant involved in numerous physiological processes. These include 
detoxification of electrophilic xenobiotic modulation of redox-regulated signal trans-
duction, regulation of immune response, prostaglandin and leukotriene metabolism, 
antioxidant defense, neurotransmitter signaling, and modulation of cell prolifera-
tion [58]. NAC reacts relatively slowly with superoxide, hydrogen peroxide, and 
peroxynitrite, which casts some doubt on the importance of these reactions under 
physiological conditions. Finally, Samuni and coworkers made the major conclusion 
that the antioxidative activity of NAC, as of other thiols, can be attributed to its fast 
reactions with OH, NO2, CO3 (−), and thiyl radicals, as well as to restitution of dam-
aged targets in vital cellular components [59].
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fActors AffectIng AntIoxIdAnt LeVeL In HIV/AIds PAtIents
opporTunisTic condiTion
Opportunistic conditions such as thrush, vomiting, and tuberculosis often lead to a 
lack of appetite, which further leads to reduced food intake or malabsorption and 
consequently micronutrient and antioxidant deficiencies.
mEdicaTion inTakE
The intake of a series of drugs such as diuretics, laxatives, bile acid, etc., often leads 
to increased loss of nutrient accompanied by micronutrients such as vitamin A, vita-
min B, zinc, etc.
combinaTion THErapy (HaarTs)
Besides the effects of the medication mentioned above, the therapy (HAARTS) used 
for HIV/AIDS treatment also affects antioxidant levels. Standard HAARTS is a com-
bination of at least three antiretroviral drugs, mostly made up of one protease inhibi-
tor combined with at least two nucleoside analogue reverse transcriptase inhibitors. 
ART/HAARTS cannot cure HIV, but its effectiveness in the suppression of plasma 
HIV-1 RNA to undetectable concentrations has been shown in several clinical tri-
als [60,61]. In the above-mentioned studies, the introduction of HAART resulted to 
about a 50% decline in AIDS mortality, decreased MTCT rate, as well as reduced 
incidence rate of opportunistic infections. Although limited studies have found a 
reduction in antiretroviral concentration due to supplementation with antioxidants, 
evidence exists that high concentrations of vitamin C may significantly reduce 
indinavir (a protease inhibitor used in the treatment of HIV patients) plasma con-
centration [62,63]. Merenstein et al., after supplementing with vitamin C, observed 
an increased rate of adherence to HAARTS; however, its effects on CD4 and viral 
load were not ascertaining [40]. Previous research by Ngondi and coworkers, in an 
attempt to observe the effects of combination therapy on oxidative stress markers, found 
that the combination treatment therapy I [stavudine (80 mg) + lamivudin (600 mg) + 
nevirapine + (400 mg) + zidovudine (600 mg)] brought about a significant reduc-
tion in the plasma concentration of protein sulfhydryl groups, thiobarbituric acid 
reactive substances, and vitamin C levels compared with therapy II [stavudine (80 
mg) + lamivudin (300 mg) + nevirapin (400 mg)] or with a combination therapy III 
[zidovudine (600 mg) + lamivudin (300 mg) with efavirenz (600 mg)] [64].
Regardless of the type of combination therapy, intake of HAARTS has always 
been linked with adverse effects such as nausea, vomiting, etc., which indirectly 
leads to reduced nutrient intake and micronutrient deficiencies (Table 15.3; Ref. [65]).
diETary inTakE
Low dietary intake of micronutrient antioxidants through fruits and vegetables and/
or antioxidant supplements will eventually lead to micronutrient deficiency, espe-
cially including vitamins A, C, and E; zinc; and selenium.
273HIV/AIDS
socioEconomic sTaTus
Micronutrient deficiency is not only limited to poor countries but also extends to 
high-income nations—especially in people with low economic and educational 
status. However, micronutrient deficiencies in HIV/AIDS patients are highly 
prevalent in developing countries, where expensive high-quality animal-derived 
products are often not affordable to the poor, and associated with important 
negative biomedical consequences. Furthermore, studies show that vitamin A 
deficiency has been associated with a lack of knowledge rather than with low 
income, contrary to iron deficiency whose main cause was mainly economically 
determined [66].
AdVerse effects of suPPLementAtIon of 
AntIoxIdAnts on HIV/AIds PAtIents
Previous studies have shown positive effects of antioxidant supplements and/or an 
antioxidant-rich diet on standard biological markers such as CD4 cells and viral 
load [32,34]. Meanwhile, some studies demonstrate the adverse effect of antioxi-
dant supplementation on the immune system. The supplementation of vitamin E, 
for example, has been shown to increase the expression of CCR5 (the major cell 
entry coreceptor for T-cell line–tropic and macrophage-tropic strains of HIV-1), 
hence an increased infection of CD4 cells and whence an increased viral load [11]. 
Meanwhile, other researchers suggest that high doses of supplemented antioxidants 
could cause fluctuating CD4 concentrations, which could indirectly increase the rate 
of oxidative stress, deteriorating the health condition [20,67].
Besides the adverse effect of supplements on health, they are often very expensive 
and unaffordable for the majority of HIV/AIDS patients in resource-limited settings 
[68].
tABLe 15.3
Adverse effects of ArV/HAArts on nutrition
medication Adverse effects 
Zidovudin (Retrovir) Nausea
Didanosin (Videx) Nausea, diarrhea, loss of taste
141 W94 (Glaxo Wellcome) Nausea, diarrhea
Abacanir (Glaxo Wellcome) Nausea
Saquinavir (Invirase) Nausea
Indinavir (Crixivan) Kidney stones (>21 days drinking)
Ritonavir (Norvir) Nausea, diarrhea 
Adefovir Lack of appetite, diarrhea, nausea
Nelfinavir (Viracept) Diarrhea
Source: Biesalski H-K et al., Medikamente mit Einfluss auf die Ernaehrung. 
Ernährungsmedizin, 3rd Ed. p. 495, 2004.
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HiV prEVEnTion
Besides the provision of antiretroviral medication and counseling on adequate nutri-
tion, HIV/AIDS prevention is one of the most important aspects of comprehensive 
care of HIV/AIDS-infected people. Addressing prevention in comprehensive care 
is vital and will go a long way to reduce the number of HIV new infection rates, 
as well as delay the onset of AIDS for already infected individuals. Strategies to 
assure effective prevention of HIV infection among children and adults include 
providing free HIV testing campaigns, strengthening the capacities of HIV preven-
tion services, providing contraceptives and counseling, and providing HIV care and 
treatment to infected persons timely. Other prevention strategies include promoting 
behavior change. Behavior change will help promote safer individual behavior and 
change in social customs, and consequently healthier forms of sexual behavior, e.g., 
correct and consistent use of condoms. Also, providing behavior change programs 
for sex workers and men who have sex with men will help reduce the prevalence of 
HIV in this group of individuals [69].
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16 Role of Herbs and Spices




Herbs and spices have a long history of both culinary and medicinal use. Ayurvedic 
traditional medicine evolved more than 5000 years ago, and uses herbs and spices 
for health, including tumeric, basil, mace, cinnamon, and ginger (Govindarajan et al. 
2005). Traditionally, the Chinese have integrated food, nutrition, and health, including 
herbs and spices in specially prepared dishes for both sustenance and for purported 
health benefits (Bellamy and Pfister 1992). Ginseng and ginkgo biloba are reportedly 
used to improve stamina and cognitive performance, respectively. Herbs and spices 
can be regarded as among the first “functional foods.” Asian and Indian diets, which 
are high in vegetables and fruits, also generally include a large amount and consider-
able variety of herbs and spices (Sinha et al. 2003). The health-promoting effect of 
these foods are attributable not only to the general nutritional profile (high in dietary 
contents
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fiber; low in fat and salt; low energy density; and high in vitamins A, C, and folate) 
but also to a wide range of nonnutrient bioactives and phytochemicals such as flavo-
noids and other phenolics, which are found in herbs and spices. Herbs and spices add 
flavor to foods without salt, thus assisting to meet the reduced daily intake of sodium. 
Herbs and spices add flavor to foods without fat, thus assisting to meet healthy fat 
intake. Inclusion of herbs and spices in diets promotes intake of plant-based foods 
that increase the nutritional quality of the daily diet. Herbs and spices, while provid-
ing flavor and aroma to our diets, also contribute diverse bioactives that may have a 
role in improving human health. Herbs and spices are hence a desirable integral part 
of daily diet.
Oxidative stress has been implicated in the etiology of cardiovascular disease, type 
2 diabetes, cataract, inflammatory diseases, neurodegenerative diseases, cancer, and 
also in the natural aging process. Reactive oxygen radicals are detrimental to cells 
since they induce lipid peroxidation in cellular membranes, generating lipid perox-
ides that cause extensive damage to membranes and membrane-mediated chromo-
somal damage. Endothelial cell injury is often the first stage of these disorders. 
The antioxidant enzymes, superoxide dismutase, catalase, and glutathione per-
oxidase, present intracellularly can directly scavenge these oxidants or prevent 
their conversion to toxic species. There is a growing interest in natural anti-
oxidants found in plants that hinder the oxidative processes and thereby delay 
or suppress oxidative stress. A wide variety of phenolic compounds present in 
spices possess potent antioxidant, anti-inflammatory, antimutagenic, and cancer-
preventive activities. This article lists a host of spice compounds that are experi-
mentally evidenced to control cellular oxidative stress both in vitro and in vivo 
and their beneficial role in preventing or ameliorating oxidative stress–mediated 
diseases—cardiovascular disease, diabetes, cataract, and cancer.
A wide variety of phenolic compounds and flavonoids present in spices 
(Figure 16.1) are now experimentally documented to possess potent antioxidant, anti-
inflammatory, antimutagenic, and anticarcinogenic activities. The antioxidative and 
anti-inflammatory properties of these bioactive compounds from spices appear to 
contribute to their chemopreventive or chemoprotective activity. Cyclooxygenase-2 
(COX-2) has been recognized as a molecular target of many chemopreventive as 
well as anti-inflammatory agents. Studies have shown that COX-2 is regulated by 
the eukaryotic transcription factor NF-κB. The molecular mechanisms underlying 
the chemopreventive effects of spice ingredients in terms of their effects on intracel-
lular signaling cascades, particularly those involving NF-κB and mitogen-activated 
protein kinases, are recently reviewed (Surh 2002). Antioxidants in foods may work 
in combination to produce synergistic effects. Plant foods, which are rich in flavo-
noids, have many different antioxidant compounds (Halvorsen et al. 2006). Many 
epidemiological studies show that consuming a diet high in antioxidant-rich fruits 
and vegetables is associated with a variety of other health benefits (Cao et al. 1998). 
Herbs and spices make an important contribution to total daily flavonoid intake 
(Baghurst 2006). Higher amounts of dietary antioxidants or higher plasma levels of 
antioxidants are associated with improved heart health and cellular function (Cao 
et al. 1998).
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AntIoxIdAnt effects of spIces And Herbs
In the context of the oxidative stress theory of aging and age-related degenerative dis-
eases, dietary phenolic or thiolic antioxidants have been shown to increase the life span 
of laboratory animals and protect against senescent immune decline. In view of the 
limitations of the “lipid theory” of atherosclerosis and the current suggestion that free 







































fIGure 16.1 Spice bioactive compounds.
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Brown 1994), the antioxidant compounds present in spices have gained more impor-
tance for their possible role in the prevention of atherogenesis. Among the several nutra-
ceutical attributes of common spices, their antioxidant potential has far-reaching health 
implication. Herbs and spices are undoubtedly a rich source of antioxidants. Culinary 
spices and herbs may contribute significantly to the total intake of plant antioxidants. 
Spices and herbs typically are a more concentrated source of dietary antioxidants than 
many other food groups such as fruits, berries, cereals, and vegetables (Tapsell et al. 
2006).
While spices typically are used at relatively low levels in foods, these data 
indicate that spices may provide a meaningful level of antioxidant activity when 
consumed at higher levels. The antioxidant capacity of herbs and spices has been 
evaluated on the basis of the oxygen radical absorbance capacity, which provides a 
measure of the scavenging capacity of antioxidants against the peroxyl radical, and 
Trolox, a water-soluble vitamin E analogue, is used as a calibration standard. There 
are many phytochemicals such as phenolics and organosulfur compounds in spices 
that possess bioactivity beyond antioxidation. The volatile oil components of thyme 
(Thymus vulgaris) include carvacrol, borneol, geraniol, and thymol. Thymol is the 
primary volatile oil constituent of thyme, and its antioxidant protection of cellular 
membranes is well documented. Thyme also contains a variety of flavonoids, which 
increase thyme’s antioxidant capacity. The antioxidative effects of spices—turmeric/
curcumin (Table 16.1), garlic and onion (Table 16.2), clove/eugenol (Table 16.3), red 
pepper/capsaicin (Table 16.4), black pepper/piperine (Table 16.4), ginger/gingerol, 
and fenugreek—and of several herbs, which have been extensively studied and evi-
denced as potential antioxidants, are specifically discussed.
Turmeric (CurCuma longa) and curcumin
The yellow compound curcumin from the rhizome of Curcuma longa has been 
claimed to be a potential antioxidant (Table 16.1) and anti-inflammatory agent with 
bioprotective and chemopreventive properties. Curcumin is shown to be a good 
inhibitor of lipid peroxidation by several investigators (Reddy and Lokesh 1992). 
Curcumin has significant abilities to protect against single-strand breaks induced 
by singlet oxygen, a reactive oxygen species (ROS) with potential genotoxic/muta-
genic properties (Subramanian et al. 1994). The ability of curcumin to protect DNA 
against oxygen free radicals seems to be related to its structure and may at least 
partly explain its therapeutic and other beneficial effects, including antimutagenic 
and anticarcinogenic properties (Figure 16.2). The antioxidant properties of turmeric 
and curcumin are also evidenced in animal studies (Reddy and Lokesh 1994a,b). 
Curcumin inhibits lipid peroxidation possibly by quenching oxygen free radicals, as 
inferred by in vitro studies, and by enhancing the activity of endogenous antioxidant 
enzymes.
Garlic (allium sativum) and OniOn (allium Cepa)
Diallyl sulfides and diallyl disulfides, which are active components of garlic, have 
known antioxidant (Table 16.2), anti-inflammatory, and antimutagenic activities. 
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tAbLe 16.1
Antioxidant effects of curcumin in In Vitro systems and in In Vivo situations
In Vitro/Animal Model effect demonstrated 
In Vitro Models
RBC membranes Curcumin inhibited lipid peroxidation 
Rat liver microsomes Curcumin inhibited ascorbate–Fe2+-induced lipid peroxidation
Xanthine–xanthine oxidase 
system
Curcumin inhibited superoxide anion and OH radical generation
Rat macrophages Curcumin inhibited SO anions, H2O2, and nitrite radical production
Plasmid DNA Curcumin diminished singlet oxygen–induced DNA strand damage
Rat liver microsomes Curcumin inhibited Fe2+-induced lipid peroxidation
Human LDL Curcumin inhibited Cu2+-induced lipid peroxidation
In Vivo situations
Mice Curcumin lowered lipid peroxidation produced by CCl4, paraquat 
Rats Curcumin suppressed CCl4-induced and 60Co-induced lipid 
peroxidation




Dietary curcumin enhanced antioxidant status of red blood cells, 
blood, and liver
Hepatoprotective effect
Rats Curcumin lowered Fe2+-induced liver hepatotoxicity and lipid peroxides
Rats Curcumin reduced alcohol-induced oxidative stress
Rats Curumin reduced lipid peroxides in chloroquine-induced 
hepatotoxicity
Mice Curcumin suppressed trichloroethylene-induced oxidative stress
cardioprotective effect 
Humans Curcuminoids reduced serum lipid peroxides
Humans Curcuma longa extract decreased blood lipid peroxides and LDL 
oxidation 
Isoproterenol-treated rat Curcumin countered lipid peroxidation in myocardial infarction 
Isoprenaline-treated rat Oral curcumin reduced oxidative stress during myocardial ischemia
Atherosclerotic rabbits Curcuma longa extract decreased susceptibility LDL to lipid 
peroxidation 
Cholesterol-fed rabbits Curcuma longa reduced oxidative stress during atherosclerosis 
oxidative stress in diabetes
STZ-diabetic rats Dietary curcumin lowered lipid peroxides in plasma and urine 
STZ-diabetic rats Curcumin countered decreased enzymic/nonenzymic antioxidants 
Antioxidant effect in cataract
Rats Curcumin decreased naphthalene-induced opacification of eye lens 
Rats Curcumin prevented selenium-induced oxidative damage in eye lens 
and delayed cataract
(Continued)
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tAbLe 16.2
Antioxidant Influence of Garlic (Allium sativum) and onion (Allium cepa)
system effect observed
Garlic (Allium sativum) and Its constituents
Hamster S-Allylcysteine suppressed the incidence of DMBA-induced 
buccal pouch tumors, decreased lipid peroxidation, and enhanced 
antioxidant enzymes
Rats Garlic intake reduced the incidence of azoxymethane-induced 
colon tumor, accompanied by reduction in lipid peroxidation and 
higher GST activity
Rats S-Allylcysteine administration inhibited NDA-induced liver cancer 
and lipid peroxidation with simultaneous increase in antioxidants 
Rats Garlic oil increased hepatic antioxidant enzyme activities
Diabetic rats Garlic oil increased plasma total thiols and decreased lipid peroxides; 
higher GST activity in erythrocytes and SOD in liver and kidney
Diabetic rats Garlic juice countered changes in lipid peroxides and activities 
of GST
Atherosclerotic patients Garlic extract lowered plasma and erythrocyte malondialdehyde 
levels 
Hypercholesterolemic subjects Garlic extract increased blood antioxidant oxidant status, superoxide 
radical scavenger activity, and decreased lipid peroxides
Human subjects Garlic supplementation increased resistance of LDL to oxidation
Rat erythrocytes AGE prevented decrease of RBC deformability induced by lipid 
peroxidation and reduced lipid peroxidation
Human LDL Garlic compounds inhibited superoxide production; suppressed 
copper-induced LDL oxidation
tAbLe 16.1 (contInued)
Antioxidant effects of curcumin in In Vitro systems and in In Vivo situations
In Vitro/Animal Model effect demonstrated 
STZ-diabetic rats Curcumin/turmeric countered oxidative stress in eye lens and 
progression of cataract
renal protective effect
Rats Curcumin lowered oxidative stress in induced renal toxicity
neuroprotective effect
Rats Curcumin protected lead-induced neurotoxicity 
Anticancer potential 
Mice Curcumin increased activities of antioxidant and phase II enzymes 
Mice Curcumin showed antitumor effect in skin induced by peroxynitrite
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tAbLe 16.2 (contInued)
Antioxidant Influence of Garlic (Allium sativum) and onion (Allium cepa)
system effect observed
onion (Allium cepa) and Its constituents
Nicotine-injected rats Onion oil showed increased resistance to lipid peroxidation and 
increased tissue antioxidants and antioxidant enzymes
Alloxan diabetic rats S-Methyl cysteine sulfoxide lowered levels of malondialdehyde, 
hydroperoxide, and conjugated dienes in tissues
Alloxan-diabetic rats Onion juice countered changes in lipid peroxides and activities of 
GST in plasma and tissues
Rats fed with high-fat/high-
sucrose diet
Onion reduced superoxide generation and increased NO 
availability in the aorta
Human volunteers Ingestion of onions resulted in increased total antioxidant capacity
Human PMNL cells Aqueous extract of onion inhibited 5′-lipoxygenase in vitro
Note: DMBA, dimethyl benzanthracene; GST, glutathione-S-transferase; NDA, N-nitroso diethylamine; 
SOD, superoxide dismutase; LDL, low-density lipoprotein; AGE, advance glycation endproducts; 
PMNL, polymorphonuclear leukocyte.
tAbLe 16.3
Antioxidant Influence of eugenol in In Vitro systems and In Vivo studies
Animal Model/In Vitro system effect demonstrated 
Human RBC Eugenol inhibited Cu2+-induced lipid peroxidation
Rat liver microsomes Eugenol inhibited ascorbate–Fe2+-induced lipid peroxidation
ROS generation in the xanthine–
xanthine oxidase system
Eugenol inhibited the generation of reactive oxygen species, and 




Eugenol decreased nitrotyrosine formation and lipid peroxidation
Human PMNL cells Eugenol inhibited 5-lipoxygenase and formation of leukotrienes
In vitro study Eugenol inhibited copper-induced oxidation of LDL
Animal Models
Rats fed unsaturated fat Dietary eugenol decreased serum and liver lipid peroxides, 
enhanced activities of antioxidant enzymes, and lowered lipid 
peroxides in liver 
7,12-Dimethyl benz(α)anthracene 
applied mice
Eugenol inhibited the number of tumors due to radical scavenging 
activity 
CCl4 -administered rat Eugenol pretreatment countered hepatotoxicity
Rats Eugenol lowered Fe2+-induced lipid peroxides; lowered 
hepatotoxicity
Rats Oral eugenol increased glutathione, GSH-transferase in the intestine
Swiss mice Eugenol protected against oxidative stress caused by γ-radiation
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Onion is a major source of flavonoids, especially the two quercetin glycosides, 
quercetin 4′-o-β-glucoside and quercetin 3,4′-o-β-diglucosides, which are recog-
nized as bioactive substances. The antioxidant effect of onion oil and garlic oil 
(100 mg/kg for 21 days) has been reported on nicotine-induced lipid peroxidation 
in rat tissues (Helen et al. 1999), as inferred by countering the increased lipid 
peroxides in the liver, lungs, heart, and kidney tissues of nicotine-treated rats and 
restoration of the activities of antioxidant enzymes, which decreased in nicotine-
treated rats.
GinGer (Zingiber offiCinale)
The antioxidant effect of the total phenols of ginger extract has been established in 
vitro (Stoilova et al. 2007). Gingerol exhibited dose-dependent inhibition of nitric 
oxide production and significant reduction of inducible nitric oxide synthase in lipo-
polysaccharide-stimulated macrophages, thus suggesting the protective ability of this 
tAbLe 16.4
Antioxidant Influence of capsaicin of red pepper (Capsicum annuum) and 
piperine of black pepper (Piper nigrum)
Animal Model effect demonstrated
capsaicin of red pepper
Human RBC Capsaicin inhibited lipid peroxidation
Rat liver microsomes Capsaicin inhibited ascorbate–Fe2+-induced lipid peroxidation
Rat liver mitochondria Capsaicin inhibited lipid peroxidation and scavenging of DPPH radicals
Human LDL Capsaicin inhibited Cu2+-induced lipid peroxidation
Human PMNL cells Capsaicin inhibited 5′-lipoxygenase
Rats Capsaicin reduced oxidative stress in the liver, lung, kidney, and muscle
High-fat-fed rats and 
hypercholesterolemic rats
Capsaicin enhanced antioxidant status of red blood cells, blood, and liver
piperine of black pepper
Rat liver Piperine inhibited ascorbate–Fe2+-induced lipid peroxidation
In vitro Piperine inhibited/quenched superoxides and hydroxyl radicals, and 
inhibited lipid peroxidation
In vitro Black pepper and piperine inhibited human PMNL 5′-lipoxygenase
Human LDL Piperine protected Cu2+-induced lipid peroxidation of human LDL
Mice Piperine decreased mitochondrial lipid peroxidation and augmented 
antioxidant defense during benzo(α)pyrene-induced lung carcinogenesis
High-fat-fed rats Black pepper/piperine reduced oxidative stress by lowering lipid 
peroxidation, and restored the activities of antioxidant enzymes and 
GSH
Rats Piperine protected against carcinogen-induced oxidative stress in the 
intestinal lumen
Streptozotocin-diabetic rats Piperine partially protected against diabetes-induced oxidative stress
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compound against peroxynitrite-mediated damage (Ippoushi et al. 2003). Capsaicin 
(trans-8-methyl-N-vanillyl-6-nonenamide) is the major pungent and irritating ingre-
dient of red pepper. The antioxidant property of capsaicin in terms of inhibiting 
lipid peroxidation in human erythrocyte membranes and in rat liver microsomes is 
documented (Reddy and Lokesh 1992).
clOve (eugenia Caryophyllus) and euGenOl
The antioxidant potency of eugenol, the principal flavor compound of clove (Table 
16.3), is recognized by the inhibition of the generation of ROS in model systems, the 
inhibition of copper-induced lipid peroxidation in human erythrocyte membranes 
(Reddy and Lokesh 1994b), and carbon tetrachloride–induced lipid peroxidation 
(Nagashima 1989). Inducible COX-2 has been implicated in the processes of inflam-
mation and carcinogenesis. Eugenol was found to potently inhibit the prostaglan-
din E2 production in lipopolysaccharide-activated mouse macrophages (Kim et al. 
2003), thus suggesting that eugenol might be a plausible COX-2 inhibitor, and thus 
acts as an anti-inflammatory or cancer chemopreventive agent. Eugenol has been 
investigated for its effects on the cytotoxicity and induction of apoptosis. Eugenol-
treated HL-60 cells displayed features of apoptosis, including DNA fragmentation, 
and demonstrated that ROS plays a critical role in eugenol-induced apoptosis, and 
this is a possible mechanism of the anticancer effect of eugenol. The antioxidant 
properties of eugenol are documented in animal studies, where dietary eugenol 
(0.05%) significantly lowered lipid peroxidation in the serum and liver of rats and 
was associated with enhanced activities of antioxidant enzymes—superoxide dis-



















fIGure 16.2 Diverse pharmacological activities of curcumin mediated through antioxi-
dant potential.
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AntIAtHeroGenIc And cArdIoprotectIve effect
Generally, the use of herbs and spices will considerably displace fats and salt in the 
diet and, hence, is likely to reduce cardiovascular risk. Consumption of garlic or 
garlic oil has been associated with a reduction in total/low-density lipoprotein (LDL) 
cholesterol and triglyceride levels (Steiner et al. 1996). Additionally, garlic extracts 
have been shown to have anticlotting properties and to cause modest reductions in 
blood pressure. Ingestion of garlic extract (1 mL/kg daily for 6 months) by athero-
sclerotic patients led to significantly lowered plasma and erythrocyte lipid peroxide 
levels (Durak et al. 2004). The results also demonstrated amelioration of oxidative 
stress by the ingestion of garlic extract. Thus, it is possible that reduced peroxidation 
processes may play a part in some of the beneficial effects of garlic in atherosclerotic 
diseases.
While hypercholesterolemia is considered a major risk factor for atherosclerosis, 
and lowering of cholesterol can significantly reduce risk for cardiovascular diseases, 
oxidation of LDL has been recognized to play an important role in the initiation and 
progression of atherosclerosis. Several garlic compounds can effectively suppress 
LDL oxidation in vitro (Lau 2001). Short-term supplementation of garlic in human 
subjects has demonstrated an increased resistance of LDL to oxidation; suppressed 
LDL oxidation may be one of the powerful mechanisms accounting for the antiath-
erosclerotic properties of garlic.
Intake of lemongrass (Cymbopogon citrates) oil (140 mg/day) by hypercholes-
terolemic subjects produced a drop in cholesterol concentrations up to 38 mg/dL 
(Huang et al. 1994). There are a large number of studies concerning the potential 
cardiovascular health benefits of antioxidants such as flavonoids of tea (Carnesecchi 
et al. 2001). Herbs and spices make an important contribution to total daily flavonoid 
intake. Basil (Ocimum basilicum) is a very good source of β-carotene (provitamin 
A), a powerful antioxidant that not only protects epithelial cells from free radical 
damage but also helps prevent free radicals from oxidizing cholesterol in the blood-
stream leading to arteriosclerosis. Spice components such as zingiber, capsaicin, and 
curcumin have been associated with a decrease in LDL cholesterol and an increase in 
high-density lipoprotein (HDL) cholesterol levels in rat studies (Lantry et al. 1997).
Daily intake of curcuminoids (0.5 g) by healthy human volunteers produced a 33% 
reduction in blood lipid peroxide levels (Soni and Kuttan 1992). Curcumin administra-
tion (500 mg/day for 7 days) was accompanied by an increase in HDL cholesterol and 
a decrease in total serum cholesterol (Quiles et al. 2002). Reduction in serum lipid 
peroxides and cholesterol suggests the potential of curcumin as a preventive substance 
against arterial diseases. Supplementation with turmeric reduced oxidative stress 
(reduced plasma lipid peroxides and restored α-tocopherol and coenzyme-Q levels) 
and attenuated the development of fatty streaks in rabbits fed on a high-cholesterol diet 
(Quiles et al. 2002).
Oxidation of LDL plays an important role in the development of atherosclerosis. 
Turmeric extract decreased the susceptibility of LDL to lipid peroxidation in ath-
erosclerotic rabbits, thus suggesting its value in the management of cardiovascular 
disease (Ramirez-Tortosa et al. 1999). In healthy humans, the daily intake of 200 mg 
turmeric extract resulted in a decrease in blood lipid peroxides as well as in HDL 
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and LDL lipid peroxidation (Miquel et al. 2002). Dietary curcumin and capsaicin 
significantly inhibited the in vivo iron-induced LDL oxidation in rats and copper-
induced oxidation of LDL in vitro (Manjunatha and Srinivasan 2006). Piperine of 
black pepper (Piper nigrum) has been demonstrated in in vitro experiments to pro-
tect against oxidative damage by inhibiting or quenching free radicals and ROS, and 
inhibit lipid peroxidation (Mittal and Gupta 2000). Piperine is shown to be an effec-
tive antioxidant and offer protection against oxidation of human LDL, as evaluated 
by copper ion–induced lipid peroxidation of human LDL (Naidu and Thippeswamy 
2002) (Table 16.4).
Orally administered curcumin effectively countered the changes in the endog-
enous antioxidant molecules and enzymes accompanying myocardial infarction 
induced by iso-proterenol in rats (Nirmala and Puvanakrishnan 1996). Curcumin 
treatment was found to protect the rat myocardium against ischemic insult, and the 
protective effect could be attributed to its antioxidant properties as well as its inhibi-
tory effects on xanthine dehydrogenase–xanthine oxidase conversion and resultant 
superoxide anion production (Manikandan et al. 2004).
cAncer-preventIve property
Animal and in vitro studies suggest that certain herbs help protect against oxida-
tive stress and inflammation, both of which are risk factors for cancer initiation 
and promotion (Surh 1999). Anti-inflammatory compounds of spices—curcumin, 
gingerol, and capsaicin—appear to act by inhibiting one or more steps in the pro-
inflammatory pathway. The natural anti-inflammatory compounds quercetin, 
curcumin, and silymarin have been shown to be as effective as indomethacin, a 
nonsteroidal anti-inflammatory drug, in inhibiting the formation of aberrant crypt 
foci in the rat (Volate et al. 2005). Herbs and spices with known anticarcinogenic 
properties in animal models of carcinogenesis include tumeric, garlic, ginger, 
basil, rosemary, mint, and lemongrass (Table 16.5).
Methanol extract of the leaves of rosemary (Rosmarinus officinalis) and its con-
stituent carnosol (a phenolic diterpene) can inhibit tumor promotion in mouse skin 
(Elson et al. 1989). Geraniol (an acyclic monoterpene alcohol) of Cymbopogon citra-
tus (lemon grass) has been shown to inhibit growth and polyamine biosynthesis in 
human colon cancer cells (Hertog et al. 1993). Perillyl alcohol (a monoterpene) found 
in lavender and mint has been shown to reduce tumor incidence and tumor multi-
plicity in a mouse lung tumor (Gujaral et al. 1978). Aqueous extract of spearmint as 
drinking fluid during treatment with a colon carcinogen showed lower numbers of 
colonic aberrant crypt foci in rats (Yu et al. 2004). Myristicin of parsley has been 
shown to inhibit tumor multiplicity in a rodent lung cancer model and induce glu-
tathione S-transferase in the liver and small intestinal mucosa (Zheng et al. 1992).
Turmeric or its constituent curcumin is found to have chemopreventive effects 
against cancers of the skin, forestomach, liver, and colon, and oral cancer in mice 
(Chuang et al. 2000; Volate et al. 2005). The effect of dietary curcumin on the activi-
ties of antioxidant and phase II–metabolizing enzymes involved in detoxification 
and production of ROS has been evaluated in mice (Srinivasan 2014). Induction 
of detoxifying enzymes by curcumin suggests the potential of this compound as a 
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protective agent against chemical carcinogenesis and other forms of electrophilic 
toxicity. In vitro and animal cancer models have shown that diallyl sulfide of garlic is 
effective in the detoxification of carcinogens through its effects on phase I and phase 
II enzymes (Wargovich et al. 2001).
The incidence of cancer at different sites may be related to oxidative damage 
to host genome by genotoxicants. Curcumin, which possesses antimutagenic prop-
erty, appears to be a promising chemopreventive agent. The antioxidant properties 
of curcumin explain the diverse pharmacological potential of this phytochemical or 
the parent spice, turmeric (Figure 16.2). The antioxidant property is also implicated 
in the cancer chemopreventive effects of curcumin against the induction of tumors 
in various target organs. S-Allylcysteine of garlic modulated 7,12-dimethyl-benz[α]
anthracene-induced buccal pouch carcinogenesis by decreasing the susceptibility 
of the buccal pouch to lipid peroxidation in Syrian hamsters, while simultaneously 
enhancing activities of antioxidant enzymes in the liver and circulation (Balasenthil 
et al. 2001). Dietary garlic (2%) has a protective effect on azoxymethane-induced 
colon carcinogenesis in Sprague–Dawley rats, which is mediated by modulation of 
oxidative stress during carcinogenesis (Sengupta et al. 2003). The phenolic com-
pounds 6-gingerol and 6-paradol present in ginger also have antitumor promo-
tional and antiproliferative effects. The chemopreventive and chemoprotective 
effects exerted by 6-gingerol are often associated with their antioxidative and anti- 
inflammatory activities.
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tested sample perceived Health effects
Basil (Ocimum basilicum) Eugenol and flavonoids Anti-inflammation in cancer 
development; inhibition of lipid 
peroxidation; antimicrobial effects
Ginseng Herb extract Hypoglycemic effect
Lemongrass (Cymbopogon 
citratus)
Citral, limonene Anti-inflammation and inhibition of 
polyamine biosynthesis in human 
colon cancer development
Oregano (Poliomintha longiflora) Herb extract Antimicrobial effects
Parsley (Petroselinum crispum) Myristicin/herb extract Inhibition of lung carcinogenesis; 
antimicrobial effects
Rosemary (Rosmarinus officinalis) Flavonoids, 
rosmarinate
Inhibition of carcinogenesis; 
anti-inflammation in cancer 
development
Sage (Salvia officinalis) Essential oil Inhibition of bone resorption; 
improvement in memory retention
Spearmint (Mentha spicata) Herb extract Antimutagenic effect
Thyme (Thymus vulgaris) Thymol Inhibition of bone resorption; 
antimicrobial effects
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Eugenol pretreatment was found to inhibit the number of tumors produced by 
the application of 7,12-dimethyl benz(α-)anthracene as initiator and croton oil as 
promoter in mice (Sukumaran et al. 1994), wherein eugenol inhibited superoxide 
formation and lipid peroxidation, suggesting that the radical scavenging activ-
ity may be responsible for its chemopreventive action. The ability of piperine to 
inhibit or reduce the oxidative changes induced by chemical carcinogens has been 
studied in a rat intestinal model (Khajuria et al. 1998). Carcinogenesis was initi-
ated in intestinal lumen of rats with 7,12-dimethyl benzanthracene, dimethyl ami-
nomethyl azobenzene, and 3-methyl cholanthrene. A protective role of piperine 
against the oxidative alterations by the carcinogen was indicated by the observed 
inhibition of lipid peroxides, a significant increase in the glutathione levels, and 
restoration in the activity of marker enzymes. Oral supplementation of piperine 
(50 mg/kg) effectively suppressed experimental lung carcinogenesis by B(α)p in 
mice, as revealed by a decrease in the extent of mitochondrial lipid peroxida-
tion and concomitant increase in the activities of enzymatic antioxidant levels 
(Selvendiran et al. 2004). This suggests that piperine may extend its chemopre-
ventive effect by modulating lipid peroxidation and augmenting the antioxidant 
defense system.
AMeLIorAtIon of oxIdAtIve stress In dIAbetes
Increasing evidence in both experimental and clinical studies suggests that oxidative 
stress plays a major role in the pathogenesis of diabetes mellitus. Streptozotocin-
induced diabetic rats maintained on curcumin diet showed lowered lipid peroxidation 
in plasma and urine (Babu and Srinivasan 1995). Oral administration of curcumin (10 
or 30 mg/kg) for 45 days ameliorated hyperglycemia, along with near-normalization 
of the antioxidant enzyme activities and the levels of lipid peroxidative markers 
(Mahesh et al. 2005). The efficacy of piperine treatment (10 mg/kg/day for 14 days) 
in diabetes-induced oxidative stress in rats has been reported (Rauscher et al. 2000). 
Treatment with piperine reversed the disturbances in antioxidant defense in nonhe-
patic tissues.
Fenugreek (Trigonella foenum-graecum) seed is reported to counter the increased 
lipid peroxidation and alterations in the content of circulating antioxidant mole-
cules—glutathione, β-carotene, and α-tocopherol—in alloxan-induced diabetic rats 
(Ravikumar and Anuradha 1999). Oxygen free radicals are presumably responsible 
for the severity and complications of diabetes. Fenugreek administration to diabetic 
animals reversed the disturbed antioxidant levels and peroxidative damage, thus 
suggesting that fenugreek seeds have a beneficial antioxidant property that can be 
exploited for the treatment/reversal of the complications of diabetes (Genet et al. 
2002).
Garlic oil (10 mg/kg for 15 days) is shown to effectively normalize the impaired 
antioxidant status (circulatory total thiols and ceruloplasmin), and activities of glutathi-
one S-transferase and superoxide dismutase in the liver and kidney in streptozotocin- 
induced diabetes (Anwar and Meki 2003). The effects of this antioxidant may be 
useful in delaying the complicated effects of diabetes such as retinopathy, nephropa-
thy, and neuropathy due to imbalance between free radicals and antioxidant systems.
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AntIcAtArActoGenesIs
Oxidative stress has been implicated in cataractogenesis. Dietary curcumin showed a 
preventive role on naphthalene-induced opacification of rat lens (Pandya et al. 2000). This 
study demonstrated that curcumin attenuates the apoptotic effect of naphthalene in rat 
lens. Wistar rat pups treated with curcumin being administered with selenium showed no 
opacities in the lens (Padmaja and Raju 2004). Curcumin cotreatment seemed to prevent 
oxidative damage and delay the development of cataract induced by selenium. Dietary 
curcumin (0.002% and 0.01%) and turmeric (0.5%) were found to be effective against the 
development of diabetic cataract in streptozotocin-induced diabetic rats (Suryanarayana 
et al. 2005). Curcumin and turmeric supplements delayed the progression and maturation 
of cataract by countering the hyperglycemia-induced oxidative stress, as indicated by 
reversal of changes with respect to lipid peroxidation, glutathione, protein carbonyl con-
tent, and activities of antioxidant enzymes. Aggregation and insolubilization of lens pro-
teins due to hyperglycemia was prevented by turmeric and curcumin. Dietary curcumin 
(0.002%) was effective against the onset and maturation of galactose-induced cataract in 
rats via exerting antioxidant and antiglycating effects, as it inhibited lipid peroxidation 
and protein aggregation (Suryanarayana et al. 2003).
neuroprotectIve potentIAL
Herbs and spices, by contributing antioxidants, may influence age-related cogni-
tive decline (Rahman 2003). Free radical–induced neuronal damage is implicated 
in cerebral ischemia reperfusion (IR) injury, and antioxidants are reported to have 
neuroprotective activity. The neuroprotective potential of curcumin (300 mg/kg) 
investigated in cerebral ischemia reperfusion injury observed in cerebral ischemia is 
mediated through its antioxidant activity by preventing the elevation in lipid peroxi-
dation (Thiyagarajan and Sharma 2004). The protective effect of curcumin against 
lead-induced neurotoxicity has been evidenced in rats, which was accompanied by 
a reversal of the decrease in glutathione levels, superoxide dismutase, and catalase 
activities in the brain regions (Shukla et al. 2003).
AntI-InfLAMMAtory effect
Lipid peroxides play a crucial role in arthritis and other inflammatory diseases. Herbs 
and spices are useful in the treatment of symptomatic osteoarthritis owing to their 
ability to reduce inflammation (Grzanna et al. 2005). Turmeric is the earliest anti-
inflammatory drug known in the indigenous system of medicine in India. Turmeric 
extract, curcuminoids, and volatile oil of turmeric have been found to be effective 
as anti-inflammatory agents in several studies involving mice, rats, and rabbits. The 
efficacy of curcuminoids was also established in experimental inflammation in mice 
and rats (Srimal 1997). Both in vitro and in vivo animal studies have documented the 
anti-inflammatory potential of the spice principles curcumin (of turmeric), capsaicin 
(of red pepper), and eugenol (of clove). Animal studies have revealed that curcumin 
and capsaicin also lower the incidence and severity of arthritis and also delay the 
onset of adjuvant-induced arthritis.
295Role of Herbs and Spices
The anti-inflammatory effect of curcumin (400 mg) in patients undergoing sur-
gery for hernia/hydrocele was found to be comparable to that of phenylbutazone 
(100 mg) (Satoskar et al. 1986). In rheumatoid arthritis patients, administration of 
curcumin produced significant improvement similar to phenylbutazone (Deodhar et 
al. 1980). Capsaicin has received considerable attention as a pain reliever. In patients 
with osteoarthritis and rheumatoid arthritis, topical application of creams contain-
ing capsaicin was an effective alternative to analgesics employed in systemic medi-
cations, which are often associated with potential adverse effects (McCarthy and 
McCarthy 1991). There is also evidence for the benefit of ginger in ameliorating 
arthritic knee pain, although the effectiveness is lesser than that of ibuprofen. Ginger 
contains pungent ingredients such as 6-gingerol and 6-paradol, which possess anti-
inflammatory properties (Surh 1999). Human trial has proven the efficacy of ginger 
extract in ameliorating arthritic knee pain. Ginger doses of 0.5–1.0 g/day have been 
found to be efficacious in osteoarthritis and rheumatoid arthritis.
Natural anti-inflammatory compounds of spices (curcumin, capsaicin, gingerol) 
appear to operate by inhibiting one or more of the steps linking pro-inflammatory 
stimuli with COX activation, such as the blocking by curcumin of NF-κB trans-
location into the nucleus. It has been shown recently that natural anti-inflamma-
tory compounds such curcumin were as effective as indomethacin (a nonsteroidal 
anti-inflammatory drug). The presence of eugenol in basil’s (Ocimum basilicum) 
volatile oils, which is known to inhibit the activity of COX-2, makes basil an anti-
inflammatory herb that can provide healing benefits along with symptomatic relief 
for individuals with inflammatory problems like rheumatoid arthritis or inflamma-
tory bowel conditions.
HepAtoprotectIve And renAL-protectIve effects
Oral (30 mg/kg for 10 days) dietary administration of curcumin to Wistar rats 
reduced the iron-induced hepatic damage by lowering lipid peroxidation (Reddy 
and Lokesh 1996). Increasing evidence demonstrates that oxidative stress plays an 
important etiologic role in the development of alcoholic liver disease. The protective 
role of curcumin on alcohol- and thermally oxidized sunflower oil (δPUFA)–induced 
oxidative stress was observed in Wistar rats; curcumin exerts its protective effect by 
decreasing the lipid peroxidation and improving antioxidant status (Rukkumani et 
al. 2004).
Eugenol (5 or 25 mg/kg) has been shown to have a protective effect against carbon 
tetrachloride–induced hepatotoxicity (Nagababu et al. 1995). Oral administration of 
eugenol (100 mg/kg for 10 days) lowered the liver and serum lipid peroxide levels, 
serum marker enzymes of hepatic damage, enhanced by intraperitoneal injection of 
iron, indicating that eugenol reduces the iron-induced hepatic damage by lowering 
lipid peroxidation (Reddy and Lokesh 1996). Furthermore, the inactivation of the 
drug-metabolizing system by carbon tetrachloride was countered by eugenol, sug-
gesting that eugenol might act as an antioxidant and inducer of phase II and phase I 
enzymes (Kumaravelu et al. 1995). The beneficial effect of curcumin in preventing 
the acute renal failure and related oxidative stress caused by chronic administration 
of cyclosporine has been demonstrated in rats (Tirkey et al. 2005).
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otHer nutrAceutIcAL propertIes of Herbs And spIces
Among the other nutraceutical properties of spices, which are independent of their 
antioxidant influence, are anticholelithogenic effect, digestive stimulant action, 
and antimicrobial activity. A persistent high-cholesterol diet leads to cholesterol 
saturation in bile, resulting in the formation of cholesterol gallstones in the gall-
bladder. The antilithogenic potential of hypocholesterolemic spices—red pepper, 
turmeric, garlic, onion, and fenugreek seeds—has been evidenced in animal stud-
ies (Srinivasan 2013). The antilithogenicity of these spices is considered to be due 
to lowering of cholesterol concentration and enhancing the bile acid concentration, 
both of which contribute to lowering of cholesterol saturation index and hence 
its crystallization. Several spices such as cumin, coriander, ajowan, fennel, mint, 
and garlic are common remedies used in traditional medicine to cure digestive 
disorders. Spices exert digestive stimulatory effects via stimulation of bile acid 
secretion and stimulation of the production and secretion of digestive enzymes 
from pancreas (Platel and Srinivasan 2004). Antimicrobial activity has been dem-
onstrated in vitro for several herbs and spices and essential oils from basil, thyme, 
oregano, parsley, cilantro, and cinnamon (Cowan 1999). Beneficial antimicrobial 
phytochemicals include polyphenols, terpenoids and essential oils, alkaloids, and 
lectins. Polyphenols are capable of forming an irreversible complex with nucleo-
philic amino acids in protein, leading to their inactivation and therefore loss of 
function. Polyphenols have been reported to disrupt microbial membranes and 
inactivate microbial enzymes.
concLusIons
Oxidative stress is clearly implicated in a wide range of disease processes, including 
cardiovascular disease, cancer, inflammatory diseases, neurodegenerative diseases, 
cataract, etc. Herbs and spices, which are normal ingredients of the human diet, 
are now known to exert health-beneficial antioxidant effects in mammalian systems 
and in several model systems through their bioactive compounds. The antioxidant 
properties of herbs and spices are of particular interest in view of the impact of oxi-
dative modification of LDL in the development of atherosclerosis, and suppression 
of oxidative stress and inflammation in their cancer-preventive role, since both oxi-
dative stress and inflammation are a risk factor for cancer initiation and promotion. 
The antioxidant potential of spices has far-reaching health implication. The studies 
to this effect are exhaustive, and experimental evidences are plenty particularly in 
the case of curcumin of turmeric and eugenol of clove. All the available informa-
tion essentially endorses that using antioxidant spices at high levels is beneficial 
to the markers of health, although it is less clearly evident that these are actually 
beneficial in preventing or protecting oxidative stress–mediated diseases. By virtue 
of antioxidant activity, these spice bioactive compounds are extrapolated to be anti-
inflammatory, antimutagenic and cancer-preventive, antiatherogenic and cardiopro-
tective, hepatoprotective, neuroprotective, anticataractogenic, etc. What essentially 
remains is integrating this knowledge to ascertain whether such health beneficial 
effects can be observed in humans.
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Although the effective dose of these dietary spices evidenced in animal studies 
to produce the desired antioxidant influence far exceeds their normal levels encoun-
tered in our daily diet, the effectiveness of lower doses of these spices cannot be 
ruled out. There is also the possibility of deriving the beneficial effect by chronic 
consumption of these spices in our daily diet. In view of the antioxidant potential of a 
number of herbs and spices with far-reaching health implication, these food adjuncts 
deserve to be considered as natural and necessary components of our daily nutrition. 
Use of spices and herbs in the diet ensures adequate intake of both essential nutri-
ents and health-promoting bioactives in the food supply. Herbs and spices can add 
substantial variety to the nutrients and bioactives available in the diet. Although the 
potential health effects of herbs and spices are reported abundantly in the scientific 
literature, it should be noted that human data of variable quality are limited; vast 
research literature from in vitro and in vivo studies suggests that specific herbs and 
spices may confer unique health benefits. The use of herbs and spices as source of 
antioxidants to combat oxidative stress warrants further attention in terms of validat-
ing the antioxidant capacity and testing their effects on markers of oxidation in clini-
cal trials that are aiming to establish antioxidants as mediators of disease prevention.
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